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Middle East respiratory syndrome coronavirus (MERS-CoV) is an emerging virus that was
first reported in humans in June 2012 [1]. To date, MERS-CoV continues to infect humans with
a fatality rate of ~35%. At least 27 countries have reported human infections with MERS-CoV
(https://www.who.int/emergencies/mers-cov/en/). MERS-CoV is a zoonotic virus. Like severe acute
respiratory syndrome coronavirus (SARS-CoV), MERS-CoV is believed to have originated from
bats [2,3]. However, whereas the bat-to-human transmission of SARS-CoV was likely mediated by
palm civets as intermediate hosts, humans likely acquired MERS-CoV from dromedary camels [4–6].
Human-to-human transmission of MERS-CoV does occur, but it is limited mostly to health care
environments [7,8]. Moreover, whereas SARS-CoV recognizes angiotensin-converting enzyme 2
(ACE2) as a cellular receptor [9,10], MERS-CoV uses dipeptidyl peptidase 4 (DPP4) to enter target
cells [11,12]. Currently, no vaccines or antiviral therapeutics have been approved for the prevention
or treatment of MERS-CoV infection, although a number of them have been developed preclinically
and/or tested clinically [13–16].
The articles in this special issue of Viruses were written by researchers working in the MERS-CoV
field. The main aims of this issue are to (i) better understand MERS-CoV transmission, epidemiology, and
pathogenesis; (ii) summarize current progress on MERS-CoV animal models, vaccines, and therapeutics;
and (iii) discuss future prospects for MERS-CoV research. This issue includes seven review articles
and nine original research papers, each providing detailed updates on current MERS-CoV studies.
Studies on the transmission, epidemiology, and pathogenesis of MERS-CoV form one of the
foundations of MERS-CoV research. In this issue, Farag and colleagues summarize the possible
drivers of the emergence of MERS-CoV and its spillover to humans in Qatar, explaining the potential
reasons for the camel-to-human transmission of MERS-CoV [17]. The review article by Song and
colleagues provides an overall description of the epidemiology, pathogenesis, and other important
aspects of MERS-CoV [18]. Widagdo and colleagues review the host determinants of the transmission
and pathogenesis of MERS-CoV, indicating that receptor DPP4 plays an important role in these
processes [19]. A research article by Yan and colleagues characterizes the role of lipid profiles in the
pathogenesis and infectivity of human coronaviruses, including MERS-CoV, suggesting that lipid
metabolism may be involved in the propagations of these coronaviruses [20]. These reports provide
insights into how MERS-CoV infects cells and spreads within and across host species. They have also
laid the foundations for developing animal models.
Animal models are essential tools for the preclinical evaluation of anti-MERS-CoV countermeasures.
Dromedary camels, alpacas, and non-human primates are susceptible to MERS-CoV infection [21–23];
however, the virus does not infect small animals such as mice, hamsters, and ferrets [24–26]. Several
mouse models that express human DPP4 (hDPP4) have been established for MERS-CoV infection [27–29].
In this issue, Widagdo and colleagues examine rabbits as potential hosts for MERS-CoV, showing
that MERS-CoV infects rabbits without causing symptoms; they also analyze the route of MERS-CoV
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transmission in rabbits [30]. Fan and colleagues report the development of an hDPP4-expressing
mouse model through inserting hDPP4 gene into a constitutive and ubiquitous gene expression locus
using CRISPR/Cas9 technology. This mouse model is susceptible to MERS-CoV infection [31]. These
articles have established platforms for testing vaccines and therapeutic agents targeting MERS-CoV.
Effective vaccines are essential for preventing MERS-CoV infection. The MERS-CoV surface
spike (S) protein is a key target for vaccine design [14]. The S protein comprises two subunits: the S1
subunit is responsible for binding to the DPP4 receptor via a receptor-binding domain (RBD), and
the S2 subunit mediates virus–host membrane fusion [32–35]. Several MERS-CoV S protein-based
vaccines have been developed; when tested in animal models, they showed protective efficacy against
MERS-CoV [14]. In this issue, Schindewolf and Menachery summarize the progress of MERS-CoV
S-protein-based vaccine development and also describe potential challenges [36]. Zhou and colleagues
review current advances in RBD-based MERS-CoV vaccines [37]. A research paper by Adney and
colleagues evaluates the efficacy of a MERS-CoV S1 subunit vaccine aided by adjuvants; the authors
report reduced and delayed viral shedding in dromedary camels as well as the complete protection of
alpacas from MERS-CoV infection [38]. This and other studies demonstrate that the protective efficacy
of MERS vaccines positively correlates with neutralizing antibody titers in serum [38,39]. In addition to
inducing neutralizing antibodies, some types of vaccines can induce cellular immune responses against
MERS-CoV. Other than the S protein, structural proteins such as the nucleocapsid (N) protein may also
serve as vaccine targets. Here, Veit and colleagues report that a MERS-CoV N protein-based vaccine,
which is delivered through a modified Vaccinia virus, induces CD8+ T cell responses in a mouse model;
they further identify a MERS-CoV N protein-specific CD8+ T cell epitope on the vaccine [40]. Overall,
these reports demonstrate that a variety of promising vaccine tools are available to prevent MERS-CoV
infection in humans and other animals.
Therapeutics are critical tools for treating MERS-CoV infection. Again, the MERS-CoV S protein
is an important target for therapeutic development [16]. MERS-CoV S2 contains two heptad repeat
regions, HR1 and HR2, that are critical for S protein-mediated membrane fusion [34]. Hence, peptides
mimicking HR1 or HR2 may interfere with the viral membrane-fusion process [34]. Moreover,
RBD-targeting neutralizing monoclonal antibodies (mAbs) can block the viral attachment step [37].
In addition to conventional mAbs, single-domain antibodies isolated from camelids, called nanobodies
(Nbs), can also block RBD/receptor interactions; these Nbs have been gaining popularity as therapeutic
agents due to their small size and high stability [41,42]. Thus, both the HR1/HR2 peptide mimics
and RBD-targeting mAbs and Nbs may serve as MERS-CoV entry inhibitors. Furthermore, small
molecules targeting the S protein or nonstructural proteins may serve as therapeutic alternatives to
peptide mimics and antibodies [16,43]. In this issue, two review articles report the current advances
in therapeutic neutralizing antibodies, one by Han and colleagues and the other by Zhou and
colleagues [37,44]. The latter article also discusses potential strategies and challenges to improving
the efficacy of therapeutic neutralizing antibodies. In a research article, He and colleagues describe
the construction and expression of dimeric and trimeric Nbs that target MERS-CoV RBD and further
demonstrate the strong stability and high neutralizing activity of these Nbs against multiple MERS-CoV
strains [42]. In another research article, Xia and colleagues report that three peptides mimicking HR2
from HKU4 (which is a MERS-related coronavirus from bats) strongly inhibit MERS-CoV infection [45].
Interestingly, Wang and colleagues report that the combination of a MERS-CoV HR2 peptide mimic
and an RBD-targeting neutralizing mAb demonstrate potent synergistic effects in inhibiting MERS-CoV
S protein-mediated viral entry [46]. In another research article, Jiang and colleagues report that
an antibody targeting complement receptor C5aR1 inhibits MERS-CoV infection, indicating that
MERS-CoV infection elicits the over-activation of the complement system, and this process can be
blocked by anti-C5aR1 antibodies [47]. Moreover, Liang and colleagues review advances in the
development of small-molecular MERS-CoV inhibitors [48]. Overall, these articles confirm that
anti-MERS-CoV therapeutics have great potentials in treating MERS-CoV infections in humans and
other animals.
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To summarize, significant progress has been made in MERS-CoV research in the past seven
years since the virus was discovered. This progress includes, but is not limited to, the epidemiology,
transmission, and pathogenesis of MERS-CoV, as well as animal models, vaccines, and antivirals for
MERS-CoV. This special issue of Viruses provides updated reports on this progress. However, challenges
remain. For example, we still do not understand how exactly MERS-CoV transmits from bats to camels
or humans. Moreover, compared to HIV and influenza viruses, the potential market for MERS-CoV
vaccines and therapeutics is much smaller, making commercialization of MERS-related products
more challenging. Nevertheless, the past two decades have witnessed the emergence of two highly
pathogenic coronaviruses, MERS-CoV and SARS-CoV. While these two viruses remain significant
threats to global health, future novel coronaviruses with pandemic potential may emerge from their
animal reservoirs and infect humans. Thus, research into MERS-CoV should remain a high priority
for the virology community. In fact, the impressive progress in MERS-CoV research has benefitted
tremendously from previous research into coronaviruses including SARS-CoV. Therefore, scientists’
current efforts regarding MERS-CoV will prepare humans to battle any future novel coronaviruses
with pandemic potential.
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Abstract: MERS-CoV (Middle East respiratory syndrome corona virus) antibodies were detected
in camels since 1983, but the first human case was only detected in 2012. This study sought to
identify and quantify possible drivers for the MERS-CoV emergence and spillover to humans. A list
of potential human, animal and environmental drivers for disease emergence were identified from
literature. Trends in possible drivers were analyzed from national and international databases,
and through structured interviews with experts in Qatar. The discovery and exploitation of oil
and gas led to a 5-fold increase in Qatar GDP coupled with a 7-fold population growth in the
past 30 years. The lifestyle gradually transformed from Bedouin life to urban sedentary life,
along with a sharp increase in obesity and other comorbidities. Owing to substantial governmental
support, camel husbandry and competitions flourished, exacerbating the already rapidly occurring
desertification that forced banning of free grazing in 2005. Consequently, camels were housed in
compact barns alongside their workers. The transition in husbandry leading to high density camel
farming along with increased exposure to humans, combined with the increase of camel movement for
the racing and breeding industry, have led to a convergence of factors driving spillover of MERS-CoV
from camels to humans.
Keywords: Drivers; MERS-CoV; Qatar
1. Introduction
Emerging infectious diseases are a cause for increasing global concern, because of their impact on
global health and economics [1]. The Ebola outbreak in West Africa during 2014-2015 showed that
pathogens which previously caused small and easy to control outbreaks had the potential to infect
thousands of people under the right circumstances [2]. This is also a concern for the Middle East
Respiratory Syndrome coronavirus (MERS-CoV), which until now has been the cause of sporadic
cases and hospital outbreaks [3]. To date, there have been 2220 confirmed laboratory cases worldwide,
with 790 deaths [4]. All MERS index cases are linked to the Arabian Peninsula. Dromedary camels have
been identified as a reservoir of MERS-CoV with occasional zoonotic transmission to humans [5,6].
Human-to-human transmission is also common, with around 30% of the MERS cases reported to
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WHO being health care associated [7,8]. However, the source of infection of many index cases remains
unclear [9,10].
Studies have shown that MERS-CoV, or related viruses have been circulating among camels
at least since 1983 [11]. Since that period, massive changes have occurred in people’s lives and in
animal husbandry across the Arabian Peninsula. Understanding these changes may help to reconstruct
the events that led to the emergence of MERS-CoV as a human disease. Past research identified
several drivers of emerging zoonoses, such as urbanisation, population growth and demography,
and environmental and agricultural changes [12–14]. The drivers which could have potentially
influenced the MERS-CoV emergence in humans have only sporadically been investigated [15,16]. By
reviewing changes involving humans and camels over the past 30 years in Qatar, this study sought to
identify the key drivers of the emergence and spread of MERS-CoV.
2. Methods
Potential drivers for disease emergence were identified from literature and from discussions with
national and international experts in MERS-CoV. The final list had the following categories: economic
development; human demography and behavior; international travel, commerce, sports and leisure;
political environment; agriculture and food industry change, including camel demography, husbandry
and movement; changes in climate and land use. Data from 1980 onwards were collected from national
and international databases. If multiple data sources were available, data from both sources were
collected. All data were entered in an excel datasheet and reviewed and discussed with the project
team (Supplementary 1).
Qualitative information and remaining data gaps were addressed by interviews with a group of
15 experts and stakeholders from Qatar. Criteria to select experts included 5 years or more experience
in a camel-related business (farming, trading and racing) or professional services related to camels
and being familiar with cultural aspects of the Qatari community. Using a structured interview guide
(Supplementary 2) and a moderator, a series of 4 interviews were conducted in Arabic, each lasting
approximately for 3 hours. The main themes that were covered during the interviews included:
(changes in) people’s living conditions; customs and purposes of camel ownership; cultural habits
related to camels; educational level and personal behaviors of camel owners and workers; camel
movement; demographic distribution of camels in Qatar; camel farming practices: feeding, grazing,
and slaughter. A detailed transcript was shared with the experts for authentication. A literature
search was done to complement findings from the quantitative and qualitative study, using PubMed,
Google Scholar and the local sources of information including the Ministry of Public Health (MoPH),
Ministry of Municipality and Environment (MME), Ministry of Development and Planning Statistics
(MDPS), and Qatar Statistical Authority (QSA).
The funder had no role in study design, data analysis, data interpretation, or writing of the review.
3. Results
3.1. Changes in the Economic Situation
Historically, Qatari inhabitants were mostly Bedouins along with a few settled people [17,18].
The Bedouins owned limited numbers of camels, sheep, and goats [19]. Camels were used as a
source of food (milk and meat) and means for transportation. In 1939, oil and natural gas resources
were discovered. However, large-scale exploitation started in the 1950s [20]. From the 1950s onwards,
Qatar’s economy has been steadily growing. However, the year 2000 marked a significant turning point
as Qatar’s GDP almost increased by more than 5-fold during the period 2000–2006 (Figure 1A) [20,21].
Qatar is currently considered to be one of the wealthiest countries in the world [20].
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3.2. Changes in Human Demography and Health
The thriving economy was paralleled by major demographic and life style changes. In the late
1950s, around 16,000 people lived in Qatar [22]. In response to demands for a larger workforce after
the exploitation of oil and gas began, foreign laborers started to migrate to Qatar from countries in
the region, like Palestine, Oman, Iran, and the Kingdom of Saudi Arabia (KSA). Later, immigrants
from Pakistan, India, Nepal, Sri Lanka, Bangladesh, the Philippines, and Indonesia joined the older
migrant populations, increasing the number of inhabitants to 369,079 by 1986 and recently to 2,617,634
(Figure 2A) [23]. In 2016, non-Qatari males made up 78% of the residents of working age (15-64) and
non-Qatari made up more than 90% of the total number of Qatar inhabitants older than 15 years of age
(Figure 2B,C) [24]. Most recent estimations of the origins of the non-Qatari population are that 25% is
Indian, 11% Bangladeshi, 14% Nepali, 10% Filipinos, 9% Egyptian, 5% Pakistani, and 2% Iranian [25].
The total number of males in Qatar increased from 67.2% of the total population in 1986 to 75.5% in
2016 (Figure 2B). In 2004, almost 50% of residents were between 15 and 39 years old, and this has risen
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Figure 1. Developments in economy, camel demography, production, and trade. (A). Development over
time of the gross domestic product per capita; (B) Development over time of the camel population; (C)
Development over time of camel import and export; (D) Development over time of camel importation
per country of origin. *Other Arab countries: Algeria, Comoros, Djibouti, Egypt, Iraq, Jordan, Lebanon,
Libya, Mauritania, Morocco, Palestine, Somalia, Sudan, Syria, Tunisia, and Yemen. **Other GCC
countries: Bahrain, Kuwait, Oman, Qatar.
Most people in Qatar live in urban areas. The percentage of residents living in cities increased
from 85.3% in 1960, to 90.4% in 1986, and 99.3% in 2016 [20]. Doha, the capital and the biggest city of
Qatar, hosts the greatest number of people. However, there has also been a large increase in number of
people living in the Al-Rayan area, where most of the camel farms are located. The number of tourists
visiting Qatar also increased, especially since 2000. Most tourists came from other GCC countries,
but the number of visitors from Europe and America were also increasing (Figure 2D) [20,27].
According to experts, the economic development and population increase coincided with major
changes in life style. The Bedouin nomadic lifestyle gradually decreased as most of the Qatari tribes
shifted to an urban, settled lifestyle; cars and planes rapidly replaced camels as transportation means.
This transformation to a more sedentary lifestyle is reflected in the profile of comorbidities. More
than 70% of adults are overweight and almost half of them obese [28]. Male obesity increased from
17% in 1986 to 34% in 2014, which is extremely high compared to the current 11% prevalence in men
worldwide [29]. In 1998, 7% of residents above 15 years were hypertensive, rising to 14% in 2006,
and 33% in 2012 [30,31]. Prevalence of high blood sugar among adults in 2015 was 14%, compared to a
worldwide prevalence of 9% [28]. The Qatar Stepwise Report reported in 2012 that 15% of adults were
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daily smokers. Yet, Qatar has a low death rate: 1.49/1000, compared to the worldwide death rate of
7.72/1000, and its healthcare system has developed rapidly over the past twenty years [28,31,32].
3.3. Changes in Camel Husbandry and Practices
The increase in the number of dromedary camels reflects the increasing popularity of camels
as sports animals (Figure 1B). With the changing life style and increasing wealth, the purchase and
breeding of (expensive) racing camels came within reach of an increasingly large segment of the Qatari
national population. According to experts, although camel racing has traditionally been part of the
Bedouin culture, the organized racing business went through major changes over the past decades.
This was partly due to financial and regulatory support from the Qatari government. This support
increased the social and economic value of camels in Qatar, further stimulating their popularity.
The Al-Shehaniya camel-racing track, one of the biggest tracks in the Gulf, was opened in 1990 [33].
The camel farms that are located near the Al-Shehaniya camel racing area are mostly used for racing
camels. There are about 1500 racing camel holdings at the Al-Shehaniya camel racing area. Some of
the camels in Qatar are used to compete in camel beauty contests that are organized around the
Arabian Peninsula. According to the FAO, in 1960 there were about 6,000 camels in Qatar. This rose to
over 43,000 in 1992, 50,000 in 2000, and more than 90,000 in 2016 (Figure 1B). More than 83% of the
animals are currently kept for racing [34]. Across the Gulf region, Qatar has the highest camel density,
with 6.77 units/km2, compared to 4.74 units/km2 in United Arab Emirates (UAE) and 0.11 units/km2
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Figure 2. Developments in human demography in Qatar; (A) Development over time of the age
structure of the population; (B) Development over time of the human sex ratio; (C) Development over
time of the ration Qatari vs. non Qatari; (D) Development over time of tourism per country of origin
*Other Arab countries: Algeria, Comoros, Djibouti, Egypt, Iraq, Jordan, Lebanon, Libya, Mauritania,
Morocco, Palestine, Somalia, Sudan, Syria, Tunisia, and Yemen. **GCC countries: Bahrain, Kuwait,
Oman, Qatar, KSA, and the United Arab Emirates.
As a result of the loss of traditional methods of rangeland management, the vegetation coverage
decreased from 10% to only 1% of total land cover. Overgrazing of the green areas due to the increased
population of camels and other livestock accelerated the desertification of Qatar [36]. Therefore,
the government decided to assign natural protected areas in 2004 [37,38], and started to sanction the
free grazing of livestock since 2005 [39]. By 2011, open grazing was completely banned [40]. According
to the experts’ opinions, this led to changes in farming practices, as herds were then moved outside
of Qatar to areas where free grazing remained possible. Moreover, in Qatar, camels are now raised
in closed systems and within 1 of 9 designated farming areas (camel complexes) in the residential
districts. Camel workers also live on the premises of the camel complexes. Typically, a camel complex
has a reception room (Majlis) for social activities of the camel owners. The Al-Rayyan municipality,
where the Al-Shehaniya camel racing area is also located, currently holds about 83% of the total
camel population and 61% of camel holdingss (Figure 3) [34,35]. According to the experts, this newly
adopted closed farming system led to the increase of disease incidence, especially of parasitic diseases.
However, we did not find any disease statistics to substantiate these findings.
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Camel market and 
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Figure 3. Human and camel density map of Qatar (adapted from Ministry of Development Planning
and Statistics, Population Concentration map, 2015). The density map shows the density of camels
(source: Ministry of Municipality and Environment) and humans in Qatar. Most people live in and
around Doha, where the Doha animal market and slaughterhouse are also located. The highest camel
density can be found in the Al-Rayyan area, where the Al-Shehaniya racing tracks are also located.
A small, but growing, part of the Qatar population also lives in the Al-Rayyan area.
3.4. Changes in Race Camel Farming and Practices
The increasing focus on camel race competitions caused big changes in camel farming practices.
Previously, the calves were weaned when the next calf was born. Currently, weaning occurs at around
7 months of age. After being weaned, young camels are directly taken for acclimatization (during the
period mid-July through mid-August) from the general livestock farms (located across the region) to
the racing farms, mostly located within the Al-Shehaniya area. This involves drastic changes in feeding
systems, intense training for races, and mock races alongside camels from other farms and older
training camels. The off-season for camel racing is during summer (mid-April to August) (Figure 4).
During this time, most of the owners travel abroad, the frequency of visits to the farms substantially
decreases, and workers are permitted to take annual vacations. From September onward, training
intensifies, in preparation of the racing season, which lasts from mid-September through mid-April.
During that time, 14,000 registered camels from different origins, ages, gender, nationalities, and breeds
compete together at the Al-Shehaniya camel-racing track. During the racing season, up to 24 rounds
take place, approximately five days per week.
3.5. Changes in International Camel Movements and Travel
An unprecedented, increasingly intensified mobility of camels inside and outside Qatar has been
seen over the recent decades. The domestic and cross border mobility does not only involve camels,
but also people who look after the camels to provide care along the journey. Import and export of
camels have especially increased since the year 2000 (Figure 1C). The imported camels mainly come
from the UAE and KSA (Figure 1D).
The dynamics and travel patterns of Qatari camels are complex (Figure 4). Camels are transported
to and from different locations, for a variety of purposes, and with a noticeable seasonal pattern.
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Mobility gets more intensive during the racing and trading season (September to April). Experts
believe that the ban of open grazing in Qatar played a key role in the intensity and frequency of camel
movements. They mention that there has been a remarkable increase after 2011 in numbers of camel
workers and owners who cross the borders to and from KSA along with their animals, although this
recently stopped with the KSA-Qatar political situation. The ban of open grazing stimulated camel
owners to establish farms in KSA and UAE where open grazing is still permitted. Therefore, camels are
moved through Gulf Countries, particularly during the winter season.
Camel races and beauty contests that are routinely organized in nearly all Gulf countries are
another factor that boost the national and international movement of camels. Compared to other types
of camels, racing camels dominate in terms of numbers and frequency of mobility both across borders
and domestically, particularly between September and April. As per the records of the Camel Racing
Committee, in the 2016 racing competitions, 14,000 camels from Qatar and camels from the other GCC
countries contested [35]. However, owing to the lack of standardized identification system, it was
difficult to determine the exact figures and the extent of these movements.
Camels are also being mobilized for reproduction purposes (Figure 4). Mating season (also known
as camels’ honeymoon) starts in the middle of August and continues through February of the next year,
with the high season in the September-October period. Female camels are usually taken from their own
location to other farms where selected males are kept particularly for reproduction purposes. About
14,000 female camels are annually being moved for mating. They spend around 1 week at a breeding
farm with male camels before they are taken back to their original farms. Programmed mating is
exclusively being practiced for race and show camels. The mating season is another seasonal activity
that entails intensive movements of camels, camel owners, workers, car drivers and veterinarians.
3.6. Changes in Camel Trade
The Doha wholesale market constitutes the primary hub for camel trading. In parallel with the
increased number of camel races, Al-Shehaniya City also grew as a market and has become a hub for
trade of racing and beauty show camels in Qatar. The wholesale market in Doha hosts camels and
other types of livestock from countries all over the Gulf region. The camels typically stay at the market
until they are sold. Camel workers live at the market premises. Camels that are being sold (calves
in particular) serve a variety of purposes. They are sold to be slaughtered at the Doha wholesale
market abattoir, for breeding purposes, to be trained as racing camel, or to be prepared for camel
show competitions.
In recent years, the Doha wholesale market has been surrounded by rapidly growing residential
areas. Animals in the market are now in close proximity to the residents. As of 2005, slaughter practices
were banned inside residential premises, and can only be performed in official slaughterhouses and
exclusively by licensed persons.
3.7. Changes in Use of Camel Meat, Milk, and Urine
Camel meat and milk are no longer part of the daily diet of most Qatar inhabitants. Nonetheless,
camel meat is a fundamental ingredient of Qatari social events and family celebrations. Production
of camel meat and milk has remained stable in the past 30 years. Camel milk is generally kept for
personal use, particularly for the perceived therapeutic merits of raw camel milk, as well as camel
urine. Experts state that there is an unshakable belief that the regular consumption of camel milk helps
to prevent and control diabetes. It is also widely believed in the Qatari community that camel urine
and milk can heal skin lesions and other diseases. Camel urine is also regularly used to whiten the
skin and face and lighten the hair. The majority of camel owners offer camel milk and urine for free,
as a practice of generosity.
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4. Discussion
The role of camels in the transmission of MERS-CoV is well documented [5]. Despite the fact
that MERS antibodies have already been detected in camels since 1983 [11] and human contact with
animals is not new, human MERS cases were only detected in 2012 [41]. Based on institutional and
literature data and in-depth interviews with key professionals, this study sought to examine the
changes involving the human, animal, and environmental drivers that may have contributed to the
spread and virus spillover to humans.
Our reconstruction of events over the past decades, based on available literature, statistics,
and expert opinions, lead to the conclusion that the discovery of oil and natural gas resources has
been the starting point of a chain of events that ultimately led to conditions favoring the emergence of
MERS-CoV (Figure 5). This discovery led to massive economic growth. Owning a camel represents the
wealth and status of its owner in Arabic culture. Governmental sponsorship of camel ownership and
camel racing further stimulated the camel industry, especially the camel-racing sector. This in turn
lead to an accelerating increase of the camel population, a change in camel farming, and a concomitant
increase in the number of camel workers [34]. The human population of Qatar has increased by 7-fold
over the last decades [23]. This is unlike other high-income countries, that have a yearly overall
population growth of only 0.6% [20]. Population growth and high population density have been
shown previously to be important risk factors for disease emergence [42]. Moreover, consistent with
the disease profile of wealthy countries where sedentary lifestyle prevails, the prevalence of chronic
diseases increased in Qatar in accordance with the increasing GPD, ultimately rendering the Qatar
population not only vulnerable to virus transmission, but also to its deadly complications [43].
The intimate nature and number of interactions between camels and humans has also increased
significantly in the past 30 years, increasing the risk of any zoonotic spillover. At camel complexes,
workers intimately reside, sleep, and eat with their camels. Camel owners, on the other hand,
pay regular visits to their barns and stay there for considerable hours every day (even longer during
weekends, holidays, and winter season) in the majlis built at the corner of their barns. Owners, who are
often of advanced age with multiple comorbidities, enjoy drinking fresh camel milk and entertaining
guests. Those who suffer certain diseases tend to visit the camel barns to use camel urine or drink
fresh camel milk for its perceived curative properties.
Among the variety of changes that involved camel husbandry in Qatar, the shift from open
grazing to close housing systems seems to be most significant. Opportunities for camel-to-camel and
camel-to-human spread have greatly increased since then. It is possible that housing camels in barns,
with poor biosecurity and hygienic standards, turned these barns into ‘melting pots’ for the virus
that ultimately acquired the ability to cross the human-animal barrier. The increase of cross-border
movement of camels increased chances and frequency of (international) virus spread. Camels are
transported freely across borders for a variety of purposes through multiple routes and means of
transportation. When camels and the humans that accompany them, arrive at the site of a race or
beauty event in Qatar, they are housed with the local camels. Owners are welcomed in the majlis at
the camel complexes. The mixing of camel and human of different origins further increase chances of
virus transmission.
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Figure 5. Visual summary/timeline of relevant events.
Although much effort was made to study MERS-CoV viral sequences and MERS-CoV
transmission between dromedary camels and humans, it is still unknown which genetic mechanisms
have caused the viral spillover of dromedary camels to humans. However, the most important
determinant of host specificity seems to be the Spike S1 protein, that recognizes and binds to host-cell
receptor DPP4 [44]. Recently it has been shown that the MERS-CoV spike can rapidly adapt to species
variation in DPP4 [45]. As such, the increasing human-animal interface that is described in this paper
may have facilitated the adaptation of the spike protein to human DDP4. However, much remains
unknown, also in view of the findings that MERS-CoV from East Africa were not phenotypically
different from the viruses from the Middle East, while human MERS patients have not been reported
from the African continent [46].
Finally, the changes in animal husbandry practices, earlier weaning, frequent grouping and
transportation of animals, and the introduction of an entirely new feeding system, may induce stress
in the camels. These changes and movements often involve young weaned animals, at the same time
as maternal antibodies are waning, which are linked to the shedding of the virus [42,47]. Most of the
limitations of this study were related to the availability of data. Firstly, statistics on animals, import
and export, animal workers, and land use were only found since 2000 onwards, limiting the chance
to study the trends and changes prior to that year. Secondly, even the available national data on the
animals, humans, and environment were found to be sometimes inconsistent, limiting the possibility
18
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to provide “hard evidence” of causality. Nevertheless, this is the first comprehensive quantitative
overview of possible drivers of MERS-CoV in Qatar.
5. Conclusions
Several key changes were shown to involve camels, humans, the economy, and the environment
in Qatar during the last 30 years. Our study indicates that the rapid increase in camel ownership,
leading to the presence of camels from different origins in a high-density environment mixed together
with human and other animal species may have offered the right circumstances for the virus to spread
from camels to humans. The other key changes that were described collectively contributed to this
situation. Further understanding of the drivers that led to the emergence of MERS-CoV can serve as
input for MERS-CoV surveillance and control measures to prevent further spread of MERS-CoV and
reduce transmission from camels to humans.
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Abstract: Coronaviruses (CoVs) have formerly been regarded as relatively harmless respiratory
pathogens to humans. However, two outbreaks of severe respiratory tract infection, caused by
the severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory
syndrome coronavirus (MERS-CoV), as a result of zoonotic CoVs crossing the species barrier, caused
high pathogenicity and mortality rates in human populations. This brought CoVs global attention and
highlighted the importance of controlling infectious pathogens at international borders. In this review,
we focus on our current understanding of the epidemiology, pathogenesis, prevention, and treatment
of SARS-CoV and MERS-CoV, as well as provides details on the pivotal structure and function of
the spike proteins (S proteins) on the surface of each of these viruses. For building up more suitable
animal models, we compare the current animal models recapitulating pathogenesis and summarize
the potential role of host receptors contributing to diverse host affinity in various species. We outline
the research still needed to fully elucidate the pathogenic mechanism of these viruses, to construct
reproducible animal models, and ultimately develop countermeasures to conquer not only SARS-CoV
and MERS-CoV, but also these emerging coronaviral diseases.
Keywords: coronaviruses; SARS-CoV; MERS-CoV; spike proteins; animal model; prevention
and treatment
1. Introduction
Before the first outbreak of severe acute respiratory syndrome (SARS), a limited number of
coronaviruses were known to be circulating in humans, causing only mild illnesses, such as the
common cold [1]. Following the 2003 SARS pandemic [2,3], it became apparent that coronaviruses
could cross the species barrier and cause life-threatening infections in humans. Therefore, further
attention needs to be paid to these new coronaviruses.
The 21st century has seen the worldwide spread of two previously unrecognized coronaviruses,
the severe acute respiratory syndrome coronavirus (SARS-CoV) [4] and Middle East respiratory
syndrome coronavirus (MERS-CoV), both of which are highly pathogenic. Starting from November
2002 in China [5], there have been unprecedented nosocomial transmissions from person to
person of SARS-CoV, accompanied by high fatality rates. A united global effort led to the
rapid identification of the SARS coronavirus and remarkable scientific advancements in epidemic
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prevention. Additionally, the zoonotic transmission of SARS from December 2003 to January 2004 [6]
provided insight for researchers into the origin of this novel coronavirus. Notably, the SARS
pandemic was declared to be over in 2004 when no more infections in patients were being detected.
Subsequently, certain SARS-CoV-like viruses found in bats demonstrated the ability to infect human
cells without prior adaptation [7,8] which indicates the possibility of the re-emergence of SARS-CoV or
SARS-CoV-like viruses.
A decade later in June 2012, another highly pathogenic and novel coronavirus, MERS-CoV,
was isolated from the sputum of a male patient who died from acute pneumonia and renal failure
in Saudi Arabia [9]. Nosocomial infections were reported, and international travel led to the
transmission of MERS-CoV to countries outside of the Arabian Peninsula, causing it to become a global
pathophoresis. In May 2015, an outbreak of MERS occurred in South Korea due to an individual
returning from the Middle East [10]. Based on the lessons learned from managing SARS-CoV
prevalence over the last decade, tremendous progress toward unraveling the biological characteristics
of MERS-CoV has been achieved at an unprecedented speed. Scientific advancements have allowed for
rapid and systemic progress in our understanding of the epidemiology and pathogenesis of MERS-CoV.
SARS-CoV and MERS-CoV share several important common features that contribute to
nosocomial transmission, preferential viral replication in the lower respiratory tract, and viral
immunopathology. This review highlights the epidemiology and pathogenesis of these viruses,
including our current understanding of their biological characteristics, their transmission, and their
replication in the host. The spike proteins (S proteins) of CoVs play pivotal roles in viral infection
and pathogenesis. As critical surface-located trimeric glycoproteins of CoVs, they guide entry into
host cells. In this review, we summarize the structure and function of the S proteins and therapeutics
designed to target them. Moreover, we will explore how CoV–host interactions cause pathogenic
outcomes and discuss potential treatment options, as well as describe recent mammalian models that
closely recapitulate the pathogenic process and have contributed to the development of prevention and
treatment strategies for SARS-CoV and MERS-CoV. Although several potential therapies have been
identified with SARS and MERS in animal and in vitro models, human clinical trials remain lacking,
hindering the advancement of these potential countermeasures.
2. Epidemiology of SARS-CoV and MERS-CoV
Prior to the outbreaks of SARS and MERS [2,9], the clinical importance and epidemic possibility of
CoVs had been recognized by researchers, (Table 1). In 2002, a SARS epidemic that originated
in Guangdong Province in China resulted in 916 deaths among more than 8098 patients in
29 countries [11], identifying SARS as the first new infectious disease of the 21st century. Ten years
later, the World Health Organization (WHO) published 2254 laboratory-confirmed cases of MERS-CoV
that occurred from 2012 to 16 September 2018, with at least 800 deaths in 27 countries. Remarkably,
more than 80% of recent research into the virology and genetics of this infection indicated that bats
could be the possible natural reservoirs of both SARS and MERS-CoV. Palm civets [12] and dromedary
camels [13] are also possible intermediary hosts of SARS and MERS, respectively, before dissemination
to humans [14].
The transmission mechanism of SARS-CoV and MERS-CoV has yet to be fully understood.
For transmission from animals to humans, direct contact with the intermediary host might be one
route. Recent reports demonstrated that camel workers in Saudi Arabia with high prevalence of
MERS-CoV infection may contribute to the transmission of MERS [15]. Some customs and habits
may also be conducive to transmission, such as the consumption of milk, urine, or uncooked meat.
In this way, MERS-CoV was transmitted from dromedary camels directly to humans, principally in
the Arabian Peninsula, and this is considered to be the main route of transmission from animals to
humans, causing significant morbidity and mortality [16,17]. Human-to-human spread has also been
detected, especially through nosocomial transmission. Delays in diagnosis in hospitals might lead to
secondary cases among healthcare workers, family members, or other patients sharing rooms [18–22].
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Among the reported cases of SARS, 22% were healthcare workers in China and more than 40% were
healthcare workers in Canada [23]. Nosocomial transmission for MERS has similarly been seen in
the Middle East [16] and in the Republic of Korea [22]. Outbreaks in other countries all resulted
from the reported cases in the Middle East or North Africa, and transmission was the result of
international travel. Both SARS and MERS caused large outbreaks with significant public health and
economic consequences.
Table 1. Epidemiology and biological characteristics of the severe acute respiratory syndrome
coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV).
SARS-CoV MERS-CoV
Genus Beta-CoVs, lineage B Beta-CoVs, lineage C
Possible Natural Reservoir Bat Bat
Possible Intermediary Host Palm civet Dromedary camel




reported to WHO More than 8098 people
2254 (from 2012 through
16 September 2018)
Affected countries 29 27
Number of deaths 916 800
Mortality More than 10% More than 35%
Transmission region Globally Regionally
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3. Pathogenesis of SARS-CoV and MERS-CoV
Although our current understanding of the pathogenesis of the SARS-CoV and MERS-CoV
infection remains unclear, we summarize what is presently known (Table 2).
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Table 2. The genomic characterization of SARS-CoV and MERS-CoV.
SARS-CoV MERS-CoV
Length of nucleotides 29,727 30,119
Open reading frames (ORFs) 11 11
Structural protein 4 4
Spike protein (length of amino acids) 1255 1353
S1 subunit
Receptor-binding




Heptad repeat 1 (HR1)
domains 892–1013 984–1104
Heptad repeat 2 (HR2)
domains 1145–1195 1246–1295
Non-structural proteins (NSPs) At least 5 16
Accessory proteins 8 5
A characteristic gene order
5′-replicase ORF1ab, spike (S),
envelope (E), membrane (M), and
nucleocapsid (N)-3′
Coronaviruses are the largest kind of positive-strand RNA viruses (26–32 kb) as they are about
125 nm in diameter [24], and comprise four genera (alpha-, beta-, gamma-, and delta-coronavirus) [25].
Currently, six human CoVs (HCoVs) have been confirmed: HCoV-NL63 and HCoV-229E, which
belong to the alpha-coronavirus genus; and HCoV-OC43, HCoV-HKU1, SARS-CoV, and MERS-CoV,
which belong to the beta-coronavirus genus. SARS-CoV and MERS-CoV are the two major causes of
severe pneumonia in humans and share some common coronavirus structural characteristics. Similarly,
their genomic organization is typical of coronaviruses, having an enveloped, single, positive-stranded
RNA genome that encodes four major viral structural proteins, namely spike (S), envelope (E),
membrane (M), and nucleocapsid (N) proteins 3–5, that follow the characteristic gene order [5′-replicase
(rep gene), spike (S), envelope (E), membrane (M), nucleocapsid (N)-3′] with short untranslated regions
at both termini (Figure 1). The viral membrane contains S, E, and M proteins, and the spike protein
plays a vital functional role in viral entry. The rep gene encodes the non-structural protein and
constitutes approximately two-thirds of the genome at the 5′ end. In detail, the S protein is in charge
of receptor-binding and subsequent viral entry into host cells, and is therefore a major therapeutic
target [26,27]. The M and E proteins play important roles in viral assembly, and the N protein is
necessary for RNA synthesis.
The SARS-CoV genome has 29,727 nucleotides in length, including 11 open reading frames
(ORFs). The SARS-CoV rep gene, containing about two-thirds of the genome, encodes at least two
polyproteins (encoded by ORF1a and ORF1b) that undergo the process of cotranslational proteolysis.
Between ORF1b and S of group 2 and some group 3 coronaviruses, there is a gene that encodes
hemagglutinin-esterase [4], while this was not detected in SARS-CoV. This virus is significantly
different from previously reported coronaviruses for many reasons, such as the short anchor of the S
protein, the specific number and location of small ORFs, and the presence of only one copy of PLPpro.
The MERS-CoV genome is larger than that of SARS-CoV at 30,119 nucleotides in length, and
comprises a 5′ terminal cap structure, along with a poly (A) tail at the 3′ end, as well as the rep gene
containing 16 non-structural proteins (nsp1–16) at the 5′ end of the genome. Four structural proteins
(S, E, M, and N) and five accessory proteins (ORF3, ORF4a, ORF4b, ORF5, and ORF8) constitute
about 10 kb at the 3′ end of the genome. Unlike some other beta-coronaviruses, the MERS-CoV
genome does not encode a hemagglutinin-esterase (HE) protein [1]. Genomic analysis of MERS-CoV
25
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implies the potential for genetic recombination during a MERS-CoV outbreak [9]. MERS-CoV and
SARS-CoV possess five and eight accessory proteins, respectively, which might help the virus evade
the immune system by being harmful to the innate immune response. These differences might lead to
greater sensitivity to the effects of induction and signaling of type 1 interferons (IFNs) in MERS-CoV
than SARS-CoV.
Figure 1. Schematic representation of the genome organization and functional domains of S protein for
SARS-CoV and MERS-CoV. The single-stranded RNA genomes of SARS-CoV and MERS-CoV encode
two large genes, the ORF1a and ORF1b genes, which encode 16 non-structural proteins (nsp1–nsp16)
that are highly conserved throughout coronaviruses. The structural genes encode the structural
proteins, spike (S), envelope (E), membrane (M), and nucleocapsid (N), which are common features to
all coronaviruses. The accessory genes (shades of green) are unique to different coronaviruses in terms
of number, genomic organization, sequence, and function. The structure of each S protein is shown
beneath the genome organization. The S protein mainly contains the S1 and S2 subunits. The residue
numbers in each region represent their positions in the S protein of SARS and MERS, respectively.
The S1/S2 cleavage sites are highlighted by dotted lines. SARS-CoV, severe acute respiratory syndrome
coronavirus; MERS-CoV, Middle East respiratory syndrome coronavirus; CP, cytoplasm domain;
FP, fusion peptide; HR, heptad repeat; RBD, receptor-binding domain; RBM, receptor-binding motif;
SP, signal peptide; TM, transmembrane domain.
4. Comparative Pathology and Life Cycles of SARS-CoV and MERS-CoV
Both SARS and MERS cause severe pneumonia resulting from these novel coronaviruses, sharing
some similarities in their pathogenesis (Figure 2) [28].
SARS is an emerging infectious viral disease characterized by severe clinical manifestations of the
lower respiratory tract, resulting in diffuse alveolar damage. SARS-CoV spreads through respiratory
secretions, such as droplets, via direct person-to-person contact. Upon exposure of the host to the virus,
the virus binds to cells expressing the virus receptors, of which the angiotensin-converting enzyme
2 (ACE2) is one of the main receptors, and CD209L is an alternative receptor with a much lower
affinity [29]. In the respiratory tract, ACE2 is widely expressed on the epithelial cells of alveoli, trachea,
bronchi, bronchial serous glands [30], and alveolar monocytes and macrophages [31]. The virus enters
26
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and replicates in these target cells. The mature virions are then released from primary cells and infect
new target cells [32]. Furthermore, as a surface molecule, ACE2 is also diffusely localized on the
endothelial cells of arteries and veins, the mucosal cells of the intestines, tubular epithelial cells of
the kidneys, epithelial cells of the renal tubules, and cerebral neurons and immune cells, providing
a variety of susceptible cells to SARS-CoV [33,34]. Respiratory secretions, urine, stools, and sweat from
patients with SARS contain infective viral particles, which may be excreted into and contaminate the
environment. Atypical pneumonia with rapid respiratory deterioration and failure can be induced
by SARS-CoV infection because of increased levels of activated proinflammatory chemokines and
cytokines [35].
 
Figure 2. The life cycle of SARS-CoV and MERS-CoV in host cells. SARS-CoV and MERS-CoV
enter target cells through an endosomal pathway. The S proteins of SARS and MERS bind to
cellular receptor angiotensin-converting enzyme 2 (ACE2) and cellular receptor dipeptidyl peptidase
4 (DPP4), respectively. Following entry of the virus into the host cell, the viral RNA is unveiled in
the cytoplasm. ORF1a and ORF1ab are translated to produce pp1a and pp1ab polyproteins, which
are cleaved by the proteases that are encoded by ORF1a to yield 16 non-structural proteins that form
the RNA replicase–transcriptase complex. This complex drives the production of negative-sense
RNAs [(−) RNA] through both replication and transcription. During replication, full-length (−)
RNA copies of the genome are produced and used as templates for full-length (+) RNA genomes.
During transcription, a subset of 7–9 sub-genomic RNAs, including those encoding all structural
proteins, is produced through discontinuous transcription. Although the different sub-genomic
mRNAs may contain several open reading frames (ORFs), only the first ORF (that closest to the 5′ end)
is translated. Viral nucleocapsids are assembled from genomic RNA and N protein in the cytoplasm,
followed by budding into the lumen of the ERGIC (endoplasmic reticulum (ER)–Golgi intermediate
compartment). Virions are then released from the infected cell through exocytosis. SARS-CoV, severe
acute respiratory syndrome coronavirus; MERS-CoV, Middle East respiratory syndrome coronavirus;
S, spike; E, envelope; M, membrane; N, nucleocapsid.
For MERS-CoV infection of humans, the primary receptor is a multifunctional cell surface protein,
dipeptidyl peptidase 4 (DPP4, also known as CD26) [36], which is widely expressed on epithelial cells
in the kidney, alveoli, small intestine, liver, and prostate, and on activated leukocytes [37]. Consistent
with this, MERS-CoV can infect several human cell lines, including lower respiratory, kidney, intestinal,
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and liver cells, as well as histiocytes, as shown by a cell-line susceptibility study [38], indicating that the
range of MERS-CoV tissue tropism in vitro was broader than that of any other CoV. MERS-CoV causes
acute, highly lethal pneumonia and renal dysfunction with various clinical symptoms, including—but
not restricted to—fever, cough, sore throat, myalgia, chest pain, diarrhea, vomiting, and abdominal
pain [39,40]. Lung infection in the MERS animal model demonstrated infiltration of neutrophils
and macrophages and alveolar edema [41]. The entry receptor (DPP4) for MERS-CoV is also highly
expressed in the kidney, causing renal dysfunctions by either hypoxic damage or direct infection of the
epithelia [42]. Remarkably, unlike SARS-CoV, MERS-CoV has the ability to infect human dendritic
cells [43] and macrophages [44] in vitro, thus helping the virus to disrupt the immune system. T cells
are another target for MERS-CoV because of their high amounts of CD26 [45]. This virus might
deregulate antiviral T-cell responses due to the stimulation of T-cell apoptosis [45,46]. MERS-CoV
might also lead to immune dysregulation [47] by stimulating attenuated innate immune responses,
with delayed proinflammatory cytokine induction in vitro and in vivo [44,48,49].
5. SARS and MERS-CoV Spike Protein: A Key Target for Antivirals
5.1. Structure of the SARS-CoV and MERS-CoV Spike Protein
Trimers of the S protein make up the spikes of SARS-CoV and provide the formation of
a 1255-amino-acids-length surface glycoprotein precursor. Most of the protein and the amino terminus
are situated on the outside of the virus particle or the cell surface [50]. The expected structure of the
S protein comprises four parts: a signal peptide located at the N terminus from amino acids 1 to 12,
an extracellular domain from amino acids 13 to 1195, a transmembrane domain from amino acids 1196
to 1215, and an intracellular domain from amino acids 1216 to 1255. Proteases such as factor Xa, trypsin,
and cathepsin L cleave the SARS-CoV S protein into two subunits, the S1 and S2 subunits. A minimal
receptor-binding domain (RBD) located in the S1 subunit (amino acids 318–510) can combine with the
host cell receptor, ACE2. The RBD displays a concave surface during interaction with the receptor.
The entire receptor-binding loop, known as the receptor-binding motif (RBM) (amino acids 424–494),
is located on the RBD and is responsible for complete contact with ACE2. Importantly, two residues
in the RBM at positions 479 and 487 determine the progression of the SARS disease and the tropism
of SARS-CoV [51,52]. Recent studies using civets, mice, and rats demonstrated that any change in
these two residues might improve animal-to-human or human-to-human transmission and facilitate
efficient cross-species infection [53]. The S2 subunit mediates the fusion between SARS-CoV and target
cells, and includes the heptad repeat 1 (HR1) and HR2 domains, whose HR1 region is longer than the
HR2 region.
Similar to SARS-CoV, during the infection process, the S protein of MERS-CoV is cleaved into
a receptor-binding subunit S1 and a membrane-fusion subunit S2 [54–57]. The MERS-CoV S1 subunit
also includes an RBD, mediating the attachment between virus and target cells [54,55,58,59]. Unlike
SARS-CoV, MERS-CoV requires DPP4 (also known as CD26) as its cellular receptor [60,61] but not
ACE2. The RBDs of MERS-CoV and SARS-CoV differ, although they share a high degree of structural
similarity in their core subdomains, explaining the different critical receptors noted above [57,62].
The core subdomain of RBD is stabilized by three disulfide bonds, and includes a five-stranded
antiparallel β-sheet and several connecting helices. The RBM comprises a four-stranded antiparallel
β-sheet for connecting to the core via loops [57,62]. Two N-linked glycans, N410 and N487, are seated
in the core and RBM, respectively. Particularly, the residues 484–567 of RBM take charge of interacting
with the extracellular β-propeller domain of DPP4. The fusion core formation of MERS-CoV resembles
that of SARS-CoV; however, it is different from that of other coronaviruses, such as the mouse hepatitis
virus (MHV) and HCoV-NL63 [63–66].
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5.2. Functions of the SARS-CoV and MERS-CoV S Protein
The SARS-CoV S protein plays pivotal roles in viral infection and pathogenesis [67,68]. The S1
subunit recognizes and binds to host receptors, and the subsequent conformational changes in
the S2 subunit mediate fusion between the viral envelope and the host cell membrane [69,70].
The RBD in the S1 subunit is responsible for virus binding to host cell receptors [61,70,71]. ACE2 is
a functional receptor for SARS-CoV that makes contact with 14 amino acids in the RBD of SARS-CoV
among its 18 residues [53]. The RBD in the S1 subunit is responsible for virus binding to host cell
receptors [61,70,71]. Position R453 in the RBD and position K341 in ACE2 play indispensable roles
in complex formation [72]. Furthermore, the N479 and T487 in the RBD of the S protein are pivotal
positions for the affinity with ACE2 [52], and R441 or D454 in the RBD influences the antigenic structure
and binding activity between RBD and ACE2 [73]. From a pre-fusion structure to a post-fusion
structure, binding of the RBD in the S1 subunit to the receptor ACE2 stimulates a conformational
change in S2. Accordingly, the supposed fusion peptide (amino acids 770–788) [74] builds in the
target cell membrane of the host. Meanwhile, a six-helix bundle fusion core structure is made
up by the HR1 and HR2 domains for bringing the viral envelope and the target cell membrane
into close proximity and contributing to fusion [74]. Resembling the S2 subunit of SARS-CoV,
the MERS-CoV S2 subunit is in charge of membrane fusion. The HR1 and HR2 regions in S2
play essential and complementary roles [56,63]. Furthermore, SARS-CoV displays an alternative
method of binding to the host cell via other potential receptors. Dendritic cell-specific intercellular
adhesion molecule-3-grabbing non-integrin (DC-SIGN) and/or liver/lymph node-SIGN (L-SIGN)
are two examples of such receptors [29,75]. Seven residue sites, at positions 109, 118, 119, 158, 227,
589, and 699 of the S protein displaying asparagine-linked glycosylation are crucial for DC-SIGN or
L-SIGN-mediated virus entry. These residues, unlike those of the ACE2-binding domain, function
independently of ACE2 [76].
5.3. Vaccines Based on the SARS-CoV and MERS-CoV S Protein
In order to control the outbreak of viruses, vaccinations were developed against SARS-CoV
and MERS-CoV. There are various approaches of different vaccines, and the development and
advantages/disadvantages of these are listed in Table 3 (this table includes updates about SARS-CoV
and MERS-CoV since 2013; SARS-CoV-related parts were modified by Graham et al. in Nature Reviews
Microbiology, 2013 [77]).
Importantly, among all the functional/non-functional structural proteins of SARS-CoV and
MERS-CoV, the S protein is the principal antigenic component that induces antibodies to block
virus-binding, stimulate host immune responses, fuse or neutralize antibodies and/or protect the
immune system against virus infection. Therefore, the S protein has been selected as a significant
target for the development of vaccines. It has been noted that antibodies raised against subunit S1
(amino acids 485–625) or S2 (amino acids 1029–1192) neutralize infection by SARS-CoV strains in
Vero E6 cells [78,79]. Researchers have constructed an attenuated parainfluenza virus encoding the
full-length S protein of the SARS-CoV Urbani strain for the vaccination of African green monkeys.
This vaccine could protect monkeys from subsequent homologous SARS-CoV infection, demonstrating
highly effective immunization with the S protein [80]. Other studies in a mouse model structured
a DNA vaccine encoding the full-length S protein of the SARS-CoV Urbani strain that not only induced
T-cell and neutralizing-antibody responses, but also stimulated protective immunity [81]. Furthermore,
monkeys or mice were vaccinated with a highly attenuated, modified vaccine virus, Ankara, encoding
the full-length S protein of the SARS-CoV strain HKU39849 or Urbani [82]. However, full-length S
protein-based SARS vaccines may induce harmful immune responses, causing liver damage in the
vaccinated animals or enhancing infection after being challenged with homologous SARS-CoV [83,84].
Researchers are thus concerned about the safety and ultimate protective efficacy of vaccines that
include the full-length SARS-CoV S protein.
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There are still no commercial vaccines available against MERS-CoV [26]. Multiple vaccine
candidates targeting the S protein, which is responsible for viral entry, have been developed, including
subunit vaccines [85,86], recombinant vector vaccines [87,88], and DNA vaccines [89,90]. Importantly,
compared with other regions of the S protein, the RBD fragment induced the highest-titer IgG
antibodies in mice [85]. Modified vaccines, including recombinant vectors of Ankara and adenoviruses
expressing the MERS-CoV S glycoprotein, showed immunogenicity in mice [25]. Attenuated
live vaccines also showed a protective function, but there were concerns regarding the degree of
attenuation [91]. After intranasal vaccination with the CoV N protein, airway memory CD4 T cells
were generated and mediated the protection following a CoV challenge [92]. These cells could induce
anti-viral innate responses at an early stage of infection, and facilitated CD8 T-cell responses by
stimulating recombinant dendritic cell migration and CD8 T-cell mobilization [92]. The stimulation of
airway memory CD4 T cells should be regarded as an essential part of any HCoV vaccine strategy,
because these CD4 T cells target a conserved epitope within the N protein that cross-reacts with
several other CoVs [92]. Furthermore, DNA vaccines expressing the MERS-CoV S1 gene produced
antigen-specific humoral and cellular immune responses in mice [89].
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5.4. S Protein-Based Therapeutics for SARS-CoV and MERS-CoV
Despite the presence of extensive research reporting on SARS-CoV and MERS-CoV therapies,
it was not possible to establish whether treatments benefited patients during their outbreak.
In the absence of fundamental, clinically proven, effective antiviral therapy against SARS-CoV and
MERS-CoV, patients mainly receive supportive care supplemented by diverse combinations of drugs.
Several approaches are being considered to treat infections of SARS-CoV [113] and MERS-CoV (Table 4,
MERS-CoV-related table previously reviewed by de Wit et al. in Nature Reviews Microbiology,
2016 [10]), including the use of antibodies, IFNs, and inhibitors of viral and host proteases.
The vital role of the S protein of SARS-CoV makes this protein an important therapeutic
target, and numerous studies have explored potential therapeutics. Firstly, peptides that block
RBD–ACE2-binding derived from both RBD [114] and ACE2 [76] could be developed as novel
therapeutics against SARS-CoV infection. Secondly, peptides binding to the S protein interfere with
the cleavage of S1 and S2. This step inhibits the production of functional S1 and S2 subunits and the
consequent fusion of the viral envelope with the host cell membrane. Thirdly, anti-SARS-CoV peptides
blocking the HR1–HR2 interaction by forming a fusion-active core have viral fusion inhibitory activity
at the micromolar level [115–117]. However, the potential selection of escape mutants with altered host
range phenotypes is one of the disadvantages of this strategy that needs further modification [118].
Furthermore, mouse monoclonal antibodies (mAbs) targeting assorted fragments of the SARS-CoV S
protein have effectively inhibited SARS-CoV infection [79,119–122]. A series of neutralizing human
mAbs were generated from the B cells of patients infected with SARS-CoV [123,124]. Another
strategy used human immunoglobulin transgenic mice immunized with full-length SARS-CoV
S proteins [125–127]. 80R and CR3014 binding to the ACE2 receptor are examples of S-specific
mAbs [128,129].
Similarly, the therapeutic agents that have been developed against MERS-CoV are based on the S
protein and basically restrain the binding of receptors or the fusion of membrane proteins, thereby
leading to the inhibition of MERS-CoV infection. These methods mainly involve peptidic fusion
inhibitors [56,63,116,130], anti-MERS-CoV neutralizing mAbs [86,131], anti-DPP4 mAbs [86,132,133],
DPP4 antagonists [134], and protease inhibitors [135–137]. However, none of these anti-MERS-CoV
curative agents are approved for commercial use in humans.
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6. The Animal Models of SARS and MERS-CoV
International coordination and cooperation led to the rapid identification of SARS-CoV and
MERS-CoV. Emergency control measures and laboratory detection systems which were put in place
in response to SARS-CoV and MERS-CoV outbreaks were both exemplary. To establish optimal
prevention and control strategies for SARS and MERS, numerous efforts to develop animal models
were undertaken in several laboratories, despite the fact that some conflicting results have been
reported. It is therefore necessary to compare and document the features and disadvantages of
different animal models to better understand viral replication, transmission, pathogenesis, prevention,
and treatment. Notably, several animal species were suggested as suitable disease models of SARS-CoV,
but most laboratory animals are refractory or only semi-permissive to MERS-CoV infection.
6.1. Animal Models of SARS-CoV
SARS-CoV replication has been studied in mice, Syrian golden and Chinese hamsters, civet
cats, and non-human primates. The most severe symptoms of SARS were observed in aged animals.
To develop epidemiological symptoms that advanced age resulted in increased mortality, aged mouse
model of SARS-CoV has been generated. Transgenic mice expressing human ACE2 were also
developed to closely mimic SARS-CoV infection in humans. Some animal models have been tested
and analyzed on the genomic and proteomics level to study the pathogenesis of SARS.
6.1.1. Mouse Models
Mouse species that have been used as SARS-CoV-infected animal models include
BALB/c [149,150], C57BL6 (B6) [151], and 129SvEv-lineage mice. The most relevant transgenic
and knockout lines are accessible based on these susceptible animals [152]. Signal transducers
and activators of transcription 1 (STAT1)-knockout and myeloid differentiation primary response
88 (MYD88)-knockout mice [149,151,153,154] are examples of mouse models with innate immune
deficiency, and such animals display severe effects of the disease, such as pneumonitis, bronchiolitis,
and weight loss, and often die within 9 days of infection. Notably, young mice require more mutations
and passages than aged mice to produce SARS-CoV mouse-adapted strains. More severe pathological
lesions and increased mortality were observed in one-year-old animals, along with fewer mutations
at miscellaneous locations throughout the genome [98,155–159]. Intranasal inoculation of four- to
eight-week-old BALB/c or B6 mice with SARS-CoV resulted in nasal turbinate in the upper respiratory
tract and a high titer of virus replication in the lungs of the lower respiratory tract, and this model
was highly reproducible without any signs of morbidity or mortality [149,151]. Neutralizing antibody
responses could be generated in sub-lethally infected mice protecting recipients from subsequent
lethal challenges, which probably reflected the situation in infected humans during an epidemic [160].
However, on day 2–3 post-infection (pi), virus replication in the respiratory tract peaked but was
not accompanied by massive pulmonary inflammation or pneumonitis. By day 5–7 pi, the virus had
been eliminated from the lungs [149,151]. It was obvious that viremia is common and long-lasting in
patients, while it is rare and transient in mouse models [161]. Mice could therefore be used as a stable
and reproducible animal model for the evaluation of vaccines, immune-prophylaxis, and antiviral
drugs against SARS-CoV [81,96,109,124,149,162–166].
6.1.2. Hamster Model
Golden Syrian and Chinese hamsters have also been evaluated and shown to be excellent models
of SARS-CoV infection, owing to their high titer of virus replication in the respiratory tract, associated
with diffuse alveolar damage, interstitial pneumonitis, and pulmonary consolidation [104,167–169].
On day 2 pi, peak levels of viral replication were detected in the lower respiratory tract, and the
virus was cleared without obvious clinical illness 7–10 days after infection. Similarly to mice,
infected hamsters also produced a protective neutralizing-antibody response to subsequent SARS-CoV
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challenges [104,170]. Resulting from the extremely high titers and reproducible pulmonary
pathological lesions in SARS-CoV-infected hamsters, this animal model is ideal for studies on the
immunoprophylaxis and treatment of SARS [104,170]. However, there are still limited resources in
terms of genetically established animal lines and accurate immunological and cellular biomarkers for
hamster models.
6.1.3. Ferret Model
Ferrets were found to be susceptible to SARS-CoV infection [171] but could also transmit the
virus at low levels by direct contact [84,172–174]. They showed diverse clinical symptoms in different
studies [171,174]. Importantly, ferrets could develop fever, which is a characteristic clinical symptom
of SARS-CoV-infected patients [93,175]. Similar to rodent models, infection of ferrets with SARS-CoV
did not result in significant mortality. However, there are still some conflicting reports regarding
the histopathological lesions and severity of clinical observations in the ferret model that require
further investigation.
6.1.4. Non-Human Primate Models
Several species of non-human primates (NHP) were evaluated as animal models for SARS.
At least six NHP species were tested including three Old World monkeys: rhesus macaques [176–180],
cynomolgus macaques [177,181,182], and African green monkeys [177]; and three New World monkeys:
the common marmoset [183], squirrel monkeys, and mustached tamarins [176–178,181–184]. Except
for squirrel monkeys and mustached tamarins [185], all of the evaluated NHP species facilitated
the replication of SARS-CoV [186]. Virus replication was detected in the respiratory tract of rhesus
macaques, cynomolgus macaques, and African green monkeys. Pneumonitis was observed in each of
these species in different studies [176–178,182]. SARS-infected common marmosets displayed a fever,
watery diarrhea, pneumonitis, and hepatitis [183]. Unfortunately, research into the clinical signs of
disease in cynomolgus and rhesus macaques gave conflicting results and therefore needs further
investigation. The main reason for the lack of reproducibility in such studies may be the limited
sample size.
6.2. Animal Models of MERS-CoV
Small animal models of MERS infection are urgently needed to elucidate MERS pathogenesis and
explore potential vaccines and antiviral drugs. Previous studies have demonstrated the difficulties in
developing such a model, such as that mice [187,188], ferrets [134], guinea pigs [189], and hamsters [189]
are not susceptible to experimental MERS-CoV infection mainly because their homologous DPP4
molecules do not function as receptors for MERS-CoV entry. After administering a high dose of
MERS-CoV, no viral replication could be detected in these animals [190]. In an animal model using
New Zealand white rabbits, regardless of the fact that detectable viral RNA existed in the respiratory
tract and moderate necrosis was observed in nasal turbinates, the animals showed no clinical symptoms
of disease [191]. In another study, attempts to infect hamsters with MERS-CoV were not successful [192].
However, despite this, MERS-CoV is a broad host-range virus in vitro [25], and there is hope that
a reproducible and stable animal model for human MERS-CoV infection can be improved in the
near future.
6.2.1. Mouse Model for MERS Infection
Despite the fact that wild-type rodents are not susceptible to MERS-CoV infection [188],
researchers have developed several models in which mice are susceptible to MERS-CoV
infection [193–195]. The first mouse model of MERS infection reported in 2014 involved transducing
animals with recombinant adenovirus 5 encoding human DPP4 (hDPP4) molecules intranasally,
and this resulted in replication of MERS-CoV in the lungs. This mouse model also showed
clinical symptoms of interstitial pneumonia, including inflammatory cell infiltration, and thickened
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alveolar and mild edema [195]. However, there are certain limitations to this model, such as the
uncontrolled expression and distribution of hDPP4. In 2015, the establishment of hDPP4 transgenic
mice was reported [194]. MERS-CoV could infect this mouse model effectively. However, similarly
to SARS-CoV-infected ACE2 transgenic mice [196], systemic expressions led to multiple organ
lesions [194], resulting in the death of the animals. Most recently, the homologous hDPP4 gene
was used in several MERS transgenic mouse models [193,197]. Remarkably, hDPP4 knockin (KI) mice,
where mouse DPP4 gene fragments had been displaced by homologous human DPP4 fragments,
showed effective receptor binding. Furthermore, a mouse-adapted MERS-CoV strain (MERSMA)
including 13–22 mutations was produced in the lungs of hDPP4-KI mice after 30 serial passages,
causing effective weight loss and mortality in this mouse model [193]. Both this hDPP4-KI mouse
and the MERSMA strain provide better tools to explore the pathogenesis of MERS and potential
novel treatments.
6.2.2. Camelidae
As a reservoir of MERS-CoV, dromedary camels showed mild upper respiratory infections after
the administration of MERS-CoV [198]. Oronasal infection of MERS-CoV in alpacas, a close relative
within the Camelidae family, resulted in an asymptomatic infection with no signs of upper or lower
respiratory tract disease [199,200]. Additionally, owing to their high cost and relatively large size,
these animal models are not available for high-throughput studies of MERS.
6.2.3. Non-Human Primates
NHPs, such as the rhesus macaques [201] and common marmosets [202], are useful models
for studying the pathogenesis of mild MERS-CoV infection and evaluating novel therapies for
humans, although the degree of replication and disease severity vary [192,201,203,204]. MERS-CoV
caused transient lower respiratory tract infection in rhesus macaques, with associated pneumonia.
Clinical signs were observed by day 1 pi and resolved as early as day 4 pi [201]. Relatively mild
clinical symptoms were observed early on in infection without fatalities, indicating that rhesus
macaques do not recapitulate the severe infections observed in human cases; however, treatment of
MERS-CoV-infected rhesus macaques with IFN-α and ribavirin decreased virus replication, alleviated
the host response, and improved the clinical outcome [205]. Infection of MERS-CoV in common
marmosets demonstrated various extents of damage depending on the study, but successfully
reproduced several features of MERS-CoV infection in humans. Importantly, one study indicated
that the infection became progressive severe pneumonia [203], while other groups found that
MERS-CoV-infected common marmosets only developed mild to moderate nonlethal respiratory
diseases by intratracheal administration [206].
7. Role of Host Receptors in Animal Models of SARS-CoV and MERS-CoV
The reasons for host restriction, none or limited clinical symptoms observed in varies animal
models are complexity. The interaction between the host receptor and functional proteins of SARS
and MERS, respectively, plays an important and predominant role. In the context of animal models of
SARS-CoV infection, researchers have compared the ACE2 amino acids that interact with the S protein
RBD from several species. In agreement with the permissive nature of these species, the ACE2 residues
of marmoset and hamster are similar to those of hACE2 [53]. By comparison, many residues of mouse
ACE2 are different from those of hACE2, and this meets with decreased replication of SARS-CoV
in mouse cells [207] and the lungs of young mice [149]. The changes at positions 353 (histidine)
and 82 (asparagine) of rat ACE2 relative to hACE2 partially disrupt the S protein-DPP4 interaction
and contribute to abrogation of binding. Interestingly, ferrets are permissive to SARS-CoV infection,
but most of their ACE2 interaction residues are different from those of hACE2 [53], while many of
the ACE2 residues between civet and ferret are the same, which may result in similar affinity [208].
For MERS-CoV, 14 residues of the S protein RBD have direct contact with 15 residues of hDPP4 [57].
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Comparisons of human DPP4 binding affinity to that of other species indicated that human DPP4
had the highest affinity to the S protein of MERS-CoV, where the decreasing order of affinity is as
follows: human > horses > camels > goats > bats [209]. Further evidence demonstrates that the host
restriction of MERS-CoV remarkably depends on the sequence of DPP4, such as the characterization of
amino acid residues at the connector of DPP4 with the RBD of S proteins in mice [187,210], hamsters,
and cotton rats [210]. However, the multiplicity in severity of disease between rhesus macaques and
common marmosets indicate that other host factors can perhaps affect the infection and replication
of the virus, such as the presence of S-cleaving proteases [187]. In general, although the structural
analysis of receptors-S protein interactions cannot fully explain all the observations for host restriction,
they agree with the improved replication in several animal models and that it should be the premier
and remarkable focus of small-animal model development. These special residues for host affinity are
important to build up transgenic animal models enhancing the permissiveness and infection of SARS
and MERS.
8. Outlook and Summary
Unlike SARS-CoV, which resolved without more reported cases, continued outbreaks of
MERS-CoV present an ongoing threat to public health. It should be noted that no specific treatment is
currently available for HCoVs, and further research into the pathogenesis of HCoV infection is therefore
imperative to identify appropriate therapeutic targets. Accordingly, at present, the prevention of viral
transmission is of utmost importance to limit the spread of MERS. The enormous ratio of nosocomial
infections indicates that preventive measures in hospitals have not been sufficiently implemented.
Additionally, as an emerging zoonotic virus, prevention of transmission from dromedary camels is
another possibility to reduce the quantity of MERS cases. Regarding clinical therapies, a combination
of treatment administered as early as possible and aimed at synchronously disrupting viral replication,
inhibiting viral dissemination, and restraining the host response is likely to be most suitable, due to the
acute clinical features of MERS with diffuse lung damage and the important role of immunopathology.
Potential treatments must undergo in vitro and in vivo studies to select the most promising
options. The development of stable and reproducible animal models of MERS, especially in NHPs, is
therefore a decisive step forward. The next step in the development of standardized and controllable
therapies against SARS and MERS will be clinical trials in humans, validating a standard protocol for
dosage and timing, and accruing data in real time during future outbreaks to monitor specific adverse
effects and help inform treatment.
The comprehensive lessons and experiences that have resulted from the outbreaks of SARS and
MERS provide valuable insight and advancements in how to react to future emerging and re-emerging
infectious agents. Rapid identification of the pathogen via effective diagnostic assays is the first step,
followed by the implementation of preventive measures, including raising awareness of the new agent,
reporting and recording (suspected) cases, and infection control management in medical facilities.
Studies are currently needed that focus on the epidemiology of these organisms, especially in terms
of pathogen transmission and potential reservoirs and/or intermediate hosts. Animal models and
prophylactic and therapeutic approaches should be promoted, followed by fast-tracked clinical trials.
Our increasing understanding of novel emerging coronaviruses will be accompanied by increasing
opportunities for the reasonable design of therapeutics. Importantly, understanding this basic
information will not only aid our public health preparedness against SARS-CoV and MERS-CoV,
but also help prepare for novel coronaviruses that may emerge.
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Abstract: Middle East respiratory syndrome coronavirus (MERS-CoV) is a zoonotic pathogen
that causes respiratory infection in humans, ranging from asymptomatic to severe pneumonia.
In dromedary camels, the virus only causes a mild infection but it spreads efficiently between
animals. Differences in the behavior of the virus observed between individuals, as well as between
humans and dromedary camels, highlight the role of host factors in MERS-CoV pathogenesis and
transmission. One of these host factors, the MERS-CoV receptor dipeptidyl peptidase-4 (DPP4),
may be a critical determinant because it is variably expressed in MERS-CoV-susceptible species as
well as in humans. This could partially explain inter- and intraspecies differences in the tropism,
pathogenesis, and transmissibility of MERS-CoV. In this review, we explore the role of DPP4 and
other host factors in MERS-CoV transmission and pathogenesis—such as sialic acids, host proteases,
and interferons. Further characterization of these host determinants may potentially offer novel
insights to develop intervention strategies to tackle ongoing outbreaks.
Keywords: MERS-CoV; transmission; pathogenesis; host factors; DPP4
1. Introduction
Middle East respiratory syndrome coronavirus (MERS-CoV) is a novel pathogen that was isolated
in late 2012 [1]. Since then, the virus has caused multiple outbreaks and infected more than 2000
individuals, [2] who then develop a respiratory infection ranging in severity from asymptomatic to
fatal [3,4]. Severe-to-fatal MERS-CoV patients have a higher chance of transmitting this virus since
they shed a higher amount of virus progeny in comparison to the asymptomatic-to-mild ones [5–8].
Identifying and quarantining these patients in healthcare facilities where outbreaks have occurred,
together with implementing proper infection control, has been effective in reducing transmission and
containing these outbreaks [9,10]. However, new MERS-CoV cases are still being reported, especially
in the Arabian Peninsula [2,11]. This is partly due to the continuous zoonotic introduction of this virus
to the human population in this region by dromedaries [12]. The dromedary camel is the only animal
species that has been reported to transmit this virus to humans [13–16]. MERS-CoV infection in these
animals merely causes mild upper respiratory tract infection [17,18], but seroepidemiological studies
showed that this virus has been circulating in dromedary camels for decades, suggesting the efficient
transmission of MERS-CoV in this species [19–22].
Although the clinical manifestations, as well as transmission, are remarkably different in
MERS-CoV-infected humans and dromedary camels, the viruses isolated from these two species
are highly similar, if not indistinguishable [12,16]. This indicates that host factors play a significant
role in MERS-CoV pathogenesis and transmission. However, the identity of these host factors and
how they affect the pathogenesis and transmission of MERS-CoV are generally not well understood.
Dipeptidyl peptidase-4 (DPP4)—the MERS-CoV receptor, sialic acids, proteases, and interferons are
Viruses 2019, 11, 280; doi:10.3390/v11030280 www.mdpi.com/journal/viruses50
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all examples of potentially critical host factors that have been shown to affect MERS-CoV infection
in vitro [23–26]. This review highlights the role of some MERS-CoV-interacting host factors—especially
DPP4—in MERS-CoV pathogenesis and transmission.
2. MERS-CoV-Interacting Host Factors
MERS-CoV infection of a target cell is initiated by the virus attachment to the cell surface [23,27].
MERS-CoV uses the N-terminal part of its spike (S)—the so called S1 protein (Figure 1A)—to
bind to two host cell surface molecules, dipeptidyl peptidase-4 (DPP4) and α2,3-sialic acids [23,24].
DPP4 is the functional receptor of MERS-CoV; its absence renders cells resistant to this virus,
while its transient expression in non-susceptible cells permits viral replication [23]. DPP4 is a serine
exopeptidase, which is either expressed at the cell surface or shed in a soluble form. It has the capacity
to cleave-off dipeptides from polypeptides with either L-proline or L-alanine at the penultimate
position. Accordingly, DPP4 is capable of cutting various substrates, such as hormones, cytokines,
chemokines, and neuropeptides, allowing it to be involved in multiple physiological functions
as well as pathophysiological conditions [28]. This enzymatic activity is mediated by the α/β
hydrolase domain of DPP4, while MERS-CoV infection is mediated by the binding of S1 protein
to the β-propeller domain of this exopeptidase (Figure 1B) [28–31]. There are 11 critical residues within
the β-propeller domain that directly interact with the S1 protein [29–31]. These residues are quite
conserved in camelids, primates, and rabbits—species shown to be susceptible to MERS-CoV [17,31–33].
In contrast, ferrets, rats, and mice resist MERS-CoV infection due to differences in some critical DPP4
residues [31,34–36]. These data illustrate that DPP4 has the capacity to determine the host range
of MERS-CoV.
Figure 1. Schematic figure depicting four structural proteins of Middle East respiratory syndrome
coronavirus (MERS-CoV), i.e., S, E, M, and N proteins (A); a cartoon representation of MERS-CoV
S1 protein binding to DPP4 (PDB code 4L72) (B). The S protein consists of the S1 and S2 subunits.
The α/β hydrolase domain of DPP4 is indicated in red, β-propeller domain in green, while part of the
MERS-CoV S1 protein is shown in blue.
Other MERS-CoV-interacting host factors besides DPP4 are less extensively studied and have
mostly been investigated in vitro. Glycotopes of α2,3-sialic acids coupled with 5-N-acetylated
neuraminic acid are recognized by the S1 protein of MERS-CoV during attachment [24]. In the
absence of these glycotopes, MERS-CoV entry is reduced but not abolished, indicating their function as
an attachment factor rather than a receptor [24]. Besides α2,3-sialic acids, CEACAM5 and GRP78 have
also been suggested to be attachment factors for MERS-CoV, but their roles in vivo during MERS-CoV
infection are not clear at this moment [37,38]. Post attachment, MERS-CoV uses the C-terminal part
of its S protein—known as S2 (Figure 1A)—to interact with host proteases, such as furin, TMPRSS2,
and cathepsins [39–42]. These proteases cleave the S protein and induce conformational changes,
allowing fusion between viral and host cellular membranes, resulting in the release of viral RNA
into the cell cytoplasm [27]. TMPRSS2 and DPP4 are held in one complex at the cell surface by
a scaffolding protein, the tetraspanin CD9, leading to a rapid and efficient entry of MERS-CoV into the
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susceptible cells [43]. Once fusion with host cell membranes has occurred, MERS-CoV subsequently
replicates its genetic material and produces viral proteins in the cell cytoplasm to generate new virus
progeny. During this stage, MERS-CoV uses its nsp3–4 polyproteins to build its replication organelles
as well as its accessory proteins such as the 4a and 4b proteins to inhibit host anti-viral defense
mechanisms [44–54]. However, the capacity of MERS-CoV accessory proteins to impede several
pathways of host immune response in the lungs may be limited. MERS-CoV inoculation of macaques
and genetically modified mice generally results in limited clinical manifestations; thus, adapting this
virus through serial passaging or defecting the type I interferon pathway may be needed to enhance
viral replication and pathogenesis in these animals [32,55–58]. These observations, together with
studies showing type I interferon capacity to inhibit MERS-CoV infection in vitro [25,59], highlight
the importance of the innate immune response, especially type I interferon, as an inhibiting factor
for MERS-CoV.
3. Host Factors in MERS-CoV Transmission
So far MERS-CoV has been isolated from dromedary camels and humans [1,60]. Both species are
not only susceptible to MERS-CoV infection, but also capable of transmitting this virus [7,12–18,22].
However, current data indicate that virus spread is more efficient in dromedary camels than in
humans [5,7,19–21,61]. This difference in transmissibility could be partially due to the different tropism
of MERS-CoV in these two species. In dromedaries, MERS-CoV has been shown to replicate in the nasal
epithelium upon experimental in vivo infection [17], while in humans, MERS-CoV mainly replicates
in the lower respiratory tract, particularly in the bronchiolar and alveolar epithelia [23,62–65]. Higher
viral RNA levels in the sputum and lavage samples of MERS-CoV patients compared to nasal and throat
swabs are consistent with the tropism of MERS-CoV in humans [66–68]. This different MERS-CoV
tropism in dromedary camels and humans is in line with the localization of DPP4 in the respiratory
tract tissues of these two species. In humans, DPP4 is absent in the nasal epithelium but present in
the lower respiratory tract epithelium, mainly in type II pneumocytes [69,70]. In contrast, DPP4 is
expressed in the nasal epithelium of dromedary camels [69]. This difference in DPP4 localization
between humans and dromedary camels therefore explains MERS-CoV tropism in these two species
and highlights DPP4 as an essential determinant of MERS-CoV tropism.
DPP4 localization has also been investigated in many other MERS-CoV-susceptible species.
In Gambian and Egyptian fruit bats, DPP4 is expressed in the respiratory tract and intestinal epithelium,
suggesting that MERS-CoV can target both tissues [71]. In line with this finding, MERS-CoV inoculation
via intranasal and intraperitoneal routes in the Jamaican fruit bat led to viral RNA shedding both in
the respiratory tract and the intestinal tract [72]. In contrast to frugivorous bats, DPP4 is limitedly
expressed in the respiratory tract epithelium of two insectivorous bats, i.e., common pipistrelle and
common serotine bats, but abundant in their intestinal epithelium [71]. Accordingly, sequences
of MERS-like-CoVs were mainly obtained from rectal swabs and fecal samples of insectivorous
bats [73–80]. These findings not only support insectivorous bats as the origin host of MERS-CoV [73–80],
but also indicate the importance of intestinal tropism and fecal–oral transmission of MERS-like-CoV in
these insectivorous bats.
Besides bats, humans, and dromedary camels, other animal species have also been proposed
as potential hosts of MERS-CoV. Remarkably, DPP4 of horses, llamas, alpacas, pigs, bovines, goats,
sheep, and rabbits has been demonstrated to recognize the S protein of MERS-CoV [81,82]. In most
of these species, there is a preferential upper respiratory tract expression of DPP4 observed. Rabbits
express DPP4 in the upper and lower respiratory tract epithelium, and thus may allow MERS-CoV to
replicate in both compartments [33,83]. Horses, llamas, and pigs mainly express DPP4 in the upper
respiratory tract—particularly the nasal epithelium [84]. Upon intranasal MERS-CoV inoculation,
llamas, alpacas, and pigs developed upper respiratory tract infection, while horses did not seroconvert
and only shed infectious virus in a limited amount [84–88]. The reason why horses seem to be
less permissive to MERS-CoV remains to be investigated, but a chronic co-infection in the guttural
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pouch, a common disease among horses, might be one of the explanations. This guttural pouch
infection results in excessive mucus production that might hinder MERS-CoV from attaching and
entering the nasal epithelium [84,89,90]. Sheep, on the other hand, did not seem to express significant
levels of DPP4 in their respiratory tract, and thus did not seroconvert nor shed infectious virus upon
experimental MERS-CoV inoculation [84,88]. Comparable to sheep, goats limitedly shed infectious
virus upon experimental infection and did not transmit this virus to other naïve goats upon direct
contact [88]. The results of experimental MERS-CoV infection in livestock animals are in line with
data from epidemiological studies. MERS-CoV seropositive llamas and alpacas are present in the field,
while horses, goats, and sheep are generally found to be seronegative [22,86,87,91–98].
Given the fact that experimental in vivo infection studies and DPP4 expression analysis in different
animal species revealed that dromedary camels are not the only animals in which MERS-CoV has
an upper respiratory tract tropism [17,18,83,84], it is then relevant to question whether other animals
can potentially spread MERS-CoV as well. New World camelids, i.e., alpacas and llamas, are able to
transmit the virus to respective naïve animals upon contact [86]. Pigs and rabbits, on the other hand,
hardly transmit the virus—neither by contact nor airborne routes [83,99]. Most likely, this is caused
by the fact that pigs and rabbits, unlike dromedary camels, shed low levels of infectious virus upon
MERS-CoV inoculation (Figure 2). This difference indicates that other host factors besides DPP4 could
cause interspecies variation in MERS-CoV infection. Indeed, several glycotopes of α2,3-sialic acids
that function as attachment factors of MERS-CoV are present in the nasal epithelium of dromedary
camels but absent in that of rabbits and pigs (Figure 3) [24,100]. The lack of these glycotopes in pigs
and rabbits might limit the susceptibility and transmission of MERS-CoV in these animals. Although
the role of these glycotopes in MERS-CoV transmission still requires further investigation, it remains
plausible that an efficient transmission of this virus might require the presence of both DPP4 and
MERS-CoV-recognized glycotopes of α2,3-sialic acids (Figure 3).
Figure 2. Schematic overview of viral RNA and infectious virus shedding of MERS-CoV-inoculated
dromedary camels, pigs, and rabbits. Each data point represents the average data from previous
experiments [17,33,84]. Viral RNA is measured in TCID50/mL genome equivalents, while infectious
virus is expressed in TCID50/mL.
Besides entry and attachment receptors, MERS-CoV has been demonstrated to use both cell
surface and lysosomal proteases to enter its target cells [39,40,43,101]. The preference of MERS-CoV
to use certain host proteases is influenced by the type of target cell and the cleavage stage of their S
protein prior to infection [40]. It has also been reported that the lysosomal proteases from bat cells
support coronavirus spike-mediated virus entry more efficiently than their counterparts from human
cells [39]. These observations suggest that host proteases from different host species may determine
the species and tissue tropism of MERS-CoV.
Because MERS-CoV has been circulating in dromedary camels for decades before emerging in the
human population [19–22], it is plausible that this virus inhibits the immune response of dromedary
camels more efficiently than that of other species, including pigs and rabbits. The difference in immune
response among MERS-CoV-susceptible species is therefore another factor that might yield interspecies
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variation in permissiveness to MERS-CoV. Characterizing the difference in host proteases and immune
responses among MERS-CoV-susceptible species, as performed for DPP4 and MERS-CoV-recognized
α2,3-sialic acid glycotopes (Figure 3), has not yet been investigated. These data, however, may further
explain interspecies variation in MERS-CoV infection and transmission.
Figure 3. Schematic representation of DPP4 expression and MERS-CoV-recognized α2,3-sialic acid
glycotopes in the respiratory tract of dromedary camel, pig, rabbit, human, and sheep.
4. Host Factors in MERS-CoV Pathogenesis
MERS-CoV causes respiratory infection in humans ranging from asymptomatic to severe
pneumonia [3,4]. However, it is currently unclear what causes this intraspecies variation. Epidemiology
data indicate that individuals with certain risk factors are at higher risk of developing severe MERS-CoV
infection [4,102]. This implies that some host factors may dictate the outcome of MERS-CoV infection,
thus rendering intraspecies variation. Two of the risk factors, i.e., smoking and chronic obstructive
pulmonary disease (COPD), have been shown to upregulate DPP4 expression in the lungs [70,102–104],
suggesting DPP4 as a possible reason for intraspecies variation observed among MERS-CoV patients.
In healthy human lungs, DPP4 is almost exclusively expressed in type II pneumocytes [69,70].
Type II pneumocytes are small cuboidal cells that can regenerate alveolar epithelium upon injury,
and roughly cover 2% of the alveolar surface area. Meanwhile, around 95% of the surface area of
the alveolus is occupied by type I pneumocytes that are morphologically flat and responsible for
gas exchange [105,106]. In the lungs of smokers and COPD patients, unlike in healthy human lungs,
DPP4 is prominently expressed in both type I and II pneumocytes, indicating upregulated expression
on type I pneumocytes [104]. Autopsy reports from fatal MERS-CoV patients showed that both
type I and II pneumocytes expressed DPP4 and became infected by MERS-CoV, proposing a role of
DPP4-expressing type I pneumocytes in MERS-CoV pathogenesis [64,107]. Damage to type I cells
in the lung alveoli during viral infection may lead to diffuse alveolar damage [108]. In line with
observations made in human MERS cases, common marmosets that express DPP4 in both type I and
II pneumocytes have been reported to produce more infectious virus upon experimental MERS-CoV
infection, compared to rhesus and cynomolgus macaques that merely expressed DPP4 in type II
pneumocytes [58,109–112]. Accordingly, these common marmosets developed moderate-to-severe
infection, while macaques generally developed mild transient pneumonia [32,58,109–112]. Similarly,
in genetically modified mice that displayed MERS-CoV tropism for type II pneumocytes, only mild
clinical manifestations were observed upon MERS-CoV infection [56,113]. Adapting MERS-CoV
through serial passaging or upregulating DPP4 expression throughout the airway epithelium in
mice, however, will induce severe clinical disease [55,56]. These data altogether support the role of
DPP4-expressing type I pneumocytes in the pathogenesis of severe MERS-CoV infection.
The differential expression of host factors that limits the infection should also be taken into
account. DPP4 in soluble form has been demonstrated to protect against MERS-CoV infection
in vitro and in a mouse model [23,114]; however, its presence in the lungs and role in MERS-CoV
pathogenesis remain to be investigated. The host immune response also has the capacity to inhibit
MERS-CoV infection. MERS-CoV has been shown to replicate to higher levels in immunocompromised
rhesus macaques [115], consistent with the observation that immunocompromised individuals have
difficulties clearing MERS-CoV upon infection [68,107,116]. The survivors of MERS-CoV infection have
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been shown to develop virus-specific CD4+ and CD8+ T cell responses, implying the role of T cells in
virus clearance [117]. However, the depletion of T cells in mice can either lead to failure in MERS-CoV
clearance or improvement in clinical outcome, depending on the type of mouse model used [57,118].
Therefore, the role of adaptive immune response in MERS-CoV pathogenesis is currently unclear.
On the other hand, one of the main components of the host innate immune response, type I interferon,
inhibits MERS-CoV replication in susceptible cells, partly by inhibiting double membrane vesicles
(DMV) formation [25,57,59,119,120]. The absence of type I interferon signaling in mice also resulted
in more severe clinical manifestations and histopathological lesions upon MERS-CoV infection [57].
Advance age, which can cause delayed type I interferon response upon viral infection, is a well-known
risk factor for fatal MERS-CoV infection [4,102,121–123]. Collectively, these data highlight the role of
host innate immune response as a potent inhibitor for MERS-CoV infection.
It is indubitable that severe MERS-CoV infection is not solely driven by the pathogen.
Additional underlying conditions increase MERS-CoV replication and induce severe-to-fatal clinical
manifestations [4,11,103,124,125]. It is plausible that more than one underlying condition is needed
to yield a fatal outcome. DPP4 upregulation in type I pneumocytes and insufficient type I interferon
response might be crucial determinants for severe MERS-CoV infection (Figure 4). Further investigation
of the host determinants of MERS-CoV pathogenesis may offer insights for developing novel
therapeutic measures.
Figure 4. MERS-CoV infection in the lungs of asymptomatic-to-mild (left panel) and severe-to-fatal
cases (right panel). Shown is a hypothetical model with two critical host determinants, DPP4 and
interferon, differentially expressed in asymptomatic-to-mild and severe-to-fatal MERS-CoV infection.
5. Concluding Remarks and Future Perspectives
Although MERS-CoV has been reported to undergo some genotypic changes since it emerged in
the human population [12,126–129], this has not resulted in distinct phenotypic changes so far [63,126].
Therefore, host factors remain the most significant determinant in explaining inter- and intraspecies
variations observed in MERS-CoV pathogenesis and transmission. DPP4 and MERS-CoV-recognized
α2,3-sialic acids might partially explain these variations, since their localization has been demonstrated
to be variable between MERS-CoV-susceptible species [69,71,84,100]. DPP4 expression in human lungs
has also been shown to vary due to certain comorbidities [70,96,104]. Nevertheless, it is undoubtable
that the inter- and intraspecies variation in MERS-CoV pathogenesis and transmission is a complex
phenomenon influenced by more than one host factor. Current data suggest proteases and interferons as
other critical host factors, but how they instigate inter- and intraspecies variations, as well as their role
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in MERS-CoV pathogenesis and transmission, still remain to be further elucidated. Characterization of
the host determinants of MERS-CoV pathogenesis and transmission could potentially offer insight into
this virus epidemiology and guide novel therapeutic development. It may also help to identify the most
vulnerable individuals to protect against MERS-CoV infection—for example, by using vaccination.
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Abstract: Lipids play numerous indispensable cellular functions and are involved in multiple
steps in the replication cycle of viruses. Infections by human-pathogenic coronaviruses result
in diverse clinical outcomes, ranging from self-limiting flu-like symptoms to severe pneumonia
with extrapulmonary manifestations. Understanding how cellular lipids may modulate the
pathogenicity of human-pathogenic coronaviruses remains poor. To this end, we utilized the
human coronavirus 229E (HCoV-229E) as a model coronavirus to comprehensively characterize
the host cell lipid response upon coronavirus infection with an ultra-high performance liquid
chromatography-mass spectrometry (UPLC–MS)-based lipidomics approach. Our results revealed
that glycerophospholipids and fatty acids (FAs) were significantly elevated in the HCoV-229E-infected
cells and the linoleic acid (LA) to arachidonic acid (AA) metabolism axis was markedly perturbed
upon HCoV-229E infection. Interestingly, exogenous supplement of LA or AA in HCoV-229E-infected
cells significantly suppressed HCoV-229E virus replication. Importantly, the inhibitory effect of LA
and AA on virus replication was also conserved for the highly pathogenic Middle East respiratory
syndrome coronavirus (MERS-CoV). Taken together, our study demonstrated that host lipid metabolic
remodeling was significantly associated with human-pathogenic coronavirus propagation. Our data
further suggested that lipid metabolism regulation would be a common and druggable target for
coronavirus infections.
Keywords: lipidomics; UHPLC–MS; HCoV-229E; MERS-CoV
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1. Introduction
Coronaviruses are enveloped viruses with a large single-strand, positive-sense RNA genome [1,2].
As of today, there are a total of six coronaviruses that are known to infect humans, including human
coronavirus OC43 (HCoV-OC43), human coronavirus 229E (HCoV-229E), severe acute respiratory
syndrome coronavirus (SARS-CoV), human coronavirus HKU1 (HCoV-HKU1), human coronavirus
NL63 (HCoV-NL63), and the Middle East respiratory syndrome coronavirus (MERS-CoV) [3]. These
human-pathogenic coronaviruses cause a broad range of clinical manifestations. HCoV-OC43,
HCoV-229E, HCoV-HKU1, and HCoV-NL63 cause mild, self-limiting upper respiratory tract infections.
In contrast, SARS-CoV and the recently emerged MERS-CoV may cause severe pneumonia with
acute respiratory distress syndrome, multi-organ failure, and death in both immunocompetent and
immunocompromised hosts [4–7].
Lipids play crucial roles at various stages in the virus life cycle. First, lipids can serve as the
direct receptors or entry co-factors for enveloped and non-enveloped viruses at the cell surface or
the endosomes [8,9]. Second, lipids and lipid synthesis play important roles in the formation and
function of the viral replication complex [10,11]. Third, lipid metabolism can generate the required
energy for efficient viral replication [12]. Moreover, lipids can dictate the proper cellular distribution of
viral proteins, as well as the trafficking, assembly, and release of virus particles [13,14]. In this regard,
the host lipid biogenesis pathways play indispensable roles in modulating virus propagation.
As in other viruses, lipids play key roles in the life cycle of coronaviruses. Coronaviruses confiscate
intracellular membranes of the host cells to generate new compartments known as double membrane
vesicles (DMVs) for the amplification of the viral genome. DMVs are membranous structures that not
only harbor viral proteins but also contain a specific array of hijacked host factors, which collectively
orchestrate a unique lipid micro-environment optimal for coronavirus replication [15]. A recent study
indicated that a key lipid processing enzyme, cytosolic phospholipase A2α enzyme (cPLA2α) that
belongs to the phospholipase A2 (PLA2) superfamily, was closely associated with DMVs’ formation
and coronaviruses’ replication [16]. The viral protein and RNA accumulation, as well as the production
of infectious virus progeny, were significantly diminished in the presence of cPLA2α inhibitor [16].
At the same time, phospholipase A2 group IID (PLA2G2D), an enzyme that predominantly contributes
to anti-inflammatory/pro-resolving lipid mediator expression, contributed to worsened outcomes in
mice infected with SARS-CoV by modulating the immune response [17]. However, to date, the change
and modulating effects of the specific lipids involved in lipid rearrangement upon coronavirus infection
remains largely unexplored.
To obtain a comprehensive and unbiased profile of perturbed lipids upon coronavirus infection,
we performed mass spectrometry (MS)-based lipidomics profiling on coronavirus-infected cells using
HCoV-229E as a model virus. Specific lipids including glycerophospholipids and fatty acids (FAs) upon
virus infection were identified, which represented the lipid species that were rearranged by HCoV-229E
infection. Further pathway analysis revealed that the linoleic acid (LA) and arachidonic acid (AA)
metabolism axis was the most perturbed pathway upon HCoV-229E infection. Importantly, supplement
of additional LA and AA to coronavirus-infected cells significantly inhibited virus replication of
both HCoV-229E and the highly virulent MERS-CoV, suggesting that the LA–AA metabolism axis
is a common and essential pathway that could modulate coronavirus replication. In this regard,
temporal modulation of the host lipid profile is a potential novel strategy to combat emerging
human coronaviruses.
2. Materials and Methods
2.1. Materials
High performance liquid chromatography (HPLC)-grade methanol, acetonitrile, chloroform and
2-propanol were purchased from Merck (Darmstadt, Germany). HPLC-grade water was prepared
using a Milli-Q water purification system (Millipore, Burlington, MA, USA). Analytical grade acetic
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acid and commercial standards used for biomarker identification were purchased from Sigma-Aldrich
(St. Louis, MO, USA). Internal standards (IS) including Arachidonic acid-d8, 15(S)-HETE-d8,
Leukotriene-B4-d4 and Platelet-activating factor C-16-d4 (PAF C-16-d4) were purchased from Cayman
Chemical (Ann Arbor, MI, USA) [18].
2.2. Viruses and Cells
Huh-7 and VeroE6 cells were maintained in Dulbecco’s modified Eagle medium (DMEM)
supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100 U/mL penicillin, and 100 g/mL
streptomycin (5% CO2 at 37 ◦C). MERS-CoV (EMC/2012 strain) was kindly provided by Professor Ron
Fouchier (Erasmus Medical Center, Rotterdam, The Netherlands). MERS-CoV and HCoV-229E were
cultured in VeroE6 cells in serum-free DMEM supplemented with 100 U/mL penicillin and 100 g/mL
streptomycin as we described previously [19–21]. The supernatants were harvested when cytopathic
effects (CPE) were observed and centrifuged to generate the viral stocks. The viral stocks were titrated
by plaque assay on VeroE6 cells and stored at −80 ◦C as previously described [22,23]. Briefly, confluent
VeroE6 cells were infected with 10-fold serial viral dilutions. The cells were incubated with diluted
viruses at 37 ◦C for 1 h and subsequently overlaid with 1% low-melting-point agarose (Promega,
Madison, WI, USA). The cells were fixed with 4% formaldehyde as the plaques were observed and then
stained with 0.2% crystal violet. All experiments involving live MERS-CoV followed the approved
standard operating procedures of the biosafety level 3 facility as previously described [24–27].
2.3. Lipid Treatment of Middle East Respiratory Syndrome Coronavirus (MERS-CoV)-Infected and Human
Coronavirus (HCoV-229E)-Infected Huh-7 Cells
Huh-7 cells were seeded into 24-well plate to reach 90% confluency and infected with MERS-CoV
or HCoV-229E at multiplicity of infection (MOI) of 0.005 or 1, respectively. After 1 h of inoculation,
the cells were washed with phosphate-buffered saline (PBS) and maintained in lipids-supplemented
medium at the indicated concentrations for 24 h. AA, LA, oleic acid (OA), and palmitic acid (PA) were
dissolved in ethanol and ethanol was used as a negative control. The lipids were purchased from
Cayman Chemical (Ann Arbor, MI, USA). The supernatants and cell lysates were collected at 24 h
post-infection. The viral genome copy numbers were determined by reverse-transcription quantitative
polymerase chain reaction (RT-qPCR) as previously described [28–30].
2.4. Lipid Extraction for Lipidomics Profiling
Confluent Huh-7 cells were mock infected or infected with HCoV-229E at MOI of 1 and incubated
in DMEM medium. At 24 hpi, cells were collected for cellular lipid extraction. The lipid extraction was
performed for liquid chromatography-mass spectrometry (LC-MS) analysis according to a previously
described protocol with slight modifications [31,32]. Inactivation of virus infectivity was confirmed
before further processing as we previously described with some modifications [33]. Briefly, 500 μL
of ice-cold 150 mM ammonium bicarbonate solution was added to dissociate cells. Two millilitres of
chloroform/methanol (v/v 2:1) containing IS were added, followed by vortexing and centrifugation
at 4500 rpm for 10 min at 4 ◦C. The bottom phase was transferred to glass vials and dried using a
vacuum concentrator for storage at −80 ◦C. The dried samples were reconstituted in 250 μL solvent
mixture containing methanol/2-propanol/water (v/v/v 5:4:1) for LC-MS analysis. After centrifugation
at 14,000 rpm for 10 min at 4 ◦C, supernatants were transferred to LC vials for LC-MS analysis.
2.5. Ultra-High Performance Liquid Chromatography-Electrospray Ionization-Quadrupole-Time of Flight-Mass
Spectrometry (UPLC-ESI-Q-TOF-MS) Analysis
The lipid extract was analyzed using an Acquity UPLC system coupled to a Synapt G2-Si High
Definition Mass Spectrometry (HDMS) system (Waters Corp., Milford, MA, USA). The chromatography
was performed on a Waters ACQUITY BEH C18 column (1.7 μm, 2.1 × 100 mm, I.D., 1.7 mm,
Waters Corp., Milford, MA, USA). The mobile phase consisted of (A) 0.1% acetic acid in water and
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(B) acetonitrile. Gradient elution applied for ultra-high performance liquid chromatography-mass
spectrometry (UPLC-MS) analysis was described in Table S1. The column and autosampler temperature
were maintained at 45 ◦C and 4 ◦C, respectively. The injection volume was 5 μL [34].
The mass spectral data were acquired in both positive and negative modes. The capillary voltage,
sampling cone voltage and source offset were maintained at 2.5 kV, 60 V, and 60 V, respectively.
Nitrogen was used as desolvation gas at a flow rate of 800 L/h. The source and desolvation
temperatures were maintained at 120 ◦C and 400 ◦C, respectively. Mass spectra were acquired
over the m/z range of 50 to 1200. The SYNAPT G2-Si HDMS system was calibrated using sodium
formate clusters and operated in sensitivity mode. Leucine enkephalin was used as a lock mass for all
experiments. MS/MS acquisition was operated in the same parameters as MS acquisition. Collision
energy was applied at the range from 20 to 40 eV for fragmentation to allow putative identification
and structural elucidation of the significant lipids.
2.6. Data Processing and Statistical Data Analysis
Acquisition of the raw data was performed using MassLynx software version 4.1 (Waters
Corp., Milford, MA, USA) and raw data were converted to the common data format (NetCDF)
files using conversion software Databridge (Waters Corp., Milford, MA, USA). The NetCDF data were
subsequently deconvolved into a usable data matrix using the XCMS software (http://metlin.scripps.
edu/download/) [35] and the grouping of features was performed using the CAMERA R package [36].
Preprocessed data were then exported as a .csv file for further data statistical analysis. MetaboAnalyst
3.0 (http://www.metaboanalyst.ca) and SIMCA-P V12.0 (Umetrics, Umeå, Sweden) were used for
univariate and multivariate statistical analysis, respectively [37]. For univariate analysis, statistical
significance of features was determined between the mock and HCoV-229E infected group using the
Student’s t-test and fold change. The p-value < 0.05 and fold change > 2 were used as criteria for
significant features selection. For multivariate analysis, the features were subjected to Pareto scaling
firstly then orthogonal partial least squares discriminant analysis (OPLS-DA) was performed as a
supervised method to find important variables with discriminative power. The OPLS-DA model was
evaluated with the relevant R2 and Q2. The variable importance in projection (VIP), which reflects
both the loading weights for each component and the variability of the response explained by this
component, was used for feature selection [38].
2.7. Lipids Identification
MS/MS fragmentation was performed on the significant features with high abundances.
The significant features identification were carried out by searching accurate MS and MS/MS
fragmentation pattern data in the METLIN database (Metabolomics Database, http://metlin.scripps.
edu/), Human Metabolome Database (http://www.hmdb.ca/), and LIPD MAPS (Lipidomics Gateway,
http://www.lipidmaps.org/). For confirmation of lipid identity using authentic chemical standard,
MS/MS fragmentation pattern of the chemical standard was compared with that of candidate lipid
under the same LC-MS condition to reveal any matching [18,39].
3. Results
3.1. Omics-Based Statistical Analysis for Significant Features
To investigate how coronavirus perturbs host lipid metabolism, we performed lipidomics analysis
on HCoV-229E-infected Huh7 cells and compared the results with those of the mock-infected cells.
The preliminary features list included precursor ions, adducts and isotope ions, which were imported
into the MetaboAnalyst and SIMCA-P software for further analysis. The R2X/ R2Y, represented
the X/Y variables explanation rate of the OPLS-DA model, were 83.0% and 98.8%, respectively.
The predicted component, as estimated by cross-validation, was 0.97 (Q2). These cross-validated
parameters were satisfactory for OPLS-DA mode (Supplementary Figure S1a). At the same time,
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the permutation test (100 times) also indicated that the validated model was satisfied (Supplementary
Figure S1b). Overall, our results demonstrated that these significant lipid features could be selected by
the validated statistical model for subsequent identification.
3.2. Identification of Lipids Specific to HCoV-229E
A total of 206 (positive mode) and 100 (negative mode) ion features were selected according
to the omics-based statistical analysis method. These ion features were significantly discriminative
between HCoV-229E-infected and mock-infected cells. To observe the discrimination trend in more
detail, a hierarchical clustering analysis was performed based on the degree of similarity of lipid
abundance profiles to show the overview trend of all significant ion features. As indicated in Figure 1,
most of the significant features from both negative mode (Figure 1A) and positive mode (Figure 1B)
expressed an up-regulation trend after HCoV-229E infection compared with the mock infection controls.
Furthermore, to identify lipids specific to HCoV-229E infection, these significant features were grouped
and annotated using the CAMERA software, and the potential precursor ions were used to perform
further MS/MS experiments for obtaining their fragmentation patterns. Finally, a total of 24 lipids
were identified, which could be classified into three lipid classes, including lysophosphatidylcholine
(lysoPC), lysophosphatidylethanolamine (lysoPE) and fatty acid (FA). The chromatogram peak heights
of these identified lipids were generated by LC-MS raw data and the ratio between infected and
mock-infected cells was determined. As demonstrated in Figure 2, we found a consistent up-regulation
trend of the identified lipids in HCoV-229E-infected cells. In particular, lysoPC was the predominant
lipid class of all identified, accounting for approximately 60% of all identified lipids with significant
elevation (Figure 2A). At the same time, arachidonic acid (AA), which belongs to the FA class, showed
the highest increase in fold-change among all identified lipids with a maximum of 7.1-fold increase
(Figure 2B). In addition, the level of lysoPEs (Figure 2C) was also up-regulated with a maximum
fold change of 2.93, which was comparatively less than that of the lysoPCs and FAs. The identities
of lysoPC (16:0/0:0), platelet-activating factor C-16 (PAF C-16), lysoPE (16:0/0:0), AA, LA, PA and
OA were confirmed by matching the retention time (RT) and MS/MS fragmentation patterns of the
authentic chemical standards that distinguish between HCoV-229E-infected cases and non-infected
controls (Figure 3). The detailed information of the 24 identified lipids was listed in Table 1. MS/MS
fragmentation patterns of five representative lipids and corresponding standards are also demonstrated
in Supplementary Figure S2.
3.3. Pathway Analysis of HCoV-229E-Infected Huh7 Cells
Based on the list of significantly up-regulated lipids after HCoV-229E-infection, MetaboAnalyst
(http://www.metaboanalyst.ca) was applied to investigate which pathway might be markedly
perturbed. The result of the pathway analysis was graphically presented in Figure 4. From the
enrichment analysis results, the LA metabolism pathway and FA biosynthesis pathway had a
statistically significant raw p-value (raw p < 0.05, as shown in the Y-axis). Pathway impact results
indicated that the LA metabolism and AA metabolism pathways presented higher impact than the other
pathways, as indicated in the X-axis value. Combining the above two analysis results, we postulated
that the LA metabolism pathway to be a markedly perturbed pathway that correlated with the lipid
rearrangement process induced by HCoV-229E infection.
68






















































































































































































































































































Viruses 2019, 11, 73
Figure 2. Liquid chromatography-mass spectrometry (LC/MS) analysis of HCoV-229E-infected cells
revealed a homeostatic change in lipid levels. Huh-7 cells were mock- or HCoV-229E-infected
and harvested at 24 hpi. The peak heights of these lipids were calculated and the fold change
plotted with GraphPad Prism 5. (A) Lysophosphatidylcholine (LysoPC), (B) fatty acid (FA),
(C) lysophosphatidylethanolamine (LysoPE). AA, arachidonic acid; LA, linoleic acid; PA, palmitic acid;
OA, oleic acid.
Figure 3. Box-whisker plots of the 7 standard confirmed lipids that were distinguished between the
HCoV-229E-infected samples and the non-infected controls. The peak height was generated by LC-MS
raw data. Control, non-infected cells; 229E, HCoV-229E-infected cells.
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Figure 4. Pathway analysis associate with HCoV-229E infection was carried out by MetaboAnalyst.
The Y-axis, “log(p)”, represented the transformation of the original p-value calculated from the
enrichment analysis. The X-axis, “Pathway Impact”, represented the value calculated from the pathway
topology analysis.
To better understand the current pathway analysis results and the cellular lipid signaling
response upon HCoV-229E infection, we constructed a global LA pathway map based on the
pathway information in the Kyoto Encyclopedia of Genes and Genomes (KEGG) database
(https://www.genome.jp/kegg/) and literature mining (Figure 5). Upon HCoV-229E infection,
the glycerophospholipids, as main components of the cell membrane, were metabolized to
lysophospholipids and FAs after cPLA2 enzyme activation. Lysophospholipids such as lysoPCs
and lysoPEs were correspondingly increased after HCoV-229E infection. Moreover, lysoPCs could be
further metabolized to platelet-activating factor. FAs were also released from glycerophospholipids
but only LA and AA could initiate downstream pathways to generate corresponding metabolites.
The up-regulation of both lysophospholipids and FAs were partially confirmed by authentic standards.
Furthermore, to investigate the downstream pathways trend of FAs, the authentic standards were also
applied in LC-MS method to confirm whether these downstream lipids were changed correspondingly.
As illustrated in Figure 5, AA is a downstream lipid of LA and the origin lipid of AA metabolism
pathway. The identity of AA was confirmed by authentic standard (Supplementary Figure S2D), which
was found to be significantly up-regulated. Therefore, combining pathway analysis and the authentic
standards verification results, our data suggested that the LA–AA metabolism axis was the most
significantly perturbed pathway and might be associated with lipids rearrangement or other processes
in HCoV-229E infection.
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Figure 5. The pathway map based on identified lipids and linoleic acid metabolism recorded in the
Kyoto Encyclopedia of Genes and Genomes (KEGG) PATHWAY Database. The star mark “*” indicates
the lipids could be matched with commercial standards and have an up-regulation trend. The red arrow
represents the up-regulation trend. The blue dashed rectangle and green solid rectangles represent
lipids and corresponding enzyme in this pathway, respectively. The orange dashed line represents the
LA–AA metabolism axis.
3.4. Lipids Treatment of Virus-Infected Cells
To investigate the potential implication of the perturbed LA-AA metabolism axis in HCoV-229E
infection, we treated HCoV-229E-infected Huh7 cells with LA and AA and included PA and OA for
comparison. The LA and AA were mapped and played a vital role in the perturbed LA-AA metabolism
axis (Figure 5). In contrast, PA and OA were not mapped in the perturbed pathway and may only
be produced from glycerophospholipids due to cPLA2 enzyme activation. Huh-7 cells were infected
with HCoV-229E and treated with AA, LA, PA, or OA. The cell lysates and culture supernatants were
harvested at 24 h post-infection to determine the viral genome copy number by RT-qPCR. As shown in
Figure 6, LA and AA consistently inhibited the replication of HCoV-229E as evidenced by the decrease
in virus genome copies in both cell lysate (Figure 6A,C) and supernatant samples (Figure 6B–D).
In contrast, PA inhibited HCoV-229E replication only when supplied at high concentration while
HCoV-229E replication was largely independent of OA (Figure 6A–D).
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Figure 6. Modulatory effect of lipids on HCoV-229E and Middle East respiratory syndrome coronavirus
(MERS-CoV). Huh-7 cells were infected with HCoV-229E. After 1 h of inoculation, the virus inoculum
was replaced with medium containing 50 μM (A,B) or 100 μM (C,D) of lipids and incubated for 24 h.
The supernatants and cell lysates were collected for reverse-transcription quantitative polymerase
chain reaction (RT-qPCR) analysis. In parallel, Huh-7 cells were infected with MERS-CoV. After 1 h
of inoculation, the virus inoculum was replaced with medium containing 100 μM (E,F) of lipids and
incubated for 24 h. The supernatants and cell lysates were collected for RT-qPCR analysis. Statistical
significance was determined by Student’s t-test by comparing the individual lipid-treated group with
the mock-treated group (n = 4). The difference was considered significant when p < 0.05.
To further investigate if the modulatory effects of LA and AA were conserved among other
human-pathogenic coronaviruses, we evaluated the effects of these lipids on the replication of the
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recently emerged and highly virulent MERS-CoV. Our data demonstrated that LA and AA potently
suppressed MERS-CoV replication in a similar manner as HCoV-229E (Figure 6E,F). Overall, our results
demonstrated that exogenously supplied LA and AA could interfere with the optimal replication of
human-pathogenic coronaviruses, which suggested that the LA–AA metabolism axis was significantly
involved in the propagation of these viruses.
4. Discussion
In this study, a MS-based lipidomics approach was established to characterize the host cell
lipid changes upon coronavirus infection. Univariate and multivariate statistical analyses were
applied in data processing for the selection of significant lipid features. A total of 24 lipids including
lysophospholipids and FAs were identified and were consistently up-regulated in HCoV-229E-infected
cells. Seven representative lipids were confirmed by authentic standards, including lysoPC (16:0/0:0),
PAF C-16, lysoPE (16:0/0:0), AA, LA, PA and OA. Subsequent pathway analysis indicated that the
LA–AA metabolism axis, consisting of LA and AA as important precursor lipids, was substantially
perturbed after HCoV-229E infection. Moreover, we demonstrated that exogenously supplied LA and
AA were capable of inhibiting the replication of HCoV-229E and the highly pathogenic MERS-CoV,
which suggested the LA–AA metabolism axis to be a conserved and essential pathway in the
propagation of human coronaviruses.
A total of 24 lipids including lysoPCs, lysoPEs and unsaturated/saturated FAs were identified
to be significantly upregulated after HCoV-229E infection. Twenty of these 24 (83.3%) lipids were
lysoPC and lysoPE. LysoPC is the most abundant lysophospholipid in humans, with a high plasma
concentration of several hundred micromoles. In addition, lysoPC was a potent inhibitor and could
reversely arrest pore expansion during syncytium formation mediated by diverse viral fusogens [40].
Another lysophospholipid, lysoPE, is present at low concentrations in vivo but they induce various
cellular responses such as activation of mitogen-activated protein kinase (MAPK) and neuronal
differentiation when applied to cells in vitro [41]. Among the identified FAs, the LA and AA both
belong to polyunsaturated omega-6 fatty acid and are essential fatty acids. In addition, LA is the
metabolic precursor of AA, both of which are key components of the cell membrane. LA and AA
also play fundamental roles in the biological function of many tissues by modulating enzymes, ion
channels, receptors, as well as inflammation [42].
Coronavirus replication is associated with intracellular membrane rearrangement and depends on
the formation of double membrane vesicles (DMVs) and other membranous structures as replicative
organelles [16]. The cell membrane components consist mainly of glycerophospholipid components
such as phosphatidylcholine (PC), phosphatidylethanolamine (PE), lysophosphatidylcholine (lysoPC),
and lysophosphatidylethanolamine (lysoPE). A specific phospholipids composition is required by
different viruses to form the optimal replicative organelles best suited for their replication [43].
Moreover, the lysoPC/PE was produced from PC/PE by cPLA2 activation, which simultaneously
generated corresponding fatty acid moiety. In this regard, cPLA2 activation is commonly believed to
be beneficial for virus replication [16,17].
In our study, we found that a number of lysophospholipids and FAs downstream of cPLA2
activation, were upregulated upon HCoV-229E infection. The upregulation of these lipid species
including LA and AA were believed to promote efficient coronavirus replication. However, when
we evaluate this hypothesis by exogenously supplementing additional LA and AA to HCoV-229E- or
MERS-CoV-infected cells, we noticed a significant reduction in virus replication. Taken together, our
data suggested that coronavirus infection did not randomly perturb the cellular lipid compositions.
Instead, we speculate that coronaviruses precisely modulate and rearrange the host lipid profile
to reach an intricate homeostasis optimized for its replication. Any exogenous manipulation that
disrupts the equilibrium may interfere with the optimal replication of the viruses. Alternatively,
supplementing LA and AA might disturb the LA–AA metabolism axis and result in feedback reversion
of lysophospholipids into phospholipids through Land’s cycle [44], thus limiting virus replication.
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In addition, LA and AA are polyunsaturated fatty acids that are biological signaling precursors.
They can be metabolized to important eicosanoids and metabolites, which play multiple roles in the
host immune response and the pathogenesis of viral infections [45–47]. However, previous study had
suggested that arachidonic acid (AA) downstream metabolites show no evidence of anti-coronaviral
activity as observed through special inhibitors of cyclooxygenases (COX) 1/2 and 5-lipoxygenase
(LOX), which are two key enzymes requiring AA as a precursor. The results indicated AA downstream
products may not have a significant effect on coronaviruses replication, at least in vitro [16,48].
In this regard, the function of the downstream metabolites of LA and AA may play key roles in
the pathogenesis of coronaviruses in vivo.
5. Conclusions
In the present study, we revealed that the cellular lipid profile was rearranged upon HCoV-229E
infection. A total of 24 lipids including lysoPCs, lysoPEs and FAs were upregulated. Among them,
LA and AA, which were mapped into the LA-AA metabolism axis, demonstrated strong modulatory
effects on the replication of HCoV-229E and the highly pathogenic MERS-CoV. In this regard, our data
suggested that optimal coronavirus replication required a specific composition of cellular lipids and
any disruption could decrease the efficiency of coronavirus replication. Thus, the MS-based lipidomics
strategy could be used to monitor virus-specific lipid requirement, to discover the perturbed pathways
and identify novel lipids to interfere with virus replication. In further studies, combining lipidomics
data with biological and immunological data may help to elucidate specific pathogenic mechanisms
and identify novel treatment strategies for virus infections.
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Abstract: Middle East respiratory syndrome coronavirus (MERS-CoV) transmission from dromedaries
to humans has resulted in major outbreaks in the Middle East. Although some other livestock animal
species have been shown to be susceptible to MERS-CoV, it is not fully understood why the spread of
the virus in these animal species has not been observed in the field. In this study, we used rabbits to
further characterize the transmission potential of MERS-CoV. In line with the presence of MERS-CoV
receptor in the rabbit nasal epithelium, high levels of viral RNA were shed from the nose following
virus inoculation. However, unlike MERS-CoV-infected dromedaries, these rabbits did not develop
clinical manifestations including nasal discharge and did shed only limited amounts of infectious
virus from the nose. Consistently, no transmission by contact or airborne routes was observed in
rabbits. Our data indicate that despite relatively high viral RNA levels produced, low levels of
infectious virus are excreted in the upper respiratory tract of rabbits as compared to dromedary
camels, thus resulting in a lack of viral transmission.
Keywords: MERS-coronavirus; transmission; rabbits
1. Introduction
Middle East respiratory syndrome coronavirus (MERS-CoV) is a novel pathogen that is known
to infect dromedary camels and humans [1,2]. Seroepidemiological studies indicate that this virus
has been circulating in dromedary camels in the Arabian Peninsula and Africa for decades [3–5].
MERS-CoV sequences obtained from these camels are largely similar to those obtained from human
MERS cases in corresponding regions, thus providing evidence that dromedary camels act as the
zoonotic source of this virus [6,7]. However, many primary human MERS cases do not have a
history of direct contact with these animals [8]. This suggests the presence of unidentified routes of
human-to-human transmission or the involvement of other animal species in spreading the virus to
humans. Besides dromedary camels, other animal species, i.e. llamas, alpacas, and pigs have been
shown to be susceptible and develop upper respiratory tract infection upon experimental intranasal
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MERS-CoV inoculation [9–11]. This is in line with the expression of the MERS-CoV receptor, dipeptidyl
peptidase-4 (DPP4), in their nasal epithelium [9]. MERS-CoV-seropositive llamas and alpacas have
been reported in the field, and MERS-CoV-experimentally-inoculated alpacas have also been shown to
transmit the virus via contact [12–14].
To further understand the zoonotic potential of MERS-CoV, it is crucial to delineate the factors
involved in the spread of the virus among dromedaries as well as other animal species. In order
to gain insight into these factors, we performed MERS-CoV transmission experiments in rabbits.
We have previously shown that rabbits are susceptible to MERS-CoV and develop both upper and
lower respiratory tract infection upon virus inoculation [15]. Naïve recipient rabbits were housed with
MERS-CoV-inoculated donor rabbits either in the same or in adjacent cages to determine whether
MERS-CoV can be transmitted via contact or airborne routes, respectively [16]. Donor rabbits were
found to shed high levels of viral RNA but a limited amount of infectious virus thus potentially
restricting MERS-CoV transmission in these animals.
2. Materials and Methods
2.1. Virus Stocks
In vivo experiments in this study were performed using Passage 7 human isolate MERS-CoV
EMC strain (HCoV-EMC/2012) and passage 3 isolate MERS-CoV (Qatar15/2015; GenBank Acc. No.
MK280984) that were propagated in Vero cells as described earlier [9]. Qatar15 was isolated from
a 69 years old Qatari man that developed severe pneumonia and was PCR confirmed to have a
MERS-CoV infection [17].
2.2. Animal Experiments
Animal experiments were approved and performed according to the guidelines from the
Institutional Animal Welfare Committee (no. 201300121 approved on 17 July 2013, 122-17-01 approved
on 28 September 2017, and AVD277002015283-WP01 approved on 2 November 2016). The studies
were performed under biosafety level 3 (BSL3) conditions. To compare whether different routes of
MERS-CoV inoculation generate similar clinical outcomes, twelve 6-month-old New Zealand rabbits
(Oryctolagus cuniculus), specific pathogen free, and seronegative for MERS-CoV were divided into four
groups. Animals were inoculated under ketamine-medetomidine anesthesia either (a) intranasally with
200 μL of 1 × 106 TCID50/mL MERS-CoV; (b) intranasally with 1 mL 1 × 106 TCID50/mL MERS-CoV;
(c) intranasally with 200 μL of 1 × 106 TCID50/mL MERS-CoV and intratracheally with 3 mL 4 × 106
TCID50/mL MERS-CoV; or (d) intranasally with 1 mL PBS. The intranasal inoculums were divided
equally over both nostrils. Nasal and throat swabs were obtained daily from day 1 up to day 4 post
inoculation. These animals were then sacrificed on day 4 and respiratory tract tissues were collected.
To compare the clinical outcomes of the MERS-CoV EMC strain and the Qatar15 strain, ten New
Zealand rabbits were divided into two groups and inoculated with 1 mL of 1 × 106 TCID50/mL of each
MERS-CoV strain intranasally. Nasal and throat swabs were obtained from day 1 up to day 4 post
inoculation and these animals were sacrificed on day 4.
To study MERS-CoV transmission, a modified version of the previously described influenza A
virus ferret transmission set-up was used. This set-up consists of two clear polymethyl methacrylate
cages of different sizes. Donor rabbits and direct contact recipients were housed in a cage of
35 cm × 30 cm × 65 cm (W × H × L), whereas airborne recipients were housed in a cage of 30 cm ×
30 cm × 55 cm (W × H × L). These cages are separated by two stainless steel grids 10 cm apart to
prevent direct contact but still allow airflow from the donor rabbit to the airborne recipient rabbit.
These transmission cages allow the experiment to be conducted in negatively pressured isolators in
the BSL3 facility, with HEPA-filtered airflow <0.1 m/s [18]. Since these cages were too small for New
Zealand rabbits, we chose a smaller-sized breed, the Netherland dwarf rabbits (Oryctolagus cuniculus),
for the MERS-CoV transmission experiment. We used both male and female rabbits with an age
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range of 6 months–3 years in these experiments. First, three MERS-CoV seronegative Netherland
dwarf rabbits were inoculated intranasally with 1 mL of 1 × 106 TCID50/mL MERS-CoV Qatar15 strain
(500 μL per nostril) to show that they are equally susceptible to MERS-CoV as the New Zealand
rabbits. Nasal and throat swabs were obtained daily up to 4 days post inoculation. These animals were
then sacrificed on day 4 and their respiratory tract tissues were collected. For the virus transmission
experiment, twelve Netherland dwarf rabbits were randomly distributed into four individually housed
groups. One naïve rabbit from each group was inoculated intranasally with 1 mL of 1 × 106 TCID50/mL
MERS-CoV (500 μL per nostril), thus acting as donor rabbits. The other two rabbits were used as direct
contact and airborne recipients, respectively. Donor and direct contact animals were of the same sex.
All animals were sacrificed at 14 days post exposure and blood was collected to assess seroconversion.
2.3. Virological Analysis
Nasal swabs, throat swabs, and respiratory tract tissue samples were evaluated for the presence of
infectious virus by virus titration, and for viral RNA by RT-qPCR against the UpE gene as previously
described [9]. Samples with a cycle threshold less than forty were considered as positive for MERS-CoV
RNA. Viral RNA was quantified as genome equivalents (GE) using MERS-CoV strain EMC (containing
106 TCID50/mL) as a calibrator. Virus titration was performed in serial 10-fold dilutions on Vero cells.
Cells were monitored under a light microscope at day 6 for cytopathic effect. The amount of infectious
virus in swab samples was calculated by determining the TCID50. Statistical analysis was performed
using the GraphPad Prism program (La Jolla, CA, USA). Kruskal–Wallis test was applied due to
the non-normal distribution of our data as priorly determined by Shapiro–Wilk test. The significant
difference between groups was determined at a P-value < 0.05.
2.4. Histopathology and Histochemistry Analysis
Respiratory tract tissue samples were collected in formalin and embedded in paraffin for
pathological analysis. Hematoxylin-eosin staining was performed for histopathological analysis.
The presence of MERS-CoV nucleoprotein and MERS-CoV RNA was detected by immunohistochemistry
and in-situ hybridization, respectively, using previously published protocols [15]. The localization of
DPP4 in the respiratory tract of non-infected New Zealand rabbits was analyzed using an optimized
immunohistochemical assay [15,19].
2.5. Serological Analysis
Collected serum samples were tested for MERS-CoV neutralizing antibodies using a virus
neutralization assay and for MERS-CoV S1-specific antibodies using MERS-CoV S1 ELISA according
to the previously published protocols [9]. Goat anti-rabbit IgG conjugated with HRP (1:2000, DAKO,
Glostrup, Denmark) was used as a secondary antibody in the ELISA.
3. Results
3.1. Dipeptidyl peptidase-4 DPP4 is Expressed in the Upper and Lower Respiratory Tract of Rabbits
Rabbits are the smallest animal species that can be naturally infected by MERS-CoV.
We previously reported that they develop both upper and lower respiratory tract infection upon
MERS-CoV inoculation [15], suggesting the expression of the viral receptor at these locations.
Using immunohistochemistry, we analyzed the DPP4 expression in rabbit respiratory tract tissues.
In the upper respiratory tract, DPP4 is strongly expressed at the apical surface of both nasal respiratory
and olfactory epithelium (Figure 1). In the lower respiratory tract, DPP4 is present in both bronchiolar
and alveolar epithelial cells, although some variation in DPP4 expression was observed throughout the
lungs. DPP4 is either absent, limitedly expressed on alveolar type II cells, or expressed on both alveolar
type I and II cells (Figure 1). Thus, these data highlight a broad DPP4 expression in the respiratory tract
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tissues of rabbits. Our results show that rabbits express DPP4 in both the upper and lower respiratory
tract epithelium, in line with MERS-CoV tropism in this species [9,19].
 
Figure 1. Dipeptidyl peptidase-1 (DPP4) expression in the respiratory tract tissues of rabbits. DPP4 is
detected using immunohistochemistry and indicated in red in the figure. Type II cells are indicated
with arrows, and type I cells with an arrowhead. Nasal epithelium and bronchiolar epithelium pictures
were taken at a 400×magnification, and alveolar epithelium at 1000×. The isotype control showed no
background signal in our assay.
3.2. Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Infects Both Upper and Lower Respiratory
Tract of Rabbits upon Intranasal Inoculation
In our previous study, we inoculated rabbits both intranasally and intratracheally [15]. Intratracheal
inoculation is quite invasive, and thus requires a skillful operator to minimize procedure-related
damage in the respiratory tract. In contrast, intranasal inoculation is less invasive and had been used
in other studies to infect rabbits with MERS-CoV [20,21]. Here we investigated whether intranasal
MERS-CoV inoculation is sufficient to induce both upper and lower respiratory tract infection in
rabbits, in comparison to combined intranasal and intratracheal inoculation. Three New Zealand
rabbits (Oryctolagus cuniculus) were inoculated with MERS-CoV EMC strain either intranasally with
200 μL of 1 × 106 TCID50/mL (group a); intranasally with 1 mL of 1 × 106 TCID50/mL (group b);
intranasally with 200 μL of 1 × 106 TCID50/mL and intratracheally with 3 mL of 4 × 106 TCID50/mL
(group c); or intranasally with 1ml of PBS as a negative control (group d). All three groups of
MERS-CoV inoculated rabbits developed minimal clinical manifestations and histopathological lesions.
The amount of viral RNA shed in the nasal and throat swabs did not vary among the inoculated groups
(Figure 2A,B). However, in the lungs of the rabbits, the amount of viral RNA was significantly lower in
group a than in groups b and c (Figure 2C). In line with these observations, fewer MERS-CoV-infected
cells were observed in the lungs of group a animals compared to groups b and c (Figure 2D). Based on
these results, we decided to use intranasal inoculation with 1 mL of 1 × 106 TCID50/mL MERS-CoV for
our subsequent experiments.
83
Viruses 2019, 11, 381
Figure 2. Middle East respiratory syndrome coronavirus (MERS-CoV) inoculation in rabbits with
different routes and volumes. Three New Zealand rabbits were each infected either with (a) 200 μL of 1×
106 TCID50/mL MERS-CoV intranasal (I.N.); (b) 1 mL of 1× 106 TCID50/mL MERS-CoV I.N.; (c) 200 μL of
1 × 106 TCID50/mL MERS-CoV I.N. combined with 3 mL of 4 × 106 TCID50/mL MERS-CoV intratracheal
(I.T.); or (d) 1mL of PBS I.N as negative control. These animals were sacrificed at day 4 post inoculation.
Viral RNA shed by the MERS-CoV-inoculated rabbits in the nasal swabs (A) and throat swabs (B) are
reported in genome equivalents per ml (GE/mL). Viral RNA detected in the lungs of these rabbits are
reported in genome equivalents per gram tissues (GE/g). Dashed lines depict the detection limit of the
assays. All error bars represent standard deviations. Statistical analysis is performed using Kruskal
wallis test (**, p value < 0.01; ***, p value < 0.001). Representative figures of immunohistochemistry
detecting MERS-CoV nucleoprotein (displayed in red) in the lungs of these rabbits were taken at a
200×magnification (D). All MERS-CoV-inoculated rabbits shed a relatively equal amount of viral RNA
in the nasal and throat swabs (A,B). However, there was significantly less viral RNA in the lungs of
rabbits in the group (a) in comparison to the other MERS-CoV-inoculated groups (C). A similar finding
is observed in our immunohistochemistry analysis detecting MERS-CoV nucleoprotein (displayed in
red) in the lungs of these rabbits (D). Pictures were taken in 200×magnification. The amount of viral
RNA is displayed either in genome equivalent per mL (GE/mL) or per gram tissues (GE/g). Dashed
lines depict the detection limit of the assays. All error bars represent standard deviations. Statistical
analysis is performed using Kruskal–Wallis test (**, p value < 0.01; ***, p value < 0.001).
Different human MERS-CoV strains have been isolated since the EMC/2012 strain was first
characterized [22,23]. However, studies that evaluate phenotypic differences between these strains in
animals are currently lacking. We investigated whether a more recent MERS-CoV strain (Qatar15/2015)
replicates differently in rabbits in comparison to the EMC strain. We found that rabbits inoculated
with the MERS-CoV EMC strain and those with the Qatar15 strain developed an equally mild infection
and shed similar levels of viral RNA in their nasal and throat swabs (Figure 3). Following this result,
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the MERS-CoV transmission experiment was performed using the Qatar15 strain, the more recent
strain of these two.
Figure 3. Middle East respiratory syndrome coronavirus (MERS-CoV) EMC strain and Qatar15 strain
replicate equally in the upper respiratory tract of rabbits. Five New Zealand rabbits were each
intranasally inoculated either with 1 mL of 1 × 106 TCID50/mL MERS-CoV EMC strain or Qatar15 strain.
Nasal and throat swabs were obtained from day 0 (before inoculation) until day 4 post inoculation.
The amount of viral RNA is displayed in genome equivalents per mL (GE/mL). Dashed lines depict the
detection limit of the assay. All error bars represent standard deviations.
3.3. Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Transmission to Contact and
Airborne-Exposed Rabbits
To study MERS-CoV transmission, an experimental set up previously used to investigate influenza
A virus transmission between ferrets was used. This set up consists of two polymethyl methacrylate
cages separated with two steel grids, 10 cm apart [16]. Because this set-up was too small to house
New Zealand rabbits, we used a smaller-sized breed, the Netherland dwarf rabbits. Prior to the
virus transmission experiment, Netherland dwarf rabbits were inoculated with MERS-CoV Qatar
15 strain to determine their susceptibility to the virus. Similar to the New Zealand rabbits [15],
Netherland dwarf rabbits shed viral RNA in the nasal and throat swabs as well as in the respiratory
tract tissues upon intranasal inoculation (Figure 4A,B). Identical to the New Zealand rabbits [15],
the MERS-CoV-inoculated Netherland dwarf rabbits did not develop any clinical signs, including
nasal discharge, and showed minimal histopathological lesions and immune cell infiltration in the
respiratory tract.
85
Viruses 2019, 11, 381
 
Figure 4. Middle East respiratory syndrome coronavirus (MERS-CoV) infects the upper and lower
respiratory tract of Netherland dwarf rabbits. The amount of viral RNA in the nasal and throat swabs
(A) as well as in the respiratory tract tissues (B) are displayed in genome equivalents per mL (GE/mL)
and genome equivalents per gram tissues (GE/g), respectively. Dashed lines depict the detection limit
of the assays. All error bars represent standard error of means.
To study MERS-CoV transmission, four Netherland dwarf rabbits were intranasally inoculated
with MERS-CoV. Six-hours later, each of them was co-housed with one naïve rabbit in the same cage,
and 24 h later another one was co-housed in an adjacent cage to determine whether MERS-CoV could be
transmitted through contact and/or airborne routes. Nasal and throat swabs were collected every other
day up to day 7 or 9 post inoculation/exposure for the donor and direct contact rabbits, respectively,
and day 9 post exposure for the airborne recipient ones. Both viral RNA and infectious virus were
quantified in these samples. We found that all donor rabbits shed high loads of viral RNA in both the
nasal swabs (~105–106 TCID50 GE/mL) and the throat swabs (~103–104 TCID50 GE/mL). The amount of
viral RNA shed by the inoculated rabbits remained high until day 7 post inoculation. On the other
hand, recipient rabbits housed in the same cage (direct contact recipients), or adjacent cage (airborne
recipients), shed limited amounts of viral RNA (~10 TCID50 GE/mL) in both nasal and throat swabs.
Among four animals in each group, only two direct contact recipient and two airborne recipient rabbits
had detectable viral RNA up to day 5 post inoculation in the nasal swabs, while in the throat swabs,
viral RNA was only detected in one direct contact recipient and one airborne recipient rabbit at day
1 post inoculation (Figure 5A,B). Infectious virus was detected at low level (~102 TCID50/mL) both
in the nasal and throat swabs of the donor rabbits; in the nasal swabs of all donor rabbits at day 1
post inoculation, and in one of the donors up to day 7. In the throat swabs, infectious virus was only
detected in two donors on day 1, up to day 5 in one of them. In contrast, none of the swabs from
recipient rabbits was positive for virus titration (Figure 5C,D). Serological analysis of samples collected
14 days after exposure showed that only the donor rabbits seroconverted and developed neutralizing
antibodies (Figure 6A,B). The antibody response of these directly inoculated rabbits was relatively
low, confirming the results of previous studies [15,21]. This indicates that these rabbits developed
MERS-CoV infection while the contact and airborne-exposed rabbits did not, supporting the results of
the virus titration.
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Figure 5. Shedding of Middle East respiratory syndrome coronavirus (MERS-CoV) RNA and infectious
virus in directly inoculated, contact-exposed and airborne-exposed rabbits. MERS-CoV RNA and
infectious virus were measured in the nasal (A,B) and throat swabs (C,D). The amount of viral RNA
is displayed in genome equivalents per mL (GE/mL), while infectious virus is shown as 50% tissue
culture infective dose per ml (TCID50/mL). Dashed lines depict the detection limit of each assay.
Figure 6. Middle East respiratory syndrome coronavirus (MERS-CoV)-specific antibody response in
rabbits. S1-specific MERS-CoV antibodies were measured with ELISA and displayed as optical density
(OD) value (A), while MERS-CoV neutralizing antibodies were measured with the virus neutralization
test (VNT) and displayed in titers (B). Dashed lines depict the detection limit of the assay.
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4. Discussion
Current data indicate that MERS-CoV is highly endemic in dromedary camels in the Arabian
Peninsula and Africa and has been circulating in these animals for decades [3–5,24]. This suggests
that this virus is easily transmitted between dromedary camels. From an epidemiological point of
view, it is important to know whether other animal species in the region may also spread the virus
to humans or other animal species. In vitro, MERS-CoV has been found to infect cells from a broad
range of animal species including Old and New World camelids as well as primates, bats, cows, sheep,
goats, pigs, horses, and rabbits [15,25,26]. The DPP4 viral receptor of these species, especially rabbits,
has high similarity to that of humans and dromedary camels, especially in the region that interacts
with the spike protein, and thus can facilitate MERS-CoV infection [25–27]. The New World camelids,
i.e. llamas and alpacas, have been shown to seroconvert to MERS-CoV when present in regions where
MERS-CoV is circulating and may transmit the virus [12–14]. It is currently unclear why, besides
camelids, other livestock animals do not seem to transmit the virus to humans [24,28–30]. To further
understand the transmission potential of MERS-CoV, we performed virus transmission experiments
using rabbits as animal model.
To perform the virus transmission experiments, we housed MERS-CoV-inoculated rabbits together
with naïve contact rabbits either in the same or adjacent cages. Rabbits developed both upper and lower
respiratory tract infection upon MERS-CoV inoculation [15], either via intranasal or combined intranasal
and intratracheal routes, in line with the localization of DPP4 in their respiratory tract epithelium.
The amount of viral RNA being shed by the inoculated rabbits during the first three days post
inoculation is almost as high as that of the MERS-CoV-inoculated dromedary camels [31,32]. However,
none of the direct contact and airborne-exposed rabbits developed any clinical signs, shed significant
levels of viral RNA, shed infectious virus, nor did they seroconvert. One possible reason for this lack
of transmission is the limited amount of infectious virus being shed by the inoculated rabbits [21].
Previous studies have shown that in the nasal and lung tissues of experimentally infected rabbits,
infectious virus was generally detected in a limited amount despite the abundant presence of viral RNA
and virus nucleoprotein [15,21]. Alternatively, low levels of infectious virus transmitted to recipient
animals may be unable to initiate a productive infection due to the presence of host proteins that
restrict replication. Comparable to rabbits, MERS-CoV-infected pigs and goats develop minimal clinical
signs, hardly shed infectious virus, and barely spread the virus to naïve animals [28,33]. In contrast,
MERS-CoV-infected dromedary camels develop nasal discharge and shed a high amount infectious
virus (104–105 TCID50/mL), almost equal to the amount of viral RNA being shed (105–106 GE/mL),
during the first 4 days post inoculation [31,32]. These interspecies differences may indicate presence of
nasal discharge and infectious virus shedding as critical factors in MERS-CoV transmission. In humans,
levels of infectious virus shed by MERS-CoV patients have rarely been reported. However, MERS-CoV
patients that transmit the virus have been shown to shed a higher amount of viral RNA in their swabs
compared to those that do not, supporting the quantity of virus shed as an important factor in the
transmission of MERS-CoV between humans [34]. For influenza A viruses, infectious virus shedding
has been documented as one of the main determinants of airborne virus transmission. Using ferrets as
an animal model, it has been reported that a reduction in infectious virus shedding in the nasal swabs
can subsequently limit virus transmission [35–37].
Our results show that despite the presence of DPP4 in the upper respiratory tract, accompanied
by MERS-CoV replication at this site, a limited amount of infectious virus was shed. Similarly,
titration of rabbit lung homogenates that show high levels of viral RNA and presence of nucleoprotein
(Figure 2C,D) resulted in only low levels of infectious virus, in line with earlier observations [15,21].
At this stage, it is not clear which host mediated mechanisms limit the production of infectious
virus while allowing viral RNA to still be shed at high levels. Since restriction of infectious virus
shedding in the rabbits already occurred one day post inoculation, activation of host innate immune
responses, including type I interferon induction, may be relevant. In vitro studies have shown that
MERS-CoV is relatively sensitive to type I interferon-mediated antiviral activities [38,39]. In human
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plasmacytoid dendritic cells, MERS-CoV inoculation leads to secretion of large amount of type I and
III interferons and production of viral RNA, but hardly any infectious virus is being produced [40].
It is also possible that most infectious virus shed by these rabbits is defective, lacking the capacity
to efficiently infect target cells. Further studies are needed to elucidate the mechanisms that restrict
MERS-CoV replication in rabbits compared to dromedary camels. Potentially, some of the MERS-CoV
accessory proteins shown to antagonize immune responses including production of interferon, may not
work efficiently in some MERS-CoV susceptible species, including rabbits. It is intriguing to investigate
whether a similar phenomenon occurs in some human MERS-CoV infections and whether this is
linked to the development of asymptomatic to mild clinical manifestations [41]. This might partly
explain why MERS-CoV transmission in humans is rather inefficient in comparison to dromedary
camels [42,43], and why camelids that secrete high levels of infectious virus are the only known
zoonotic source of MERS-CoV [2,7,14,31]. Deciphering these mechanisms could potentially offer
insight into understanding MERS-CoV transmission as well as developing novel treatments to tackle
the ongoing outbreaks.
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Abstract: Infection by the Middle East respiratory syndrome coronavirus (MERS-CoV) causes
respiratory illness and has a high mortality rate (~35%). The requirement for the virus to be
manipulated in a biosafety level three (BSL-3) facility has impeded development of urgently-needed
antiviral agents. Here, we established anovel mouse model by inserting human dipeptidyl peptidase
4 (hDPP4) into the Rosa26 locus using CRISPR/Cas9, resulting in global expression of the transgene in
a genetically stable mouse line. The mice were highly susceptible to infection by MERS-CoV clinical
strain hCoV-EMC, which induced severe diffuse pulmonary disease in the animals, and could
also be infected by an optimized pseudotyped MERS-CoV. Administration of the neutralizing
monoclonal antibodies, H111-1 and m336, as well as a fusion inhibitor peptide, HR2P-M2, protected
mice from challenge with authentic and pseudotyped MERS-CoV. These results confirmed that the
hDPP4-knockin mouse is a novel model for studies of MERS-CoV pathogenesis and anti-MERS-CoV
antiviral agents in BSL-3 and BSL-2facilities, respectively.
Keywords: mouse model; hDPP4; MERS-CoV; pseudotyped virus; authentic virus
1. Introduction
According to the World Health Organization’s (WHO) latest report, the Middle East respiratory
syndrome coronavirus (MERS-CoV) has caused 2121 laboratory-confirmed infections and 740 deaths
(~35% mortality rate) in 27 countries since the virus was first isolated in Saudi Arabia in September,
2012 (http://www.who.int/emergencies/mers-cov/en/). Although no cases of the closely-related
severe acute respiratory syndrome coronavirus (SARS-CoV) have been reported since 2005 [1],
the incidence of MERS-CoV infections and the number of affected countries both continue to increase.
Epidemiological trends indicate that prevention of potential epidemic spread of MERS-CoV is likely to
be a long and tough battle [2]. Unfortunately, no clinically-approved antiviral monoclonal antibodies
(mAbs), small molecule drugs or vaccines against MERS-CoV are available.
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Preclinical animal models that mimic the human pathogenesis of MERS-CoV infection are urgently
needed for the development of vaccines and therapies. The classification of MERS-CoV as a biosafety
level three (BSL-3) agent is an additional hurdle to progress in this area. Since the emergence of
MERS-CoV, several animal species have been evaluated as potential models, including wild-type
mice, mice deficient in innate immunity [3], Syrian hamsters [4], ferrets [5] and non-human primates
(NHPs) [4,6]. Two NHPs (rhesus macaques and marmosets) were found to be susceptible to MERS-CoV
infection, but other species including mice are naturally non-permissive to infection. Although
human DPP4 (hDPP4) has been identified as the receptor for MERS-CoV [7] that mediates infection,
mouse DPP4 (mDPP4) is not functional in this respect [8]. Mice adenovirally transduced with hDPP4
could be transiently infected by MERS-CoV but did not develop fatal MERS disease [9].Moreover,
hDPP4-transgenic (Tg) mice expressing hDPP4 under the control of either the cytokeratin 18
promoter [10] or a ubiquitous promoter [11] were susceptible to MERS-CoV infection and developed
fatal disease, but also developed unrelated lethal encephalitis. Two knock-in (KI) mice in which mDPP4
was replaced with hDPP4 using CRISPR/Cas9 [8,12] could be infected by high-titer MERS-CoV isolates
but were more susceptible to mouse-adapted MERS-CoV strains. Since mDPP4 is central to normal
glucose homeostasis [13] and plays an important role in immunity [14], altering its sequence may
disrupt these functions.
Neutralizing antiviral mAbs are promising candidates for treatment and prevention of MERS-CoV
infection [15]. Several highly potent mouse, human and humanized neutralizing mAbs targeting the
receptor-binding domain (RBD) of the spike (S) protein have been reported [16–20], and antiviral
compounds and prophylactic vaccines are also under development. These vaccines and therapeutic
agents have typically been evaluated in in vitro systems using MERS-CoV pseudoviruses; however,
their efficacy must eventually be confirmed in vivo using a suitable animal model. Several Tg or KI
mice susceptible to MERS-CoV are available [9,11,12,21], and challenge experiments under BSL-3
conditions have been done for the evaluation of potential therapeutics and vaccines.
In this study, we established a novel KI mouse by inserting the full-length hDPP4 gene into
the C57BL/6 mouse genome at the Rosa26 locus (used for constitutive, ubiquitous gene expression)
using CRISPR/Cas9 gene editing technology. This mouse, termed R26-hDPP4, displayed severe
lung disease related to acute respiratory symptoms (ARDS) as well as central nervous system (CNS)
involvement after infection with authentic MERS-CoV clinical isolates at low dose. Moreover, high-titer
MERS-CoV pseudovirus could also productively infect R26-hDPP4 mice, with effects comparable to
those following authentic infection.
2. Materials and Methods
2.1. Ethics Statement
Wild-type C57BL/6 mice and genetically-modified mice were supplied by the Institute for
Laboratory Animal Resources, National Institute for Food and Drug Control (Beijing, China).
All studies were performed in compliance with animal protocols (#2017-B-004) approved by the
Institutional Animal Care and Use Committee of the National Institute for Food and Drug Control,
China Food and Drug Administration (CFDA, Beijing, China) and in compliance with the “Guide
for the Care and Use of Laboratory Animals” (National Academies Press: Washington, DC, USA,
2011; 8th ed.). The license number of the Animal Use Certificate issued by the Science & Technology
Department of China (Beijing, China) was SYXK 2016-004, approved on 18 February 2016
2.2. Construction of hDPP4-KIMice
To construct the targeting vector, cDNA encoding hDPP4 (also known as CD26 [14])
linked to the red fluorescent protein tdTomato by an internal ribosomal entry site (IRES)
sequence was inserted between homologous recombination sequences at the Rosa26 locus.
The targeting vector, sgRNA specific for the Rosa26 locus and Cas9 mRNA were microinjected
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into C57BL/6 zygotes, which were subsequently implanted into pseudo-pregnant mice. Offspring
were genotyped using primers Dpp4f (5′-CTGCAGTACCCAAAGACTGTACGGG-3′) and Dpp4r
(5′-GACACCTTTCCGGATTCAGCTCACA-3′). The expected amplicon size using these primers was
628bp. Genotype-positive founders were back-crossed with C57BL/6 mice to produce generation
F1. Tail tips of four F1-positive mice were subjected to Southern blotting to confirm correct insertion
of hDPP4.
2.3. Generation of Pseudoviruses
Replication-incompetent HIV virions pseudotyped with MERS-CoVS protein (human
beta-coronavirus 2c EMC/2012, AFS88936.1) and expressing firefly luciferase (Fluc) were generated
as previously described [22,23]. The MERS-CoV S protein sequence was codon optimized for
Homo sapiens by GENEWIZ (Suzhou, China) and cloned into an expression vector to yield
pcDNA3.1-opti-MERS-CoV-Spike. Briefly, human embryonic kidney (HEK) 293T or 293 cells (both
from ATCC) were co-transfected with pcDNA3.1-opti-MERS-CoV-Spike and the lentiviral vector
pSG3.Δenv.Fluc [22] using various transfection reagents including Lipofectamine 2000 (Invitrogen,
11668019, Carlsbad, CA, USA), Lipofectamine 3000 (Invitrogen, L3000015, USA), polyethylenimine
(Alfa Aesar, 43896, Lancashire, UK), Neofect, VigoFect (Vigorous Biotechnology, T001, Beijing, China),
and TurboFect (Thermo Scientific, R0531, Waltham, MA, USA). After incubation for 48 h, culture
supernatants were centrifuged at 210× g for 5 min, filtered through 0.45-μM filters, and concentrated
with 30-kDa ultrafiltration devices (Millipore, Boston, MA, USA). All experiments involving
pseudotyped MERS-CoV were performed in a BSL-2facility.
2.4. In Vitro Neutralization Tests
To conduct high-throughput in vitro neutralization assays, an optimized dose of MERS-CoV
pseudovirus was incubated with each mAb for 1 h at 37 ◦C, and then the mixture was added to
human Huh7 hepatoma cells (Fengh Bio. Inc., Changsha, China) or other cell types in a 96-well plate
and incubated for 48 h. The infectivity of MERS-CoV pseudoviruses was determined by measuring
bioluminescence as described previously [24].
2.5. MERS-CoV-Neutralizing Monoclonal Antibodies
Recombinant extracellular domain of the MERS-CoV spike (S) protein (40069-V08B) from human
beta-coronavirus 2c EMC/2012 and its recombinant RBD (40071-V08B1) were purchased from Sino
Biological, Inc. (Beijing, China). Phage library construction and antibody selections were carried
out as described below. Six-week-old female BALB/c mice were immunized intraperitoneally (I.P.)
with 5 μg of recombinant S protein. RNA was extracted from spleen cells and used to construct a
phage-displayed antibody library. Recombinant RBD protein was used to screen antibodies. After four
rounds of panning, antibodies that specifically recognized the S protein were obtained. The variable
regions of the light and heavy chains of these antibodies were fused to mouse kappa or IgG1 constant
regions using PCR and cloned into the pSTEP2 HEK-293 transient expression vector. Suspension
HEK-293 cells were transfected with light chain and heavy chain expression vectors and recombinant
mouse mAbs were purified from culture supernatants using protein A affinity chromatography.
The positive control mAbm336 was prepared and provided by Prof. Tianlei Ying [25]. The peptide
inhibitor of MERS-CoV was provided by Prof. Shibo Jiang [26,27].
The variable regions of the light and heavy chains of mouse antibody MERS-H111 were
aligned to human germline genes, and the most homologous human framework was chosen for
humanization [28,29]. The murine sequence was preserved at key residues to maintain structural
stability. Codon-optimized light-chain and heavy-chain variable region sequences were synthesized
and cloned into expression vectors containing kappa and IgG1 constant regions. Suspension HEK-293
cells were transfected with expression vectors encoding the light and heavy chains of MERS-H111-1,
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and the expressed antibody was purified from the supernatant using protein A affinity chromatography
after 7 days.
2.6. Murine Model of MERS-CoV Pseudovirus Infection
Mice were challenged by different routes with varying doses of pseudotyped MERS-CoV.
The IVIS-Lumina II imaging system (Xenogen, Baltimore, MD, USA) was used to detect
bioluminescence as described previously [30,31]. Prior to measuring luminescence, mice were
anesthetized by I.P. injection of sodium pentobarbital (240 mg/kg). The exposure time was 60 s,
and fluorescence intensity in regions of interest was analyzed using Living Image software (Caliper
Life Sciences, Baltimore, MD, USA). Different wavelengths were used for detecting pseudovirus and
tdTomato fluorescence. The substrate, D-luciferin (50 mg/kg, Xenogen-Caliper Corp., Alameda, CA,
USA), was injected I.P. and imaging was conducted 10 min later. The relative intensities of emitted
light were represented as colors ranging from red (intense) to blue (weak) and quantitatively presented
as photon flux in photon/s/cm2/sr.
2.7. Authentic Virus Infection of Mice and Plaque Assays
Four-week-old R26-hDPP4 and wild-type mice were challenged with authentic MERS-CoV strain
hCoV-EMC (1.5 × 105 PFUs) by the intranasal (I.N.) route and body weight was measured daily.
On the fifth day post-infection (p.i.), all mice were sacrificed for sample collection. The timing of
sacrifice was based on the consideration of humane euthanasia for body weight loss exceeding 25% [8].
Viral titers in lung tissues were determined by plaque assays on Vero cells following a protocol
described previously [18]. The authentic MERS-CoV strain hCoV-EMC was maintained and tested
in the BSL-3 facility (facility No. ABSL-3059) of the Institute of Laboratory Animal Sciences, CAM &
PUMC, Beijing China, with strict use of personal protective equipment as described previously [32].
2.8. RNA Extraction and Real-Time QuantitativePCR
Tissues were dissected, immediately immersed in RNAlater® stabilization reagent (Invitrogen,
USA) and stored at −80 ◦C. Total RNA was extracted from individual tissues using
TRIzol and quantified using a spectrophotometer at a wavelength of 260 nm. Random
hexamers were used to prime reverse-transcription reactions using a reverse transcription
(RT)-PCR kit containing SYBR green dye (Takara, Shiga, Japan). Real-time quantitative
PCR (RT-qPCR) was performed using a Light Cycler 480 Real-Time PCR system (Roche,
Indianapolis, IN, USA). Each reaction was performed in triplicate. Relative expression level
of DPP4 was determined using primers DPP4-Q-F (5′-GGGTCACATGGTCACCAGTG-3′) and
DPP4-Q-R (5′-TCTGTGTCGTTAAATTGGGCATA-3′) and normalized to expression of GAPDH
(glyceraldehyde 3-phosphate dehydrogenase). Viral loads were quantified using primers gag-F1
(5′-AGCACAGCAAGCAGCAGC-3′), gag-R1 (5′-GTGGCTCCTTCTGATAATGCTGAA-3′) and a
TaqMan probe (5′Fam-ACAGGAAACAGCAGCCAGGTCAGCCGA-3′Tamra). Data were presented
as log viral RNA copies/GAPDH copies.
2.9. Western Blotting
Mouse tissues were homogenized in RIPA lysis buffer (50 mM Tris-HCl, pH 7.4, containing
150 mM NaCl, 100 mM EDTA, and 0.1% SDS) supplemented with 1× Proteinase Inhibitor (PI)
(Roche, Basel, Switzerland). The denatured protein lysates were separated using 10% SDS-PAGE gels.
After transfer, anti-hDPP4 mouse monoclonal antibody (1:3000 dilution, Origene, Rockville, MD, USA)
and anti-GAPDH antibody (1:5000, Abcam, Cambridge, UK) were added, followed by horseradish
peroxidase (HRP)-conjugated anti-mouse IgG (1:20,000, Santa Cruz Biotechnology, Santa Cruz, CA,
USA). The Immobilon Western Chemiluminescent HRP Substrate kit (Millipore Corporation, Billerica,
MA, USA) was used for development.
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2.10. Immunohistochemistry
Mouse tissues were fixed in 10% neutral-buffered formalin, embedded in paraffin, and sectioned
to about 3-μm thickness. Tissue sections were stained with hematoxylin and eosin for histopathological
examination. For immunohistochemistry (IHC), tissue sections were rehydrated and incubated in
Coplin jars filled with Citra buffer (pH 6.0) at 96 ◦C in a microwave oven for 10 min, cooled at room
temperature for 60 min and then blocked with 10% normal goat serum at 37 ◦C for 60 min. The sections
were incubated overnight at 4 ◦C with either 1:200 rabbit R723mAb (produced by phage display,
with specificity against the receptor-binding domain of MERS-CoV; kindly provided by Beijing Wantai
Biological Pharmacy Enterprise Co., Ltd., Beijing, China) or normal goat serum (control). Sections
were washed with PBS and incubated with HRP-conjugated goat-anti-rabbit secondary antibody
(Zhongshan Golden Bridge Biocompany, Beijing, China) for 40 min at room temperature, followed by
development with 3,3′-diaminobenzidinesubstrate (Zhongshan Golden Bridge Biocompany, Beijing,
China) and counterstaining with hematoxylin.
2.11. Data and Statistical Analysis
Sample sizes in each group were calculated based on anticipated effect sizes to yield statistically
significant differences. Inhibition rates of mAbs were calculated using the following formula: (value
of positive group−value of mAb treatment group)/value of positive group. The value represented
either fluorescence derived from pseudovirus infection or authentic viral titers in lung tissues. Data
were analyzed using SPSS (ver. 18.0; IBM, Armonk, NY, USA) or GraphPad Prism 5.0 (GraphPad
Software, San Diego, CA, USA). Results from each experiment were presented as means plus standard
deviations (SD) or standard error of mean (SEM). Student’s t-tests were used to assess differences
between groups. Dunnett’s tests were performed for multiple comparisons. p values less than 0.05
were considered statistically significant.
3. Results
3.1. A HDPP4-Knockin Mouse (R26-hDPP4) Was Established Using CRISPR/Cas9
A KI mouse was generated by inserting the full-length hDPP4 gene [7] into the Rosa26 locus,
which has been shown to be a safe harbor for developing genetically stable KI mouse lines [33].
Expression of hDDP4cDNA was driven by the splice acceptor, which allowed ubiquitous expression
of hDPP4 under control of the Rosa26 promoter. The tdTomato gene was inserted downstream of
hDPP4 with an internal ribosome entry site allowing co-expression of tdTomato and hDPP4. A poly(A)
sequence and a woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) were added
to enhance mRNA stability and translation efficiency (Figure 1A). The targeting vector along with
subgenomic RNA (sgRNA) and Cas9 mRNA were injected into zygotes of C57BL/6 mice. Successful
insertion in nine of 41 offspring was positively confirmed by Southern blotting and the results for
five mice are presented in Figure 1B. One male founder and one female founder died before weaning
and two founders were too emaciated to mate. Five founders were backcrossed with C57BL/6 mice,
and two matings produced F1-positive offspring. Tail tips of F1-positive mice were subjected to PCR
genotyping (Figure 1C) and Southern blotting to confirm correct insertion of hDPP4. Homozygous mice
were termed B6-Gt (Rosa) 26 Sortm1 (SA-hDPP4-tdTomato), abbreviated to R26-hDPP4. Significant
hDPP4 expression could be detected by RT-PCR in all R26-hDPP4 mouse tissues tested (Figure 1D),
but no expression was detected in wild-type mice. Western blotting of lung and brain tissues confirmed
hDPP4 expression (Figure 1E). Unlike Tg mice, which showed the highest-level expression of hDPP4
in heart and brain [11], R26-hDPP4 mice had the highest hDPP4 expression in lung. Profiting from the
insertion of tdTomato downstream of hDPP4, the global expression patterns of hDPP4 were examined
visually (Figure 1F) via bioluminescent imaging (BLI). Since the liver, intestine and lung have bigger
volumes, they have brighter images than other organs.
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Figure 1. Establishment of a R26-hDPP4-knockin mouse model. (A) Schematic strategy for generation
of R26-hDPP4-knockin mice via CRISPR/Cas9. (B) For the R26 probe, genomic DNA was digested
with SpeI, and the expected sizes of wild-type and gene-targeted bands were 8.9 kb and 14.2 kb,
respectively. For the WPRE probe, genomic DNA was digested with BglII, and the expected size of
the gene-targeted band was 5.1 kb. Four representative results are shown. (C) PCR genotyping of
R26-hDPP4 mice. The primer pair was designed to anneal in the coding region of hDPP4, and the
expected PCR amplicon was 628 bp in length. (D) Quantitative reverse transcription PCR (RT-qPCR)
of hDPP4 mRNA in R26-hDPP4 mice and wild-type C57BL/6 mice. Values are presented as means
± SEMs of three independent experiments and were normalized to GAPDH levels. No expression of
R26-hDPP4 in wild-type mice was detected. (E) Detection of DPP4 protein by western blotting in brain
and lung. Weaker blotting signal was detected in wild-type mice, indicating the anti-hDPP4 antibody
could recognize mDPP4. (F) Bioluminescence imaging (BLI) of newborn R26-hDPP4-knockin mice
showing hDPP4 expression in their organs. The imaged organs were: (1) thymus, (2) liver, (3) stomach,
(4) kidney, (5) intestine, (6) spleen, (7) heart, (8) lung, (9) and (10) the whole bodies of wild-type mice
and R26-hDPP4 mice, respectively.
3.2. R26-hDPP4 Mice Were Susceptible to Authentic MERS-CoV Infection, with Infected Mice Exhibiting
Disease Symptoms Similar to Those of MERS-CoV-Infected Human Patients
To test whether R26-hDPP4 mice could support efficient infection by and replication of MERS-CoV,
4- to 5-week-old R26-hDPP4 and wild-type mice were infected I.N. with MERS-CoV clinical strain
hCoV-EMC [34] at a dose of 1.5 × 105 PFUs. The bodyweights of wild-type mice increased
approximately 24% (Figure 2A) by day 5 p.i., while R26-hDPP4 mice experienced significant weight loss
of up to 28% (23–33.5%). By day 4 p.i., all R26-hDPP4 mice had lost at least 20% of their bodyweights,
meeting the typical cut-off used in humane euthanasia criteria [8]. Two mice (2/4) had lost more than
30% of their body weights by day 4 p.i.
Viral titers in the lungs of R26-hDPP4 mice were measured as approximately 103 PFU sat 5 days
p.i. while no virus was detected in the lungs of wild-type mice (Figure 2B; mean difference 2.958 log
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PFUs, 95% CI 1.266–4.699 log PFUs). Although weight loss and viral loads provide important measures
of mouse susceptibility, these parameters do not directly reflect pathologic changes. Therefore,
the lungs, brains, livers, and kidneys collected from infected mice were subjected to histopathological
analysis and IHC (Figure 2C–O). By quantitative analysis of pathological scores, the symptoms of
R26-hDPP4 mice were significantly different compared with wild-type mice (Figure 2C). Associated
with these pathological changes, significant viral loads were detected in lung (Figure 2E). In the
cerebellum, cerebral ganglia and cerebrum of R26-hDPP4 mice, perivascular gliosis was observed
(Figure 2F; Supplementary Figure S1C) with accompanying virus detected in this organ (Figure 2G).
No obvious lesions were observed in liver and kidney (Figure 2H) and no virus was detected in
these organs (Figure 2I), despite the fact that a MERS-CoV-infected patient with acute nephritis
has been reported [35]. By contrast, in the corresponding organs of wild-type mice, no or minimal
pathological changes were observed and no virus could be detected (Figure 2J–O). These results
indicated that R26-hDPP4 mice were permissive to infection by authentic MERS-CoV and that infection
was accompanied by severe disease symptoms similar to those of MERS-CoV-infected human patients.
Figure 2. R26-hDPP4-knockin mice were susceptible to infection by authentic MERS-CoV at low
dose. (A) Weight loss in R26-hDPP4 mice challenged with hCoV-EMC at a dose of 1.5 × 105 PFUs.
(B) Viral titers in lungs of challenged R26-hDPP4 mice on day 5 p.i. LOD (limitation of detection):
0.85 PFU. (C) Quantitative analysis of pathological lesions in lungs. W. A. S. = widened alveolar septa;
I. S. F. = inflammatory cells, serous and fibrinous exudation; D. N. B. = degeneration and necrosis
of bronchial epithelial cells; P. I. I. = perivascular inflammatory cell infiltration; V. H. = vasodilator
hyperemia. (D–O) Histopathological changes and viral loads in the lungs, brains, and kidneys of mice.
R26-hDDP4 mice exhibited disease symptoms similar to those of MERS-CoV-infected human patients
(D), while no or mild symptoms were observed in wild-type mice. (J). Perivascular gliosis in the
cerebellum was observed in R26-hDPP4 mice (F) but not in wild-type mice (L). No pathological lesions
were identified in the kidneys of either R26-hDPP4 or wild-type mice (I,O). IHC assays confirmed viral
loads in lungs (E) and cerebella (G) of R26-hDPP4 mice; little or no virus was detected in the lungs (K)
and cerebella (M) of wild-type mice. Four mice in each group were infected, and samples from all mice
were subjected to tittering and histopathological analysis (* p < 0.05; ** p < 0.01; *** p < 0.001).
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3.3. A MERS-CoV S-RBD-Specific Neutralizing Antibody Protected R26-hDPP4 Mice from Challenge with
Authentic MERS-CoV
Next, we evaluated the effects of a neutralizing mAbon R26-hDPP4 mice infected with authentic
virus. To this end, a humanized mAb, H111-1, was generated by phage display methods and
administered intravenously (I.V.) ata single dose (either 1 mg/kg or 5 mg/kg) 6 h after infection with
hCoV-EMC (1.5 × 105 PFUs). Administration of H111-1 significantly decreased viral titers in lungs
(from 3 log PFUs to 0.9 log PFUs and1.2 log PFUS for the 5 mg/kg and 1 mg/kg groups, respectively;
Figure 3A), and reduced weight loss in a dose-dependent manner (Table 1). Viral titers in the higher
mAb dose group were below the limit of detection. The average inhibition rates of authentic virus
were 70% for 5 mg/kg mAb and 60% for 1 mg/kg mAb, respectively. Notably, mAbH111-1 completely
ablated viral loads in the lungs in two of four mice in both low- and high- dose mAb groups (Figure 3A).
IHC results confirmed lower viral loads in the lungs of mAb-treated mice (Figure 3(C,C)), while a
reduction of viral load in cerebellum was less clear (Figure 3(C,C)). In addition, treatment with mAb
H111-1 alleviated symptoms in both lung and brain (Figure 3(C,C,C,C	)), with degeneration and
necrosis of bronchial epithelial cells improving significantly in treated animals (Figure 3B, p < 0.05).
These results indicated that humanized mAb H111 is a promising antiviral agent for preventing
MERS-CoV infection. Importantly, these results also implied that the R26-hDPP4 mouse could be an
effective model for evaluating antiviral agents against MERS-CoV in vivo.
Figure 3. MERS-CoV S-RBD-specific humanized neutralizing antibody H111-1 protected R26-hDPP4
mice from challenge with authentic MERS-CoV. Four-week-old mice were administered either PBS
(control), 1 mg/kg mAb H111-1 or 5 mg/kg mAb H111-1 via the I.P. route, and 6 h later they were
challenged I.N. with hCoV-EMC (1.5 × 105 PFUs). On day 5 p.i., mice were sacrificed for virus titering
and pathological analysis. (A) Treatment with mAb H111-1 significantly decreased viral titers in lungs.
The dashed line indicates the LOD. (B) Efficacy of mAbH111-1 in abating pathological lesions caused by
infection with authentic MERS-CoV. Explanation of pathological changes is given in Figure 2. (C–C)
Histopathological changes and viral loads in lungs and brains of R26-hDPP4 mice administered 1
mg/kg mAb H111-1 (C,C,C,C) or 5 mg/kg mAb H111-1 (C,C,C	,C), * p < 0.05.
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Table 1. Administration of neutralizing mAb H111-1 prevented weight loss in R26-hDPP4 mice infected
with MERS-CoV *#.
Days p.i. 0 1 2 3 4 5
R26-hDPP4 + PBS 0 1.9 ± 2.2 −14.1 ± 1.9 −18.5 ± 5.1 −24.0 ± 4.5 −28.0 ± 5.6
R26-hDPP4 + 1
mg/kgmAbH111-1 0 −0.5 ± 1.4 −13.0 ± 3.5 −17.0 ± 3.0 −22.9 ± 2.7 −27.5 ± 1.9
R26-hDPP4 + 5
mg/kgmAbH111-1 0 −0.1 ± 2.3 −7.6 ± 4.8 −13.1 ± 3.0 −19.0 ± 3.6 −24.8 ± 3.6
Note: * All R26-hDPP4 mice were challenged with authentic MERS-CoV at a dose of 1.5 × 105 PFUs. # Four mice
per group. Numbers represent percentage weight loss compared with weight prior to infection.
3.4. AMurine Model of Infection with Pseudotyped MERS-CoV was Established Using R26-hDPP4 Mice
3.4.1. Optimization of Pseudotyped MERS-CoV System and Establishment of a Model of Pseudotyped
MERS-CoV Infection Using R26-hDPP4 Mice
Zhao et al [2] reported a MERS-CoV pseudovirus that allowed for single-round infection of
several cell lines expressing hDPP4. However, despite using several proven methods [22], we at
first failed to infect R26-hDPP4 mice, which were otherwise permissive to infection by authentic
virus, using pseudotyped virus. At first, we attributed this failure to low pseudovirus titer and
therefore we optimized the parameters of pseudovirus production (Supplementary Figure S2A–D).
Finally, pseudovirus with titers up to 1.27 × 107.5 TCID50/mL (Supplementary Figure S2E) was
obtained. The pseudovirus was then titrated in 4-week-old R26-hDPP4 mice, and the 50% animal
infectious dose (AID50) was determined to be 10 TCID50/mL viatheintrathoracic (I.T.) route.
To establish an in vitro neutralization assay, the cellular tropism of pHIV/MERSS/Fluc was tested
in various cell lines. All 12 cell lines tested were permissive to pHIV/MERSS/Fluc infection, but Huh7
cells showed the highest infection efficiency (Supplementary Figure S2F), demonstrating the wide
cellular tropism of the pseudotyped virions. As a result, the Huh7 cell line was chosen to establish a
chemiluminescence-based, high-throughput antibody neutralization assay. The assay displayed good
sensitivity and specificity.
Since the I.P. infection route was efficient for a pseudotyped Ebola virus model [36], groups
of 4-week-old R26-hDPP4 mice were administered pseudotyped virus I.P. Mice were anaesthetized
and observed with a BLI system at various days p.i. Bioluminescence of the transgene-encoded
Fluc reporter was first observed at day 2 p.i. in the abdomen, close to the injection site (Figure 4A).
The bioluminescence then spread to the thoracic cavity by day 6 p.i. Bioluminescence reached peak
intensity and then gradually weakened up to day 20 p.i. (Figure 4B). To identify the sites of infection,
mice were dissected and their organs were observed on the day of peak infection. Figure 4C showed
that thymus, liver, spleen, kidney, lung and muscle, among other organs and tissues, were infected by
pseudovirus. Higher pseudoviruscopy numbers were detected in these organs (Figure 4D), illustrating
that R26-hDPP4 mice could be efficiently infected by pseudovirus. Since MERS-CoV infection mainly
causes clinical ARDS [37,38], the primary site of infection should be the respiratory tract. Therefore,
to maximize infection in the respiratory tract, we infected mice via the I.T. route. Live-animal imaging
showed that infection was mainly localized to the chest, with maximal infection occurring on days
10 and 11 p.i. Using the I.T. route, the major infected organs were the thymus, heart and lung
(Figure 3C). A uniform infection profile was observed in all mice, indicating that I.T. challenge had
some advantages over I.P. challenge. I.N. and I.V. challenge were also attempted but did not result
in productive infection. To test the influence of the animals’ age on susceptibility to infection, 4- to
9-week-old mice were inoculated with pseudovirus. Both younger and older mice could be infected,
but younger mice were more susceptible (Figure 4E,F). As reported previously [30], fluorescence
intensity and virus copy number in tissues were strongly correlated, suggesting that fluorescence
intensity could be used as an indicator of pseudovirus infection. Pseudovirus infection caused no
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histopathological changes, indicating that this tool was safe in mice (Figure 4G). Notably, through BLI
visualization and confirmation by IHC, we found that pseudovirus tended to infect bronchi (Figure 4H),
a tropism shared with authentic virus (Figure 2E).
Figure 4. Establishment of the R26-hDDP4 knockin model of infection with MERS-CoV pseudovirus.
(A–C) Four-week-old R26-hDPP4 mice were inoculated with 1.27 × 107.5 TCID50 (I.P. route) or
3.8 × 106.5 TCID50 (I.T. route) of pHIV/MERSS/Fluc per animal. (B) Bioluminescent images (BLI) are
shown at different days p.i. Relative bioluminescence intensity was shown in pseudocolor, with red
representing the strongest and blue representing the weakest photon fluxes. Data are shown as
means ± deviation (C). Organs were examined for Fluc expression using BLI: 1 = thymus; 2 = heart;
3 = liver; 4 = spleen; 5 = kidney; 6 = lung; 7 = lymph node; 8 = muscle; 9 = skin; 10 = ovary or testis;
11 = brain; 12 = intestine. (D) The copy number of pHIV/MERSS/Flucmeasured by RT-qPCR
(I.P. challenge route). (E,F) Susceptibility tests for mice at different ages. Four- to 9- week-old
mice could be infected, but younger mice were more susceptible, * p < 0.05. (G) Histopathological
examination of organs of pseudovirus-infected mice; no histopathological changes were observed.
(H) Pseudotypedvirions mainly infected the bronchi as shown by IHC and BLI. Bright spots indicate
bronchi separated from lung (n = 4–6/group).
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3.4.2. Relevance of the R26-hDPP4 Mouse Model of Infection by Pseudotyped and Authentic
MERS-CoV
We compared the infection profile between R26-hDDP4 mice infected with pseudotyped
and authentic MERS-CoV (Table S1). Lungs were the major infected organs for both types of
virus (Figure 5A,B), and pulmonary bronchial epithelial cells were the common sites of infection
(Figure 5C,D). Lung tissue tropism was also supported by measurement of pseudovirus copy number
(Figure 4D) and authentic virus titering (Figure 2B). The dose conversion of pseudovirus and authentic
virus is shown in Figure 5E. Authentic virus was observed in the CNS (Figures 2G and 3(C,C))
of infected mice. Interestingly, we observed that pseudovirus could also enter the CNS, as it was
detectable by qRT-PCR or BLI in the brain. How pseudovirus crosses the blood-brain barrier requires
further investigation.
Figure 5. Relationship between pseudovirus and authentic virus models. (A–D) Pseudovirus and
authentic virus infection in the lungs of R26-hDPP4 mice showed a similar pattern, as shown by
IHC using mAb R723 against the RBD of the MERS-CoV S protein. (C,D) Both pseudovirus and
authentic virus infected ciliated columnar epithelium of bronchi. (E) Dose conversion of pseudovirus
and authentic virus. The full black line represented the inhibition rate (
) of humanized mAb H111-1
(1 mg/kg) in vivo using different pseudovirus doses. The blue dashed line represents inhibition rate of
H111-1 against authentic virus. When the dose of authentic virus was 1.5 × 105 PFUs, we calculated
that the inhibition rate of H111-1 at a dose of 1 mg/kg would be 60% (see main text). From the
inhibition rate curve of pseudovirus, the corresponding pseudovirus dose was 3.25 × 107 TCID50.
That is, 1 TCID50 of pseudovirus corresponded to 0.0046 PFU of authentic virus (1.5 × 105/3.25 × 107).
n = 4–6 mice per group.
103
Viruses 2018, 10, 448
3.5. MERS-CoV S-RBD-Specific Neutralizing Antibodies Protected R26-hDPP4 Mice against Challenge with
Pseudotyped MERS-CoV
Monoclonal antibodies can provide robust strategy protection against infection caused by
MERS-CoV [18,19,39]. In vitro pseudovirus neutralization assays are useful tools to test the efficacy
of mAbs [2]. Therefore, the in vitro efficacy of the humanized neutralizing mAb H111-1 to protect
R26-hDPP4 mice against infection by pseudotyped MERS-CoV was assessed. As a comparison,
the in vitro efficacy of the fully human neutralizing mAb m336 [25] to protect R26-hDPP4 mice against
infection was also determined. The 50% inhibitory concentrations (IC50s) of mAbs H111-1 and m336
were determined to be 4.5 and 2.7 ng/mL, respectively, representing high in vitro inhibitory activity.
Both mAbs were administered I.T.to R26-hDPP4 mice at a dose of 1 mg/mouse prior to challenge
with pseudovirus (1.27 × 107.5 TCID50). On day 8 and day 11 p.i., when peak signal could be detected,
BLI images of the whole body and organs were obtained. Both mAbs demonstrated strong protective
efficacy as shown in Figure 6A–F; H111-1 ablated pseudovirus infection when administered by either
the I.P. or I.T. routes (Figure 6A,B,D). The pseudovirus reporter signal in mice administered m336
also decreased significantly in the whole body as well as in lung and thymus (Figure 6C,E,F, p < 0.05
or 0.01).
Next, a dose conversion between pseudovirus and authentic virus was calculated in order to
establish a safety profile. Three groups of R26-hDPP4 mice were challenged with different doses of
pseudovirus (1.25, 3.20, and 3.85 × 107 TCID50) either with or without treatment with mAb H111-1
(1 mg/kg) 6 h prior to challenge. BLI of all mice was performed on day 6 p.i. and inhibition rates
were calculated. As shown in Figure 4E, when mice were challenged with 1.5 × 105 PFUs of authentic
virus, the inhibition rate of H111-1 (1 mg/kg) was 60%. From the inhibition rate curve for pseudovirus
infection, we deduced that the pseudovirus dose corresponding to 60% inhibition was 3.25 × 107
TCID50. That is, 1 TCID50 of pseudovirus was equivalent to 0.0046 PFU of authentic virus. We assumed
that this quantitative parameter would be useful for screening antiviral agents and evaluating vaccines
against MERS-CoV. Since the R26-hDPP4 mouse provided a suitable model for infection by both
pseudotyped and authentic MERS-CoV, the pseudovirus model is a convenient tool to evaluate
the in vivo efficacy of anti-MERS-CoV agents or vaccines in most biological laboratories that lack
BSL-3 facilities.
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Figure 6. Inhibition of pseudotyped MERS-CoV infection in R26-hDPP4 mice by the novel mAb H111-1
and the well-characterized mAb m336. For evaluation of H111-1, mice were administered 1 mg/kg of
mAb either I.P. (A) or I.T. (B) and 6 h later, challenged with pseudovirus I.T. at a dose of 3.8 × 106.5
TCID50. On day 11 p.i., BLI of the whole body or specific organs was conducted (D). To evaluate the
efficacy of m336 (C), mice were administered mAb and challenged using the same doses as for H111-1,
and typical images (E) are shown. (F) Bar of photo flux; for details see Figure 2. N = 4 mice in each
group, * means p < 0.05, ** means p < 0.01.
3.6. A MERS-CoV S-HR1-Specific Fusion Inhibitor Peptide Protected R26-DPP4 Mice from Infection by
Pseudotyped MERS-CoV
Since peptides derived from the heptad repeat (HR)2 of the MERS-CoV S protein such as HR2P or
its analogue HR2P-M2 [27] have been shown to protect RAG−/− mice from infection by MERS-CoV
(EMC/2012 strain) [26], we investigated whether HR2P-M2 could also prevent pseudovirus infection
in R26-hDPP4 mice. We tested the in vitro inhibitory effect of HR2P-M2 in the Huh7 cell line, and
its IC50 was determined to be 4504.5 ng/mL. In order to determine the in vivo protective effect
of HR2P-M2, 5-week-old R26-DPP4 mice were administered 1000 μg of peptide per mouse I.T.,
and 30 min later challenged with 3.8 × 106.5 TCID50 of pseudovirus using the same route. As shown
in Figure 7, pseudovirus infection was clearly prevented by HR2P-M2: in one representative mouse,
the pseudovirus signal decreased to levels similar to uninfected mice, representing full protection
(Figure 7A,B). No or very weak pseudovirus signals were detected in lung, thymus and heart after
dissection (Figure 7B), indicating that the R26-hDPP4 mouse model, like previous animal models, can
be used for evaluation of antiviral peptides.
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Figure 7. Inhibition of pseudotyped MERS-CoV infection in R26-hDPP4-knockin mice by peptide
HR2P-M2. Mice were administered HR2P-M2 peptide or phosphate-buffered saline (PBS) I.T.,
respectively. Thirty min later, mice were infected I.T. with pseudotyped MERS-CoV (3.8 × 106.5
TCID50). BLI images were taken on day 11 p.i., and pseudovirus signals were recorded for the whole
body or specific organs. (A) Flux value of pseudovirus for assessment of the protective efficacy of
HR2P-M2. (B) BLI images of whole mice or their organs. (C) Bar of photo flux; for details see Figure 2.
Four mice were used for each group, and representative images are shown.
4. Discussion
MERS-CoV infection causes acute respiratory distress [8,37], neurologic syndromes [40],
and death. MAbs are promising tools for both therapeutic and prophylactic interventions against this
pathogen [19,41–43]. However, the dearth of clinically-effective vaccines and therapeutics compelled
us to develop a novel animal model that could faithfully mimic the characteristics of human disease
and enable better evaluation of potential vaccines and therapies.
Respiratory disease (such as ARDS) and acute renal failure are the main symptoms of MERS-CoV
infection, although patients with fatal disease in the CNS have been reported [40]. Therefore,
an animal model of MERS-CoV disease that recapitulates the pathological characteristics in both
respiratory tract and CNS, supports high-level virus replication in vivo, and exhibits lung pathology
associated with ARDS is required. Moreover, the animal model must be economical, genetically
stable, and show reproducible results [8]. Mouse-adapted viral strains have been widely used to
establish infection models. Wherever possible, clinical isolates should be used in challenge experiments
(http://www.gryphonscientific.com/gain-of-function/) [12]. Targeting transgenes to specific sites
of the mouse genome has many advantages over the random insertion typically used in transgenic
methods. Two hDPP4-KI mice created by CRISPR/Cas9 gene editing were recently reported [8,12].
In these mice, mDPP4 gene was either replaced by hDPP4 or mutated and its function was disrupted.
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Since mDPP4 is endowed with different biological activities [44] in immunity and glycometabolism
compared with hDPP4, we established KI mice by inserting full-length human DPP4 into the Rosa26
locus via CRISR/Cas9 to spare the function of mDPP4. Notably, the R26-hDPP4 mouse displayed
an unusual expression profile, in which transgenic hDPP4 was stably and highly expressed in lung
and also expressed to a lesser extent in brain and other organs (Figure 1D–F). We reasoned that
this expression pattern might support robust infection and lesions in lung and brain, both using
pseudotyped and authentic MERS-CoV. We further reasoned that insertion ofhDPP4 into the safe
harbor of the Rosa26 locus and conserving mDPP4 function would be an appropriate strategy for
establishing a genetically stable animal model. The insertion of hDPP4 mean, and whether it has
implications for the expression of mDPP4 and its biological activities, is not clear.
We observed that R26-hDPP4 mice could be infected by the clinically authentic strain
hCoV-EMC [34] at a dose of 1.5 × 105 PFUs, and that infection caused disease symptoms in both
lung and brain similar to those observed in clinical patients. Infected R26-hDPP4 mice experienced
significant loss of body weight, up to 33.6%, which was comparable to that observed in mice infected
with a mouse-adapted strain [21]. Higher viral titers than in previous reports [8] were detected in lungs
and were accompanied by diffuse pathogenesis including widened alveolar septa, vascular dilatation
and hyperemia, perivascular infiltration of inflammatory cells, necrosis of bronchial epithelial cells,
edema and hyaline membrane formation (Figure 2, Supplementary Figure S1). The pathophysiological
findings were closely associated with clinical manifestations [45]. All infected R26-hDPP4mice had
uniform disease symptoms with a significant difference observed between KI and wild-type mice,
as revealed by quantitative pathological scores (Figure 2).
Very few reports have described the sites of MERS-CoV infection in patients, even though these
data are crucial for understanding viral pathogenesis. For both cultural and religious reasons, no tissue
samples have been made available [37]. However, studies using several animal models has been
helpful in addressing this problem. In rhesus macaques, transient lower respiratory tract infection
was accompanied by inflammatory cell infiltration [4]. By contrast, severe interstitial pneumonia
within filtration and alveolar edema were observed in infected marmosets [6]. Research using small
animal models, such as a mouse transduced with an Ad5 vector expressing hDPP4 [9], a Tg mouse
model [11], and KI mice created with CRISPR/Cas9 technology [8,12],provide uncontested evidence
that the respiratory system is the main site of MERS-CoV infection, in agreement with most clinical
manifestations [37]. In this study, we also showed that the lungs, especially the bronchi, were the
primary sites of infection both for pseudotyped and authentic virus (Figures 2–5; Table S1).
Whether MERS-CoV is able infect the nervous system remains controversial. Agrawal et al. [11]
reported high viral loads in the brain, but no necrosis or inflammatory reactions were observed.
In KI mice infected with a mouse-adapted viral strain, no viral replication was detected in brain,
even at challenge doses of 5 × 106 PFUs. This animal model was heralded as having the advantage
of mimicking the clinical manifestations of ARDS in the absence of CNS complications. However,
even though respiratory infection and ARDS are common clinical symptoms of MERS-CoV infection,
patients with severe neurological syndrome, including confusion, coma and ataxia as well as focal
motor deficit, have been reported [40]. Here, when R26-hDDP4 mice were infected with the clinical
strain hCoV-EMC at a dose of 1.5 × 105 PFUs, viral loads were detected using IHC assays (Figure 2)
in the cerebellum, cerebral ganglia and cerebrum. In association with these viral loads, perivascular
gliosis, an indicator of inflammatory reactions, was observed in these organs in all 12 R26-hDPP4mice
irrespective of mAb administration or mAb ablation of inflammation (Figure 3). These phenomena
were not observed in any wild-type mice challenged in the same manner. Since virus was mainly
detected on the membranes of motor neurons, we reasoned that the dyskinesia observed in patients
would also be manifested in mice. Additional studies to assess the possible nerve infection are being
conducted, and viral loads in nervous system are considered to be titrated.
Pseudotyped virus, which has been widely used for many pathogens [2,30,46], is a useful,
safe, and convenient tool for viral infection studies and therapeutic testing [23]. Pseudovirus cell
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models are popularly applied since they are relatively easy to develop; however, pseudovirus animal
models are not as widely available, even though they have more extensive potential applications.
Pseudovirus animal models may be difficult to achieve due to lack of susceptibility and the absence
of suitably infectious pseudoviruses. Previously, an inhibition assay based on the pseudovirus cell
model was established and used to detect neutralizing antibodies against MERS-CoV [2]. However,
these pseudoviruses failed to infect the R26-hDPP4 mouse, which was shown to be particularly
susceptible to authentic virus. We presumed that this effect might be caused by low pseudovirus
titer. Therefore, the codons of the S protein, backbone plasmid [22], and production conditions were
optimized systematically, resulting in an increase in titer of about 1000-fold (Supplementary Figure S2)
and finally resulting in the successful infection of R26-hDPP4 mice.
To challenge mice, authentic virus is often administered by the I.N. route [18], which has the
advantage of mimicking clinical respiratory tract infection. We tried to infect R26-hDPP4-KI mice
with pseudovirus by the I.N. route but this was unsuccessful. This failure might have resulted from
the use of less than 50 μL of pseudovirus inoculum for nasal dripping; this dosage may not have
been sufficient for a single round of infection. We found that different infection routes might result
in different biodistribution. Pseudovirus was detected by BLI in the thymus, liver, spleen, kidney,
lung, muscle and intestine of mice infected via the I.P. route. However, for challenge via the I.T.
route, pseudovirus was only observed in the thymus, heart and lung. Thus, the route of infection
also had some effect on pseudovirus distribution. For example, viral loads might fail to be detected
in the lungs of mice with minor I.P. infections. However, the I.T. route resulted in uniform infection
patterns in the lungs, and especially in the bronchi (Figures 4 and 5). The pseudovirus distribution
pattern (Figure 4) was similar to that of Tg mice infected with authentic virus [11]. Mice as old as
9 weeks could be infected, but younger mice (i.e., those 4 to 5 weeks old) had better susceptibility.
The pseudovirus infection caused no pathological lesions in multiple organs, indicating that this model
was safe (Figure 4).
To verify the potential of the R26-hDPP4 mouse model for evaluating different antiviral agents
against MERS-CoV, we tested a newly generated humanized neutralizing mAb, H111-1, as well as
a known MERS-CoV-neutralizing mAb, m336, in our pseudovirus model. As expected, m336 and
H111-1 both showed outstanding inhibitory activity in the pseudovirus cell model (IC50 = 4.5 ng/mL)
and pseudovirus mouse model. Moreover, mAb H111-1 was also effective in protecting R26-hDPP4
mice from authentic virus infection. The protective effects of a well-characterized peptide inhibitor,
HR2P-M2 [26], were assessed in the pseudovirus model with results similar to those described above.
Overall, this pseudovirus mouse model showed outcomes that were consistent with those of the
authentic virus mouse model, and the R26-hDPP4-KI mouse is, therefore, a unique animal model for
evaluating the in vivo efficacy of anti-MERS-CoV therapeutics and vaccines in biological laboratories
lacking BSL-3 facilities.
Some researchers have advanced skepticism regarding pseudovirus models, stating that infection
by pseudovirus could not cause pathological changes. To allay these doubts, a combination analysis
was deemed necessary in this study. As shown in Figure 5, the relevance of the pseudotyped and
authentic virus models was demonstrated. We showed that the manifestations of infection in the lung,
the main target of MERS-CoV infection, were very similar between the authentic and pseudovirus
models and that in both cases infection was localized to the epithelial cells of the bronchi. A dose
conversion between pseudotyped virus and authentic virus was calculated, indicating that this
pseudovirus mouse model is reliable and can be used to evaluate the effects of antiviral agents.
However, pseudovirus represents a single-cycle infection and without replication in vivo, it does not
cause pathological changes. Authentic MERS-CoV infection model is a better choice when studying
disease pathogenesis.
In summary, we have presented a novel KI mouse model (the R26-hDPP4 mouse) characterized
by its genetic stability, its susceptibility to infection by both authentic and pseudotyed MERS-CoVs,
its clear sites of infection, and its presentation of disease symptoms, both in the respiratory tract and
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CNS, similar to those of clinical patients. These findings imply that this is a unique model for studying
human pathogenesis. The established pseudovirus model has the advantages of strong signals, good
repeatability and safety, making it as efficient as the authentic virus model for evaluating antiviral
agents and vaccines in a typical biological laboratory.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1999-4915/10/9/
448/s1.
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Abstract: Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) is an infectious virus
that was first reported in 2012. The MERS-CoV genome encodes four major structural proteins, among
which the spike (S) protein has a key role in viral infection and pathogenesis. The receptor-binding
domain (RBD) of the S protein contains a critical neutralizing domain and is an important target for
development of MERS vaccines and therapeutics. In this review, we describe the relevant features
of the MERS-CoV S-protein RBD, summarize recent advances in the development of MERS-CoV
RBD-based vaccines and therapeutic antibodies, and illustrate potential challenges and strategies to
further improve their efficacy.
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1. Introduction
Middle East respiratory syndrome (MERS) coronavirus (CoV) is an infectious virus that
was first reported in June 2012 [1]. MERS-CoV may infect people of any age, but older age,
underlying comorbidity (such as diabetes mellitus, renal disease, respiratory disease, heart disease,
and hypertension), and delayed confirmation or late diagnosis are all factors that affect MERS
disease outcomes and mortality [2–7]. Sex could be a factor in MERS epidemiology, as more males
seem to be affected than females [8–10]. MERS-CoV infection of women during pregnancy has
adverse outcomes, with fetal mortality of ~27%; however, only a limited number of pediatric
MERS-CoV infections occur [11–14]. At the end of December 2018, 2,279 laboratory-confirmed
MERS infections were reported globally (in 27 countries), leading to 806 deaths, and a mortality
of 35.3%. Among these infections, 1,901 (83.4%) were reported in Saudi Arabia, with mortality in
732 individuals (38.5%) (http://www.emro.who.int/health-topics/mers-cov/mers-outbreaks.html).
The largest MERS outbreak outside Saudi Arabia occurred in South Korea in 2015, with 186 cases
and 38 deaths [9,15,16]. The most recent MERS cases were reported in 2018 in South Korea, the
United Kingdom, and Malaysia, in addition to Saudi Arabia, the United Arab Emirates, and Oman
(http://www.who.int/emergencies/mers-cov/en/).
MERS-CoV is thought to have originated in bats [17–20]. MERS-like viruses have been isolated
from bats that use (at lower efficiency) the same receptor for cell entry as the MERS-CoV isolated
from humans [21–23]. Dromedary camels are potential intermediates for long-term evolution of
MERS-CoV and seasonal zoonotic transfer of virus to humans [24–27]. Antibodies specific to
MERS-CoV, particularly neutralizing antibodies that neutralize MERS-CoV infection, have been
Viruses 2019, 11, 60; doi:10.3390/v11010060 www.mdpi.com/journal/viruses113
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detected in the sera of dromedary camels from a number of countries and regions, with high positive
detection rates [28–34]. In addition to camel-to-camel transmission of MERS-CoV, camel-to-human
transmission can occur via direct or indirect contact with sick animals [35]. There is a high prevalence
of MERS-CoV infection in camel workers, particularly in Saudi Arabia [27]. Following infection of
individuals, human-to-human transmission of MERS-CoV occurs frequently, and mainly contributes
to community or healthcare-associated outbreaks [36–45]. Infection of humans by MERS-CoV, which
mainly occurs through the lower respiratory tract, causes severe respiratory symptoms, leading to
failure of the respiratory system and/or other organs [7,46,47]. On rare occasions, the human intestinal
tract can be an alternative infection route [46,48].
Anti-MERS-CoV antibodies, including neutralizing antibodies, are found in infected patients,
some of whom have persistently presented such antibodies for up to 34 months after the disease
outbreak [49,50]. Antibody responses, and particularly neutralizing antibody responses, are crucial
factors in the successful treatment of MERS-CoV infections in humans [50–52]. In this regard, the
plasma of convalescent MERS-CoV-infected patients is useful for treatment of MERS-CoV infection
clinically, but it requires a neutralizing antibody titer (e.g., 50% plaque-reduction neutralization titer:
PRNT50) ≥1:80 to obtain effective therapeutic results [51–53]. Currently, a human polyclonal IgG
antibody (SAB-301) that is produced by transchromosomic cattle immunized with a MERS-CoV
vaccine [54], as well as several vaccine candidates (https://clinicaltrials.gov/ct2/show/NCT03399578;
https://clinicaltrials.gov/ct2/show/NCT03615911) [55], have been tested in human clinical trials.
However, as yet no vaccines or therapeutic agents have been approved for the prevention or treatment
of MERS, indicating the need for further development of novel and effective vaccines and therapeutics
against MERS-CoV infection.
In the following review, we will briefly describe MERS-CoV spike (S) protein receptor-binding
domain (RBD), and summarize recent advances in the development of RBD-based MERS-CoV
vaccines and therapeutics, as well as the potential challenges and future expectations for their
successful development.
2. MERS-CoV S Protein RBD
MERS-CoV belongs to the genus Betacoronavirus, as does the severe acute respiratory syndrome
(SARS)-CoV [56,57]. MERS-CoV is a positive-sense, single-stranded RNA virus with a genome that
encodes the structural proteins S, envelope (E), membrane (M), and nucleocapsid (N), as well as
non-structural proteins (nsp1–16) translated from open reading frames (ORFs) 1a and 1b, and several
accessory proteins, such as 3, 4a, 4b, 5, and 8b (Figure 1A,B) [58–61]. The functions of these proteins
have been elucidated. As an example, nsp1 is known to have an endonucleolytic RNA-cleavage
function in the promotion of infectious virus particle production in human cells [62], and it also
participates in efficient viral replication through interaction with viral RNA, probably via a cis-acting
element at the 5′-terminal coding region [63]. Evidence indicates that nsp16 is necessary for interferon
resistance and viral pathogenesis [64], whereas nsp15 is a nidoviral uridylate-specific endoribonuclease,
the structure of which has recently been resolved, and its activity may be mediated by catalytic
residues, oligomeric assembly, or RNA-binding efficiency [65]. In addition, 4a protein recognizes
and binds double-stranded (ds)RNA, in which four residues of the protein might be crucial for
4a-dsRNA stability [66], and it also inhibits protein kinase R-mediated antiviral stress responses [67].
4a mediated-inhibition of stress-granule formation may facilitate viral translation, resulting in efficient
MERS-CoV replication [68]. The MERS-CoV 4b protein interferes with the NF-κB-dependent innate
immune response during infection [69].
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Figure 1. Schematic structures of MERS-CoV S protein. (A) MERS-CoV genomic structure, with the
untranslated region (UTR), open reading frame regions ORF1a and ORF1b, spike (S), envelope (E),
membrane (M), and nucleocapsid (N) genes. (B) Schematic structure of the MERS-CoV virion and
its major structural proteins. (C) Schematic structure of the MERS-CoV S protein and its functional
domains, including the N-terminal domain (NTD), receptor-binding domain (RBD), receptor-binding
motif (RBM), fusion peptide (FP), heptad repeat region 1 and 2 (HR1 and HR2), transmembrane
region (TM), and cytoplasmic tail (CP). aa, amino acid; MERS-CoV, Middle East respiratory syndrome
coronavirus; nt, nucleotide.
MERS-CoV S protein has an important role in viral pathogenesis, determining host tropism
and entry into host cells [58,70,71]. The S protein contains an S1 subunit at the N terminus and an
S2 subunit at the C terminus. The S1 subunit is composed of the N-terminal domain (NTD) and
RBD [58,72,73]. The RBD has a key role in the mediation of binding of MERS-CoV to cells expressing
dipeptidyl peptidase 4 (DPP4) receptor, enabling the virus to enter into target cells by fusing with cell
membranes through the formation of a fusion core (Figure 1C) [74–77]. The S protein requires host
cellular proteases for its activity in viral entry, but although evidence initially indicated that cellular
furin activates S protein, subsequent results have demonstrated no evidence for the involvement of
furin during viral entry [71,78]. The DPP4 receptor varies among different host species, and MERS-CoV
is thought to use multiple pathways to enable rapid adaptation to species-specific variations [79–81].
In addition to DPP4, MERS-CoV can bind to sialic acid via the S1 subunit of S protein, or utilize
the membrane-associated 78 kDa glucose-regulated protein (GRP78) to attach to target cells, suggesting
that these proteins may also have roles in virion attachment [82,83].
The structures of MERS-CoV RBD alone and complexed with DPP4 have been determined
(Figure 2) [77,84,85]. The RBD has a fold-rich tertiary structure, which consists of a core and a
receptor-binding motif (RBM), with stabilization provided by four disulfide bonds and two glycans [77].
A number of RBD residues are located at the DPP4-binding interface, and they have a critical role
in RBD–DPP4 binding [77,84,85]. Structural analysis of MERS-CoV trimeric S protein has identified
specific features of the RBD and its complex with DPP4. Notably, in the prefusion conformation of the
S trimer, individual RBDs are either buried (lying state) or exposed (standing state), and this flexibility
presumably facilitates recognition by DPP4 [86]. Other structural studies have revealed four S-trimer
conformational states, in which each RBD is either tightly packed at the membrane-distal apex or
rotated into a receptor-accessible conformation, suggesting fusion initiation through sequential RBD
115
Viruses 2019, 11, 60
events [87]. In configurations with one, two, or three RBDs rotated out, RBD determinants are exposed
at the apex of the RBD–DPP4 complex, and they are accessible for interaction with DPP4 (Figure 3) [87].
Figure 2. Structural basis of MERS-CoV S-protein RBD–DPP4 interaction. Structural data for the
complex of MERS-CoV S-protein RBD bound to DPP4 are from the protein data bank (PDB) (ID: 4KR0).
The MERS-CoV RBD core is colored in blue, the RBM is colored in red, and DPP4 is colored in green.
The RBM residues directly involved in DPP4 binding are shown as sticks. DPP4, dipeptidyl peptidase
4; RBD, receptor-binding domain; RBM, receptor-binding motif; S, spike protein.
 
Figure 3. Models of the MERS-CoV S-protein trimer bound to DPP4. The models were generated by
superimposing the MERS-CoV RBD in the structure of the MERS-CoV S-protein RBD–DPP4 complex
(PDB ID: 4KR0) onto the RBDs in the structures of MERS-CoV S-protein trimers with (A) one RBD
(PDB ID: 5X5F), (B) two RBDs (PDB ID: 5X5C), or (C) three RBDs (PDB ID: 5X59) in the “standing”
conformation. The MERS-CoV S-protein trimers are colored in gray, with three RBDs colored in red,
blue, and green. Three DPP4 dimers are colored in plum, orange, and yellow. DPP4, dipeptidyl
peptidase 4; PDB, protein data bank; RBD, receptor-binding domain; S, spike protein.
The function and structure of the S-protein RBD demonstrate that it is an important target for
development of vaccines and therapeutic agents against MERS-CoV.
3. Recent Advances in the Development of Vaccines Based on the MERS-CoV S-Protein RBD
A number of MERS vaccines have been developed based on viral RBD, including nanoparticles,
virus-like particles (VLPs), and recombinant proteins, and their protective efficacy has been evaluated
in animal models, including mice with adenovirus 5 (Ad5)-directed expression of human DPP4
(Ad5/hDPP4), hDPP4-transgenic (hDPP4-Tg) mice, and non-human primates (NHPs) [88–94]. Features
of these RBD-based vaccines, in terms of functionality, antigenicity, immunogenicity, and protective
ability, are shown in Table 1.
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A soluble nanoparticle vaccine formed in Escherichia coli by the RNA-mediated folding of a
RBD-ferritin (FR) hybrid elicits robust RBD-specific antibody and cellular immune responses in mice,
producing antisera that effectively block the binding of RBD to hDPP4 in vitro [89]. The adjuvants alum
and the squalene-based MF59 significantly augment the antibody titers and T-cell responses induced
by RBD–FR nanoparticle vaccines engineered with or without a SSG linker [89]. Similarly, a chimeric,
spherical VLP (sVLP) vaccine expressing MERS-CoV RBD induces specific antibody and cellular
immune responses in mice, preventing pseudotyped MERS-CoV entry into susceptible cells [90]. The
protective efficacy of these two types of MERS vaccine does not yet seem to have been investigated in
a viral-challenge animal model.
Recombinant vaccines involving RBD subunits have been extensively studied for protection
against MERS-CoV infection in MERS-CoV-susceptible animal models [93,95–97,100,101]. A
recombinant RBD (rRBD) fragment (residues 367–606) expressed in insect cells elicits an antibody
response and the production of neutralizing antibodies in mice and NHPs [88,91]. It gives
incomplete protection in MERS-CoV-challenged NHPs, with the alleviation of pneumonia and clinical
manifestations, as well as the reduction of viral load in lung, trachea, and oropharyngeal swabs [91].
A MERS-CoV S-protein RBD fragment containing residues 377–588 has been identified as a critical
neutralizing domain [95]. A treatment regimen involving two doses of a fusion of this fragment
and the Fc region of human IgG (S377-588-Fc) four weeks apart is able to induce strong, long-term
antibody responses (including production of neutralizing antibodies) in mice [98]. These responses
are significantly greater than those with a single dose or two doses at intervals of one, two, or
three weeks [98]. rRBDs with single or multiple mutations corresponding to S-protein sequences of
MERS-CoV strains isolated from humans or camels from 2012 to 2015 have also been studied [100].
All these rRBDs bind RBD-specific neutralizing monoclonal antibodies (mAbs) and DPP4, and are
highly immunogenic, eliciting the production of S1-specific antibodies in mice, which cross-neutralizes
multiple MERS pseudoviruses and live MERS-CoV [100]. A trimeric RBD-Fd protein formed by
fusing a MERS-CoV RBD fragment (residues 377–588) to the foldon trimerization motif, binds strongly
to DPP4, and elicits robust and long-term responses with the production of MERS-CoV S1-specific
antibodies and neutralizing antibodies in mice, and protects hDPP4-Tg mice against MERS-CoV
infection [94].
The protection provided by existing subunit vaccines based on wild-type MERS-CoV RBD is not
complete, with survival rates in hDPP4-Tg mice after a MERS-CoV challenge of ~67% for S377-588-Fc
and 83% for RBD-Fd [94,98]. However, a variant RBD (T579N) vaccine produced by masking a
non-neutralizing epitope at residue 579 with a glycan probe has both functionality in binding DPP4,
and antigenicity in binding four potent MERS-CoV RBD-specific neutralizing mAbs (hHS-1, m336,
m337, and m338) [93]. The T579N vaccine has significantly greater efficacy than the wild-type RBD
vaccine, and it fully protects against a lethal MERS-CoV challenge in immunized hDPP4-Tg mice [93],
demonstrating the possibility of developing RBD-based MERS-CoV vaccines with high efficacy.
4. Recent Advances in the Development of Therapeutics Based on the MERS-CoV S-Protein RBD
MERS-CoV RBD-targeting antibodies have been developed as effective tools to prevent and
treat MERS-CoV infections [102–109]. These antibodies generally have greater neutralizing activity
against MERS-CoV infection than non-RBD S1-based or S2-based antibodies [58,103,110,111]. The
prophylactic and therapeutic efficacies of RBD-targeting antibodies have been tested in Ad5/hDPP4
mice, hDPP4-Tg mice, and NHPs [102,104,112–114].
In an earlier review, we described the antiviral mechanisms, in vivo protection, and crystal
structures of previously reported MERS-CoV RBD-specific mAbs, including mouse mAbs Mersmab1,
2E6, 4C2, F11, and D12, and human mAbs LCA60, MERS-4, MERS-27, REGN3048, REGN3051, 1E9,
1F8, 3A1, 3B11, 3B12, 3B11-N, 3C12, M14D3, m336, m337, m338, hMS-1, and 4C2h [58]. In this review,
we focus on newly reported antibodies targeting MERS-CoV S-protein RBD, or on newly identified
features of existing mAbs that were not described previously (Table 2) [102,112–115].
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4.1. MERS-CoV S-Protein RBD-Targeting mAbs
RBD-targeting human mAbs have been extensively reported. Most of these mAbs can neutralize
pseudotyped or live MERS-CoV in vitro, and some have shown protection against MERS-CoV
infection in animal models in vivo [102,112–115]. The structures of several of these mAbs with their
antigen-binding fragments (Fabs) or single-chain variable fragments (scFvs) complexed with RBD are
known (Figure 4) [102,112–115]. Binding of these mAbs to RBD involves two major recognition modes,
with binding to RBD residues contacted by or overlapping with DPP4 (as is the case for GD-27, MCA1,
and CDC2-C2), or with binding to the RBD residues outside of the DPP4-binding interface (as seen
with MERS-4) (Table 2).
Figure 4. Structural basis for MERS-CoV RBD recognition by neutralizing mAbs. (A) Crystal
structure of MERS-CoV RBD complexed with MCA1 mAb (PDB ID: 5GMQ). (B) Crystal structure
of the MERS-CoV RBD complexed with CDC2-C2 mAb (PDB ID: 6C6Z). (C) Crystal structure of the
MERS-CoV RBD complexed with JC57-14 mAb (PDB ID: 6C6Y). (D) Crystal structure of MERS-CoV
RBD complexed with MERS-4 mAb (PDB ID: 5ZXV). The MERS-CoV RBD core is colored in blue, the
RBM is colored in red, and the heavy chains and light chains of each mAb are colored in green and
yellow, respectively. The DPP4-binding residues that are blocked by each mAb are shown as sticks.
mAb, monoclonal antibody; MERS-CoV, Middle East respiratory syndrome coronavirus; PDB, protein
data bank; RBD, receptor-binding domain; RBM, receptor-binding motif.
The human mAbs MERS-GD27 and MERS-GD33 each recognize distinct regions of the RBD [113].
These mAbs have a synergistic effect in the neutralization of pseudotyped MERS-CoV in vitro,
with a much lower half-maximal inhibitory concentration (IC50) for their use in combination than
separately [113]. An analysis of crystal structures has indicated that MERS-GD27 binds RBD at
the DPP4-binding site, and that the neutralization and recognition epitopes almost completely
overlap this site, as seen previously for MERS-CoV RBD-targeting neutralizing mAbs, such as
m336 [106,113]. The MERS-GD27 mAb protects hDPP4-Tg mice from MERS-CoV challenge, both
preventively and therapeutically, with significantly lower lung virus titers and RNA copy numbers
at day 5 post-challenge, and higher survival rates (60% for pre-challenge vaccination and 40% for
post-challenge vaccination) relative to control mice treated with an irrelevant mAb [112].
The human mAb MCA1 was isolated from a MERS survivor via the construction of a
phage-display antibody library from peripheral B cells [114]. Crystal structure analysis indicates
that MCA1 binds MERS-CoV S-protein RBD at residues involved in receptor binding, thus interfering
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with RBD binding to hDPP4 (Figure 4A) [114]. This mAb prophylactically and therapeutically inhibits
MERS-CoV replication in common marmosets, resulting in significantly improved outcomes and
reduced lung disease, compared with unvaccinated controls, and undetectable virus titers 3 days
post-challenge [114].
A probe-based single-B-cell cloning strategy has been used for the isolation of CDC2-C2 and
CDC2-C5 mAbs from a patient convalescing from MERS, as well as for the isolation of JC57-11 and
JC57-14 mAbs from NHPs immunized with MERS-CoV full-length S DNA and protein [102]. All these
antibodies have neutralizing activities against both pseudotyped and live MERS-CoV. Among them,
CDC2-C2 is the most potent against 10 pseudotyped MERS-CoV strains, with neutralization IC50
values ranging from 0.002 μg/mL to 0.011 μg/mL [102]. Crystal-structure analysis of the CDC2-C2
and JC57-14 Fab–RBD complexes indicates that both mAbs bind RBD in the “out” (exposed) position,
with the CDC2-C2 RBD binding overlapping with the DPP4-contacting residues (Figure 4B,C) [102]. In
addition, CDC2-C2 prophylactically protects hDPP4-Tg mice from MERS-CoV infection, resulting in
no detectable viral replication in the lungs three days post-challenge, and no fatalities over 28 days of
observation [102].
The human mAb MERS-4 also neutralizes pseudotyped MERS-CoV and, notably, displays
synergistic neutralization in combination with the MERS-CoV S-protein RBD-targeting MERS-27
and m336 mAbs [106,118], as well as the S-protein NTD-targeting 5F9 mAb, in each case with dramatic
reduction of the IC50 compared with individual mAbs [115]. Structural analysis of a MERS-4-Fab–RBD
complex revealed that MERS-4 binds the RBD from outside the DPP4-binding interface, rather than
competing with DPP4 (Figure 4D). Unlike MERS-27, which binds RBD regardless of its conformational
state within the S trimer, MERS-4 binds RBD in the “standing” position where its epitopes are readily
exposed and accessible [115]. Thus, MERS-4 displays unique epitope specificity, and an unusual
mechanism of action involving indirect interference with DPP4 binding through conformational
changes, which may explain the observation of synergistic neutralization in combination with other
mAbs [115].
4.2. Nanobodies Targeting the MERS-CoV S-protein RBD
Single-domain antibody fragments (VHHs), or nanobodies, are the antigen-recognition regions of
camelid heavy-chain-only antibodies (HcAbs), which do not contain light chains. VHHs are easily
expressed with high yield, and they have intrinsic stability, strong binding affinity, and specificity to
target antigens, and they have therefore been developed as important therapeutic tools against viral
infection, including that of MERS-CoV [116,117,119–123].
Four VHHs (VHH-1, VHH-4, VHH-83, and VHH-101) have been identified from bone marrow
cells of dromedary camels immunized with modified vaccinia virus (MVA) expressing MERS-CoV S
protein, and challenged with MERS-CoV [116]. These VHHs bind MERS-CoV S protein with low Kd
values (0.1–1 nM), recognize an epitope at residue D539 of RBD, and neutralize MERS-CoV (PRNT50,
0.0014–0.012 μg/mL) [116]. These four monomeric VHHs have each been fused with a C-terminal
human IgG2 tag to generate four HCAbs (HCAb-1, HCAb-4, HCAb-83, and HCAb-101), with a higher
binding affinity and a longer half-life than the free VHHs [116]. Studies of protective efficacy show that
hDPP4-Tg mice (K18) injected with monomeric VHH-83 (20 or 200 μg per mouse) lose weight, and die
within seven days post-infection, possibly because of the short half-life of the VHH. However, when
the mice are injected with HCAb-83 (200 μg per mouse), which has an extended half-life (~4.5 days),
protection against MERS-CoV is complete, with no viral titers or pathological changes in the lungs of
virally challenged mice [116].
By immunizing llamas with a recombinant RBD fragment (residues 377–588) fused to a C-terminal
human IgG Fc tag (S377-588-Fc), we constructed a VHH library, and we used it to generate a monomeric
VHH, NbMS10, and a human Fc-fused VHH, NbMS10-Fc [117]. Both VHHs can be expressed in a yeast
expression system to high purity, and bind RBD with high affinity, recognizing a conformational epitope
(residue 539) at the RBD–DPP4 interface, and blocking the binding of RBD to DPP4. These VHHs,
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particularly NbMS10-Fc, potently cross-neutralize pseudotyped MERS-CoV strains isolated from
different countries, hosts, and time periods [117]. Importantly, the Fc-fused NbMS10-Fc significantly
improves the serum half-life of NbMS10, and a single-dose treatment of hDPP4-Tg mice with this
agent completely protects them against lethal MERS-CoV challenge [117]. These single-domain VHHs
demonstrate the feasibility of developing cost-effective, potent, and broad-spectrum therapeutic
antibodies against MERS-CoV infection.
5. Potential Challenges and Future Perspectives
Compared with vaccines based on MERS-CoV full-length S protein, which have the potential to
attenuate neutralizing activity or enhance immune pathology, vaccines developed from MERS-CoV
S-protein RBD are safer, and they do not cause immunological toxicity or eosinophilic immune
enhancement [55,99,110,124]. Moreover, RBD-based therapeutic antibodies are generally more
potent than non-RBD S1-based or S2-based antibodies [58,104,111]. Hence, RBD-based vaccines
and therapeutic antibodies have the potential for further development as effective tools to prevent and
treat MERS-CoV infection.
Despite their acknowledged advantages, there are some issues associated with RBD-based
interventions that need to be addressed. For example, RBD is under a high level of pressure of positive
selection, and mutations occur in the RBD-DPP4 binding interface that might reduce the efficacy of
these treatments [100,125–127]. One possible way to avoid this effect, and to delay the emergence
of escape mutants is to combine RBD-targeting therapeutics with those targeting other regions of
the S protein, or to combine antibodies recognizing distinct epitopes within the RBD [102,128]. Such
combinatorial strategies could also dramatically reduce antibody neutralization doses, providing
feasible means to combat the continual threat of MERS-CoV.
Some recent advances have been made in the structure-guided design of anti-MERS-CoV
interventions. Structurally designed inhibitors of the 3CL protease have demonstrated potency against
MERS-CoV [129]. Also, a structurally designed S-protein trimer in the optimal prefusion conformation
is shown to elicit production of high titers of anti-MERS-CoV neutralizing antibodies [87]. Indeed,
based on the previous studies on the structural design of MERS-CoV RBD, non-neutralizing epitopes
in the RBD can be masked, to refocus the immunogenicity of the RBD on the neutralizing epitopes, and
thus to enhance its ability to confer immune protection [93]. Results from these structure-based studies
will help to inform the design of innovative RBD-based anti-MERS-CoV vaccines and therapeutics
with improved efficacy.
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Abstract: Efforts towards developing a vaccine for Middle East respiratory syndrome coronavirus
(MERS-CoV) have yielded promising results. Utilizing a variety of platforms, several vaccine
approaches have shown efficacy in animal models and begun to enter clinical trials. In this review,
we summarize the current progress towards a MERS-CoV vaccine and highlight potential roadblocks
identified from previous attempts to generate coronavirus vaccines.
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1. Introduction
In recent years, viral zoonotic diseases have caused outbreaks marked by rapid spread and
high mortality, including the 2002 emergence of severe acute respiratory syndrome coronavirus
(SARS-CoV) [1], the 2009 H1N1 swine flu pandemic [2], and the 2013 Ebola outbreak in West
Africa [3]. Such outbreaks are difficult to predict as new strains emerge or reemerge from zoonotic
reservoirs [4]. Coronaviruses (CoVs), large positive-stranded RNA viruses of the order Nidovirales [5],
were considered minor human pathogens, causing cold-like symptoms and occasionally associated
with pneumonia and more severe disease [6]. However, the emergence of SARS-CoV in 2002 and
Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012, members of βCoV lineages B and
C, respectively, marked a shift in our understanding of the pathogenic potential of coronaviruses [7].
As these more virulent viruses are genetically similar to those currently circulating in bats [8,9], CoVs
may pose a threat for future zoonoses [10].
Since the emergence of MERS-CoV in Saudi Arabia in 2012, over 2200 confirmed cases
have been reported in at least 27 countries, with an overall mortality rate of 35% (https://
www.who.int/emergencies/mers-cov). Additionally, more severe disease has been noted in the
aged, immunocompromised, and those with chronic health conditions [11]. Camels, which show
seropositivity to MERS-CoV in archived sera dating back to 1983 [12], serve as intermediate hosts and
are able to spread the virus to humans [13], who may then spread the infection person-to-person [14].
While a range of therapeutics have been explored for CoV disease [15–17], a MERS-CoV vaccine
remains the most scalable, cost-effective prophylactic measure. Currently, a vaccine for MERS-CoV is
not available, although several candidates have been developed using a variety of approaches. Vaccine
studies were initially hampered by a lack of small animal models of MERS-CoV disease [18]. While
rodents possess homologues for dipeptidyl peptidase 4 (DPP4), the human receptor for MERS-CoV [19],
rodent DPP4 homologues are incompatible with MERS-CoV infection [20–22]. However, several in vivo
approaches have been developed to overcome these barriers and facilitate MERS-CoV vaccine testing
in small animal models [23–27].
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Preclinical vaccine development for both SARS-CoV and MERS-CoV has largely aimed to stimulate
a robust immune response against the viral envelope-protruding spike (S) glycoprotein [28,29], a class I
fusion protein, and/or the nucleocapsid (N) protein [30,31]. MERS-CoV S is proteolytically cleaved by
host furin [32] during maturation into an S1 domain responsible for binding to DPP4 as well as an
S2 domain containing two heptad-repeat regions that facilitate membrane fusion (Figure 1). The S1
domain can be further divided into the N-terminal domain (NTD), or S1A, associated with binding
sialic acid [33], and the receptor binding domain (RBD), comprising the majority of the C-terminal
domain of S1. Cryo-electron microscopy studies have shown that the RBD is flexible and opens
upward or away from the viral envelope in order to establish contact with DPP4, which may expose
S2’ [34], a second protease cleavage site within S2. Cleavage at S2’ is necessary for membrane fusion
upon viral entry [32]. The centrality of S to viral entry helps explain why antibodies that target it are
potently neutralizing [35]. On the other hand, while CoV N proteins are abundantly expressed during
infection [36], immunization with SARS-CoV N did not induce strongly neutralizing antibodies [37],
likely because N is not displayed on the viral surface. However, N is more conserved than S within
CoV lineage [38], and vaccination with SARS-CoV N was shown to induce cytotoxic T cell responses in
mice [39]. Therefore, N may help induce cell-mediated immunity to CoV infection [40], as may S [41].
CD4+ and CD8+ T cell responses from recovered MERS-CoV patients were particularly strong towards
N peptides [42]. However, vaccination with N-based immunogens may carry risks associated with
Th2-related eosinophilic immune enhancement [43], as may S-based vaccines [44]. Notwithstanding,
because of the protection afforded by the robust immune response it generates, S has been the target of
most vaccine candidates for MERS-CoV. In this review, we summarize the current state of MERS-CoV
vaccine candidates and also describe potential barriers to MERS-CoV vaccine efficacy that first surfaced
during research on developing a SARS-CoV vaccine.
 
Figure 1. The MERS-CoV spike (S) glycoprotein, a Class I fusion protein and the target of the majority
of vaccine candidates, exists naturally in trimer form as shown in this simplified diagram. DPP4:
dipeptidyl peptidase 4, the receptor for S. S1: S1 domain of S. S2: S2 domain of S. RBD: receptor binding
domain. NTD: N-terminal domain of S1. TMD: transmembrane domain. Structural configurations
adapted from [34,45,46].
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2. Subunit Vaccines: Immunogenically Focused
Subunit vaccines comprise one or more immunogenic components derived from a pathogen [47].
They have gained popularity in recent decades due to the relative ease of their production and
their reduced risks in vivo compared to vaccine types that involve live virus, namely live attenuated
vaccines, viral vector vaccines, and even improperly prepared inactivated vaccines.
2.1. Receptor Binding Domain
It is known from studies of recovered SARS-CoV patients that antibodies generated against the
receptor binding domain (RBD) are both long-lasting (>3 years) and neutralizing [48]. The RBD in the
MERS-CoV S glycoprotein was initially mapped to a region spanning residues 358 to 662 [49,50];
antisera from RBD protein-immunized mice or rabbits protected against in vitro infection with
MERS-CoV. In further studies exploring immune correlates of protection, intranasal administration of
RBD protein induced S1-specific immunoglobulin (Ig) G1, IgG2a, IgG3, lung IgA, and neutralizing
antibodies (NAb, that is, untyped antibodies shown to functionally inhibit free virus from infecting
cells) [51], as well as cell-mediated responses as measured by IL-2 and IFN-γ production in
antigen-stimulated CD4+ and CD8+ splenocytes [52]. In this and subsequent studies, the RBD
protein was fused to a fragment crystallizable (Fc) region of human IgG1 to increase the in vivo
half-life of the immunogen [53]. Profiling of the immunogenic region of the RBD indicated residues
377-588 bound with the highest affinity to soluble DPP4 and induced the highest NAb titers, when
administered to both mice and rabbits [54]. This range-refined RBD protein vaccine has been stably
expressed in a modified high-yield CHO cell line [55]. Purified and adjuvanted with AddaVaxTM
(MF59-like), the RBD protein vaccine was protective when administered intramuscularly to transgenic
mice expressing human DPP4 (hDPP4), with no evidence of immunological toxicity or eosinophilic
immune enhancement.
Since the S glycoprotein exists in trimeric form on the virion, a quality lost in shortened forms of
the protein, a trimer of this RBD protein vaccine has been generated containing a foldon trimerization
motif [56]. This RBD protein trimer has been shown to elicit long-lasting NAb and be protective in
challenged hDPP4-transgenic mice [57]. Independently, a monomeric RBD protein vaccine has been
developed and tested in rhesus macaques, where it reduced MERS-associated lung pathology and
reduced viral loads when adjuvanted with alum and administered intramuscularly in a three-dose
regimen prior to challenge [58]. Finally, RBD proteins encoding sequences from different strains of
MERS-CoV have been shown to induce cross-neutralizing antibodies against divergent human and
camel MERS-CoV strains as well as monoclonal antibody (mAb) escape mutants, confirming the
promise of the RBD as a valid vaccine target [59].
2.2. Full-Length S
Targeting the entire S glycoprotein has the advantage of including non-RBD neutralizing epitopes,
including those in the more conserved domains. S protein “nanoparticles,” protein aggregates
containing full-length S, have been proposed as a subunit vaccine, as nanoparticle vaccination
adjuvanted with Matrix-M1TM elicited NAb in mice [60] protected adenovirally hDPP4-transduced
mice [24] from MERS-CoV challenge [61]. Measurements of viral titer and viral RNA were near the limit
of detection in these vaccinated mice. However, despite these promising results, antibody-dependent
enhancement (ADE) of infection was previously noted in the context of vaccination with full-length
SARS-CoV S protein vaccine [62]. While ADE has not been demonstrated with full length S from
MERS-CoV, further studies must consider this as a potential issue.
A variation of the full-length S glycoprotein vaccine is a trimer of S ectodomain (all but the
transmembrane domain) conformationally locked in the prefusion state by the substitution of two
proline residues in the S2 domain [34]. Work on related fusion proteins such as the F glycoprotein of
respiratory syncytial virus has shown that stabilizing the glycoprotein in its prefusion state helps elicit
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a stronger neutralizing antibody response [63]. This “prefusion” S administered to mice elicited sera
with greater neutralization activity against a panel of pseudoviruses bearing strain-specific variants of
MERS-CoV S as compared to wild-type S. Since the S2 domain of CoVs is more conserved than the S1
domain [64], targeting epitopes in S2 may provide broader protection against different MERS-CoV
strains and other lineage C βCoVs.
2.3. N-Terminal Domain
RBD- and full-length S-based protein vaccines build upon prior vaccine efforts for SARS-CoV.
In contrast, vaccines targeting the N-terminal domain of S1 (NTD) offer a novel target. The NTD of S1
does not contain the RBD for MERS-CoV; however, the NTD binds sialic acid and is key to infecting
certain cell types [33]. Immunization with NTD protein protected against MERS-CoV challenge
in adenovirally hDPP4-transduced mice, inducing cell-mediated responses in splenocytes (CD8+
IFN-γ production, CD4+ IL-2 production, and IL-17A production) as well as humoral responses
(IgG and NAb), although NAb titer was lower compared to that of an RBD protein vaccine [65].
Overall, these results suggest that targeting S1 domains outside the RBD may be a viable strategy for
MERS-CoV vaccines.
3. DNA Vaccines: Efficient Protection
DNA vaccines offer a rapid platform to design and deliver immunogenic proteins, typically
encoded on plasmid vectors and injected into tissue with accompanying electroporation [66]. DNA
vaccine administration via electroporation has been tested in clinical trials with immunogenicity
comparable to other vaccine types and predominantly low-grade adverse events reported [67].
The in vivo expression of plasmid-encoded proteins recapitulates native post-translational
modifications while maintaining the capacity to stimulate both humoral and cell-mediated
immunity [68]. While concerns about the safety of DNA vaccines and their potential to integrate into
host cell chromosomes were voiced early in their development [69], integration using various plasmids
and inserts appears to be extremely rare [70]. Several DNA vaccines for MERS-CoV have been reported
to date.
3.1. Full-Length S
pVax1TM is a proprietary, optimized plasmid vaccine vector that has been developed as a
MERS-CoV vaccine by encoding a consensus MERS-CoV S glycoprotein containing codon and other
proprietary optimizations, as well as an IgE leader sequence to promote expression and mRNA
export [71]. Intramuscular administration of this construct with electroporation induced antibodies
with cross-MERS-CoV-strain neutralization and antigen-specific, polyfunctional T cell responses in
rhesus macaques. These humoral and cell-mediated immune responses correlated with minimal lung
pathology and reduced lung viral loads upon MERS-CoV challenge. The same study reported NAb
induction in dromedary camels, which indicates that the vaccine could be used in zoonotic reservoirs.
Building upon these preclinical results, the pVax1TM vaccine (GLS-5300) has completed a Phase I
clinical trial (clinicaltrials.gov/ct2/show/NCT02670187).
A second vaccine platform utilizes pVRC8400 [72,73], a plasmid vector engineered for high
transgene expression and enhanced cell-mediated responses. A vaccine regimen consisting of
intramuscular administration of MERS-CoV strain England1 full-length S encoded on pVRC8400,
with electroporation, and an AlPO4-adjuvanted S1 protein booster, induced NAb in rhesus macaques
up to 10 weeks following booster [74]. This vaccine resulted in lower lung pathology upon challenge
with the MERS-CoV strain JordanN3. In the same study, the full-length S DNA/S1 protein vaccine
induced higher NAb titer in mice than other prime/boost combinations involving constructs encoding
either S1 or S with the transmembrane domain (TMD) deleted. Consistent with this finding, the study
reported that mAbs induced against domains outside the RBD were able to neutralize MERS-CoV
pseudovirus. Together, these results reiterated the immunogenic potential of non-RBD epitopes
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including those derived from S quaternary (trimer) structure, which could help generate immune
responses able to minimize escape variants derived from immunization targeting either the RBD or
the S1 domain alone.
3.2. S1 Domain
The S1 domain from MERS-CoV strain Al-Hasa_15_2013 encoded on pcDNATM3.1(+),
a proprietary plasmid from which pVax1TM is derived, has also been tested as a vaccine platform.
This vaccine induced NAb in mice when given intramuscularly and antigen-specific cytokine
production including CD4+ and CD8+ production of both IL-4 and IFN-γ in murine splenocytes [75].
In addition, the vaccine protected adenovirally hDPP4-transduced mice against challenge with
MERS-CoV strain EMC/2012. Moreover, this S1 vaccine elicited more NAb than did full-length
S in the same vector. This result was attributed to increased secretion of the S1 protein, which lacked
a TMD, and greater uptake by antigen-presenting cells [76]. A separate group’s study comparing
full-length S- and S1-encoding pcDNATM3.1 vaccines found that the S1 vaccine elicited a more balanced
IgG2a/IgG1 ratio in mice compared to that elicited by full-length S [77] suggesting a balanced Th1/Th2
response [78]. Together, these results show that multiple plasmid vaccine vectors encoding either
full-length S or the S1 domain induce adaptive immunity and protect against MERS-CoV challenge.
4. Viral Vector Vaccines: Optimized Delivery
Viral vector vaccines contain one or more immunogenic proteins of the pathogen of interest in the
context of an attenuated virus backbone. This approach takes advantage of cellular entry by the virus
as well as adjuvantation from viral components, and induces both humoral and strong cell-mediated
responses [79]. Early studies into viral vector vaccines for MERS-CoV built upon established platforms
and have subsequently transitioned to newer viral vector approaches.
Venezuelan equine encephalitis (VEE) virus replicon particles (VRPs), an alphavirus-based
platform that replaces the VEE structural genes with a foreign transgene, has been shown to induce
strong humoral and cellular immune responses [80,81]. A VRP encoding MERS-CoV S elicited NAb in
both young and aged mice [38]. Additional studies with this vector have shown that immunization
with an N protein-expressing VRP protected adenovirally hDPP4-transduced mice from MERS-CoV
challenge in a CD4+ T cell- and IFN-γ-dependent manner [82]. Moreover, a specific N protein epitope
was stimulatory in mice transgenic for human leukocyte antigen DR2 and DR3, highlighting the
relevance of this epitope to human antigen recognition and to promoting cell-mediated immunity
in humans.
Modified vaccinia virus Ankara (MVA) [83,84], a well-established vaccine platform, has been
developed to encode full-length MERS-CoV S. This vaccine induced NAb and CD8+ T cell
responses in mice [85] and also protected against MERS-CoV-induced histopathology in adenovirally
hDPP4-transduced mice before challenge [86]. Moreover, minimal inflammation and lymph node
hyperplasia was observed at the site of injection [87]. This same MVA-MERS-CoV S vaccine
injected intramuscularly into dromedary camels was shown to induce NAb and to limit excretion of
infectious virus upon intranasal challenge with MERS-CoV [88]. A Phase I clinical trial is underway
(clinicaltrials.gov/ct2/show/NCT03615911).
Adenoviruses compose a third platform of viral vectors for MERS-CoV vaccines.
Adenovirus-vectored vaccines have been tested in clinical trials for a wide variety of diseases,
notably HIV [89]. However, their efficacy may be hampered by pre-existing immunity to prevalent
adenovirus serotypes [90,91]. For example, pre-existing immunity to human adenovirus serotype 5
(Ad5) was shown to result in reduced CD8+ T cell responses against an Ad5-vectored transgene [92].
To take advantage of the shared respiratory route of infection of both MERS-CoV and adenovirus,
Ad5-vectored full-length S and S1 vaccines have been developed [93]. These elicited antigen-specific
IgG and NAb when administered intramuscularly to mice with subsequent intranasal boosting.
Importantly, this study did not detect immunity against the Ad5 vector in dromedary camels,
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the intended vaccination population. Moreover, camel peripheral blood mononuclear cells and
a camel-derived fibroblast cell line were able to be infected with Ad5. Another Ad5-MERS-CoV
S vaccine has been separately developed, as has a human adenovirus type 41 (Ad41)-MERS-CoV
S vaccine [94]. Adenovirus type 41 (Ad41) is an enteric pathogen with potential use as an orally
administered vaccine [95]. Both of these vaccines, Ad5-MERS-CoV S and Ad41-MERS-CoV S, were
reported to induce humoral responses when administered intragastrically in mice. In addition to
humoral responses, they also induced long-lasting cell-mediated responses in the lung and spleen
when administered intramuscularly. One final Ad5-based MERS-CoV immunization regimen has been
reported [96]. Immunizing with Ad5-vectored S followed by boosting with S nanoparticles induced
S-specific IgG, NAb, and both Th1 and Th2 cell-mediated responses in mice, and also protected
adenovirally hDPP4-transduced mice from MERS-CoV challenge.
To circumvent the seroprevalence of circulating human adenoviruses, chimpanzee adenoviruses
have also been developed as viral vaccine vectors [97] and have entered clinical trials [98]. A MERS-CoV
S-encoding vaccine based on a chimpanzee adenoviral vector (ChAdOx1) was shown to induce high
levels of NAb and cell-mediated responses (CD8+ IFN-γ, TNFα, and IL-17 production) in mice 4 weeks
post-immunization [99]. This vaccine was constructed with a codon-optimized S glycoprotein sequence
and the tissue plasminogen activator (tPA) gene leader sequence to promote secretion [100,101].
The ChAdOx1-MERS-CoV S vaccine protected against lethal challenge in a transgenic hDPP4 mouse
model [102]. Based on previous work with the ChAdOx1 vector demonstrating its safety in humans,
the ChAdOx1-MERS-CoV S vaccine is undergoing a Phase I clinical trial (clinicaltrials.gov/ct2/show/
NCT03399578).
Several additional viral vectors have been employed as MERS-CoV vaccines. Measles virus vector
platforms have been developed over the past two decades [103]. A full-length or soluble form of
S encoded in measles vaccine strain MVvac2 induced NAb, proliferation of T cells, S-specific IFN-γ
production, and cytotoxic activity [104]. The vaccine also protected against MERS-CoV challenge
in adenovirally hDPP4-transduced mice that were transgenic for a measles virus receptor. Further
characterization of the T cell responses induced by this vaccine has been performed [105]. Of note, 5-fold
higher numbers of reactive T cells were induced by vaccination with MVvac2-S than those induced by
N protein using the same vector. Additionally, antigen-specific IFN-γ production by T cells could be
induced in older mice (7 months old) at levels near those induced in younger mice (6–12 weeks old).
Newcastle disease virus (NDV) has been explored as a vaccine vector as it infects the respiratory
tract and can induce systemic and mucosal immunity in non-human primates [106]. An NVD vector
expressing MERS-CoV S was shown to induce long-lasting (up 14 weeks post-immunization) NAb
titers in camels [107]. The research group behind this study also examined vesicular stomatitis virus
(VSV) [108] as a viral vector. S expressed from a VSV reverse genetics system was shown to incorporate
onto the surface of virions rescued in cell culture. Purified vaccine was able to infect cells in an
hDPP4-dependent manner, induced S-specific IgG and NAb in mice, and stimulated humoral and
cell-mediated (IFN-γ-production) responses in rhesus macaques [109].
Similar to the VSV platform, a rabies virus (RABV) vector has been explored. Inspired by studies
combining rabies and Ebola vaccine platforms [110], a β-propiolactone-inactivated dual rabies/MERS
vaccine has been proposed which incorporates the MERS-CoV S1 domain fused to rabies virus G
protein on the RABV virion [111]. This vaccine elicited S-specific IgG and NAb and fully protected
adenovirally hDPP4-transduced mice from MERS-CoV challenge. The VSV and RABV approaches
described here are unique in that they encode S (or S1) in the vector genome and also display it on the
virion surface.
Finally, virus-like particles (VLPs), which comprise self-assembling immunogenic proteins, but no
genome [112], have also been used as viral vectors. A baculovirus VLP containing S as well as
MERS-CoV envelope and matrix proteins elicited RBD-specific IgG and IFN-γ responses in rhesus
macaques [113]. A subsequent baculovirus VLP vaccine was developed that focused only on a fusion
of the RBD from S and the immunogenic VP2 protein of canine parvovirus. This vaccine induced
136
Viruses 2019, 11, 74
RBD-specific IgG, NAb, and cell-mediated responses including IFN-γ, IL-2, and IL-4 production in
mice, and also activated dendritic cells in inguinal lymph nodes [114]. In summary, a variety of viral
vector vaccines for MERS-CoV induce promising immune responses in animal models and often
demonstrate protection from challenge.
5. Live Attenuated and Inactivated Vaccines: Situationally Useful
A final approach to developing MERS-CoV vaccines delivers the whole virus, either inactivated
or live but attenuated. Both of these vaccine types resemble the original virus, preserving structural
features and a full or nearly-full repertoire of immunogenic components. Inactivated viruses may
contain structural deformations introduced by inactivation, but, unlike attenuated viruses, they
pose no risks, if properly inactivated, either of reversion to a virulent state or persistent infection
in immunocompromised patients. Fewer examples of whole virus vaccines, compared to the other
vaccine types, have been developed for MERS-CoV.
5.1. Inactivated
Development of inactivated vaccines for MERS-CoV has been stymied by prior concerns with
SARS-CoV inactivated vaccines. Eosinophil-related lung pathology was observed for a SARS-CoV
vaccine doubly inactivated with both formalin and UV irradiation [115]. This response was particularly
notable in aged mice versus young mice, and following heterologous versus homologous challenge.
Similarly, immunization with a gamma-irradiated MERS-CoV vaccine adjuvanted with either alum
or MF59 elicited NAb and reduced viral titer upon challenge in hDPP4-transgenic mice, but induced
eosinophil-related lung pathology in vaccinated mice after challenge [116].
A different inactivation method was tried for a second MERS-CoV inactivated vaccine.
Formalin-inactivated MERS-CoV adjuvanted with alum and oligodeoxynucleotides containing
unmethylated CpG motifs was shown to elicit levels of NAb on par with those elicited by an S
glycoprotein-only vaccine [117]. Moreover, the vaccine offered better protection than S alone based
on reduction of lung viral titer in adenovirally hDPP4-transduced mice after MERS-CoV challenge.
Remarkably, eosinophil-mediated vaccine-related pathology was not observed in this animal model.
Interestingly, it has also been shown that including Toll-like receptor agonists in a UV-inactivated
SARS-CoV vaccine reduced Th2-associated pathology in lungs after challenge [118]. These results
suggest that inactivated CoV vaccines may remain viable options for further development with the
right inactivation method and adjuvants.
5.2. Live Attenuated
Live attenuated vaccines for MERS-CoV show efficacy in animal models, but so far have not been
pursued in subsequent studies. While riskier than other vaccine types, live attenuated vaccines have
historically offered protection against a variety of threatening illnesses [119] and may be reserved
for outbreak scenarios where they offer an immunogenically robust solution. The CoV envelope (E)
protein is important in virion assembly and egress, and has also been shown to inhibit the host cell
stress response [120]. An E-deletion mutant of SARS-CoV was previously found to be protective
in vivo against SARS-CoV challenge [121]. An initial study into a MERS-CoV reverse genetics system
reported on a replication-competent, but propagation-defective mutant lacking the E protein that could
be rescued in cell culture with E expressed in trans [122]. However, the E-deletion mutant was rescued
at 100-fold lower titer compared to wild-type MERS-CoV, perhaps explaining why this mutant has not
been further developed as a live attenuated vaccine candidate.
Other CoV components have been targeted in live attenuated vaccine development. Nonstructural
protein 14 (nsp14) contains an exoribonuclease (ExoN) essential to replication fidelity that is found in all
known nidoviruses with genome sizes greater than 20 kb [5]. A stable deficiency in nsp14 attenuated
SARS-CoV in young, aged, and immunocompromised mice, and was able to induce protection
following vaccination [123]. However, ExoN mutants for MERS-CoV have not been reported.
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CoV gene nonstructural protein 16 (nsp16) is a 2′-O-methyl-transferase involved in viral mRNA
capping [124] and was previously inactivated in a SARS-CoV live attenuated vaccine [125,126].
A live nsp16-deficient MERS-CoV vaccine was similarly attenuated in a type I interferon- and
IFIT1-dependent manner. Immunization with the MERS-CoV nsp16 mutant induced NAb and
protected CRISPR-engineered hDPP4-transgenic mice [23] from challenge with a mouse-adapted
MERS-CoV strain [127].
Finally, live attenuated vaccines lacking CoV accessory proteins have also been considered. CoV
accessory proteins are dispensable for viral replication but have been shown to modulate interferon
signaling and pro-inflammatory cytokine production [128]. A MERS-CoV strain lacking accessory
open reading frames (ORFs) 3, 4, and 5 was attenuated in vivo, induced NAb, and like the nsp16
mutant, protected CRISPR-engineered hDPP4-transgenic mice from challenge with a mouse-adapted
MERS-CoV strain [129]. Overall, whole vaccine approaches to MERS-CoV vaccination appear both
protective and safe in animal models.
6. Conclusions and Future Directions
Aided by knowledge gained from vaccine development against SARS-CoV and other
contemporary viral diseases, MERS-CoV vaccine development efforts have multiplied since its
emergence, yielding promising vaccine candidates spanning multiple platforms (Table 1). Nevertheless,
key barriers to vaccine efficacy first noted for SARS-CoV may also hold true for MERS-CoV. As with
SARS-CoV [130], mortality from MERS-CoV has disproportionately affected the aged. Additionally,
immunocompromised individuals and those with chronic conditions are at greater risk of mortality
from MERS-CoV infection [11]. A universal MERS-CoV vaccine must offer protection to these
vulnerable classes of people.
More studies on the effectiveness of the proposed MERS-CoV vaccines in models of
immunosenescence, immunocompromise, and chronic conditions are needed. In this regard,
vaccination studies with SARS-CoV have indicated that vaccines may be capable of inducing
protection in young animals while failing to protect aged animals [115]. In light of the threat of
related coronavirus strains emerging, MERS-CoV vaccine studies must also consider heterologous
challenge models to ensure safety from vaccine-induced immunopathology, especially in older
individuals [115]. In short, vaccine-induced immunopathology, especially Th2-related eosinophilic
immune enhancement [131], from both homologous and heterologous challenge should be specifically
monitored in vulnerable populations. Interestingly, it was shown that pathology resulting from
MERS-CoV challenge in the lungs of immunosuppressed rhesus macaques was lower compared to that
of non-immunosuppressed macaques, underscoring the immunopathogenic component of respiratory
disease caused by CoVs [132].
The different vaccine platforms described herein have unique advantages and disadvantages.
Since severe CoV disease maintains an immunopathogenic component, a successful vaccine must
strike a balance between protection and excessive immune activation. As seen with full-length S [44] as
well as inactivated virus [116], vaccination may produce immunopathology under certain conditions.
Alternatively, protection must be thorough enough to prevent NAb escape, a phenomenon inversely
correlated with the number of immunogenic epitopes. While antibodies induced against S of either
SARS-CoV or MERS-CoV poorly cross-neutralize across their respective lineages [38], a vaccine that
contains multiple immunogenic epitopes would perhaps also offer greater cross-protection against
heterologous strains within lineage as they emerge, especially if conserved epitopes are included
in vaccine design. A greater understanding of MERS-CoV pathology will also help guide future
vaccine development efforts by illuminating possibly critical differences in vaccine responses between
MERS-CoV and SARS-CoV, the latter of which has largely influenced vaccine development against
the former.
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Overall, MERS-CoV vaccines have shown encouraging results in preclinical studies and we
hope these vaccines stand up to safety considerations in order to proceed through clinical trials.
While development of therapeutic treatment is critical, vaccination carries the promise of mitigating
future outbreaks and alleviating disease burden from the most vulnerable populations including the
aged, the immunosuppressed, healthcare workers, family members of infected patients, and those in
endemic areas.






Protective in: Clinical Trial Source (s)
Subunit
RBD M, P M, P M, P [50,55,58]
S nanoparticles M M [61]
Prefusion-locked S M [34]
NTD M M M [65]
DNA
pVax1-S M, P, C M, P P Phase I [71]
pVRC8400-S 1 M, P P [74]
pcDNA3.1(+)-S1 or S M M M [75,77]
Viral Vector
VEEV-S M [38]
VEEV-N M M [82]
MVA-S M, C M M, C Phase I [88]
Ad5-S or S1 M M [93,94]
Ad5-S 2 M M M [96]
Ad41-S M M [94]
ChAdOx1-S M M M Phase I [102]
MVvac2-S M M M [104]
Newcastle-S M, C [107]
VSV-S M, P P [109]
Rabies-S1 M M [111]
Bac-S,E,M P P [113]
Bac-RBD+VP2 M M [114]
Whole
Formalin inactivated M M [117]
MERS-ΔE [122]
MERS-dNSP16 M M [127]
MERS-dORF3-5 M M [129]
Humoral response denotes any antibody response generated, in most cases a NAb response. Cell-mediated
responses denote T cell activation markers including IFN-γ. S: MERS-CoV spike protein. N: MERS-CoV
nucleocapsid. RBD: receptor binding domain. NTD: N-terminal domain. S1: spike subdomain S1. Bac: baculovirus
VLP. E: MERS-CoV envelope protein. M (under Vaccine Type): MERS-CoV membrane protein. VP2: canine
parvovirus VP2 protein. M (under Protective in:): mouse. P: non-human primate. C: camel. 1 With S1 protein booster;
2 with S nanoparticles booster.
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Abstract: MERS-CoV is present in dromedary camels throughout the Middle East and Africa.
Dromedary camels are the primary zoonotic reservoir for human infections. Interruption of the
zoonotic transmission chain from camels to humans, therefore, may be an effective strategy to control
the ongoing MERS-CoV outbreak. Here we show that vaccination with an adjuvanted MERS-CoV
Spike protein subunit vaccine confers complete protection from MERS-CoV disease in alpaca and
results in reduced and delayed viral shedding in the upper airways of dromedary camels. Protection
in alpaca correlates with high serum neutralizing antibody titers. Lower titers of serum neutralizing
antibodies correlate with delayed and significantly reduced shedding in the nasal turbinates of
dromedary camels. Together, these data indicate that induction of robust neutralizing humoral
immune responses by vaccination of naïve animals reduces shedding that potentially could diminish
the risk of zoonotic transmission.
Keywords: MERS-CoV; camels; vaccines; One Health
1. Introduction
Since the emergence of the Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012,
there have been more than 2279 confirmed human cases and 806 deaths, yielding a case fatality ratio of
35% [1,2]. Nearly all cases either have occurred in or been exported from the Middle East. Dromedary
camels have been identified as the primary reservoir of MERS-CoV through multiple studies that have
employed combinations of diagnostic platforms, to include serology, molecular detection of viral RNA,
and virus isolation [3–15]. Serologic studies suggest that MERS-CoV has been present in dromedary
Viruses 2019, 11, 212; doi:10.3390/v11030212 www.mdpi.com/journal/viruses148
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camels for at least three decades in regions as wide ranging as the Middle East, North Africa, and East
Africa [16]. The outbreak among human populations has persisted—albeit in low numbers—despite a
lack of sustained human-to-human transmission [17,18]. Data from molecular epidemiologic studies
suggest that the outbreak has endured through multiple zoonotic spillover events from dromedary
camels to humans. Additionally, several studies in Saudi Arabia and Qatar have demonstrated a clear
epidemiologic link between camel and human populations [4,19–26].
Although MERS-CoV typically causes severe pneumonia in humans, the virus primarily infects
the upper respiratory tract of dromedary camels, from where viable virus is shed in high quantities
for approximately 7 days, and where viral RNA can be detected up to 35 days [27]. Occupational
exposure that involves close proximity to infected dromedary camels is a major risk factor for human
acquisition. This risk profile has been confirmed by studies in Saudi Arabia where camel herders and
slaughterhouse workers were much more likely than the general population to either have serologic
evidence of past exposure to MERS-CoV or develop MERS [20,26].
The high case fatality rate, continued zoonotic transmission, and sustained animal reservoir
of MERS-CoV underscore the need for intervention strategies focused on preventing zoonotic
transmission. Here, we evaluated the efficacy of an intramuscular, adjuvanted S1 subunit vaccine to
prevent infection or reduce shedding in dromedary camels (Camelus dromedarius) and alpaca (Vicugna
pacos).
2. Materials and Methods
2.1. Vaccine Development
DNA expression vectors were produced encoding the S1 portion of the Spike glycoprotein of
MERS-CoV England1 strain (strain England1, GenBank ID: AFY13307) (Figure 1). Sequences were
reverse-translated and codon-optimized for human cell expression as described [28]. Proteins were
produced by transfecting Expi293 cells with the mammalian expression vector VRC8400 expressing
the codon-optimized S1 gene. Protein was purified from transfected cell culture supernatants with
HisTrap HP Hiload 16/60 Superdex columns (GE Healthcare, Piscataway, NJ, USA), and stored at
−80 ◦C in PBS until use.
2.2. Ethics Statement
All experiments were approved by the Colorado State University Institutional Animal Care and
Use Committee. Work with infectious MERS-CoV strains under BSL3 conditions was approved by the
Institutional Biosafety Committee (IBC). Inactivation and removal of samples from high containment
was performed according to IBC-approved standards.
2.3. Study Design
To evaluate the effect of vaccination on MERS-CoV shedding, we used both the actual animal
reservoir (camels) and a surrogate infection model (alpaca) [27,29]. Five MERS-CoV seronegative
dromedary camels and four alpaca were purchased by private sale for use in this study. All animals
were born in the United States and were all adult intact males for the Alpaca; one intact adult male,
one castrated adult male, and one adult female for the vaccinated dromedary camels; and three intact
male dromedary camels for the unvaccinated control animals. Animals were fed ad libitum, housed in
outdoor pens during immunization and moved into an Animal Biosafety Level 3 facility one week
prior to challenge to allow for acclimation to the facility.
Vaccinated animals were given 400 μg S1 protein combined with 40 mg Advax HCXL adjuvant (a
delta inulin formulation, Vaxine Pty Ltd., Bedford Park, SA, Australia), in two 1 mL intramuscular
injections given on each shoulder on day 0 and day 28, and then given 400 μg S1 protein in the
Sigma Adjuvant System (an oil-in-water emulsion, Sigma-Aldrich, St. Louis, MO, USA) on day 105.
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The Advax adjuvant was chosen for stimulating broad immunogenicity in dromedary camels [30],
the Sigma Adjuvant System for known induction of MERS-CoV neutralizing antibodies [28].
Animals were challenged with MERS-CoV strain HCoV/EMC/2012 in three groups along a
staggered schedule, due to facility limitations. Group 1 was inoculated 130 days after first vaccination
and consisted of vaccinated camel 3 (CA3), group 2 was inoculated 131 days after first vaccination
and consisted of unvaccinated camels 4 and 5 (CA4 and CA5) and vaccinated alpaca 1 and 2 (A1
and A2), and group 3 was inoculated 132 days after first vaccination and consisted of vaccinated
camels 1 and 2 (CA1 and CA2) and unvaccinated alpaca 3 and 4 (A3 and A4). Animals were sedated
with xylazine and then inoculated intranasally with a total dose of 107 TCID50 of a human isolate of
MERS-CoV (strain HCoV-EMC/2012) as described previously [27]. Camels were inoculated with 5 mL
per nare, and alpaca were inoculated with 3 mL per nare. All animals were evaluated at least once daily
for temperature, nasal discharge, activity level, and food consumption. Nasal swabs were collected
daily and placed immediately into viral transport medium or virus lysis buffer and then frozen
until processing. Animals were sedated on day 5 post-inoculation and humanely euthanized with
intravenous pentobarbital. The following tissues were collected for viral isolation and formalin-fixed
for immunohistochemistry and histopathology: nasal turbinates, larynx, trachea, lung (right apical,
left apical, right caudal, left caudal lobes), kidney, spleen, mediastinal and mesenteric lymph nodes and
muscle. Historical samples from a previously infected camel euthanized on day 5 post inoculation [27]
were included as an additional control (CA6). CA6 in the present study corresponds to camel 1 in the






















Figure 1. Vaccine immunogens and neutralizing antibody responses. (A) Schematic representation
of the full MERS-CoV spike protein (top) and the S1 subunit used as antigen for vaccination
(bottom). (B) Schematic overview of the immunization timeline with the immunization (blue arrows),
serum sampling (red triangle), and challenge and euthanasia (black arrows) time points indicated.
(C) Neutralizing antibody titers in dromedary camels and alpacas vaccinated with adjuvanted
MERS-CoV S1 as determined by PRNT (90% neutralization).
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2.4. Immunization and Serology
Blood was collected on day 0, 21, 28, 35, 63, 98, 112 after first vaccination and at time of challenge
(day 130–132) into serum-separating tubes. Serum was analyzed for MERS-CoV neutralization activity
by plaque reduction neutralization test (PRNT) as described previously using a 90% neutralization
cutoff [27].
2.5. Virus Titration
Nasal swabs and tissue samples were titrated by plaque assay in Vero E6 cells. In short,
homogenized tissue was titrated in BA-1 medium and plaques were counted on both days 1 and 3
following the second overlay as described previously [27].
2.6. RNA Extraction and qRT-PCR
RNA was extracted from swabs, urine and fecal samples using the QiaAmp Viral RNA kit
(Qiagen). For detection of viral RNA, 5 μL of RNA was used in a one-step real-time RT-PCR upE assay
using the Rotor-GeneTM probe kit (Qiagen) as described previously. Standard dilutions of a titered
virus stock were run in parallel, to calculate TCID50 equivalents in the samples.
2.7. MERS-CoV Spike Glycoprotein Sequencing
Total RNA from nasal turbinate tissue samples from dromedary camels and alpaca were extracted
using the RNeasy Mini Kit (Qiagen) and cDNAs were synthesized using random hexamers and the
High Capacity RNA to cDNA Kit (Thermo Fisher, Waltham, MA, USA). cDNA was subsequently
used to PCR-amplify the MERS-CoV S using iProof High-Fidelity DNA Polymerase (Biorad, Hercules,
CA, USA) according to the manufacturer’s protocol; primer sequences are available upon request.
Sequences were assembled on SeqMan Pro (DNASTAR, Madison, WI, USA) and analyzed on
MegAlign (DNASTAR, Madison, WI, USA) by comparison to the MERS-CoV (strain HCoV-EMC/2012)
input sequence.
2.8. Histopathology and Immunohistochemistry
Dromedary camel and alpaca tissues were evaluated for pathology and presence of viral
antigens. Tissues were fixed for >7 days in 10% neutral-buffered formalin and placed in cassettes
and processed with a Sakura VIP-5 Tissue Tek, on a 12-hour automated schedule, using a graded
series of ethanol, xylene, and ParaPlast Extra. Embedded tissues are sectioned at 5 μm and dried
overnight at 42 degrees C prior to staining. All tissues were processed for immunohistochemistry
using the Discovery XT automated processor (Ventana Medical Systems) with a DABMap (Ventana
Medical Systems) kit. To detect MERS-CoV antigen, immunohistochemistry was performed using a
rabbit polyclonal antiserum against HCoV-EMC/2012 (1:1000) as a primary antibody as described
previously [27]. Grading of histopathology and immunohistochemistry was done blinded by a
board-certified veterinary pathologist.
2.9. Statistical Analysis
p values were calculated in a 2-way ANOVA with Sidak’s multiple comparisons test using the
Prism software (Version 6.04, GraphPad, La Jolla, CA, USA). Statistically significant differences met a
threshold (α) of 0.05.
3. Results
3.1. Humoral Responses in Dromedary Camels and Alpaca Vaccinated against MERS-CoV
Three dromedary camels (CA1, CA2, CA3) and two alpaca (A1, A2) were vaccinated with an
adjuvanted S1-protein subunit vaccine. Three camels (CA4, CA5, CA6) served as unvaccinated controls;
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CA6 is a historical control [27]. Two alpaca (A3, A4) served as unvaccinated controls for the alpaca
group. Animals were vaccinated on days 0 and 28 with 400 μg of S1 protein (Figure 1A) co-formulated
with 40 mg AdvaxTM HCXL adjuvant (Vaxine Pty Ltd, Adelaide, Australia) [30]. The admixed product
was delivered at each time point as two 1 mL intramuscular injections in each shoulder. All animals
were boosted on day 105 with 400 μg of S1 protein emulsified in Sigma Adjuvant System (Sigma Aldrich
Co. LLC. St. Louis, MO, USA) to complete a 0, 4-, and 15-week immunization schedule (Figure 1B).
Serum from vaccinated animals was collected and evaluated by plaque reduction neutralization test
(PRNT) with MERS-CoV strain HCoV-EMC/2012 (Figure 1C). On day 28 after priming vaccination,
low levels of MERS-CoV neutralizing antibodies were detected in two of three the camels (virus
neutralizing titers of 1:40, 1:10, and <10 respectively; Figure 1C). The day 28 boost did not result in
an increase in neutralizing titers in the PRNT assay and neutralizing titers decreased between the
second and third boost. The third immunization resulted in a quick increase in neutralizing titer in the
two camels that responded to the vaccine; neutralizing titers were high in these two camels by the
time of challenge. Neutralizing antibodies were not detected in CA3 (<1:10) at any point during the
experiment (Figure 1C). A stronger neutralizing response was observed in the alpaca after vaccination,
with virus neutralizing titers of 1:640 and 1:40 four weeks after the initial vaccination to end titers of
1:2560 and 1:640 at the time of challenge (Figure 1C).
3.2. Vaccine Efficacy in Preventing MERS-CoV Disease and Virus Shedding
Animals were challenged intranasally with 107 50% tissue culture infectious dose (TCID50) of
MERS-CoV (strain HCoV-EMC/2012) and euthanized and necropsied at 5 days post-inoculation (dpi).
Only the unvaccinated control camels developed mild clinical disease. Nasal discharge was observed
in concurrent control camels at 2 dpi, but quickly resolved. Observable nasal discharge was not
detected in the vaccinated camels nor in any of the alpaca. Minor temperature fluctuations were
detected in several of the camels and alpaca; however, there was no appreciable fever associated with
infection (Figure S1).
Virus shedding was first detected in nasal swabs from unvaccinated control camels at 1 dpi
and every day thereafter until euthanasia at 5 dpi (Figure 2A). Despite the presence of neutralizing
antibodies in two of the three vaccinated camels, all animals shed virus after challenge. The two
vaccinated camels with a detectable humoral immune response (CA1 and CA2) exhibited reduced
viral shedding through 4 dpi. At 5 dpi, there were no differences in MERS-CoV titers measured
in nasal swabs between vaccinated and control camels. The vaccinated camel without detectable
neutralizing antibody titers (CA3) did not shed virus on 1 dpi but otherwise exhibited virus shedding
kinetics that were similar to those of unvaccinated controls. Overall, infectious MERS-CoV titers
in nasal swabs differed statistically significantly between vaccinated and unvaccinated camels on 1
and 3 dpi (p < 0.05). In contrast to the camels, vaccination of alpaca resulted in complete protection
from MERS-CoV shedding. No infectious virus was detected in the nasal swabs collected from the
vaccinated alpaca (A1, A2), while infectious virus was detected in unvaccinated alpaca every day until
necropsy at 5 dpi (Figure 2B).
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Figure 2. Virus shedding in nasal swabs of vaccinated and unvaccinated dromedary camels and alpaca
after challenge with MERS-CoV. Nasal swabs were obtained from dromedary camels (A) and alpaca
(B) daily after MERS-CoV challenge and virus titers in swabs were determined in a plaque assay. Red
bars indicate vaccinated animals and blue bars indicate unvaccinated control animals. A dashed line
indicates the detection limit of the assay. Asterisks indicate statistically significant difference between
geometric mean titers (p < 0.05).
Infectious virus was detected in the nasal turbinates, larynx, and trachea of all unvaccinated
camels (Figure 3A), confirming that the virus stock prepared for challenge resulted in productive
infection. Additionally, infectious virus was detected in 1 of 4 lung lobes of CA6. All three vaccinated
camels had infectious virus in their nasal turbinates at titers similar to those of the unvaccinated camels.
However, virus titers in the larynx and trachea were significantly lower in the vaccinated camels than
in unvaccinated controls (Figure 3A). Viral RNA was also detected outside the respiratory tract of
camels, predominantly in the lymph nodes (Figure S2A).
Both unvaccinated alpaca had high titers of infectious virus present in their nasal turbinates and
lower titers in the larynx and trachea. Neither infectious virus nor viral RNA could be detected in the
respiratory tract tissues of the vaccinated alpaca (Figure 3B and Figure S2B). In the unvaccinated control
alpaca, low amounts of viral genomic RNA were detected outside the respiratory tract (Figure S2B).
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Figure 3. Infectious virus in respiratory tissues of vaccinated and unvaccinated dromedary camels
and alpaca after challenge with MERS-CoV. Dromedary camels (A) and alpaca (B) were euthanized
on 5 dpi, tissues were collected, and virus titers were determined in a plaque assay. Red bars indicate
vaccinated animals and blue bars indicate unvaccinated control animals. A dashed line indicates the
detection limit of the assay. Asterisks indicate statistically significant difference between geometric
mean titers (** p < 0.01; **** p < 0.0001). L: left; R: right.
3.3. Histopathological Changes in Vaccinated Versus Control Animals
All camels displayed, on histologic section, a multifocal, minimal-to-mild, acute rhinitis
(Figure 4A,G). The nasal turbinates exhibited a loss of cilia and cellular polarity, occasional necrotic
epithelial cells admixed with small numbers of neutrophils, and rare erosions of respiratory epithelium.
The underlying submucosa was infiltrated by small-to-moderate numbers of lymphocytes and plasma
cells with fewer macrophages and neutrophils. The non-responsive vaccinated camel, CA3, and control
CA4 displayed a minimal-to-mild multifocal acute tracheitis, as evidenced by a loss of individual
epithelial cells and cell polarity. Necrosis and infiltration of the epithelium by small numbers of
neutrophils were observed. None of the camels showed pathological changes in the lower respiratory
tract (Figure 4B,C,H,I). Immunohistochemistry (IHC) demonstrated the presence of MERS-CoV antigen
in the epithelial cells of the nasal turbinates of CA1-5 (Figure 4D,J). Viral antigen was also detected in
the tracheal epithelial cells of CA3 and CA4, but not in CA1 or CA2 (Figure 4E).
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Figure 4. Histopathological changes in the respiratory tract of vaccinated and unvaccinated dromedary
camels after challenge with MERS-CoV. Nasal turbinate, trachea, and lung were collected from
vaccinated (A–F; CA3 shown) and unvaccinated control animals (G–L; CA5 shown) on 5 dpi and
stained with hematoxylin and eosin (A–C and G–I), or a polyclonal anti-MERS-CoV antibody panels
(D–F and J–L). MERS-CoV antigen is visible as a red brown staining in the immunohistochemistry
panel. Vaccinated and unvaccinated camel groups displayed multifocal, minimal-to-mild, acute rhinitis.
MERS-CoV antigen was primarily detected in the nasal turbinates. Magnification: 400×.
Similar to the camels, the unvaccinated alpaca displayed a multifocal, minimal-to-mild, acute
rhinitis (Figure 5G) with loss of cilia and cellular polarity, occasional necrotic epithelial cells admixed
with small numbers of neutrophils, and rare erosions of respiratory epithelium. The subjacent
submucosa was infiltrated by small-to-moderate numbers of lymphocytes and plasma cells with
fewer macrophages and neutrophils. IHC confirmed the presence of MERS-CoV antigen within the
epithelial cells of the nasal turbinates of these control alpaca (Figure 5J). No histopathological changes
or MERS-CoV antigen were detected in any of the vaccinated alpaca (Figure 5G–L).
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Figure 5. Histopathological changes in the respiratory tract of vaccinated and unvaccinated alpaca
after challenge with MERS-CoV. Nasal turbinate, trachea, and lung were collected from vaccinated
(A–F; A1 shown) and unvaccinated control animals (G–L; A3 shown) on 5 dpi and stained with
hematoxylin and eosin (A–C and G–I), or a polyclonal anti-MERS-CoV antibody panels (D–F and
J–L). MERS-CoV antigen is visible as a red brown staining in the immunohistochemistry panel.
No histopathological changes were observed in the vaccinated alpaca whereas the unvaccinated
control alpaca displayed multifocal, minimal-to-mild, acute rhinitis. MERS-CoV antigen was only
detected in the nasal turbinates. Magnification: 400×.
4. Discussion
Given the importance of the zoonotic reservoir of MERS-CoV in sustaining the current human
epidemic, strategies to interrupt the transmission from dromedary camels to humans may serve as
an effective countermeasure [31]. This strategy has been implemented in the setting of Hendra virus
infection in Australia, where vaccination of horses is aimed at interrupting the transmission chain of
Hendra virus from fruit bats to horses to humans [32]. Likewise, dromedary camels are the drivers
of zoonotic transmission of MERS-CoV and vaccination of dromedary camels to reduce shedding of
MERS-CoV would likely limit its potential for zoonotic transmission.
Large fractions of dromedary camels in the Middle East and North and East Africa have antibodies
specific to MERS-CoV [3,6,8,9,12,14,33,34]. The degree of protection from reinfection provided by these
antibodies is currently unclear. Evidence points to the ability of MERS-CoV to re-infect dromedary
camels despite the presence of antibodies in serum, as MERS-CoV seropositive camels that still shed
detectable MERS-CoV from the respiratory tract have been found in the Middle East [8]. However,
a correlation between strong humoral responses in seropositive adult dromedary camels and low
prevalence of MERS-CoV was observed in Jordan, whereas seropositive young camels <3 years old
with weaker humoral responses displayed high MERS-CoV prevalence [34], suggesting that antibodies
against MERS-CoV afford some protection from reinfection or virus shedding. This observation also
suggests that younger animals are the main driving force behind the circulation of MERS-CoV and
should be the primary target for vaccination strategies.
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This study highlights several important issues to consider when developing a dromedary camel
vaccine against MERS-CoV. First of all, virus shedding was reduced, but not completely absent in
the presence of antibodies in dromedary camels after vaccination. However, virus replication in
vaccinated animals was largely confined to the nasal turbinates, whereas the MERS-CoV replication
in unvaccinated animals extended deeper down the respiratory tract into the trachea. In a study
using intranasal administration of a modified vaccinia virus Ankara virus vector vaccine expressing
full length Spike protein, delayed shedding was also observed in one of the vaccinated dromedary
camels [35]. After vaccination, low neutralizing antibody titers were detected in the upper respiratory
tract. The apparent low neutralizing capacity of the upper respiratory tract combined with continuous
exposure to MERS-CoV (from co-housed animals) could potentially deplete the neutralizing capacity
by scavenging the available neutralizing antibodies until the neutralizing capacity is sufficiently
reduced to allow for virus replication. Therefore, vaccine platforms aimed specifically at inducing high
levels of mucosal immunity or those that induce humoral as well as cellular immunity may be required
for complete protection. In-depth studies to determine the correlates of protection in dromedary
camels would aid the development of better-targeted vaccines, especially the correlation of levels
of neutralizing antibodies in the serum vs. protection against MERS-CoV in the upper respiratory
tract. Second, the response to vaccination in dromedary camels varies widely, as one out of three
camels in the present study did not respond to vaccination at all. This camel was a ten-year-old male,
housed in a pen adjacent to a mature female. Most of the vaccination schedule coincided with the
mating period of this camel. Thus, it is possible, though unclear, that reproductive status impacted
the camel’s immune response. Variable neutralizing responses after MERS-CoV vaccination have
been reported in a previous dromedary camel vaccine study. One animal in a group of three failed
to mount a detectable neutralizing response after vaccination with a DNA vaccine expressing full
length Spike protein [36]. Vaccine development efforts should thus focus on vaccine platforms that
uniformly induce immunity in dromedary camels. Finally, intranasal challenge with MERS-CoV
yielded distinctly different outcomes in the alpaca and dromedary camels. Upon viral challenge,
both immunized alpaca were completely protected from MERS-CoV infection. Thus, although alpaca
are an attractive alternative experimental model to dromedary camels since MERS-CoV replication
dynamics in alpaca appear to be similar to those in dromedary camels [29,37] but alpaca are easier to
obtain and house, vaccine efficacy ultimately has to be confirmed in the dromedary camel model.
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Abstract: Middle East respiratory syndrome coronavirus (MERS-CoV), a novel infectious agent
causing severe respiratory disease and death in humans, was first described in 2012. Antibodies
directed against the MERS-CoV spike (S) protein are thought to play a major role in controlling
MERS-CoV infection and in mediating vaccine-induced protective immunity. In contrast, relatively
little is known about the role of T cell responses and the antigenic targets of MERS-CoV that are
recognized by CD8+ T cells. In this study, the highly conserved MERS-CoV nucleocapsid (N)
protein served as a target immunogen to elicit MERS-CoV-specific cellular immune responses.
Modified Vaccinia virus Ankara (MVA), a safety-tested strain of vaccinia virus for preclinical and
clinical vaccine research, was used for generating MVA-MERS-N expressing recombinant N protein.
Overlapping peptides spanning the whole MERS-CoV N polypeptide were used to identify major
histocompatibility complex class I/II-restricted T cell responses in BALB/c mice immunized with
MVA-MERS-N. We have identified a H2-d restricted decamer peptide epitope in the MERS-N
protein with CD8+ T cell antigenicity. The identification of this epitope, and the availability of
the MVA-MERS-N candidate vaccine, will help to evaluate MERS-N-specific immune responses and
the potential immune correlates of vaccine-mediated protection in the appropriate murine models of
MERS-CoV infection.
Keywords: MERS-CoV; MERS-CoV nucleocapsid protein; murine CD8+ T cell epitope; MVA vaccine
1. Introduction
The Middle East respiratory syndrome coronavirus (MERS-CoV), a hitherto unknown β-coronavirus,
emerged as a causative agent of a severe respiratory disease in humans in 2012. This new coronavirus
was first isolated from the sputum of a patient suffering from severe pneumonia and renal failure [1].
To date, the MERS-CoV still causes disease and death in humans with a total of 2260 confirmed
cases including 803 fatalities [2,3]. Epidemiological data suggest that the MERS-CoV is endemic in
Saudi Arabia, which accounts for the majority of primary community-acquired cases. Many of those
primary cases are due to virus exposure through direct contact with dromedary camels, the primary
animal reservoir of MERS-CoV. Alternatively, camel workers undergoing subclinical infections are
suggested to mediate virus transmission to other susceptible individuals [4,5]. Other outbreaks of
MERS have been caused by nosocomial transmissions in health care settings [6–9]. Most of the
MERS-CoV infections occur within the Arabian Peninsula, i.e., Saudi Arabia, Qatar, and United Arab
Emirates, however MERS cases have been reported in various other countries around the world [9,10].
At present, there is still relatively little known about the pathogenesis of MERS-CoV. The highest
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incidence of severe disease is observed in elderly and immunocompromised individuals [11]. Those
at general risk for infections are health care workers and people in close contact with dromedary
camels [12,13]. These groups are therefore considered relevant target populations for prophylactic
vaccination against MERS-CoV infection and prevention of MERS. The World Health Organization
(WHO) and the Coalition for Epidemic Preparedness Innovations (CEPI) have listed MERS as priority
target for vaccine development [14]. However, so far, no candidate vaccines have proceeded beyond
phase I/IIa clinical testing [15]. One of these candidate vaccines is based on Modified Vaccinia virus
Ankara (MVA), a safety-tested and replication-deficient vaccinia virus serving as an advanced viral
vector platform for the development of new vaccines against infectious diseases and cancer (for
review see [16]). In that context, we still know relatively little about the correlates of vaccine induced
protection against MERS-CoV. It is well-known that virus-neutralizing antibodies directed against
the spike glycoprotein (S protein) correlate with protective immunity against coronavirus infections
in general [17–20]. Since the S protein is present on the cell surface, S protein is considered as the
major antigen to induce virus neutralizing antibodies and as a key immunogen for the development of
MERS-CoV candidate vaccines [21–25]. However, based on current knowledge from the biology of
β-coronaviruses, we hypothesize that also other viral proteins warrant consideration as immunogens
and targets of virus-specific antibodies and T cells. Among those, the nucleocapsid protein (N protein)
is produced at high levels in infected cells and has been proposed as useful candidate protein for clinical
diagnosis [26–30]. The coronavirus N proteins have been associated with multiple functions in the
virus life cycle including the regulation of viral RNA synthesis, the packaging of the viral RNA in helical
nucleocapsids, and in virion assembly through interaction with the viral M protein [31–34]. Furthermore,
several reports suggest that the severe acute respiratory syndrome coronavirus (SARS-CoV) N protein
functions as an immune evasion protein and an antagonist of the host interferon response [35–37].
Recently, the overexpression of MERS-CoV N in human A549 cells was found to be linked to an
up-regulation of antiviral host gene expression including the synthesis of the inflammatory chemokine
CXCL10 [38]. Despite this possible immune modulatory activity, SARS-CoV N-specific immune
responses are reported to be long-lived and more broadly reactive when compared to SARS-CoV
S-specific immunity [39]. Likewise, we were curious as to the suitability of the MERS-CoV N protein
to serve as a vaccine antigen. The N protein is not present on the surface of MERS-CoV particles
nor is it predicted to be expressed on the surface membrane of MVA infected cells. From this we
hypothesized that the most relevant part of MERS-CoV N-specific immunity is based on CD8+ T cell
responses relying on the processing and presentation of intracellular antigens. Currently, there is
little information about MERS-CoV N-specific immune responses including the in vivo induction of
N-specific cellular immunity.
In this study, we investigated the synthesis and delivery of the MERS-CoV N protein as a privileged
antigen by a MVA vector virus. The recombinant MVA expressing a synthetic gene sequence of full-length
MERS-CoV N (MVA-MERS-N) proved genetically stable and fully replication-competent in chicken
embryo fibroblasts, an established cell substrate for MVA vaccine manufacturing. Upon in vitro
infection, MVA-MERS-N produced high amounts of the heterologous protein that were detectable
with MERS-CoV N-specific antibodies. Furthermore, MVA-MERS-N was tested as an experimental
vaccine in BALB/c mice and elicited MERS-CoV N-specific interferon γ (IFN-γ)-producing CD8+ T
cells. Using peptide library covering the whole MERS-CoV N polypeptide, we identified new H2-d
restricted peptide epitopes of MERS-CoV N in BALB/c mice. This data will be highly relevant for
further assessment of N antigen-specific immune responses in the well-established MERS-CoV-BALB/c
mouse immunization/challenge model [40–44].
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2. Materials and Methods
2.1. Mice
Female BALB/c mice (6 to 10-week-old) were purchased from Charles River Laboratories (Sulzfeld,
Germany). For experimental work, mice were housed in an isolated (ISO) cage unit (Tecniplast,
Hohenpeißenberg, Germany) and had free access to food and water. All animal experiments were
handled in compliance with the German regulations for animal experimentation (Animal Welfare Act,
approved by the Government of Upper Bavaria, Munich, Germany).
2.2. Cells
Primary chicken embryo fibroblasts (CEF) were prepared from 10-day-old chicken embryos
(SPF eggs, VALO, Cuxhaven, Germany) and maintained in Minimum Essential Medium
Eagle (MEM) (SIGMA-ALDRICH, Taufkirchen, Germany) containing 10% heat-inactivated fetal
bovine serum (FBS) (SIGMA-ALDRICH, Taufkirchen, Germany), 1% Penicillin-Streptomycin
(SIGMA-ALDRICH, Taufkirchen, Germany), and 1% MEM non-essential amino acid solution
(SIGMA-ALDRICH, Taufkirchen, Germany). Human HeLa (ATCC CCL-2) cells were maintained
in MEM containing 10% FBS and 1% Penicillin-Streptomycin. Human HaCat (CLS Cell Lines
Service GmbH, Eppelheim, Germany) cells were cultured in Dulbecco‘s Modified Eagle‘s Medium
(SIGMA-ALDRICH, Taufkirchen, Germany) supplemented with 10% heat-inactivated FBS, 2%
HEPES-solution (SIGMA-ALDRICH, Taufkirchen, Germany) and antibiotics as described above.
All cells were maintained at 37 ◦C and 5% CO2 atmosphere.
2.3. Plasmid Constructions
The cDNA encoding the entire amino acid (aa) sequence (413 aa) of the MERS-CoV N protein
was in silico modified by introducing silent codon alterations to remove three termination signals
(TTTTTNT) for vaccinia virus early transcription and two G/C nucleotide runs from the original
MERS-CoV gene sequence (Human betacoronavirus 2c EMC/2012, GenBank accession no. JX869059).
A cDNA fragment was generated by DNA synthesis (Invitrogen Life Technology, Regensburg,
Germany) and cloned into the MVA transfer plasmid pIIIH5red [45] to place the MERS-CoV N
gene sequence under the transcriptional control of the vaccinia virus early/late promoter PmH5 [46]
resulting in the MVA vector plasmid pIIIH5red-MERS-N.
2.4. Generation of Recombinant Virus
Recombinant MVA was generated using standard methodology as described previously [45].
Briefly, monolayers of nearly confluent CEF grown in six-well tissue culture plates (Sarstedt, Nürnbrecht,
Germany) were infected with non-recombinant MVA (clonal isolate MVA F6) at 0.05 multiplicity of
infection (MOI) and, 45 min after infection, CEF cells were transfected with plasmid pIIIH5red-MERS-N
DNA using X-tremeGENE DNA Transfection Reagent Lipofectamine (Roche Diagnostics, Penzberg,
Germany) as recommended by the manufacturer. At 48 h after infection, the cell cultures were
harvested and recombinant MVA expressing the MERS-CoV N protein was clonally isolated by
consecutive rounds of plaque purification in CEF by screening for transient co-expression of the red
fluorescent marker protein mCherry.
Quality control experiments were performed using standard methodology [45]. Genetic identity
and genetic stability of the recombinant virus were assessed via polymerase chain reaction (PCR)
analysis of the genomic viral DNA. Replicative capacities of the MVA vector virus was tested in
multi-step growth experiments in CEF and human HaCat and HeLa cells.
To generate high titer vaccine preparations for preclinical studies, recombinant MVA was
amplified in CEF, purified by ultracentrifugation through 36% sucrose cushions, resuspended in
10 mM Tris-HCl buffer, pH 9.0, and stored at −80 ◦C. The sucrose purified MVA-MERS-N vaccine
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preparations corresponded in total protein/total DNA content to the purity profile of a MVA candidate
vaccine for human use.
2.5. Western Blot Analysis of Recombinant Proteins
Confluent cell monolayers of CEF or HaCat cells were infected at a MOI of 5 with recombinant
MVA expressing the MERS-CoV N or S protein [23]. Non-infected (mock) or wild-type MVA-infected
cells served as controls. Cell lysates were prepared at different time points after infection and stored at
−80 ◦C. Total cell proteins were resolved by electrophoresis in a sodium dodecyl sulfate (SDS)-10%
polyacrylamide gel (SDS-PAGE) and subsequently transferred onto a nitrocellulose membrane via
electroblotting. After 1 h blocking in a phosphate buffered saline (PBS) buffer containing 1% (w/v)
non-fat dried milk and 0.1% (v/v) NP-40 detergent, the blots were incubated with monoclonal mouse
anti-MERS-CoV Nucleocapsid antibody (Sino Biological, Beijing, China, 1:1000), monoclonal rabbit
anti-MERS-CoV Spike Protein S1 Antibody (Sino Biological, 1:500), or polyclonal sera from MERS-CoV
infected rabbits or cynomolgus macaques (kindly provided by Dr. Bart Haagmans, Erasmus Medical
Center, Rotterdam, 1:1000) [23] as primary antibodies. After washing with 0.1% NP-40 in PBS, the blots
were incubated with anti-mouse IgG (1:5000), or anti-rabbit IgG antibody (1:5000), or protein A (1:1000)
conjugated to horseradish peroxidase (Cell Signaling Technology, Frankfurt am Main, Germany). After
further washing, blots were developed using SuperSignal®West Dura Extended Duration substrate
(Thermo Fisher Scientific, Planegg, Gemany).
2.6. Immunization Experiments in Mice
Groups of female BALB/c mice (n = 2 to 5) were immunized twice within a 21-day interval with
108 plaque-forming-units (PFU) of recombinant MVA-MERS-N or non-recombinant MVA (MVA) or
PBS as mock vaccine. Vaccinations were given via the intramuscular (i.m.) or intraperitoneal (i.p.)
route using 25 μL (i.m.) or 200 μL (i.p.) volumes per inoculation. All mice were monitored daily
for welfare and potential adverse events of immunization. At day 8 post prime-boost immunization,
animals were sacrificed by cervical dislocation and spleens were taken for T cell analysis.
2.7. Synthetic Peptides and Design of Peptide Pools
For T cell immune monitoring, we identified 101 individual synthetic peptides (assigned as
1 to 101) in silico spanning the entire MERS-CoV N protein sequence (Human betacoronavirus 2c
EMC/2012, GenBank accession no. JX869059). This peptide library was designed to contain 15-mer
peptides overlapping by 11 aa. Eighty-four peptides could be synthesized (Thermo Fisher Scientific)
and were organized into two-dimensional matrix peptide pools (V1 to V9 and H1 to H9) containing 9
or 10 peptides as described previously [47,48]. For further T cell epitope mapping, the 11 aa sequence
shared between peptide #89 and #90 was trimmed into 8-10-mer peptides, which were also obtained
from Thermo Fisher Scientific. All peptides were dissolved in PBS to a concentration of 2 mg/mL and
stored at −20 ◦C until use.
2.8. T cell Analysis by Enzyme-Linked Immunospot (ELISPOT)
Spleens were harvested on day 8 post prime-boost vaccination. Splenocytes were prepared by
passing through a 70 μm strainer (Falcon®, A Corning Brand, Corning, USA) and incubating with
Red Blood Cell Lysis Buffer (SIGMA-ALDRICH, Taufkirchen, Germany). Cells were washed and
resuspended in RPMI 1640 medium (SIGMA-ALDRICH) containing 10% heat inactivated FBS and 1%
Penicillin-Streptomycin. Splenocytes were further processed by using the QuadroMACS Kit (Miltenyi
Biotec, Bergisch Gladbach, Germany) to separate CD8+ and CD4+ splenocytes with MACS Micro
Beads (Miltenyi Biotec, Bergisch Gladbach, Germany).
IFN-γ-producing T cells were measured using ELISPOT assays (Elispot kit for mouse IFN-γ,
MABTECH, Germany) following the manufacturer‘s instructions. Briefly, 1 × 106 splenocytes were
seeded in 96-well plates (Sarstedt, Nürnbrecht, Germany) and stimulated with peptide pools or
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individual peptides (2 μg peptide/mL RPMI 1640 medium) at 37 ◦C for 48 h. Non-stimulated
cells and cells treated with phorbol myristate acetate (PMA) (SIGMA-ALDRICH) and ionomycin
(SIGMA-ALDRICH, Taufkirchen, Germany) or MVA F2L26-34 peptide (F2L, SPGAAGYDL, Thermo
Fisher Scientific, Planegg, Germany) [49] served as negative and positive controls, respectively.
Automated ELISPOT plate reader software (A.EL.VIS Eli.Scan, A.EL.VIS ELISPOT Analysis Software,
Hannover, Germany) was used to count and analyze spots.
2.9. T Cell Analysis by Intracellular Cytokine Staining (ICS) and Flow Cytometry
Splenocytes were prepared as described above. Splenocytes were added to 96-well plates
(1 × 106 cells/well) and stimulated for 6 h with MERS-CoV N-specific peptide (at 8 μg peptide/mL
RPMI 1640 medium) in presence of the protein transport inhibitor Brefeldin A (Biolegend, San Diego,
CA, USA; 5 μg/mL). Non-stimulated cells served as a background control and cells stimulated with
5 ng/mL PMA and 500 ng/mL ionomycin or with F2L peptide (8 μg/mL RPMI 1640 medium) were
used as positive controls. After stimulation, cell surface antigens were stained using PE-conjugated
anti-mouse CD3 (clone: 17A2, Biolegend, San Diego, CA, USA), PE/Cy7-conjugated anti-mouse CD4
(clone: GK1.5, Biolegend, San Diego, CA, USA), or FITC-conjugated anti-mouse CD8a (clone: 5H10-1,
Biolegend, San Diego, CA, USA) antibody and incubated for 30 min on ice. The surface-stained cells
were washed with staining buffer (MACS QuantTM Running Buffer, Miltenyi Biotec), then fixed
and permeabilized with Fixation- and Perm/Wash-Buffer (Biolegend, San Diego, CA, USA), and
finally stained for intracellular IFN-γ expression using APC-conjugated anti-mouse-IFN-γ antibody
(clone: XMG1.2, Biolegend, San Diego, CA, USA) for 30 min on ice. Following final washes, cells were
resuspended in staining buffer and analyzed using the MACS Quant®VYB flow cytometer (Miltenyi
Biotec, Bergisch Gladbach, Germany).
2.10. Statistical Analysis
Statistical analysis was performed by t-test using GraphPad Prism version 5 software (GraphPad
software, San Diego CA, USA); P-values less than 0.05 were considered to be statistically significant.
3. Results
3.1. Construction and Characterization of Recombinant MVA Expressing MERS-CoV N Gene
Encoding Sequences
Recombinant virus MVA-MERS-N was formed in CEF that were infected with MVA and
transfected with the MVA vector plasmid pIIIH5red-MERS-N (Figure 1a). The MVA DNA sequences
in pIIIH5red-MERS-N (flank-1, flank-2) targeted the insertion of the N gene sequences into the site
of deletion III within the MVA genome. The clonal isolation was facilitated by co-production of the
red fluorescent reporter protein mCherry allowing for the convenient detection of MVA-MERS-N
infected cells during plaque purification. The repetitive DNA sequence of flank-1 (FR) served to
remove the marker gene mCherry from the genome of the final recombinant virus through initiating
an intragenomic homologous recombination (marker gene deletion). After PCR analysis confirmed
the presence of more than 95% MVA-MERS-N recombinant viruses in the cultures, we selected the
final marker-free recombinant viruses by plaque purification and screening for plaques without
mCherry fluorescence. To confirm genetic integrity and proper insertion of the heterologous N
gene sequences within the MVA-MERS-N genome, we analyzed viral genomic DNA by PCR using
specific oligonucleotide primers specific for MVA sequences adjacent to the deletion III insertion site
(Figure 1b). Additional PCRs specific for MVA sequences within the C7L gene locus or adjacent to
the major deletion sites I, II, IV, V, and VI served to control for the genetic identity and genomic
stability of MVA-MERS-N (Figure 1c, and data not shown). Next, we evaluated the recombinant virus
MVA-MERS-N by multi-step growth analysis in different cell lines (Figure 1d). In CEF, the cell culture
routinely used to propagate recombinant MVA vaccines, MVA-MERS-N efficiently replicated to titers
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similar to those obtained with non-recombinant MVA. In contrast, the human cell lines HaCat and
HeLa proved non-permissive for productive virus growth confirming the well-preserved replication
deficiency of the recombinant MVA-MERS-N in cells of mammalian origin.
Figure 1. Generation and characterization of recombinant Modified Vaccinia virus Ankara expressing
the Middle East respiratory syndrome coronavirus N protein (MVA-MERS-N); (a) Schematic diagram
of the MVA genome indicating the major deletion sites I-VI on the top. Flank-1 and flank-2 refer
to MVA DNA sequences adjacent to corresponding insertion site. Deletion III was used to insert
MERS-N encoding gene sequences under the transcriptional control of the vaccinia virus promoter
PmH5. Repetitive sequences (FR) were designed to remove the mCherry marker by intragenomic
homologous recombination (marker gene deletion); (b,c) PCR analyses of genomic viral DNA using
oligonucleotide primers to confirm the correct insertion of recombinant MERS-N gene into deletion
III (b), and the genetic integrity of the MVA genome for the C7L gene locus (c); (d) Multi-step growth
analysis of recombinant MVA-MERS-N and non-recombinant MVA (MVA); Chicken embryo fibroblasts
(CEF) and human HaCat or HeLa cells were infected at a multiplicity of infection (MOI) of 0.05 with
MVA-MERS-N or MVA. Infected cells were collected at different time points after infection and titrated
on CEF cells.
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To confirm the synthesis of MERS-CoV N protein upon MVA-MERS-N infection, total cell proteins
from infected CEF and HaCat cells were separated by SDS-PAGE and analyzed by immunoblotting
(Figure 2). Consistent with the expected molecular mass of the MERS-CoV N protein we readily
detected a ~45 kDa polypeptide using the N-specific mouse monoclonal antibody. At 24 hours post
infection (hpi) a prominent band of N protein was visible in the lysates from both cell lines suggesting
efficient synthesis of the recombinant protein under permissive and non-permissive growth conditions
for MVA-MERS-N (Figure 2a).
 
Figure 2. Analysis of recombinant MVA-MERS proteins; (a) Western Blot analysis of MERS-CoV
N protein produced in CEF or HaCat cells. Lysates from cells infected with recombinant MVA
(MVA-MERS-N, MVA-MERS-S) or non-recombinant MVA (MVA) at a MOI of five, or from non-infected
cells (mock) were prepared at eight, 12, or 24 hpi. Proteins were analyzed by immunoblotting with a
monoclonal anti-MERS-N antibody; (b–d) Western Blot analysis of MERS-CoV N and S proteins
produced in CEF. Total cell extracts from CEF infected with recombinant MVA (MVA-MERS-N,
MVA-MERS-S) or non-recombinant MVA (MVA) at a MOI of five, or from non-infected cells (mock)
were prepared at 24 hpi. Cell lysates and proteins were tested by immunoblotting using monoclonal
anti MERS-N and anti MERS-S antibody (b) or polyclonal sera from MERS-CoV infected rabbits (c) or
cynomolgus macaques (d). Arrows indicate the N- or S-specific protein bands.
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In addition, the comparative Western blot analysis of cell lysates from MVA-MERS-N or MVA-MERS-S
infected CEF with antigen-specific mouse monoclonal antibodies suggested the production of
comparable amounts of both MERS-CoV candidate antigens (Figure 2b). This observation is in
line with the fact that the MVA-MERS-S candidate vector vaccine expresses the MERS-CoV S gene
sequences using the identical PmH5 promoter system [23]. As shown in previous studies, we detected
two MERS-CoV S-specific protein bands upon infection with MVA-MERS-S indicating the authentic
proteolytic cleavage of the full-length S glycoprotein (~210 kDa) into an N-terminal (~120 kDa S1
domain) and a C-terminal (~85 kDa S2 domain; not detected) subunit [23,50,51]. Following this,
we used the total protein lysates from MVA-MERS-N or MVA-MERS-S infected CEF to assess the
recognition of the MERS-CoV N and S antigens by sera from experimentally MERS-CoV infected
animals. The Western blot analysis of sera from an infected rabbit (Figure 2c) or a cynomolgus monkey
(Figure 2d) revealed the presence of antibodies specific for the MERS-CoV N protein. The recognition of
the MERS-CoV N protein was at least as prominent as the MERS-CoV S antigen, which was suggestive
of the induction of substantial N-specific antibody responses after experimental MERS-CoV infections.
3.2. Characterization of MERS-CoV N-specific T Cell Responses
3.2.1. Initial Screen of MERS-CoV N Epitopes Using Overlapping Peptide Pools
T cell responses against coronaviruses are known to be long lived and mostly target the more
conserved CoV internal structural N protein. However, information on MERS-CoV N antigen-specific
T cell specificities is still limited. Thus, we aimed first to identify N polypeptide-specific T cell epitopes
in BALB/c mice immunized twice with recombinant virus MVA-MERS-N or non-recombinant MVA
as a control via the intraperitoneal and intramuscular routes. Eight days after the final immunization,
splenocytes were prepared and the purified CD4+ and CD8+ T cells were restimulated in vitro
with overlapping peptides corresponding to the N protein. Overlapping peptides were pooled
using a two-dimensional, pooled-peptide matrix system (Table S1) and screened by IFN-γ ELISPOT.
The stimulation of splenoctyes from MVA-MERS-N immunized mice with the peptides from 16 out of
the total 18 peptide pools did not result in the detection of IFN-γ producing T cells above background
numbers obtained with splenocytes from mock or MVA-control vaccinated animals. Stimulation with
the peptides from pools H8 (n = 10) and V8 (n = 10) as well as the use of the vaccinia virus positive
peptide F2L [49] (data not shown) showed elevated numbers of IFN-γ spot forming cells (SFC) in CD8+
T cell cultures (Figure 3a,b). MVA-MERS-N immunizations given by i.p. and i.m. routes resulted in
comparable T cell stimulatory capacities of overlapping N-specific peptides from pools V8 and H8.
In contrast, peptides from other pools showed no or only minor stimulatory activities, as exemplified
for peptides in pools V4 and V6.
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Figure 3. Screening for H2-d restricted T cell epitopes in MERS-CoV N protein using matrix peptide
pools; (a–b) groups of BALB/c mice (n = 2 to 6) were vaccinated twice (21-day interval) by i.p. (a) or
i.m. (b) application with 108 plaque-forming-units (PFU) of recombinant MVA-MERS-N (MVA-N).
Mice inoculated with non-recombinant MVA (MVA) or phosphate-buffered saline (PBS) were used as
controls. Splenocytes were restimulated in vitro with pools of overlapping peptides corresponding
to MERS-CoV N protein. IFN-γ spot-forming CD8+ T cells (IFN-γ SFC) were measured by ELISPOT.
The lines represent means.
3.2.2. Reassessment of Positive Reacting Peptides Pools for MERS-CoV N T Cell Epitopes
Following this, the peptides within the V8 and H8 peptide pools were used to elucidate in more
detail the T cell epitope specificities. We subdivided the peptides from H8 and V8 in four new pools
each containing five peptides (H8.1, H8.2, V8.1, V8.2). In addition, we separately tested the two 15-mer
peptides #89 and #90, which were shared between pools H8 and V8. We again vaccinated BALB/c
mice with MVA-MERS-N using i.p. or i.m. inoculations in a prime-boost regime. Splenocytes were
prepared at day eight after the last vaccination and purified CD8+ T cells were restimulated with
subpools V8.1., V8.2., H8.1, and H8.2 (Figure 4a). Stimulation with peptides from pools V8.1 or H8.1
activated only minor levels of IFN-γ producing cells with mean levels about 23 SFC/106 splenocytes.
Yet, the stimulation with subpools V8.2 and H8.2 revealed clearly higher numbers of activated T
cells with 83-176 IFN-γ SFC/106 splenocytes. Comparable numbers of IFN-γ producing cells were
again induced by i.p. or i.m. immunization. Of note, the stimulations with the 15-mer peptides #89
(N353-367 = QNIDAYKTFPKKEKK) or #90 (N357-371 = AYKTFPKKEKKQKAP) alone resulted in detection
of substantial quantities of IFN-γ producing cells (mean levels about 71–107 SFC/106 splenocytes) in
mice that had been vaccinated with MVA-MERS-N by both immunization routes (Figure 4b). CD8+
T cells purified from mice receiving non-recombinant MVA or mock vaccine (PBS) did not produce
IFN-γ following stimulation with peptides from subpools V8.1-H8.2 and with peptides #89 and #90.
When checking for the specific peptides contained within the subpools, we observed that the strongly
stimulatory peptides #89 and #90 were part of the subpools V8.2 and H8.2, whereas these peptides
were absent in V8.1 and H8.1. This data suggested that the overlapping 15-mer peptides #89 and #90
contained a valuable antigen epitope for the activation of MERS-CoV N-specific CD8+ T cell responses.
169
Viruses 2018, 10, 718
Figure 4. Mapping of H2-d restricted T cell epitopes in MERS-CoV N protein; (a–b) BALB/c mice (n = 2
to 4) were immunized twice (21-day interval) i.p. or i.m. with 108 PFU of recombinant MVA-MERS-N
(MVA-N), non-recombinant MVA (MVA) or PBS. Splenocytes from vaccinated mice were incubated in
the presence of subpools (V8.1, V8.2, H8.1, H8.2) from positive matrix pools (a) or individual 15-mers
peptides #89 or #90 (b). IFN-γ spot-forming CD8+ T cells (IFN-γ SFC) were quantified by ELISPOT.
The lines represent means.
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3.2.3. Identification of MERS-CoV N-specific T Cell Epitope
To map more precisely this specific epitope within the MERS-CoV N protein, we concentrated
on the overlapping 11-mer peptide shared between peptides #89 and #90 and obtained nine 8-10-mer
peptides (Table 1).














1 The common 11 amino acid sequence between positive 15-mers #89 and #90 was truncated into 8-10-mer peptides
and tested by ELISPOT and ICS assay.
Using these peptides for the stimulation of splenoctyes from MVA-MERS-N vaccinated mice,
we obtained the highest numbers of IFN-γ producing T cells with peptide 10.2 (mean levels of 94 to
97 SFC/106 splenocytes), while the other peptides (10.1, 9.1, 9.2, 9.3, 8.1, 8.2, 8.3, 8.4) induced weaker
responses with a mean of 5–76 IFN-γ SFC/106 splenocytes (Figure 5a,b).
Furthermore, we tested the 10.2 peptide to monitor N-specific T cell responses by IFN-γ ICS and
fluorescence activated cell sorting (FACS) analysis. Indeed, we could detect significant numbers of
10.2 peptide-specific CD8+ T cells being induced and activated by the MVA-MERS-N prime-boost
vaccination. In comparison, the CD4+ T cell populations from splenocytes of immunized animals
demonstrated only background levels of IFN-γ producing cells (Figure 5c). The vaccinia virus-specific
immunodominant CD8+ T cell determinant F2L [49] served as control peptide for the detection of
MVA-specific CD8+ T cells (Figure 5d).
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Figure 5. Identification of an H2-d restricted T cell epitope in MERS-CoV N protein; (a–d) Groups of
BALB/c mice (n = 3 to 8) were vaccinated in a prime-boost regime with 108 PFU of MVA-MERS-N
via i.p. (a) or i.m. (b–d) application. Mice immunized with non-recombinant MVA (MVA) and PBS
served as negative controls. (a-b) Splenocytes were stimulated with individual 8-11-mer peptides and
IFN-γ spot-forming CD8+ T cells (IFN-γ SFC) were measured by ELISPOT. (c–d) Splenocytes were
stimulated with positive MERS-CoV N 10.2 peptide (c) or F2L26-34 peptide (d) and IFN-γ producing
CD8+ or CD4+ T cells were measured using intracellular cytokine staining assay and FACS analysis.
The lines represent means. *< 0.05, **< 0.005.
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4. Discussion
The availability of appropriate MERS-CoV-specific immune monitoring tools is a prerequisite
for the successful development of vaccines and therapeutic approaches. The development of these
tools is hampered by the fact that we still know little about the relevant viral antigens and the overall
pathogenesis of the MERS-CoV infection. Recent studies describe a number of cases with asymptomatic
MERS-CoV infection in humans and raise questions as to which factors influence the clinical
manifestation of MERS [52,53]. Since asymptomatic or mild clinical manifestations of MERS-CoV
infection are often associated with low levels of seropositivity, the analysis of MERS-CoV-specific
cellular immune responses may facilitate further insight into the immune correlates of disease
prevention. Moreover, in order to characterize the pathogenesis of MERS-CoV infection, it will
be indispensable to monitor the role of virus-specific T cells in animal models of MERS and to precisely
identify the antigen specificities of these T cell responses.
In the present study, we identified a major histocompatibility complex (MHC) haplotype H2-d
restricted peptide epitope in the MERS-CoV N protein by stimulating T cells from MVA-MERS-N
vaccinated BALB/c mice with a 2-D matrix pool of overlapping peptides. These mice have already
been used in various preclinical studies to establish the MERS-CoV S protein as an important
vaccine antigen for induction of virus neutralizing antibodies [23,40–42,54]. Moreover, BALB/c mice
transduced with the human cell surface receptor dipeptidyl peptidase 4 (hDPP4) using an adenovirus
vector are susceptible to productive MERS-CoV lung infection, which allows for the testing of the
protective efficacy of MERS-CoV-specific immunization using the MERS-CoV S protein [24,40,41,43,44].
Here, we wished to specifically assess the suitability of an MVA-delivered MERS-CoV N antigen
for the activation of cellular immune responses in mice. In general, the N protein is a well conserved
internal protein and the major structural component incorporating the viral RNA within the viral
nucleocapsid [55]. In previous studies, the SARS-CoV N protein has also been used as candidate
antigen for vaccine development [56], and an experimental DNA vaccine efficiently induced SARS-CoV
N-specific cellular immunity [57,58]. In line with this data, recent studies in MERS patients
demonstrated that both antibody and T cell responses are associated with recovery from MERS-CoV
infection [59].
The recombinant virus MVA-MERS-N produced stable amounts of MERS-CoV N antigen upon
in vitro infection of human cells indicating the unimpaired expression of the target gene at the level of
viral late transcription using the synthetic vaccinia virus-specific promoter PmH5 [46]. Moreover, the
MERS-CoV N antigen produced in MVA-MERS-N infected cells was strongly recognized by antibodies
from experimentally infected laboratory animals suggesting that N-specific immune responses were
potently activated upon MERS-CoV infection. It seems noteworthy that MERS-CoV productively
replicates in rabbits, but viral loads are low and the animals develop no overt disease symptoms.
However, Haagmans et al. found infectious virus in the lung tissues of the rabbits and revealed
the presence of the MERS-CoV N antigen in bronchiolar epithelial cells and in the epithelial cells
of the nose [60]. The localization of N in these respiratory epithelial cells may result in an efficient
recognition by innate and also adaptive immune cells similar to those described for other viruses
inducing robust protective immunity [61]. This might be a possible explanation for efficient activation
of MERS-CoV N-specific antibodies despite a barely productive MERS-CoV infection. Similar outcomes
of infection were observed upon MERS-CoV infection in cynomolgus macaques and other relevant
non-human primate models [62,63]. Thus, the induction of N-specific immune responses in these
animals emphasizes the potential usefulness of the MERS-CoV N protein to serve as vaccine antigen.
Nevertheless, the immunogenicity of N requires further characterization in preclinical models for
MERS-CoV infection. In addition to the induction of MERS-CoV-specific antibodies, the MERS-CoV
N protein holds promise to efficiently activate virus-specific CD8+ T cell responses. For more
detailed studies characterizing the possible role of these T cell specificities in MERS-CoV-associated
immunity or pathogenesis it is highly relevant to determine the N peptide epitopes allowing for the
appropriate MHC-restricted antigen presentation and the activation of virus-specific T cells. In this
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study, we identified a new H2-d restricted CD8+ T cell epitope in the MERS-CoV N protein using a 2-D
matrix and pools of 84 overlapping 15-mer N peptides. First, we have identified two MERS-CoV N
derived peptides (N353-367 = QNIDAYKTFPKKEKK and N357-371 = AYKTFPKKEKKQKAP) and further
mapped these 15-mer peptides to the minimal aa sequence of N358-367 = YKTFPKKEKK representing a
decamer peptide epitope (Figure S1) [64]. Analysis of MERS-CoV sequences reveals that N358-367 is
conserved among different strains of MERS-CoV (Table S2) [65]. The availability of such an epitope
may allow for more detailed experimental monitoring of cellular immune responses induced by a
MVA based candidate vaccine against MERS-CoV in the mouse model and potentially also in other
preclinical models. Of note, the H2-d restricted CD8+ T cell epitope enables characterization of T
cell responses in BALB/c mice that serve as a well-established MERS-CoV infection model following
adenovirus vector mediated transduction with hDPP4 [24,40,41,43,44]. A particular feature of MERS in
humans, as observed upon the investigation of cluster outbreaks in hospitals, is the lack of detectable
MERS-CoV neutralizing antibodies in patients with confirmed disease [66,67]. This observation is
attributed to the emergence of specific virus mutants evading the neutralizing antibody response,
as already described for SARS-CoV [68,69]. Thus, future use of a T cell-specific immune monitoring
might contribute to a more detailed understanding of MERS pathogenesis. Here, studies on the
function of MERS-CoV-specific CD8+ T cells in this BALB/c mouse MERS-CoV lung infection model
will be helpful to better estimate the role of cellular immunity in vaccine mediated protection in
MERS-CoV infection.
Finally, the MVA-MERS-N vector virus generated for this study proved to be a stable recombinant
virus that can be readily amplified to obtain vaccine preparations technically fulfilling all requirements for
further preclinical or even clinical development. Future work with MVA-MERS-N candidate vaccines
should help to elucidate the potential protective capacity of N-specific immune responses in MERS-CoV
infections models and contribute to our better understanding of MERS vaccine-induced protection.
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Abstract: Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV), an infectious
coronavirus first reported in 2012, has a mortality rate greater than 35%. Therapeutic antibodies
are key tools for preventing and treating MERS-CoV infection, but to date no such agents have
been approved for treatment of this virus. Nanobodies (Nbs) are camelid heavy chain variable
domains with properties distinct from those of conventional antibodies and antibody fragments.
We generated two oligomeric Nbs by linking two or three monomeric Nbs (Mono-Nbs) targeting the
MERS-CoV receptor-binding domain (RBD), and compared their RBD-binding affinity, RBD–receptor
binding inhibition, stability, and neutralizing and cross-neutralizing activity against MERS-CoV.
Relative to Mono-Nb, dimeric Nb (Di-Nb) and trimeric Nb (Tri-Nb) had significantly greater
ability to bind MERS-CoV RBD proteins with or without mutations in the RBD, thereby potently
blocking RBD–MERS-CoV receptor binding. The engineered oligomeric Nbs were very stable under
extreme conditions, including low or high pH, protease (pepsin), chaotropic denaturant (urea),
and high temperature. Importantly, Di-Nb and Tri-Nb exerted significantly elevated broad-spectrum
neutralizing activity against at least 19 human and camel MERS-CoV strains isolated in different
countries and years. Overall, the engineered Nbs could be developed into effective therapeutic agents
for prevention and treatment of MERS-CoV infection.
Keywords: Coronavirus; MERS-CoV; receptor-binding domain; therapeutic antibodies; nanobodies;
cross-neutralization
1. Introduction
Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV), an emerging infectious
coronavirus, was first reported in humans in Saudi Arabia in 2012 [1]. Bats are a likely natural reservoir
of this virus, and dromedary camels are an important intermediate [2–6]. Camels are an important
mode of transportation, particularly in the Middle East, and this application of these animals contributes
significantly to camel-to-camel and camel-to-human transmission of MERS-CoV [7,8]. In addition,
MERS-CoV may also be transmitted between humans in community or hospital settings [9–13].
Since its first emergence, MERS-CoV has continued to infect humans with a high mortality rate
(>35%) (http://www.who.int/emergencies/mers-cov/en/). This situation calls for a consistent effort to
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develop effective countermeasures, including therapeutic antibodies and vaccines, to prevent and treat
MERS-CoV infection.
MERS-CoV spike (S) protein, an enveloped glycoprotein, plays a key role in viral infection,
viral attachment, and viral entry [14,15]. It is composed of S1 and S2 subunits: the receptor-binding
domain (RBD) in the S1 subunit mediates MERS-CoV binding to its cellular receptor, dipeptidyl
peptidase 4 (DPP4), and the S2 subunit subsequently mediates viral and cell membrane fusion, leading
to viral entry into target cells [16–20]. The RBD of MERS-CoV S protein contains a critical neutralizing
domain fragment capable of inducing strong neutralizing antibodies, and it is therefore considered to
be an important therapeutic and vaccine target [21–26].
Several monoclonal antibodies (mAbs) have been developed to prevent and treat MERS-CoV
infection, and most of these agents are based on the RBD [26–31]. However, conventional IgG mAbs
and antibody fragments often have complex structures and unstable behavior [32–34]. Consequently,
anti-MERS-CoV therapeutic antibodies with strong stability and simplified structures would be
clinically valuable.
Camelid heavy chain variable domains (VHHs), also termed nanobodies (Nbs), are derived from the
variable domains of the camelid heavy chain-only antibodies (HcAbs). These antibodies have distinctive
properties, including high binding affinity, strong specificity for target antigens, good tissue penetration,
and intrinsic stability under harsh conditions, such as extreme pH values, proteases, chemicals, and high
temperature. Accordingly, they represent promising therapeutic tools for the treatment of human
diseases [35–37]. Moreover, because Nbs do not require paired light and heavy chain domains to
maintain antigen-binding activity, they can be easily modified by protein engineering techniques without
loss of functionality [38]. Several monomeric Nbs can be readily fused to form multivalent or multispecific
constructs, thereby improving their binding affinity and functionality. For example, monomeric proteins
have been engineered into dimeric or trimeric proteins [38,39]. Also, multidomain Nbs have been
generated by linking different Nbs targeting influenza virus hemagglutinin protein; the resultant agents
have greater breadth, avidity, potency, and cross-neutralizing activity against divergent influenza viruses
than the parent molecules [40], demonstrating the feasibility of engineering Nbs targeting multiple
epitopes to increase their activity. It is therefore worthwhile to attempt to generate multidomain Nbs
with improved activity against other emerging and re-emerging infectious viruses.
Previously, by immunizing llamas with a recombinant MERS-CoV RBD protein, we generated
a monomeric Nb (Mono-Nb, NbMS10) that targets the RBD of MERS-CoV S protein [41]. In this
study, we constructed two oligomeric Nbs, including dimeric Nb (Di-Nb) and trimeric Nb (Tri-Nb),
and compared them to the Mono-Nb in terms of their ability to bind RBD proteins, inhibit RBD–DPP4
receptor binding, and cross-neutralize MERS-CoV infection. In addition, to demonstrate the advantages
of the oligomeric Nbs relative to conventional antibodies, we evaluated the stability of these Nbs under
the extreme conditions mentioned above. Overall, our data show that the engineered oligomeric Nbs
have been significantly improved from the standpoint of binding affinity to the RBD, inhibition of the
RBD-DPP4 binding, and cross-neutralizing activity against divergent strains of MERS-CoV. They also
maintained greater pH, protease, chemical, and thermal stability than their mAb counterparts.
2. Materials and Methods
2.1. Construction and Expression of MERS-CoV RBD-Specific Dimeric and Trimeric Nbs
Dimeric and trimeric Nbs specific for MERS-CoV RBD were constructed by linking two or three
monomeric Nb (Mono-Nb: NbMS10) [41] with a GGGGS linker and a C-terminal His6 tag followed by
insertion into the Pichia pastoris yeast secretory expression vector pPICZαA (Invitrogen, Carlsbad, CA,
USA). The recombinant Nbs were expressed in Pichia pastoris GS115 cells and purified using Ni-NTA
columns (GE Healthcare, Cincinnati, OH, USA).
180
Viruses 2019, 11, 166
2.2. SDS-PAGE and Western Blot
MERS-CoV RBD-specific Nbs were detected by SDS-PAGE and Western blot, as previously
described [42,43]. Briefly, Nbs (3 μg) were resolved on 10% Tris-Glycine SDS-PAGE gels, followed by
staining with Coomassie Brilliant Blue or transferring to nitrocellulose membranes. The membranes were
further blocked overnight at 4 ◦C with PBST containing 5% non-fat milk, and incubated for 1 h at room
temperature with goat anti-llama IgG antibody (1:3000, Abcam, Cambridge, MA, USA) and horseradish
peroxidase (HRP)-conjugated anti-goat IgG antibody (1:1000, R&D Systems, Minneapolis, MN, USA).
The treated membranes were further incubated with ECL Western blot substrate reagents (Abcam) and
visualized using Amersham Hyperfilm (GE Healthcare). A MERS-CoV RBD-specific mouse mAb (MERS
mAb) and a SARS-CoV RBD-specific mouse mAb (SARS mAb) [44] were included as controls.
2.3. ELISA
Binding between Nbs and MERS-CoV RBD proteins was detected by ELISA as previously
described [42,45]. Briefly, ELISA plates were coated overnight at 4 ◦C with recombinant wild-type or
mutant MERS-CoV RBDs containing a C-terminal human Fc tag. The plates were blocked with 2%
PBST at 37 ◦C for 2 h, and sequentially incubated at 37 ◦C with serially diluted Nbs, goat anti-llama
antibody (1:5000, Abcam), and HRP-conjugated anti-goat IgG antibody (1:3000, Abcam) for 1 h each.
After washing, the plates were further incubated with substrate (3,3’,5,5’-tetramethylbenzidine, Sigma,
St. Louis, MO, USA), and the reactions were stopped with 1 N H2SO4. Absorbance at 450 nm (A450)
was measured by ELISA microplate reader (Tecan, Morrisville, NC, USA). To compare binding activity,
the median effective concentration (EC50) was calculated as previously described [46].
2.4. Surface Plasmon Resonance (SPR)
Binding between Nbs and MERS-CoV RBD protein was detected using a BiacoreS200 instrument
(GE Healthcare) as previously described [41]. Briefly, recombinant Fc-fused MERS-CoV RBD protein
(5 μg/mL) was captured on a Sensor Chip Protein A (GE Healthcare), and recombinant His6-tagged
NbMS10 Nb at various concentrations was flowed over the chip surface in 10 mM HEPES (pH 7.4),
150 mM NaCl, 3 mM EDTA, and 0.05% surfactant P20 buffer. The sensorgram was analyzed using the
Biacore S200 software (GE Healthcare). A 1:1 binding model was fitted to the data.
2.5. Flow Cytometry
Inhibition of binding between MERS-CoV RBD and cell-surface hDPP4 receptor by Nbs was
analyzed by flow cytometry as previously described [24]. Briefly, hDPP4-expressing Huh-7 cells were
incubated at room temperature for 30 min with MERS-CoV RBD-Fc protein (20 μg/mL), with or
without serially diluted Nbs. The cells were incubated for 30 min with FITC-labeled anti-human IgG
antibody (1:50, Sigma), and then analyzed by flow cytometry. Percentage inhibition was calculated
based on the fluorescence intensity of RBD–Huh-7 binding in the presence vs. absence of Nbs.
2.6. MERS-CoV Micro-Neutralization Assay
The neutralizing activity of MERS-CoV RBD-specific Nbs was initially measured by a live
MERS-CoV-based neutralization assay, as previously described [28,45]. Briefly, MERS-CoV (EMC2012
strain, 100 TCID50: median tissue culture infective dose) was incubated with Nbs at 37 ◦C for 1 h.
The Nb/virus mixture was added to Vero E6 cells, which were then cultured for 72 h at 37 ◦C.
The cytopathic effect (CPE) was observed daily. The neutralizing activity of the Nbs was reported as
50% neutralization dose (ND50). The Reed–Muench method was used to calculate the values of ND50
for each Nb [47].
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2.7. MERS Pseudovirus Neutralization Assay
The cross-neutralizing activity of MERS-CoV RBD-specific Nbs was measured by pseudotyped
MERS-CoV neutralization assay as previously described [24,45]. Briefly, 293T cells were cotransfected
with a plasmid encoding Env-defective, luciferase-expressing HIV-1 genome (pNL4-3.luc.RE) and a
plasmid encoding the MERS-CoV S protein. Pseudotyped MERS-CoV was harvested from culture
supernatants 72 h after transfection, incubated with serially diluted Nbs at 37 ◦C for 1 h, and added to
Huh-7 cells. After 72 h, the cells were lysed in cell lysis buffer (Promega, Madison, WI, USA), incubated
with luciferase substrate (Promega), and assayed for relative luciferase activity by Tecan Infinite 200
PRO Luminator (Tecan). The ND50 of Nbs was calculated as previously described [46].
2.8. Detection of Nb Stability
The stability of Nbs with respect to changes in pH was evaluated by incubation in PBS at various
pH values (5.0, 7.0, or 8.0) for 24 h at room temperature [48]. The stability of Nbs in the presence of
chaotropic denaturants was evaluated by incubation in PBS containing a gradient of concentrations
of urea (Sigma) for 24 h at 25 ◦C [49]. The stability of Nbs with respect to proteolysis was evaluated
by incubation in 10 mM HCl buffer (pH 2.0) containing various concentrations of pepsin (Sigma)
for 1 h at 37 ◦C [49,50]. The thermal stability of Nbs was evaluated by incubation in PBS at various
temperatures (4 ◦C, 37 ◦C, and 60 ◦C) for 24 h [49]. Treated and non-treated Nbs were subjected to the
MERS pseudovirus neutralization assay. MERS mAb and SARS mAb were included as controls.
2.9. Statistical Analysis
Statistical analysis was performed by Student’s two-tailed t-test using the GraphPad Prism
statistical software (San Diego, CA, USA). p values lower than 0.05 were considered statistically
significant. *, **, and *** indicate p < 0.05, p < 0.01, and p < 0.001, respectively.
3. Results
3.1. Construction and Characterization of MERS-CoV RBD-Targeting Dimeric and Trimeric Nbs
HcAbs, presented in camelids and sharks, contain heavy chains but no light chains. The antigen-binding
fragments of camelid HcAbs are also called VHHs (Figure 1A, left). Previously, using PCR to amplify the
MERS-CoV RBD-specific VHH gene, we constructed a Mono-Nb targeting the MERS-CoV RBD. We linked
this construct to a C-terminal His6 tag for easy purification [41], resulting in a total molecular weight of about
16 kDa. We generated the Di-Nb and Tri-Nb specific for MERS-CoV RBD by linearly linking two and three
Mono-Nbs, respectively, with a flexible GGGGS linker between each Mono-Nb and a C-terminal His6 tag
(Figure 1A, right). As with Mono-Nb, Di-Nb and Tri-Nb were expressed in culture supernatants of yeast
expression cells at high yield and purity, and formed dimers and trimers with molecular weights of about
32 and 48 kDa, respectively (Figure 1B, left). These MERS-CoV RBD-targeting Nbs reacted strongly with
an anti-llama antibody (Figure 1B, right). These data suggest that, like Mono-Nb, MERS-CoV RBD-specific
Di-Nb and Tri-Nb maintained their native conformations and strong antigenicity.
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Figure 1. Construction and characterization of dimeric and trimeric nanobodies (Nbs) targeting
the Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV). (A) Heavy chain-only
antibody (HcAb) consists of two constant heavy domains (CH2 and CH3) and heavy chain variable
domains (VHHs). Monomeric Nb (Mono-Nb) was constructed previously by linking a MERS-CoV
receptor-binding domain (RBD)-specific VHH and a C-terminal His6, and dimeric Nb (Di-Nb) and
trimeric Nb (Tri-Nb) were constructed by linking two or three Mono-Nbs with GGGGS linkers and
a C-terminal His6 tag for easy purification. (B) SDS-PAGE (left) and Western blot (right) analysis of
MERS-CoV RBD-specific Nbs. The molecular weight marker (in kDa) is shown on the left. MERS-CoV
RBD-targeting Mono-Nb was included as comparison, and MERS-CoV RBD-specific mAb (MERS mAb)
and SARS-CoV RBD-specific mAb (SARS mAb) were used as controls. Anti-llama antibody was used
for Western blot analysis.
3.2. MERS-CoV RBD-Targeting Dimeric and Trimeric Nbs Exhibited Superior Binding toward MERS-CoV
RBD, Neutralization of MERS-CoV Infection, and Inhibition of RBD–hDPP4 Binding
To determine whether the engineered Nbs had stronger binding affinity to MERS-CoV RBD
proteins, we performed ELISA to test their binding to wild-type MERS-CoV RBD protein fused
to C-terminal hIgG1-Fc (RBD-WT), as well as Fc-fused RBD proteins containing mutations from
MERS-CoV strains isolated from human and camel in 2012, 2013, 2014, and 2015 [24]. The results
revealed that, relative to Mono-Nb, Di-Nb and especially Tri-Nb bound significantly more strongly to
all RBDs tested; as expected, binding was dose-dependent (Figure 2A). In addition, the binding affinity
of the MERS mAb control was similar to that of Mono-Nb, whereas the binding of the SARS mAb
control was indistinguishable from background (Figure 2A). We then performed a SPR assay to test
the binding affinity of these Nbs for RBD-WT. The results revealed that Mono-Nb, Di-Nb, and Tri-Nb
had antibody binding affinity (Kd) values of 0.87 nM, 5.9 pM, and 7 pM, respectively, toward RBD-WT
(Figure 2B).
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Figure 2. Detection of binding between MERS-CoV RBD-specific Nbs and MERS-CoV RBD proteins.
(A) ELISA for binding between Di-Nb or Tri-Nb and RBD wild-type (RBD-WT) protein of the
EMC2012 strain and mutant proteins containing RBD mutations from strains isolated from human and
camel in 2012, 2013, 2014, and 2015. MERS-CoV RBD-targeting Mono-Nb was used for comparison,
and MERS-CoV RBD-specific mAb (MERS mAb) and SARS-CoV RBD-specific mAb (SARS mAb) were
included as controls. Data are presented as mean A450 ± standard error (s.e.m.) (n = 2). Experiments
were repeated twice, yielding similar results. Significant differences in median effective concentration
(EC50) ± s.e.m. were observed between Di-Nb and Mono-Nb, as well as between Tri-Nb and Mono-Nb,
indicated by red and green asterisk (*, **, and ***), respectively. Concentration (in nM) was calculated
based on predicted molecular weights of 16, 32, 48, and 150 kDa for Mono-Nb, Di-Nb, Tri-Nb, and mAb,
respectively. (B) Surface Plasmon Resonance (SPR) analysis of binding between Di-Nb or Tri-Nb and
RBD protein (i.e., RBD-WT). MERS-CoV RBD-targeting Mono-Nb was used for comparison. Binding
parameters are shown in each figure.
We then performed a micro-neutralization assay to investigate the neutralizing activity of
the engineered MERS-CoV RBD-specific Nbs against live MERS-CoV (EMC2012 strain) infection.
The results revealed that both Di-Nb and Tri-Nb potently neutralized MERS-CoV infection with a
significantly lower ND50 than Mono-Nb (Figure 3A). Previously, we demonstrated that the molecular
mechanism of MERS-CoV RBD-specific Mono-Nb suppression of MERS-CoV involves inhibition of
RBD–DPP4 receptor binding [41]. Here, we performed ELISA and flow cytometry assays to investigate
whether the engineered Di-Nb and Tri-Nb could inhibit RBD-DPP4 binding to a greater extent than
Mono-Nb. The ELISA result revealed that Di-Nb and Tri-Nb blocked the binding of MERS-CoV
RBD (i.e., RBD-WT) to hDPP4 more strongly than Mono-Nb; the inhibition was dose-dependent
(Figure 3B). The flow cytometry assay revealed that both Di-Nb and Tri-Nb had significantly greater
ability than Mono-Nb to block the binding of RBD (i.e., RBD-WT) to Huh-7 cell-associated hDPP4;
again, the inhibition was dose-dependent (Figure 3C). In both cases, the MERS mAb control inhibited
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RBD–DPP4 binding as well as or better than Mono-Nb, whereas inhibition by the SARS mAb control
was indistinguishable from background (Figure 3B,C).
Taken together, the data described above suggest that, relative to monomeric Nb, MERS-CoV
RBD-specific dimeric and trimer Nbs exhibited significantly improved binding affinity toward
MERS-CoV RBD proteins, elevated neutralizing activity toward MERS-CoV infection, and more
potent inhibition of MERS-CoV RBD binding to the DPP4 receptor.
 
Figure 3. Detection of the neutralizing activity of MERS-CoV RBD-specific Nbs and their inhibition of
RBD–DPP4 binding. (A) Neutralizing activity of Di-Nb and Tri-Nb against the prototypic MERS-CoV
(EMC2012 strain). The neutralizing activity of the Nbs is expressed as the Nb concentration (nM)
that completely inhibited the cytopathic effect (CPE) of MERS-CoV in at least 50% of the wells (50%
neutralization dose: ND50). Data are expressed as mean ND50 ± s.e.m. (n = 3). (B) Inhibition
of binding between Di-Nb or Tri-Nb and hDPP4 protein, as determined by ELISA. Percentage
inhibition is expressed as RBD–hDPP4 binding in the presence or absence of Nbs based on the
formula (1 – [RBD–hDPP4-Nb]/[RBD–hDPP4]) × 100. Data are presented as mean percentage
inhibition ± s.e.m. (n = 2). (C) Inhibition of binding between Di-Nb or Tri-Nb and hDPP4-expressing
Huh-7 cells, as determined by flow cytometry analysis. Percentage inhibition is expressed as
RBD–Huh-7 binding in the presence or absence of Nbs, which is calculated based on the formula
(1–[RBD–Huh-7–Nb]/[RBD–Huh-7]) × 100. Data are presented as mean percentage inhibition ± s.e.m.
(n = 2). For (A)–(C), MERS-CoV RBD-targeting Mono-Nb was used for comparison, and MERS mAb
and SARS mAb were included as controls. Experiments were repeated twice, yielding similar results.
Significant differences among groups were compared by ND50 ± s.e.m. (A) or median inhibitory
concentration (IC50) ± s.e.m. (A,C). Significant differences between Di-Nb and Mono-Nb are shown as
red asterisk, and those between Tri-Nb and Mono-Nb are shown as green asterisk (** and ***).
3.3. MERS-CoV RBD-Targeting Nbs Maintain Strong pH, Protease, Chemical, and Thermal Stability
Nbs generally have intrinsic stability under a variety of extreme conditions, including low or
high pH and temperatures, exposure to proteases (such as pepsin), and chaotropic agents (such as
urea) [36,37]. To investigate the stability of MERS-CoV RBD-targeting Nbs, we subjected them to
these extreme conditions, and then tested their neutralizing activity against pseudotyped MERS-CoV
expressing the S protein of strain EMC2012. As shown in Table 1, all Nbs, including Mono-Nb, Di-Nb,
and Tri-Nb, were still able to neutralize pseudotyped MERS-CoV infection after treatment at three
different pH values (pH 5.0, 7.0, and 8.0), various concentrations of pepsin and urea, and three
temperatures (4 ◦C, 37 ◦C, and 60 ◦C). All samples maintained neutralizing activity similar to
their respective untreated counterparts. Although MERS mAb control, treated or not treated at the
three pH values, maintained similar neutralizing activity against pseudotyped MERS-CoV infection,
it significantly lost neutralizing ability after incubation with urea or pepsin, or after pre-treatment
at 37 ◦C or 60 ◦C. As expected, the SARS mAb control had no cross-neutralizing activity against
MERS-CoV after any of these treatments. These data indicate that, relative to traditional mAbs
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targeting MERS-CoV RBD, MERS-CoV RBD-specific Nbs maintain greater stability under all extreme
conditions tested.
Table 1. Stability of MERS-CoV RBD-specific Nbs against extreme conditions.
Conditions Treatment
ND50 (nM, Mean Value)
Mono-Nb Di-Nb Tri-Nb MERS mAb SARS mAb
pH
pH 5.0 1.94 0.21 0.03 0.53 ND
pH 7.0 2.00 0.21 0.03 0.57 ND
pH 8.0 1.93 0.21 0.03 0.53 ND
No treatment 2.00 0.23 0.03 0.56 ND
Pepsin
0 μg/mL 2.23 0.29 0.04 0.56 ND
25 μg/mL 2.24 0.27 0.04 1.19 ** ND
625 μg/mL 2.20 0.26 0.04 1.86 ** ND
No treatment 2.15 0.24 0.04 0.55 ND
Urea
0 mM 2.27 0.25 0.04 0.56 ND
50 mM 2.01 0.29 0.04 0.85 ** ND
400 mM 2.18 0.25 0.03 1.46 ** ND
No treatment 2.19 0.25 0.04 0.54 ND
Temperature
4 ◦C 2.06 0.25 0.03 0.56 ND
37 ◦C 1.80 0.22 0.04 1.32 ** ND
60 ◦C 2.21 0.26 0.03 2.06 *** ND
No treatment 2.17 0.26 0.04 0.58 ND
Note: Nbs were tested for stability under extreme conditions, including pH, protease (pepsin), chaotropic agent
(urea), and temperature. Nbs were treated at different pH values (pH 5.0, 7.0, and 8.0) for 24 h at room temperature,
the indicated concentrations of pepsin for 1 h at 37 ◦C or urea for 24 h at 25 ◦C, and different temperatures (4 ◦C,
37 ◦C, and 60 ◦C) for 24 h, followed by measurement of their neutralizing activity against pseudotyped MERS-CoV
(EMC2012 strain) infection. Neutralizing activity of Nbs is expressed as mean 50% neutralization dose (ND50)
(n = 2). Experiments were repeated twice, yielding similar results. MERS mAb and SARS mAb were used as controls.
Significant differences between treatment and no-treatment groups under each condition were compared by mean
ND50 ± s.e.m. *, **, and *** indicate the level of significance of the differences between MERS mAb, with or without
treatment under the indicated conditions. ND, not detectable.
3.4. MERS-CoV RBD-Targeting Dimeric and Trimeric Nbs Had Significantly Elevated Cross-Neutralizing
Activity Against Multiple Heterologous MERS-CoV Isolates
MERS-CoV has undergone a number of mutations, including those in the RBD [24]. Hence,
it is critical that MERS-CoV RBD-specific Nbs maintain potent cross-neutralizing activity against
MERS-CoV of divergent strains. In addition to pseudotyped MERS-CoV expressing the S protein of
the prototypic MERS-CoV strain (EMC2012), we constructed 18 additional pseudotyped MERS-CoVs
containing RBD mutations from MERS-CoVs isolated from seven countries (Saudi Arabia, UK, Qatar,
Oman, Jordan, South Korea, and UAE), different time periods (2012–2016), and two hosts (human
and camel) (Table 2). In addition, we tested the neutralizing activity of MERS-CoV RBD-specific Nbs.
As shown in Table 2, relative to Mono-Nb, Di-Nb, and especially Tri-Nb, had significantly elevated
neutralizing activity against all these 18 viruses tested. ND50 ranged from 0.81 to 27.1 nM for Mono-Nb,
from 0.07 to 3.29 nM for Di-Nb, and from 0.01 to 0.61 nM for Tri-Nb. The neutralizing activity of
MERS mAb was much lower than that of Di-Nb and Tri-Nb against all MERS-CoV strains tested,
and SARS mAb had no neutralizing activity against these viruses. These data indicate that MERS-CoV
RBD-specific oligomeric Nbs exhibited higher levels of cross-neutralization activity against divergent
MERS-CoV strains.
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4. Discussion
MERS-CoV continues to pose a severe threat to public health worldwide due to its high mortality
rate and the steady increase in clinical cases, particularly in Saudi Arabia. Currently, no MERS vaccines
or therapeutics have been approved for use in humans, creating an urgent demand for efficacious
vaccines and therapeutic agents capable of preventing MERS-CoV transmission and infection, as well
as treating MERS-CoV-infected humans and camels. In terms of antibody therapy, antibodies with
high productivity, good antigen-binding affinity, and potent neutralizing activity against divergent
strains of MERS-CoV infection would be of the greatest practical use.
Unlike conventional IgG antibodies (~150 kDa), or antibody fragments such as antigen-binding
fragment (Fab, ~55 kDa) and single-chain variable fragment (scFv, 28 kDa), Nb monomers generally
exhibit excellent solubility, strong stability, and good tissue penetration, mainly due to their small
size (~15–16 kDa) [32,33,51]. In some cases, to increase efficacy against viral infection, bispecific,
multispecific, or multivalent Nbs can be constructed by tandemly linking two or more Nb monomers
recognizing either the same or different epitopes [52]. In contrast to mAb fragments, which might
exhibit reduced expression, stability, or affinity after engineering or recombination, engineered Nbs
exhibit elevated antigen-binding affinity, thus extending the time period during which Nbs are bound to
their targets, while maintaining their beneficial characteristics, without negatively affecting production
yields, solubility, or stability [53–55].
Taking advantage of the properties of Nbs, especially their ability to form functional bi- or
multi-specific Nbs with elevated activity, we constructed two MERS-CoV RBD-targeting oligomeric
Nbs, Di-Nb and Tri-Nb, based on the previously developed Mono-Nb [41], with the goal of identifying
anti-MERS-CoV Nbs with improved binding ability, superior inhibition, and broad-spectrum neutralizing
activity against MERS-CoV infection without negatively affecting expression level or stability.
Di-Nb and Tri-Nb had molecular weights of about 32 and 48 kDa that were double and
triple the size of Mono-Nb (~16 kDa), respectively. As expected, engineering of the RBD-specific
Mono-Nb had no impact on antibody expression. As with Mono-Nb, Di-Nb and Tri-Nb could be
expressed at high levels in a yeast cell expression system and purified with high purity, retaining
their conformation and antigenicity. In addition, the larger size of the oligomeric Nbs did not affect
their stability. Like Mono-Nb, the oligomerized Di-Nb and Tri-Nb maintained stability under all
extreme conditions tested, including acidic or alkaline pH, protease (pepsin), chaotropic denaturant
(urea), and high temperature. By contrast, the protease, chemical, and thermal stability of MERS
mAb significantly decreased after these treatments. Thus, unlike the mAb control, the engineered
MERS-CoV RBD-specific Nbs developed in this study maintained the key characteristics of Nbs,
including intrinsic stability, high expression, and intact conformation. Because these Nbs are stable
under above extreme conditions, they can be transported and stored without the need for refrigeration
or special care, a marked advantage relative to traditional antibodies. This will significantly simplify
the transportation and therapeutic processes of antibodies, particularly in Middle Eastern countries
that generally have inadequate transport services and high temperatures during summer.
The MERS-CoV RBD-specific dimeric and trimeric Nbs developed in this study also have several
important features related to interference with three critical steps of MERS-CoV infection. First,
they exhibited significantly greater ability than the Mono-Nb to bind MERS-CoV RBD proteins with or
without RBD mutations from divergent MERS-CoV strains isolated from different years and hosts,
facilitating the Nb–RBD interaction and increasing the time that the Nbs are bound to MERS-CoV.
We have previously demonstrated that the Mono-Nb recognizes an epitope at residue around D539
of MERS-CoV RBD [41]. Second, relative to Mono-Nb, the engineered oligomeric Nbs strongly
blocked RBD binding to MERS-CoV receptor DPP4, which is involved in a key step of viral entry and
infection [14,56], thereby more effectively blocking entry of MERS-CoV into its target cells. Third,
Di-Nb and Tri-Nb had significantly greater capacities to neutralize homologous MERS-CoV (EMC2012
strain), as well as potently cross-neutralize dozens of heterologous MERS-CoV strains harboring one
or two mutations in their RBDs, all of which were isolated from different countries, hosts (human and
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camel), and time periods. Overall, the engineered oligomeric Nbs have great potential to neutralize
new MERS-CoV strains with mutations in the RBD, and could therefore play a key role in preventing
camel-to-human and human-to-human transmissions of MERS-CoV.
Despite the significant advantages of Nbs, it should be noted that the engineered dimeric (~32 kDa)
and trimeric (~48 kDa) Nbs, as well as their monomeric counterpart (~16 kDa), are smaller than IgG
antibodies (~150 kDa), and their molecular weights are far below the kidney filtration threshold (~60 kDa).
Therefore, these small Nbs may be rapidly eliminated from the bloodstream by renal clearance, thus they
might have shorter half-lives than mAbs [41,55]. One approach of increasing the in vivo half-life of
Nbs is to fuse them with albumin-binding domain (ABD) or human Fc (hFc) [55,57,58]. We have also
successfully fused monomeric Nb with a C-terminal hFc, increasing its half-life as well as its therapeutic
and prophylactic efficacy against MERS-CoV infection [41]. In future studies, we plan to extend the
half-lives of the constructed oligomeric Nbs by fusing them with ABD or hFc, and then compare their
in vivo efficacy with that of Mono-Nb with or without hFc against MERS-CoV.
To summarize, in this study we developed oligomeric MERS-CoV RBD-specific Nbs and
demonstrated that their in vitro activities were superior to those of their monomeric Nb counterparts,
including antigen-binding affinity, inhibition of virus–receptor binding, and enhanced neutralizing
and cross-neutralizing activity against variant strains of MERS-CoV infection, without reducing their
stability under harsh conditions. These Nbs have the potential to be developed as therapeutics to
prevent and treat MERS-CoV infection. Similar strategies could be applied to developing therapeutic
agents against other emerging and re-emerging infectious viruses with pandemic potential.
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Abstract: Since emerging in 2012, Middle East Respiratory Syndrome Coronavirus (MERS-CoV) has
been a global public health threat with a high fatality rate and worldwide distribution. There are
no approved vaccines or therapies for MERS until now. Passive immunotherapy with neutralizing
monoclonal antibodies (mAbs) is an effective prophylactic and therapeutic reagent against emerging
viruses. In this article, we review current advances in neutralizing mAbs against MERS-CoV.
The receptor-binding domain (RBD) in the spike protein of MERS-CoV is a major target, and
mouse, camel, or human-derived neutralizing mAbs targeting RBD have been developed. A major
problem with neutralizing mAb therapy is mutant escape under selective pressure, which can be
solved by combination of neutralizing mAbs targeting different epitopes. Neutralizing mAbs are
currently under preclinical evaluation, and they are promising candidate therapeutic agents against
MERS-CoV infection.
Keywords: Middle East Respiratory Syndrome Virus; MERS-CoV; neutralizing
monoclonal antibodies
1. Introduction
Middle East Respiratory Syndrome (MERS) emerged in 2012 in Saudi Arabia with the death
of a man with pneumonia; the causative agent was subsequently identified as MERS-CoV, which
belonged to lineage C betacoronaviruses [1]. With dromedary camels (Camelus dromedarius, also known
as Arabian camel) as direct sources and bats as potential reservoirs [2], MERS-CoV has been frequently
introduced into human populations. Once MERS-CoV is introduced into a person, person-to-person
transmission might occur, and is responsible for approximately 40% of MERS cases globally [3].
MERS-CoV has been a consistent threat to humans. As of October 2018, MERS-CoV has caused 2254
laboratory-confirmed human cases, including 800 deaths in 27 countries, with the fatality rate as
high as 35% (http://www.who.int/emergencies/mers-cov/en/). Although MERS cases are primarily
reported in the Middle East, facilitated by international travelling, MERS-CoV can also be a worldwide
threat, which is well illustrated by the MERS outbreak in South Korea in 2015 [4]. Given the potential
risk of causing worldwide public health emergencies and the absence of licensed vaccines and antiviral
therapeutics, the World Health Organization has listed MERS-CoV in the “List of Blueprint priority
diseases” (http://www.who.int/blueprint/priority-diseases/en/).
Vaccines are the most important approach against viral infections, but usually take a long time to
develop. They are also unable to provide either immediate prophylactic protection or treat ongoing
viral infections. Neutralizing monoclonal antibodies (mAbs) have recently emerged as a powerful tool
to provide prophylactic and therapeutic protection against emerging viruses [5]. Potent neutralizing
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mAbs can be achieved by various technologies, such as hybridoma technology, humanized mouse,
phage or yeast display, and single B cell isolation [5].
2. Spike (S) Protein of MERS-CoV as Target for Neutralizing mAbs
MERS-CoV is a single, positive-stranded RNA virus of about 30 kb, which encodes four major
viral structural proteins—including spike (S), envelope (E), membrane (M) and nucleocapsid (N)—as
well as several accessory proteins [6]. The S protein (1353 aa) plays an important role in virus infection
and consists of a receptor-binding subunit S1 (aa 18–751) and a membrane-fusion subunit S2 (aa
752–1353). S1 mediates viral attachment to host cells and S2 mediates virus-cell membrane fusion [7].
The S1 subunit contains a receptor-binding domain (RBD) (aa 367–606) [8] that can bind to cell receptor
dipeptidyl peptidase 4 (DPP4, also known as CD26), and mediates viral attachment target cells [9].
The RBD consists of a core subdomain and a receptor-binding motif (RBM) (aa 484–567). The schematic
representation of MERS-CoV S protein is shown in Figure 1A.
Figure 1. (A) Schematic representation of MERS-CoV S protein. (B) Residues on RBD critical for mAb
neutralization. SP: signal peptide; NTD: N-terminal domain; RBD: receptor-binding domain; RBM:
receptor-binding motif. Conserved residues on RBM critical for hDPP4 binding are shown in red.
Neutralizing mAbs binding to the S protein of MERS-CoV can prevent viral attachment to the
cell receptor and inhibit viral entry [7]. The S protein of MERS-CoV is a key target for antivirals, and
RBD is the most popular focus. In this study, we review the current knowledge on neutralizing mAbs
targeting the RBD of MERS-CoV.
194
Viruses 2018, 10, 680
3. Mouse Neutralizing mAbs
3.1. 4C2 and 2E6
Stable hybridoma cell lines were generated by fusing myeloma cells with splenocytes of mice that
were immunized with MERS-RBD protein. Two neutralizing mAbs, 4C2 and 2E6, had high affinity
for the RBD of MERS-CoV and blocked both pseudovirus and live MERS-CoV entry into cells with
high efficacy [10]. Humanized 4C2 showed similar neutralizing activity in cell entry tests. In vivo tests
indicated that 4C2 could significantly reduce the virus titers in the lungs of Ad5-hCD26-transduced
mice which were infected with MERS-CoV, highlighting its potential application in humans not only
for preventing but also treating MERS-CoV infection. Crystallization of the 4C2 Fab/MERS-RBD
complex showed that the 4C2 recognized conformational epitopes (Y397-N398, K400, L495-K496,
P525, V527-S532, W535-E536, and D539-Q544), which were partially overlapped the receptor-binding
footprint in the RBD of MERS-CoV. The 4C2 complex interfered with MERS-CoV binding to DPP4 by
both steric hindrance and interface-residue competition. 2E6 competed with 4C2 to bind to MERS-RBD,
indicating that they recognized proximate or overlapping epitopes [10].
3.2. Mersmab1
Neutralizing mAb Mersmab1 was obtained by fusing myeloma cells with splenocytes of a mouse
that was immunized with recombinant MERS-CoV S1 [11]. Mersmab1 effectively blocked the entry
of pseudovirus and live MERS-CoV into cells. Structural analysis showed that Mersmab1 bound to
the RBD of MERS-CoV through recognizing conformational epitopes, and all of the residues critical
for Mersmab1 binding were located on the left ridge of RBM. Mersmab1 neutralized MERS-CoV by
competitively blocking the binding of MERS-CoV RBD to DPP4. Based on escape mutant analysis of
the key residues on the RBD, it was found that residue L506, D510, R511, E513, and W553 were critical
for Mersmab1 binding to the RBD, while mutation of E536, D539, or E565 did not affect the interaction
of Mersmab1 and the RBD at all [11].
4. Human Neutralizing mAbs
4.1. 3B11
An ultra-large nonimmune human antibody-phage display library was constructed with B cells
of unimmunized donors. With a unique spanning strategy, seven human neutralizing mAbs with
varying neutralization efficacy to MERS-CoV were identified [12]. Binding detection demonstrated
that the epitopes of these mAbs lay within aa 349–590 of the S protein, which overlapped a large part
of the RBD of MERS-CoV. Binding competition assays showed that these mAbs recognized at least
three distinct epitope groups, which was further confirmed by escape studies. With no cross-epitope
resistance, these mAbs neutralized MERS-CoV by competitively blocking the binding of the RBD of
MERS-CoV to DPP4. Escape mutant assays showed that five residues were critical for neutralization
of these mAbs, namely L506, T512, Y540, R542, and P547. Of the seven mAbs, 3B11 exhibited the best
neutralization activity against both pseudovirus and live MERS-CoV infectivity in cells. Moreover,
under the selective pressure of these mAbs, the IgG form of 3B11 was superior, since it did not induce
neutralization escape [12]. In vivo tests demonstrated that 3B11 reduced lung pathology in rhesus
monkeys infected with MERS-CoV [13]. With its high neutralizing activity and suppression of mutant
escape, 3B11 in the IgG form is a promising therapeutic mAb against MERS-CoV.
4.2. m336
Three human mAbs—m336, m337, and m338—were identified from a large naïve human phage
display antibody library, which was constructed with peripheral blood mononuclear cells from healthy
volunteers [14]. The binding sties of the three mAbs were within the RBD of MERS-CoV (aa 377–588),
therefore they neutralized MERS-CoV by competing with DPP4 binding to the RBD. The three mAbs
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also competed with each other to bind to the RBD of MERS-CoV, and mutant analysis showed that the
three mAbs possessed overlapping but distinct epitopes. Of the three mAbs, m336 neutralized both
pseudovirus and live MERS-CoV infectivity in cells with exceptional potency (m336 inhibited 90%
MERS-CoV pseudovirus infection at a concentration of 0.039 g/mL, and neutralized live MERS-CoV
with IC95 of 1 g/mL and IC50 of 0.07 g/mL). Residues in the RBD crucial for m336 binding were L506,
D510, E536, D539, W553, and V555 [14]. In vivo study demonstrated that prophylaxis with m336
reduced virus titers in the lung of rabbits infected with MERS-CoV [15], and m336 also provided
transgenic mice expressing human DPP4 with full prophylactic and therapeutic protection from
MERS-CoV [16]. However, another study with a non-human primate, the common marmoset showed
that m336 could only alleviate the severity of the disease, and did not provide complete protection
against MERS-CoV [17].
4.3. LCA60
IgG+ memory B cells were isolated from a MERS patient, and were subsequently immortalized
with Epstein–Barr virus. A neutralizing mAbs, LCA60, was identified, and was the first fully
human neutralizing mAb with naïve heavy and light chain pairs [18]. LCA60 efficiently neutralize
MERS-CoV infectivity in cells. In vivo study showed that LCA60 provided BALB/c mice transduced
with adenoviral vectors expressing human DPP4 (hDPP4) with both prophylactic and postexposure
protection against MERS-CoV. Furthermore, the neutralizing efficacy of LCA60 was evaluated in
IFN-α/β receptor-knockout mice that were more stringent models of MERS-CoV infection. After
transducing with hDPP4, these mice showed more profound clinical symptoms when challenged with
MERS-CoV [19]; administration of LCA60 reduced MERS-CoV titer in the lungs of these mice more
effectively (lung viral titer reduced by three logs in one day for IFN-α/β receptor-knockout mice vs.
three days for BALB/c mice) [18]. With naïve heavy and light chain pairs, LCA60 was more potent than
3B11 and comparable to m336. Cross-competition experiment demonstrated that LCA60 competed
with 3B11 to bind to the RBD. LCA60 interacted with RBD residues around K493, and the LCA60
footprint on the RBD was partially overlapped with that of DPP4. Four residues in the RBD affected
the binding of LCA60—namely T489, K493, E536, and E565—which were conserved in all MERS-CoV
isolates. Moreover, compared with DPP4, the binding affinity of LCA60 to RBD was significantly
higher (~500-fold). Therefore, one major neutralization mechanism of LCA60 was to competitively
inhibit the interaction of the RBD with DPP4. Interestingly, virus escape studies demonstrated that
under the selective pressure of LCA60, a mutant variant (V33A) in the N-terminal domain (NTD)
of MERS-CoV S1 subunit was also generated [18]. A GMP-approved cell line (LCA60.273.1) that
expresses LCA60 in high concentrations has been established, highlighting its application as promising
therapeutics against MERS-CoV infection [20].
4.4. REGN3051 and REGN3048
Hybridoma B cells producing neutralizing mAbs against the S protein of MERS-CoV were
generated by immunizing humanized transgenic mice (VelocImmune mice) with DNA encoding
the MERS-CoV S protein. Two fully human neutralizing mAbs, REGN3051 and REGN3048, were
obtained [21]. The two mAbs bound with high affinity to distinct epitopes on the RBD of MERS-CoV,
which were conserved during the natural evolution of MERS-CoV. Mutation as a result of selective
pressure by one mAb should not affect the binding of the other mAb. REGN3051 neutralized a broad
range of MERS-CoV isolates, the prototype EMC/2012 strain and all clinical mutants including A431P,
S457G, S460F, A482V, L506F, D509G, and V534A. With the exception of V534A variant, REGN3048
achieved similar neutralizing activity. In vivo study demonstrated that REGN3051 and REGN3048
reduced MERS-CoV replication in humanized DPP4 mice in both prophylactic and therapeutic
settings [21]. When evaluated in the common marmoset, both mAbs seemed to be more effective for
prophylaxis rather than for treatment of MERS-CoV infection [22].
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4.5. MCA1
An anti-MERS-CoV phage display antibody library was constructed with the peripheral B cells of a
MERS survivor, and a human neutralizing mAb against MERS-CoV, MCA1, was identified [23]. MCA1
showed potent neutralizing activity against MERS-CoV in cell entry tests. In vivo, MCA1 completely
inhibited the replication of MERS-CoV in common marmosets when administrated prophylactically or
therapeutically. Structure analysis of the MCA1 Fab-RBD complex showed that MCA1 formed direct
contacts with the receptor-binding site (RBS) subdomain on the RBD. Epitopes on the RBS critical for
MCA1 binding were D510, W535, E536, D539, Y540, R542, and Q544. Superimposed structure analysis
of MCA1-RBD and hDPP4-RBD complexes showed that the binding interface of MCA1 was largely
overlapped with that of hDPP4. Therefore, the neutralizing mechanism of MCA1 was achieved by
competing with DPP4 for binding to the RBD [23].
4.6. MERS-4 and MERS-27
Two potent human neutralizing mAbs, MERS-4 and MERS-27, were derived from a nonimmune
human yeast display antibody library, which was constructed with spleen and lymph node
polyadenylated RNA from normal humans [24]. MERS-4 and MERS-27 inhibited the entry of both
pseudovirus and live MERS-CoV into cells. Mutant analysis suggested that MERS-4 and MERS-27
recognized distinct epitopes in the RBD of MERS-CoV, and the epitopes of MERS-27 might be located
away from those that recognized by MERS-4. Mutant analysis also demonstrated that residues D455,
L507, E513, R542, L545, S546, P547, G549, and S508 in the RBD were critical for MERS-4 binding, while
only S508 was important for MERS-27 binding. Combined use of MERS-4 and MERS-27 demonstrated
a synergistic effect against pseudotyped MERS-CoV. MERS-4 bound to the RBD with about 45-fold
higher affinity than DPP4. The primary neutralizing mechanism of MERS-4 and MERS-27 was
through blocking the binding of the RBD to DPP4 [24]. Further structural analysis showed that
MERS-4 bound to unique epitopes and caused conformational changes in the RBD interface critical
for accommodating DPP4, therefore indirectly disrupting the interaction between the two. Moreover,
MERS-4 also demonstrated synergistic effects with m336 and 5F9 (a NTD-specific mAb). The special
neutralizing mechanism made MERS-4 a valuable addition for the combined use of mAbs against
MERS-CoV infection [25].
4.7. MERS-GD27 and MERS-GD33
Thirteen ultrapotent neutralizing mAbs, which all targeted the RBD of MERS-CoV were
generated following a protocol for the rapid production of antigen-specific human mAbs [26]. Briefly,
antibody-secreting B cells were isolated from the whole blood of a MERS patient, and the antibody
genes were amplified and cloned into vectors to transfect human cell lines for mAb production. Of
the 13 mAbs, MERS-GD27 and MERS-GD33 exhibited the strongest neutralizing activity against both
pseudovirus and live MERS-CoV in cell infection tests. MERS-GD27 directly competed with DPP4
to bind to the RBD to DPP4, and the crystal structure of MERS-GD27 showed that its epitopes were
almost completely overlapped with DPP4-binding sites. MERS-GD27 and MERS-GD33 recognized
distinct epitopes on the RBD, and had a low level of competing activity. The combined use of the two
mAbs demonstrated synergistic effects in neutralization against pseudotyped MERS-CoV. Mutant
analysis demonstrated that residues L506, D509, V534, E536, and A556 on RBD were important for the
neutralizing activity of MERS-GD27, and residue R511was critical for MERS-GD33 [26]. Moreover,
In vivo study found that MERS-GD27 could provide both prophylactic and therapeutic protection for
hDPP4-trangenic mice against MERS-CoV infection [27].
5. Camel Neutralizing mAbs
Dromedary camels exposed to MERS-CoV showed mild clinical signs but developed exceptionally
potent neutralizing antibodies. Camelid species naturally produced heavy chain-only antibodies
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(HCAbs) [28], which are dimeric and devoid of light chains, and their antigen recognition region is
solely formed by the variable heavy chains (VHHs) (also called nanobodies, Nbs). VHHs or Nbs
have long complementarity-determining region 3 (CDR3) loops and are capable of binding to unique
epitopes not accessible to conventional antibodies [29]. Notably, camelid VHHs are relatively stable
and can be produced with high yields in prokaryotic systems [30]. Because of their small size; good
tissue permeability; and cost-effective production, storage, and transportation [31–33], VHHs or Nbs
have been gaining acceptance as antiviral agents.
5.1. Chimeric Camel/Human HCAb-83
A VHH complementary DNA library was constructed with the bone marrow of dromedary
camels infected with MERS-CoV. Four VHHs (VHH-1, VHH-4, VHH-83, and VHH-101) with high
neutralizing activity were identified by direct cloning and screening of the phage display antibody
library [34]. The four VHHs competed for a single epitope that partially overlapped with the RBD-DPP4
interface. Mutant analysis showed that the four VHHs did not bind to the D539N variant, which was a
critical residue on the RBD for DPP4 binding [8,35]. Therefore, these VHHs most likely neutralized
MERS-CoV by blocking its binding to DPP4. Of the 4 VHHs, VHH-83 showed the best neutralizing
activity and epitope recognition. VHH-83 efficiently blocked the entry of MERS-CoV into cells, and it
also prophylactically protected K18 transgenic mouse expressing hDPP4 from MERS-CoV infection.
To extend the half-life of VHH-83 in serum, it was linked to a human Fc domain lacking the CH1
exon to construct the chimeric camel/human HCAb-83, which showed similar neutralizing activity as
VHH-83. The chimeric camel/human HCAb-83 was highly stable in mice and provided K18 mice with
fully prophylactic protection against MERS-CoV infection [34].
5.2. NbMS10 and NbMS10-Fc
Alpacas were immunized with recombinant MERS-CoV RBD-containing a C-terminal human
IgG1 Fc tag, and VHHs were amplified from their peripheral blood mononuclear cells to construct a
VHH phage display library. A neutralizing Nb, NbMS10, which bound with high affinity to the RBD of
MERS-CoV and blocked the binding of RBD to DPP4, was identified [36]. To extend its in vivo half-life,
the human-Fc-fused version, NbMS10-Fc, was constructed. NbMS10 competed with DPP4 to bind to
RBD, indicating that the binding site of NbMS10 on RBD overlapped with that of DPP4. The binding
site of the NbMS10 on the RBD was mapped to be around residue D539, which is part of a highly
conserved conformational epitope at the receptor-binding interface in almost all the natural MERS-CoV
published to date. NbMS10 did not neutralize psuedotyped MERS-CoV bearing a mutation in D539,
confirming that residue D539 was critical for NbMS10 binding. NbMS10 efficiently neutralized the cell
entry of live MERS-CoV. Moreover, NbMS10 showed potent prophylactic and therapeutic efficacy in
protecting hDPP4-transgenic mice against MERS-CoV infection [36].
6. Discussion
For their exceptionally high neutralization activity in vitro and in vivo, these newly identified
neutralizing mAbs are promising candidate therapeutics against the infection of MERS-CoV. However,
the use of a single neutralizing antibody bears the risk of selecting escape mutants, a fact that has
been observed for LCA60 and other described antibodies [12,18,37]. Notably, the majority of these
escape mutations had little impact on viral fitness and the interaction of DPP4 with the RBD [12].
Moreover, mutants of MERS-CoV during natural infection have also been reported [38]. Escape
from neutralization is a major concern with therapeutic neutralizing mAbs, however, this potential
problem can be solved by combining mAbs that target distinct epitopes and show different neutralizing
mechanisms [37]. This strategy can take advantage of the synergistic effects while decreasing the
possibility of viral escape.
Currently, most of the MERS-CoV neutralizing mAbs compete with DPP4 binding to the RBD,
and residues on the RBD critical for mAb neutralization are identified by mutant analysis. Almost
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all of the residues identified critical for mAb neutralization are located in RBM, and overlap with
those critical for DPP4 binding (Figure 1B). With the availability of crystal structure of mAb Fab-RBD
complex, the neutralization mechanism of these mAbs will be better illustrated.
Based on the crystal structure of RBD-DPP4, it was found that several conserved residues in
the RBD are critical for the interaction of the RBD with DPP4 (Y499, L506, D510, E513, E536, D537,
D539, Y540, R542, W553, and V555) [35,39]. Development of therapeutic neutralizing mAbs targeting
those critically conserved residues might be important for combating MERS-CoV. Moreover, a study
found a mouse-derived neutralizing mAb, 5F9, which bound to a possible linear epitope in the NTD
of the MERS-CoV S1 subunit, exhibited efficient neutralizing activity against pseudovirus and live
MERS-CoV in cell entry tests. This study highlighted the important role of NTD during the infection
process of MERS-CoV. NTD might have significant implications for the development of prophylactic
and therapeutic mAbs against MERS-CoV infection [40]. Although the in vitro neutralizing potency of
5F9 was approximately 10-fold lower than that of the RBD-targeting neutralizing mAbs [40], it may
provide an alternative for the immunotherapy against MERS-CoV, once the virus mutates and is no
longer susceptible to RBD-specific mAbs.
So far, there is a lack of appropriate animal models to mimic the pathology of MERD-CoV
in humans. Commonly-used laboratory animals—such as wild-type mouse, ferret, hamster, and
guinea pig—are not susceptible to MERS-CoV infection due to differences in critical amino acids in
the S-binding domain of their DPP4 [41–43]. New Zealand rabbits, hDPP4-transduced/transgenic
mice, camelids and non-human primates (rhesus macaque and common marmoset) are susceptible
to MERS-CoV infection, however, rabbits showed asymptomatic infection [44]; dromedary
camels displayed different clinical manifestations to that of humans [45]; rhesus macaque only
showed transient lower respiratory infection [46], while common marmoset developed progressive
pneumonia [47]; hDPP4-trangenic mouse expressed hDPP4 extensively, and resulted in multiple organ
damage [48]; hDPP4-transduced mouse only exhibited mild transient clinical diseases [19]. With robust
animal models, the protective effects of these neutralizing mAbs will be better evaluated. Furthermore,
ongoing efforts on developing therapeutic neutralizing mAbs against MERS-CoV should also consider
the different target populations (dromedary camels and humans) and their protective efficacy.
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Abstract: The Middle East respiratory syndrome coronavirus (MERS-CoV) emerged in 2012 and
caused continual outbreaks worldwide with high mortality. However, no effective anti-MERS-CoV
drug is currently available. Recently, numerous evolutionary studies have suggested that MERS-CoV
originated from bat coronavirus (BatCoV). We herein reported that three peptides derived from
the HR2 region in spike protein of BatCoV HKU4, including HKU4-HR2P1, HKU4-HR2P2 and
HKU4-HR2P3, could bind the MERS-CoV HR1-derived peptide to form a six-helix bundle (6-HB)
with high stability. Moreover, these peptides, particularly HKU4-HR2P2 and HKU4-HR2P3,
exhibited potent inhibitory activity against MERS-CoV S-mediated cell–cell fusion and viral infection,
suggesting that these HKU4 HR2-derived peptides could be candidates for futher development as
antiviral agents against MERS-CoV infection.
Keywords: MERS-CoV; fusion inhibitor; peptide; cell–cell fusion; HKU4
1. Introduction
Middle East respiratory syndrome coronavirus (MERS-CoV), a novel human coronavirus
(Figure 1A), emerged in Saudi Arabia in 2012 [1], rapidly spread wordwide, and caused continuous
outbreaks with significant mortality and morbidity [2,3]. As of 27 November 2018, the World
Health Organization (WHO) reported 2266 laboratory-confirmed cases of infection with MERS-CoV
and 804 MERS-associated deaths (about 36% fatality rate) in 27 countries (available online:
http://www.who.int/emergencies/mers-cov/en/). MERS-CoV uses dipeptidyl peptidase-4 (DPP4,
also named CD26), a type-II transmembrane glycoprotein, as the cellular receptor to infect humans
and cause severe respiratory disease and other severe complications, including renal failure and even
multiorgan failure [4–8]. However, no licensed vaccines or effective therapeutics against MERS-CoV
infection have been approved by the U.S. Food and Drug Administration (FDA). This calls for the
urgent development of effective therapeutics against MERS-CoV infection for clinical use.
Similar to other coronaviruses [9], MERS-CoV is an enveloped positive-sense single-stranded
RNA virus and belongs to the lineage C betacoronavirus in the family coronaviridae [10]. MERS-CoV
displays its spike protein (S), a type I transmembrane glycoprotein, on its enveloped membrane surface
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in a trimer state. S protein contains two subunits: S1 subunit (S1) and S2 subunit (S2). S1 recognizes
and binds the cellular receptor, while S2 mediates viral and cellular membrane fusion. The interaction
between the receptor-binding domain (RBD) in S1 and the receptor (DPP4) on the host cell surface
induces S2 structural changes, including the insertion of N-terminal fusion peptide into the host
cell membrane, the formation of a homotrimer by heptad repeat 1 (HR1) helices, exposing three
hydrophobic grooves on the surface, and the binding of three heptad repeat 2 (HR2) molecules to
the hydrophobic grooves of HR1 trimer to form a six-helix bundle (6-HB), which brings the viral
and cell membranes close together for fusion. Finally, MERS-CoV releases its genetic materials into
target cells (Figure 1B) [11,12]. Disrupting the process of MERS-6HB formation can inhibit virus–cell
membrane fusion and abolish viral infection [13,14]. Our previous studies found that a peptide,
MERS-HR2P, derived from the MERS-CoV HR2 region, could prevent the formation of the fusion
core by competitively binding to HR1 and blocking the native interaction between HR1 and HR2
(Figure 1B). MERS-HR2P has no effect on SARS-CoV infection, and SARS-CoV HR2-derived peptide,
CP-1, failed to inhibit MERS-CoV infection [14,15], suggesting that MERS-HR2P is specific for inibiting
MERS-CoV infection. Whether other novel and potent peptide fusion inhibitors can be developed
against MERS-CoV from other coronavirus HR2 regions is still unclear.
Although camels are the intermediate host for the transmission of MERS-CoV, bats are likely to be
its original source and serve as the natural host [10,16–18]. Phylogenetically, MERS-CoV is very closely
related to Tylonycteris sp. Bat CoV HKU4 (Ty-BatCoV HKU4) (Figure 1A). Similar to MERS-CoV, HKU4
also harbors the ability to use human DPP4 as the receptor for infecting the target cell [19,20]. We herein
identified that HKU4-HR2P1, HKU4-HR2P2 and HKU4-HR2P3 peptides, derived from the HKU4
HR2 region, could bind MERS-HR1P, a MERS-CoV HR1-derived peptide, and mimic the interaction of
MERS-CoV HR1 and HR2 regions to form stable 6-HB. Moreover, these peptides exhibited significant
inhibitory activity in both MERS-CoV S-mediated cell–cell fusion assay and pseudovirus infection assay,
with even more potency than that of the reported peptide, MERS-HR2P. Taken together, these HKU4
HR2-derived peptides could be considered as candidates for the development of anti-MERS-CoV
agents for clinical use.
2. Materials and Methods
2.1. Cells, Viruses and Peptides
Huh-7 and 293T cells were obtained from the Chinese Academy of Sciences Cell Bank (Shanghai,
China). All cell lines were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) with 10%
fetal bovine serum (FBS). Plasmids, including pcDNA3.1-MERS-S, pcDNA3.1-MERS-S with Q1020H
or Q1020R mutation, pAAV-IRES-S-GFP and pNL4-3.Luc.R-E, were constructed in our laboratory.
All peptides were synthesized by KareBay Biochem (Monmouth Junction, NJ, USA) with HPLC
purity >90% [21,22]. The average hydrophilicity of peptides was predicted by using an online
peptide-calculator program (available online: http://www.bachem.com/service-support/peptide-
calculator/).
2.2. Coronavirus Phylogenetic Analysis
Phylogenetic tree was constructed using MEGA6.06. Accession numbers utilized for phylogenetic
analysis are as follows: BtCoV-HKU4 (NC_009019.1), BtCoV-HKU5 (NC_009020), MERS-CoV
(AID55097.1), BtSCoV-WIV1 (KF367457), BtCoV-HKU9 (EF065516), and IBV (KY421672).
2.3. Circular Dichroism Spectroscopic Analysis
Circular dichroism spectra (198-260 nm) were collected on a J-815 spectropolarimeter (Jasco, Inc.,
Tokyo, Japan) to evaluate the secondary structure of the individual peptide or the complexes dissolved
in phosphate-buffered saline (PBS) with the final concentration at 10 μM [15,23]. The ellipticity value
of −33,000 deg cm2 dmol−1 at 222 nm was taken as 100% α-helicity [24,25]. Thermal denaturation of
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peptide complexes was monitored from 20 ◦C to 100 ◦C at 222 nm with a thermal gradient of 5◦C/ min.
The midpoint of the thermal unfolding transition (Tm) values was acquired by Jasco software utilities.
2.4. Native Polyacrylamide Gel Electrophoresis (N-PAGE)
Native polyacrylamide gel electrophoresis (N-PAGE) was conducted as described elsewhere [15].
Briefly, each HKU4 HR2-derived peptide (40 μM) in PBS was incubated with HKU4-HR1P or
MERS-HR1Ps (20, 40, 80 μM), respectively, at 37◦C for 30 min, using PBS as control, and then loaded
on a tris-glycine gel (12%) with tricine glycine running buffer (pH 8.6). Finally, staining was performed
with Coomassie blue, and the images were visualized on the FluorChem Imaging System (Alpha
Innotech/ProteinSimple).
2.5. Cell–Cell Fusion Assay
The assay for MERS-CoV S protein-mediated cell–cell fusion was performed as described
elsewhere [14,26–28]. Briefly, 293T cells transiently co-expressing MERS-CoV S protein and GFP
protein on cell surface and in cytoplasm, respectively, were used as the effector cells (293T/S/GFP),
and Huh-7 cells were used as the target cells. Then the effector cells (1 × 104 cells per well) and target
cells (5 × 104 cells per well) were cocultured in the wells of a flat-bottom 96-well plate at 37 ◦C for 2 h
in the presence or absence of peptides at the indicated concentrations. Finally, the fused and unfused
cells were visualized, photographed and counted under an inverted fluorescence microscope (Nikon
Eclipse Ti-S). PBS without peptides was used as no inhibition control, and the median inhibitory
concentration (IC50) was calculated using the CalcuSyn software [29].
2.6. Generation and Packaging of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Pseudovirus
The package of MERS-CoV pseudovirus was described in our previous studies [14,27]. Briefly,
we cotransfected 293T cells with plasmid pcDNA3.1-MERS-S with or without Q1020H/R mutation
and plasmid pNL4-3.luc.R-E encoding Env-defective, luciferase-expressing HIV-1 [30]. Then,
the pseudoviruses in the supernatant were collected 48–72 h post-transfection and quantified by
the level of lentivirus p24. Target cells, Huh-7, were preplated in 96-well plates (1 × 104 cells per well).
The MERS-CoV pseudovirus was premixed with peptide at indicated concentration and incubated for
30 min at 37 ◦C. PBS was used as no inhibition control. Then, the mixture was added to the Huh-7 cells,
replaced by fresh medium 12 h post-infection, and then incubated for an additional 48 h. Transduced
Huh-7 cells were lysed for detection of relative light units (RLU) according to the luciferase assay
system manual (Promega, Madison, WI, USA) [31].
2.7. Time-of-Addition Assay
The time-of-addition assay was conducted as described in our previous study [14]. Briefly, Huh-7
cells plated in 96-well plates were incubated with MERS-CoV PsV, while each peptide at a final
concentration of 10 μM was added 0, 0.5, 1, 2, 4 or 6 h post-infection. Cells were lysed 72 h later to
determine the entry inhibition ratio.
2.8. Time-of-Removal Assay
Each peptide (10 μM) was added to Huh-7 cells, followed by an incubation at 37 ◦C for 30 min,
respectively. The cells were then washed with PBS to remove the unbound peptide and the cells that
were not washed were used as control, followed by addition of the MERS-CoV pseudovirus. After
co-culture at 37 ◦C for 3 days, cells were lysed to test the inhibitory activity of peptides.
2.9. Cytotoxicity Assay
The cytotoxicity of peptides to Huh-7 cells was measured following the instructions in the manual
provided in the Cell Counting Kit-8 (CCK-8; Dojindo, Kumamoto, Kyushu, Japan) [22]. Briefly,
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each peptide with indicated concentrations was mixed with 104 target cells in each well of 96-well
plates to co-incubate for 48 h. Then culture medium was replaced by fresh cell medium with 4% CCK-8
solution for an additional incubation 2 h at 37 ◦C. Finally, the absorbance was detected at 450 nm
(A450).
3. Results
3.1. Design of HKU4 HR2-Peptides
Our previous studies crystallized the fusion core structure of the MERS-CoV S2 subunit and
designed peptides MERS-HR1P and MERS-HR2P based on the fusion structure [14]. These peptides
can mimic the interaction of HR1 and HR2 regions to form 6-HB [14]. Through multiple sequence
alignment with the MERS-CoV S protein S2 subunit, we found that the S2 subunit of HKU4 also
harbors a fusion peptide (FP, residues 942–981), an HR1 domain (residues 983–1103), an HR2 domain
(residues 1247–1296), a transmembrane domain (residues 1296–1319) and an intracellular domain
(residues1319–1352). The designated HKU4-HR1P spans residues 997–1038 in the HR1, while peptides
HKU4-HR2P1, HKU4-HR2P2, HKU4-HR2P3 span residues 1247–1282, 1252–1287, and 1261–1296,
respectively (Figure 1C). Similar to MERS-HR2P, the three HKU4 HR2-derived peptides all contain the
helical region (residues1263–1281), which contains some different amino acids, such as 1264S, 1265D,
1268A, 1269M, 1272E, 1276Q and1279D (Figure 1C). However, the a and d residues in the HKU4 HR2
helical region, which are fully the same as those of the MERS-CoV HR2 helical region, are responsible
for interaction with the g and e residues in the HR1 region, correspondingly [14], suggesting that the
HKU4 HR2-derived peptides might cross-target the MERS-CoV HR1 region, as does MERS-HR2P.
 
Figure 1. The design of HKU4 HR2-derived peptides. (A) Neighbor-joining tree created with the
spike sequence of representative bat-CoVs and Infectious Bronchitis Virus (IBV). (B) The antiviral
mechanism of HR2-derived peptides. (C) Schematic representation of HKU4 S protein S2 subunit.
FP, fusion peptide; HR, heptad repeat domain; TM, transmembrane domain; CP, cytoplasmic domain.
Corresponding sequences of the designed peptides (HKU4-HR1P and HKU4-HR2Ps) are shown in
the diagram. The helical region in the HR1- and HR2-derived peptides is highlighted in the red boxes,
according to the sequences of MERS-HR1P and MERS-HR2P. The identical amino acids at the e and g
positions in HR1 and those at a and d positions in HR2 of MERS-CoV and HKU4 are highlighted in
red. The different amino acids in HR1Ps and HR2Ps between MERS-CoV and HKU4 are highlighted
in green.
3.2. Interaction between MERS-HR1P and HKU4 HR2-Derived Peptides
To investigate whether the HKU4-HR2Ps could interact with HKU4-HR1P to mimic the HR1 and
HR2 regions, we determined their interaction by using N-PAGE. After coincubation of HKU4-HR1P at
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20, 40, and 80 μM and HKU-HR2P1 (or HKU1-HR2P2 or HKU4-HR2P3) in PBS at 40 μM, respectively,
the samples were loaded into the tris-glycine gel for electrophoresis. As shown in Figure 2A–C,
individual HKU4 HR2-derived peptides moved down to the lowest part of the gel under native
electrophoresis, mainly by their carried negative charges. On the contrary, HKU4-HR1P with positive
charges could not move into the gel. Meanwhile, the mixtures of HKU4-HR1P and each HKU4
HR2-derived peptide showed new bands at the upper part in the gel (lanes 3, 4 and 5), confirming that
all three HKU4-HR2 peptides could, indeed, bind to HKU4-HR1P.
Figure 2. Determination of the interactions between HKU4-HR1P with HKU4-HR2P1 (A),
HKU4-HR2P2 (B) and HKU4-HR2P3 (C), as well as the interaction between MERS-HR1P
with HKU4-HR2P1 (D), HKU4-HR2P2 (E) and HKU4-HR2P3 (F) by native polyacrylamide gel
electrophoresis (N-PAGE).
We subsequently assessed the ability of HKU4 HR2-derived peptides to bind the MERS-CoV
HR1 region, thereby allowing us to detect the interaction between HKU4-HR2Ps and MERS-HR1P,
which was derived from the MERS-CoV HR1 region. We saw that MERS-HR1P did interact with all
three HKU4-HR2 peptides and form new bands on N-PAGE, as well as HKU4-HR1P (Figure 2D,E),
suggesting that the HKU4-HR2 peptides could cross-target the MERS-CoV HR1 region.
To characterize the interaction between MERS-HR1P and those HR2-derived peptides, we
used circular dichroism (CD) to determine the secondary structures of each peptide and their
complexes. As shown in Figure 3A–D, each peptide (MERS-HR2P, HKU4-HR2P1, HKU4-HR2P2,
HKU4-HR2P3 or MERS-HR1P) exhibited a low α-helicity structure (10.5%-13.5%), whereas the CD
spectrum of HKU4-HR2P1/MERS-HR1P, HKU4-HR2P1/MERS-HR1P, HKU4-HR2P2/MERS-HR1P
and HKU4-HR2P3/MERS-HR1P complexes display the characteristic α-helical structure, i.e., double
negative peak at 208 and 222 nm, and possess helicity at 70.9%, 66.4%, 80.3% and 66.8%, respectively.
Consistent with our previous studies [14], the complex of MERS-HR1P/MERS-HR2P showed high
thermostability with the Tm value of 87.1 ◦C. Similarly, the complexes formed by MERS-HR1P and
HKU4-HR2P peptides also possess strong thermostability with Tm values ranging from 83.5 to 90.5 ◦C
(Figure 3E). These results show that all three HKU4-HR2 peptides can bind MERS-HR1P and form
6-HB formation with good stability. Among them, HKU4-HR2P2 exhibited the highest binding affinity
to MERS-HR1P and formed the most α-helicity, suggesting that it alone might have the most potent
anti-MERS-CoV effect.
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Figure 3. Circular dichroism (CD) spectra of MERS-HR1P, MERS-HR2P and MERS-HR1P/MERS-HR2P
complex (A), MERS-HR1P, HKU4-HR2P1 and MERS-HR1P/ HKU4-HR2P1 complex (B), MERS-HR1P,
HKU4-HR2P2 and MERS-HR1P/ HKU4-HR2P2 complex (C), MERS-HR1P, HKU4-HR2P3 and
MERS-HR1P/ HKU4-HR2P3 complex (D) in phosphate buffer (pH 7.2). (E) Melting curves of
the complexes formed by MERS-HR1P and MERS-HR2P, HKU4-HR2P1, HKU4-HR2P2,
or HKU4-HR2P3, respectively.
3.3. Inhibition of MERS-CoV S Protein-Mediated Cell–Cell Fusion
To determine whether the peptides could inhibit MERS-CoV S-mediated cell–cell fusion, we tested
them with a MERS-CoV S-mediated cell–cell fusion assay, in which the GFP of effector cells diffused
into the target cells such that the fused cells showed larger size and weaker fluorescence than unfused
effector cells. Similar to MERS-HR2P, HKU4-HR2P1, HKU4-HR2P2 and HKU4-HR2P3 peptides could
effectively inhibit MERS-CoV S-mediated cell–cell fusion with IC50s at concentrations of 1.09, 0.38 and
0.55 μM, respectively (Figure 4A,B, and Table 1). However, HKU4-HR1P did not show fusion-inhibitory
activity comparable to that of MERS-HR1P, whereas HKU4-HR2P2 and HKU4-HR2P3 showed more
potent inhibitory activity than that of MERS-HR2P (IC50 = 1.07 μM), which was, in fact, derived from
the MERS-CoV HR2 region, indicating that HKU4-HR2P2 and HKU4-HR2P3 are good candidates for
development as potent anti-MERS-CoV agents.
3.4. Inhibition of Pseudotyped MERS-CoVs Infection
To further assess the anti-MERS-CoV activities of the HKU4 HR2-derived peptides, we tested
them using a MERS-CoV pseudovirus infection assay, which is able to mimic the entry process of
authentic MERS-CoV and has been widely used in basic and antiviral research [14]. HKU4-HR2P1,
HKU4-HR2P2 and HKU4-HR2P3 peptides inhibited entry of MERS-CoV in a dose-dependent manner
with IC50s of 2.15, 0.34 and 0.48 μM (Figure 5A and Table 1), respectively, and did so in a manner
comparable with that of MERS-HR2P (IC50 = 1.14 μM), whereas neither MERS-HR1P nor HKU4-HR1P
exhibited inhibitory activity. The results from the time-of-addition assay indicated that the inhibitory
activity of HKU4-HR2P2 and HKU4-HR2P3 on pseudotyped MERS-CoV infection was significantly
decreased when the peptides were added to cells 4 h post-infection (Figure S1), suggesting that these
peptides target the viral fusion and entry stages.
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Figure 4. Inhibitory activity of peptides as demonstrated by MERS-CoV S-mediated cell–cell fusion
assay. (A) Images of MERS-CoV S protein-mediated cell–cell fusion in the presence of MERS-HR1P,
MERS-HR2P, HKU4-HR2P1, HKU4-HR2P2, HKU4-HR2P3 and HKU4-HR1P, respectively, all at the
concentration of 10 μM. Arrows show the fused cells. Scale bars, 800 μm. (B) Inhibitory activities of
MERS-HR2P, HKU4-HR2P1, HKU4-HR2P2, HKU4-HR2P3, HKU4-HR1P and MERS-HR1P against
MERS-CoV S-mediated cell–cell fusion. Each sample was tested in triplicate and the data are
expressed as means ± standard deviation (SD). Each experiment was repeated twice and similar
results were obtained.
Figure 5. Inhibitory activity of peptides as demonstrated by pseudotyped MERS-CoV infection
mediated by S protein (A) or S protein with Q1020H (B) or Q1020R (C). Each sample was tested in
triplicate and the data are expressed as means ± SD. Each experiment was repeated twice and similar
results were obtained.
Based on numerous epidemiological studies, researchers have found some mutant sites in the
spike protein of MERS-CoV, in particular Q1020, which is under strong positive selection in the S2
subunit [32,33]. More importantly, Q1020 is located at the MERS-CoV HR1 region, which is the target
site for peptide fusion inhibitors, including HKU4 HR2-derived peptides, and might affect the antiviral
activity of these peptides. Therefore, to further assess whether these new peptides would possess
broad-spectrum anti-MERS-CoV activity, we used the pseudotyped S-mediated MERS-CoVs with
Q1020H and Q1020R mutant sites to infect target cells in the presence of each peptide. As shown in
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Figure 5B,C, similar to MERS-HR2P, the three HKU4-HR2 peptides could effectively inhibit infection
caused by the two pseudotyped MERS-CoV mutants. Again, HKU4-HR2P2 and HKU4-HR2P3
exhibited more potent inhibitory activity than either that of MERS-HR2P or HKU4-HR2P1. However,
these peptides exhibited no obvious inhibition on vesicular stomatitis virus (VSV) G protein-mediated
pseudovirus infection at the concentration up to 10 μM (Figure S2A). The results from a time-of-removal
assay indicated that the inhibitory activity of the peptides on MERS-CoV pseudovirus is not associated
with the binding of the peptides to the target cells (Figure S2B). Besides, these peptide at high
concentration (100 μM) showed no cytotoxicity (Figure S2C). All these results suggest that the fusion
inhibitory activity of these peptides is not because of their non-specific interaction with the viral or
cellular membranes or proteins, nor their cytotoxicity to the target cells.




Solubility (μM) in Inhibitory Activity of Peptides, IC50 (μM)
PBS (pH 7.2) Water
Cell–Cell Fusion Pseudovirus Infection
Q1020 Q1020H Q1020R
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
HKU4-HR2P1 0.0 1569 110 651 40 1.09 0.21 2.15 0.17 2.72 0.59 2.42 0.93
HKU4-HR2P2 0.2 2924 131 150 25 0.38 0.01 0.34 0.06 0.44 0.1 0.3 0.04
HKU4-HR2P3 0.0 118 13 1674 73 0.55 0.06 0.48 0.08 0.52 0.1 0.4 0.03
MERS-HR2P −0.2 105 12 29 14 1.07 0.22 1.14 0.02 1.71 0.02 1.31 0.07
IC50: Concentration of peptide at which 50% of HCoV S-mediated cell–cell fusion was blocked.
4. Discussion
In the early 1990s, Jiang et al and Wild et al identified potent HIV-1 fusion inhibitory peptides
derived from the HIV-1 gp41 CHR (or HR2) domain, SJ-2176 and DP-178 (it was later renamed
as T-20) [34,35]. Subsequently, there have been numerous reports showing that peptides derived
from the HR2 domain in the class I membrane fusion proteins of some enveloped viruses, such as
respiratory syncytial virus (RSV) [36], paramyxoviruses simian virus 5 (SV5) [37], Nipah virus [38],
and mouse hepatitis virus (MHV) [39], exhibit inhibitory activity against the corresponding viruses.
Similarly, in our previous work, we found that both MERS-HR2P, derived from MERS-CoV HR2 region,
and CP-1, derived from SARS-CoV HR2 region, exhibited effective fusion-inhibitory activity against
MERS-CoV and SARS-CoV, respectively [14,15]. However, MERS-HR2P had no inhibitory activity
against SARS-CoV, and SARS-HR2P (CP-1) had no inhibitory activity on MERS-CoV, suggesting
that the HR2-derived peptides lacked cross-inhibitory activity, thus limiting the development of
broad HCoV fusion inhibitors. To the best of our knowledge, we herein report, for the first time,
that BatCoV HR2-derived peptides, namely HKU4-HR2P1, HKU4-HR2P2 and HKU4-HR2P3, could
successfully cross-bind MERS-HR1P to form stable 6-HB. These peptides, especially HKU4-HR2P2
and HKU4-HR2P3, exhibited potent inhibitory activity against MERS-CoV S-mediated cell–cell fusion
and effectively blocked pseudotyped MERS-CoV infection, indicating the existence of a potent fusion
inhibitor against MERS-CoV infection in the natural BatCoV HR2 region.
We previously reported that the fusion core region of HR1 and HR2 is important for the
formation of 6-HB [14]; therefore, we herein designed HKU4 HR2-derived peptides containing the
helical region. All peptides exhibited antiviral activity against MERS-CoV infection. Apart from
HR2 helices, previous studies also suggested that the N- and C-terminal tail regions of HR2
could be important to the inhibitory activity of peptides [40]. Indeed, the three HKU4 HR2-derived
peptides possess different terminal tail regions and exhibited various antiviral activity against
MERS-CoV infection. On the other hand, the location of HKU4-HR2P2 in the HKU4 HR2
region is the same as that of MERS-HR2P in the MERS-CoV HR2 region. However, the higher
helicity (80.3%) and Tm value (90.5 ◦C) of the HKU4-HR2P2/MERS-HR2 complex than those of
the MERS-HR2P2/MERS-HR2 complex may contribute to the higher anti-MERS-CoV activity of
HKU4-HR2P2 than that of MERS-HR2P.
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More interestingly, the values of helicity and Tm of the HKU4-HR2P3/MERS-HR1P complex
are equal to those of HKU4-HR2P1/MERS-HR1P, but lower than those of MERS-HR2P/MERS-HR1P,
while HKU4-HR2P3 showed more potent antiviral activity compared to either HKU4-HR2P1 or
MERS-HR2P. The precise antiviral mechanism is worth elucidating in future studies, but it can be
speculated here that the answer might lie in the C-terminal tail of HKU4-HR2P3, which belongs to
the tryptophan (Trp)-rich membrane proximal external region (MPER). This is best exemplified by
SARS-CoV MPER-derived peptide, which can interact with the internal fusion peptide (IFP23) to
inhibit the formation of MPER-IFP heteromer, a putative quaternary structure that extends from the
6-HB and functions in membrane fusion [41,42]. Moreover, the MPER-derived peptide could directly
inhibit the SARS-CoV entry. HKU4-HR2P3 exhibited similar potent inhibitory activity likely from the
blocking of MERS-CoV 6-HB formation and disturbance of the interaction between MPER and IFP
in MERS-CoV infection. This clearly constitutes a novel strategy for the development of MERS-CoV
peptide fusion inhibitors with bispecific targets: HR1 and IFP.
Consistent with the reports that unlike the HR2 (or CHR) peptides, the HR1 (or NHR) peptides
derived from the enveloped viruses with class I membrane fusion proteins (e.g., HIV-1, SARS-CoV,
and MERS-CoV) have no or low activity to inhibit 6-HB formation, cell–cell fusion, and viral infection,
mainly because these HR1 peptides tend to aggregate in physiological solutions [14,15,43–45], we found
that MERS-HR1P and HKU4-HR1P also exhibited no fusion inhibitory activity, possibly for the same
reason described above. Nonetheless, we have previously reported that conjugation of the T4 fibritin
trimerization domain, Foldon (Fd), to the HR1 (or NHR) peptides derived from the HIV-1 gp41, such
as N36Fd and N28Fd, make the NHR peptides fold into stable and soluble trimeric coiled-coils with
potent HIV-1 fusion inhibitory activity [46]. We will use a similar approach to construct MERS-HR1P-Fd
and HKU4-HR1P-Fd with MERS-CoV and HKU4 fusion inhibitory activity, respectively.
The HKU4 coronavirus is closely related to MERS-CoV, and it can recognize and bind the same
receptor, human DPP4 [47]. More importantly, the risk of infecting humans could be sharply increased
through the simple induction of two mutants in S protein [48]. However, only sparse information about
the HKU4 fusion core is currently available, and no effective fusion inhibitors have been reported.
Here, based on the structure of the MERS-CoV 6-HB fusion core, we designed HKU4-HR1P and
HKU4-HR2P peptides, which can interact to mimic the formation process of 6-HB by their own HR1
and HR2 regions. Hence, this study contributes to a better understanding about the mechanism of
HKU4 infection and provides more information for the development of HKU4 peptide fusion inhibitors
in the event that HKU4 crosses the species barrier to infect humans.
In summary, we have developed a series of bat-CoV-derived peptide fusion inhibitors, including
HKU4-HR2P1, HKU4-HR2P2 and HKU4-HR2P3, which can interact with MERS- HR1P to form highly
stable 6-HB, mimicking the formation of MERS-CoV 6-HB structure. Additionally, these peptides,
especially HKU4-HR2P2 and HKU4-HR2P3, exhibited potent inhibitory activity against MERS-CoV
infection, indicating that these bat-CoV peptides are promising as candidates for development as
clinical agents against MERS-CoV infection.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1999-4915/11/1/56/s1.
Author Contributions: L.L., S.J., and H.L. conceived and designed the experiments; S.X., Q.L., J.P., C.W., Z.L.,
W.X. and Q.W. performed the experiments; S.X., Q.L., C.W., Z.L., and W.X. analyzed the data; S.X., L.L., S.J., and
H.L. wrote the paper. All authors revised the paper. All authors discussed the results and contributed to the
final manuscript.
Funding: This work was supported by the National Megaprojects of China for Major Infectious Diseases
(2018ZX10301403 to L.L.), Ministry of Science and Technology of the People’s Republic of China (2016YFC1201000
and 2016YFC1200405 to S.J. and 2016YFC1202901 to L.L.), Wuhan Science and Technology Project
(2016060101010066 to H.L.), and China Postdoctoral Science Foundation (2018M640341 to S.X.).
Conflicts of Interest: The authors declare no conflicts of interest. The funding sponsors had no role in the
writing of the manuscript or the decision to publish this article.
211
Viruses 2019, 11, 56
References
1. Zaki, A.M.; van Boheemen, S.; Bestebroer, T.M.; Osterhaus, A.D.; Fouchier, R.A. Isolation of a novel
coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 2012, 367, 1814–1820. [CrossRef]
[PubMed]
2. Bermingham, A.; Chand, M.A.; Brown, C.S.; Aarons, E.; Tong, C.; Langrish, C.; Hoschler, K.; Brown, K.;
Galiano, M.; Myers, R.; et al. Severe respiratory illness caused by a novel coronavirus, in a patient
transferred to the United Kingdom from the Middle East, September 2012. Eurosurveillance 2012, 17, 20290.
[PubMed]
3. Muller, M.A.; Raj, V.S.; Muth, D.; Meyer, B.; Kallies, S.; Smits, S.L.; Wollny, R.; Bestebroer, T.M.; Specht, S.;
Suliman, T.; et al. Human coronavirus EMC does not require the SARS-coronavirus receptor and maintains
broad replicative capability in mammalian cell lines. MBio 2012, 3, e00515-12. [CrossRef]
4. Letko, M.; Miazgowicz, K.; McMinn, R.; Seifert, S.N.; Sola, I.; Enjuanes, L.; Carmody, A.; van Doremalen, N.;
Munster, V. Adaptive evolution of MERS-CoV to species variation in DPP4. Cell Rep. 2018, 24, 1730–1737.
[CrossRef] [PubMed]
5. Lu, G.W.; Hu, Y.W.; Wang, Q.H.; Qi, J.X.; Gao, F.; Li, Y.; Zhang, Y.F.; Zhang, W.; Yuan, Y.; Bao, J.K.; et al.
Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature
2013, 500, 227–231. [CrossRef] [PubMed]
6. Chan, J.F.; Lau, S.K.; To, K.K.; Cheng, V.C.; Woo, P.C.; Yuen, K.Y. Middle East respiratory syndrome
coronavirus: Another zoonotic betacoronavirus causing SARS-like disease. Clin. Microbiol. Rev. 2015, 28,
465–522. [CrossRef]
7. Chan, J.F.; Li, K.S.; To, K.K.; Cheng, V.C.; Chen, H.; Yuen, K.Y. Is the discovery of the novel human
betacoronavirus 2c EMC/2012 (HCoV-EMC) the beginning of another SARS-like pandemic? J. Infect. 2012,
65, 477–489. [CrossRef]
8. Lu, L.; Xia, S.; Ying, T.L.; Jiang, S.B. Urgent development of effective therapeutic and prophylactic agents to
control the emerging threat of Middle East respiratory syndrome (MERS). Emerg. Microbes Infect. 2015, 4, e37.
[CrossRef]
9. Yuan, Y.; Cao, D.; Zhang, Y.; Ma, J.; Qi, J.; Wang, Q.; Lu, G.; Wu, Y.; Yan, J.; Shi, Y.; et al. Cryo-EM structures of
MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains. Nat. Commun.
2017, 8, 15092. [CrossRef]
10. Woo, P.C.; Lau, S.K.; Huang, Y.; Yuen, K.Y. Coronavirus diversity, phylogeny and interspecies jumping.
Exp. Biol. Med. 2009, 234, 1117–1127. [CrossRef]
11. Du, L.Y.; Zhao, G.Y.; Kou, Z.H.; Ma, C.Q.; Sun, S.H.; Poon, V.K.M.; Lu, L.; Wang, L.L.; Debnath, A.K.;
Zheng, B.J.; et al. Identification of a receptor-binding domain in the s protein of the novel human coronavirus
Middle East respiratory syndrome coronavirus as an essential target for vaccine development. J. Virol. 2013,
87, 11963. [CrossRef]
12. Xia, S.; Liu, Q.; Wang, Q.; Sun, Z.; Su, S.; Du, L.; Ying, T.; Lu, L.; Jiang, S. Middle East respiratory syndrome
coronavirus (MERS-CoV) entry inhibitors targeting spike protein. Virus. Res. 2014, 194, 200–210. [CrossRef]
[PubMed]
13. Gao, J.; Lu, G.W.; Qi, J.X.; Li, Y.; Wu, Y.; Deng, Y.; Geng, H.Y.; Li, H.B.; Wang, Q.H.; Xiao, H.X.; et al. Structure
of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the s protein of Middle
East respiratory syndrome coronavirus. J. Virol. 2013, 87, 13134–13140. [CrossRef] [PubMed]
14. Lu, L.; Liu, Q.; Zhu, Y.; Chan, K.H.; Qin, L.; Li, Y.; Wang, Q.; Chan, J.F.; Du, L.; Yu, F.; et al. Structure-based
discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat. Commun. 2014, 5, 3067.
[CrossRef] [PubMed]
15. Liu, S.W.; Xiao, G.F.; Chen, Y.B.; He, Y.X.; Niu, J.K.; Escalante, C.R.; Xiong, H.B.; Farmar, J.; Debnath, A.K.;
Tien, P.; et al. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated
coronavirus: Implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet 2004,
363, 938–947. [CrossRef]
16. Anthony, S.J.; Gilardi, K.; Menachery, V.D.; Goldstein, T.; Ssebide, B.; Mbabazi, R.; Navarrete-Macias, I.;
Liang, E.; Wells, H.; Hicks, A.; et al. Further evidence for bats as the evolutionary source of Middle East
respiratory syndrome coronavirus. Mbio 2017, 8, e00373-17. [CrossRef] [PubMed]
212
Viruses 2019, 11, 56
17. Mohd, H.A.; Al-Tawfiq, J.A.; Memish, Z.A. Middle East respiratory syndrome coronavirus (MERS-CoV)
origin and animal reservoir. Virol. J. 2016, 13, 87. [CrossRef]
18. Dudas, G.; Carvalho, L.M.; Rambaut, A.; Bedford, T. MERS-CoV spillover at the camel-human interface. Elife
2018, 7, e31257. [CrossRef]
19. Lau, S.K.P.; Zhang, L.B.; Luk, H.K.H.; Xiong, L.F.; Peng, X.W.; Li, K.S.M.; He, X.Y.; Zhao, P.S.H.; Fan, R.Y.Y.;
Wong, A.C.P.; et al. Receptor usage of a novel bat lineage c betacoronavirus reveals evolution of Middle East
respiratory syndrome-related coronavirus spike proteins for human dipeptidyl peptidase 4 binding. J. Infect.
Dis. 2018, 218, 197–207. [CrossRef]
20. Wang, Q.H.; Qi, J.X.; Yuan, Y.; Xuan, Y.F.; Han, P.C.; Wan, Y.H.; Ji, W.; Li, Y.; Wu, Y.; Wang, J.W.; et al. Bat
origins of MERS-CoV supported by bat coronavirus HKU4 usage of human receptor CD26. Cell Host Microbe
2014, 16, 328–337. [CrossRef]
21. Su, S.; Zhu, Y.; Ye, S.; Qi, Q.Q.; Xia, S.; Ma, Z.X.; Yu, F.; Wang, Q.; Zhang, R.G.; Jiang, S.B.; et al. Creating
an artificial tail anchor as a novel strategy to enhance the potency of peptide-based HIV fusion inhibitors.
J. Virol. 2017, 91, e01445-16. [CrossRef] [PubMed]
22. Xia, S.; Xu, W.; Wang, Q.; Wang, C.; Hua, C.; Li, W.H.; Lu, L.; Jiang, S.B. Peptide-based membrane fusion
inhibitors targeting HCoV-229E spike protein HR1 and HR2 domains. Int. J. Mol. Sci. 2018, 19, 487.
[CrossRef] [PubMed]
23. Chan, D.C.; Fass, D.; Berger, J.M.; Kim, P.S. Core structure of gp41 from the HIV envelope glycoprotein. Cell
1997, 89, 263–273. [CrossRef]
24. Weng, Y.K.; Weiss, C.D. Mutational analysis of residues in the coiled-coil domain of human immunodeficiency
virus type 1 transmembrane protein gp41. J. Virol. 1998, 72, 9676–9682. [PubMed]
25. Takeda, K.; Sasa, K.; Nagao, M.; Batra, P.P. Secondary structural-changes of non-reduced and reduced
ribonuclease-a in solutions of urea, guanidine-hydrochloride and sodium dodecyl-sulfate. Biochim. Biophys.
Acta 1988, 957, 340–344. [CrossRef]
26. Wang, C.; Zhao, L.; Xia, S.; Zhang, T.; Cao, R.; Liang, G.; Li, Y.; Meng, G.; Wang, W.; Shi, W.; et al. De novo
design of alpha-helical lipopeptides targeting viral fusion proteins: A promising strategy for relatively
broad-spectrum antiviral drug discovery. J. Med. Chem. 2018, 61, 8734–8745. [CrossRef] [PubMed]
27. Channappanavar, R.; Lu, L.; Xia, S.; Du, L.; Meyerholz, D.K.; Perlman, S.; Jiang, S. Protective Effect of
Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor
Against MERS-CoV Infection. J. Infect. Dis. 2015, 212, 1894–1903. [CrossRef]
28. Liu, Q.; Xia, S.; Sun, Z.; Wang, Q.; Du, L.; Lu, L.; Jiang, S. Testing of Middle East respiratory syndrome
coronavirus replication inhibitors for the ability to block viral entry. Antimicrob. Agents Chemother. 2015, 59,
742–744. [CrossRef]
29. Chou, T.C. Theoretical basis, experimental design, and computerized simulation of synergism and
antagonism in drug combination studies. Pharmacol. Rev. 2006, 58, 621–681. [CrossRef]
30. Zhao, G.Y.; Du, L.Y.; Ma, C.Q.; Li, Y.; Li, L.; Poon, V.K.M.; Wang, L.L.; Yu, F.; Zheng, B.J.; Jiang, S.B.; et al.
A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for
viral entry inhibitors against the novel human coronavirus MERS-CoV. Virol. J. 2013, 10, 266. [CrossRef]
31. Jiang, S.B.; Lu, H.; Liu, S.W.; Zhao, Q.; He, Y.X.; Debnath, A.K. N-substituted pyrrole derivatives as novel
human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation
and block virus fusion. Antimicrob. Agents Chemother. 2004, 48, 4349–4359. [CrossRef] [PubMed]
32. Cotten, M.; Watson, S.J.; Zumla, A.I.; Makhdoom, H.Q.; Palser, A.L.; Ong, S.H.; Al Rabeeah, A.A.;
Alhakeem, R.F.; Assiri, A.; Al-Tawfiq, J.A.; et al. Spread, circulation, and evolution of the Middle East
respiratory syndrome coronavirus. Mbio 2014, 5, e01062-13. [CrossRef] [PubMed]
33. Forni, D.; Filippi, G.; Cagliani, R.; De Gioia, L.; Pozzoli, U.; Al-Daghri, N.; Clerici, M.; Sironi, M. The heptad
repeat region is a major selection target in MERS-CoV and related coronaviruses. Sci. Rep. 2015, 5, 14480.
[CrossRef] [PubMed]
34. Jiang, S.; Lin, K.; Strick, N.; Neurath, A.R. HIV-1 inhibition by a peptide. Nature 1993, 365, 113. [CrossRef]
[PubMed]
35. Wild, C.; Greenwell, T.; Matthews, T. A Synthetic peptide from HIV-1 gp41 Is a potent inhibitor of
virus-mediated cell-cell fusion. Aids Res. Hum. Retrovir. 1993, 9, 1051–1053. [CrossRef] [PubMed]
213
Viruses 2019, 11, 56
36. Lawless-Delmedico, M.K.; Sista, P.; Sen, R.; Moore, N.C.; Antczak, J.B.; White, J.M.; Greene, R.J.; Leanza, K.C.;
Matthews, T.J.; Lambert, D.M. Heptad-repeat regions of respiratory syncytial virus F1 protein form a
six-membered coiled-coil complex. Biochemistry 2000, 39, 11684–11695. [CrossRef] [PubMed]
37. Russell, C.J.; Jardetzky, T.S.; Lamb, R.A. Membrane fusion machines of paramyxoviruses: Capture of
intermediates of fusion. EMBO J. 2001, 20, 4024–4034. [CrossRef]
38. Bossart, K.N.; Mungall, B.A.; Crameri, G.; Wang, L.F.; Eaton, B.T.; Broder, C.C. Inhibition of Henipavirus
fusion and infection by heptad-derived peptides of the Nipah virus fusion glycoprotein. Virol. J. 2005, 2, 57.
[CrossRef]
39. Bosch, B.J.; van der Zee, R.; de Haan, C.A.M.; Rottier, P.J.M. The coronavirus spike protein is a class I virus
fusion protein: Structural and functional characterization of the fusion core complex. J. Virol. 2003, 77,
8801–8811. [CrossRef]
40. Wang, C.; Xia, S.; Zhang, P.; Zhang, T.; Wang, W.; Tian, Y.; Meng, G.; Jiang, S.; Liu, K. Discovery
of hydrocarbon-stapled short alpha-helical peptides as promising Middle East respiratory syndrome
coronavirus (MERS-CoV) fusion inhibitors. J. Med. Chem. 2018, 61, 2018–2026. [CrossRef]
41. Liao, Y.; Zhang, S.M.; Neo, T.L.; Tam, J.P. Tryptophan-dependent membrane interaction and heteromerization
with the internal fusion peptide by the membrane proximal external region of SARS-CoV spike protein.
Biochemistry 2015, 54, 1819–1830. [CrossRef] [PubMed]
42. Lu, Y.N.; Neo, T.L.; Liu, D.X.; Tam, J.P. Importance of SARS-CoV spike protein Trp-rich region in viral
infectivity. Biochem. Biophys. Res. Commun. 2008, 371, 356–360. [CrossRef] [PubMed]
43. Lu, M.; Blacklow, S.C.; Kim, P.S. A trimeric structural domain of the HIV-1 transmembrane glycoprotein.
Nat. Struct. Biol. 1995, 2, 1075–1082. [CrossRef]
44. Lu, M.; Kim, P.S. A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein. J. Biomol. Struct.
Dyn. 1997, 15, 465–471. [CrossRef] [PubMed]
45. Liu, S.; Lu, H.; Niu, J.; Xu, Y.; Wu, S.; Jiang, S. Different from the HIV fusion inhibitor C34, the anti-HIV drug
Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J. Biol. Chem. 2005, 280,
11259–11273. [CrossRef] [PubMed]
46. Chen, X.; Lu, L.; Qi, Z.; Lu, H.; Wang, J.; Yu, X.; Chen, Y.; Jiang, S. Novel recombinant engineered gp41
N-terminal heptad repeat trimers and their potential as anti-HIV-1 therapeutics or microbicides. J. Biol. Chem.
2010, 285, 25506–25515. [CrossRef] [PubMed]
47. Yang, Y.; Du, L.Y.; Liu, C.; Wang, L.L.; Ma, C.Q.; Tang, J.; Baric, R.S.; Jiang, S.; Li, F. Receptor usage and
cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus.
Proc. Natl. Acad. Sci. USA 2014, 111, 12516–12521. [CrossRef]
48. Yang, Y.; Liu, C.; Du, L.Y.; Jiang, S.B.; Shi, Z.L.; Baric, R.S.; Li, F. Two mutations were critical for bat-to-human
transmission of Middle East respiratory syndrome coronavirus. J. Virol. 2015, 89, 9119–9123. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution




Combining a Fusion Inhibitory Peptide Targeting the
MERS-CoV S2 Protein HR1 Domain and a
Neutralizing Antibody Specific for the S1 Protein
Receptor-Binding Domain (RBD) Showed Potent
Synergism against Pseudotyped MERS-CoV with or
without Mutations in RBD
Cong Wang 1,†, Chen Hua 1,†, Shuai Xia 1, Weihua Li 2, Lu Lu 1,* and Shibo Jiang 1,2,*
1 Key Laboratory of Medical Molecular Virology of MOE/MOH, School of Basic Medical Sciences and
Shanghai Public Health Clinical Center, Fudan University, Shanghai 200032, China;
16111010068@fudan.edu.cn (C.W.); 16211010047@fudan.edu.cn (C.H.); 15111010053@fudan.edu.cn (S.X.)
2 NHC Key Laboratory of Reproduction Regulation (Shanghai Institute of Planned Parenthood Research),
Fudan University, Shanghai 200032, China; weihua.li@sippr.org.cn
* Correspondence: lul@fudan.edu.cn (L.L.); shibojiang@fudan.edu.cn (S.J.); Tel.: +86-21-5423-7673 (L.L.);
+86-21-5423-7673 (S.J.)
† These authors contributed equally to this work.
Received: 9 December 2018; Accepted: 2 January 2019; Published: 6 January 2019
Abstract: Middle East respiratory syndrome coronavirus (MERS-CoV) has continuously posed a
threat to public health worldwide, yet no therapeutics or vaccines are currently available to prevent or
treat MERS-CoV infection. We previously identified a fusion inhibitory peptide (HR2P-M2) targeting
the MERS-CoV S2 protein HR1 domain and a highly potent neutralizing monoclonal antibody (m336)
specific to the S1 spike protein receptor-binding domain (RBD). However, m336 was found to have
reduced efficacy against MERS-CoV strains with mutations in RBD, and HR2P-M2 showed low
potency, thus limiting the clinical application of each when administered separately. However, we
herein report that the combination of m336 and HR2P-M2 exhibited potent synergism in inhibiting
MERS-CoV S protein-mediated cell–cell fusion and infection by MERS-CoV pseudoviruses with or
without mutations in the RBD, resulting in the enhancement of antiviral activity in contrast to either
one administered alone. Thus, this combinatorial strategy could be used in clinics for the urgent
treatment of MERS-CoV-infected patients.
Keywords: MERS-CoV; RBD; mutation; peptide; neutralizing antibody; combination
1. Introduction
Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV), a lineage C beta-coronavirus,
was reported to cause severe respiratory tract infection [1,2]. To date, 2266 laboratory-confirmed cases
of infection with MERS-CoV, including 804 MERS-CoV associated deaths, have been reported to the
World Health Organization (WHO) from 27 countries. Currently, no effective therapeutics or vaccines
are available to treat or prevent MERS-CoV infection.
The spike (S) protein of MERS-CoV plays important roles in virus attachment, fusion, and entry
into the target cell [3–5]. Similar to other coronaviruses, the S protein of MERS-CoV consists of S1 and
S2 subunits. The S1 subunit is responsible for the binding of the virion by its receptor binding domain
(RBD) to the cellular receptor, dipeptidyl peptidase-4 (DPP4), while the S2 subunit mediates the fusion
between viral and cellular membranes through the interaction between its HR1 and HR2 domains
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and entry of the viral genetic materials into the host cell [5–8]. Thus, both the RBD in S1 subunit and
HR1 domain in S2 subunit can serve as important targets for development of antiviral agents against
MERS-CoV infection.
Recently, we identified a peptide derived from the HR2 domain of MERS-CoV S protein S2 subunit,
designated HR2P, which could interact with the HR1 domain of S protein S2 subunit to form a six-helix
bundle (6-HB) complex and block viral fusion and replication with IC50s ranging from 0.6 to 1 μM [5].
By replacing amino acid residues at the i to i + 4 positions with a negatively charged amino acid (e.g., E)
and a positively charged amino acid (e.g., K) in HR2P for introduction of intramolecular salt-bridges, the
resultant peptide HR2P-M2 exhibited improved solubility, stability, and anti-MERS-CoV activity [5,9].
However, its potency is still not strong enough to warrant clinical development.
By screening an extra-large phage-displayed antibody Fab library, Ying et al. identified a human
neutralizing monoclonal antibody (hmAb), m336, which is specific for the RBD in the S protein S1
subunit. It exhibited highly potent neutralizing activity against MERS-CoV infection, both in vitro and
in vivo [10–13]. X-ray crystallography has shown that the binding epitope of m336 on MERS-CoV S
protein almost completely overlaps with the binding site of DPP4 [14]. However, the future clinical
application of m336 could be limited by its inability to neutralize MERS-CoV strains with mutations in
RBD, like the mouse neutralizing mAb Mersmab1 with similar weakness [15,16].
In this study, we compared the sensitivity of a pseudotyped MERS-CoV wild-type strain with that
of strains with key mutations, including D509G, D510G, Q522H, and I529T, which were detected in the
RBD of some MERS-CoV strains isolated from different regions and at different times throughout the
course of the MERS outbreak from 2012 to 2015 [17,18]. We found that these strains with mutations
in RBD were significantly less sensitive than the wild-type strain to the neutralizing activity of m336,
while the pseudoviruses with or without mutations showed equal sensitivity to the fusion inhibitory
activity of HR2P-M2. Interestingly, when m336 was combined with HR2P-M2, a strong synergism
emerged against MERS-CoV S-mediated cell–cell fusion and infection by pseudotyped MERS-CoV
strains with or without mutations in RBD, suggesting that this combinational therapy could be further
developed for clinical use to treat patients infected by the MERS-CoV strains with or without mutations
in RBD.
2. Materials and Methods
2.1. Cells, Peptides, Human mAb m336, and Plasmids
The 293T cell line was obtained from ATCC (Manassas, VA, USA), and the Huh-7 cell line was
from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). These two cell lines
were propagated in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal
bovine serum (FBS). Peptide HR2P-M2 was synthesized by solid phase peptide synthesis at SYN Inc.
(Shanghai, China), and human mAb m336 was provided by Prof. Tianlei Ying at Fudan University,
Shanghai, China. Recombinant plasmids encoding the MERS-CoV S protein with D509G, D510G,
Q522H, or I529T mutations were kindly provided by Dr. Lanying Du at the New York Blood Center,
NY, USA.
2.2. Production of Pseudoviruses
MERS-CoV pseudoviruses were constructed as described previously [19,20]. Briefly, 293T
cells were plated in a T175 tissue culture flask and incubated at 37 ◦C for 16 h. Cells were
cotransfected with plasmids pNL4-3.luc.RE encoding Env-defective, luciferase-expressing HIV-1 and
pcDNA3.1-MERS-CoV-S encoding S protein with or without mutation in RBD at mass ratio of 1:1 using
VigoFect (Vigorous Biotechnology, Beijing, China), according to the manufacturer’s recommendation.
The supernatant was replaced with fresh DMEM at 8–10 h post-transfection and harvested after
incubation for an additional 72 h. In order to remove cell debris, the supernatant was centrifuged at
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3000 rpm for 10 min, followed by filtration through a 0.45 μm filter. MERS-CoV pseudovirus in the
supernatant was quantified by testing p24 content in the product of MERS-CoV pseudovirus.
2.3. Inhibition of Pseudotyped MERS-CoV Infection
A MERS-CoV pseudovirus inhibition assay was performed as previously described [5,15,21].
Briefly, Huh-7 cells were seeded (104 cells/well) into a 96-well plate and incubated overnight at
37 ◦C. MERS-CoV pseudovirus was incubated with a serially diluted inhibitor for 30 min at 37 ◦C,
followed by the addition of Huh-7 cells. The cells were incubated with or without pseudovirus as virus
control and cell control, respectively. The culture was replaced with fresh medium 12 h post-infection
and incubated for an additional 72 h. Cells were lysed using lysis reagent (Promega, Madison, WI,
USA), and cell lysates were transferred to a 96-well Costar flat-bottom luminometer plate (Corning
Costar, New York, NY, USA), followed by the addition of luciferase substrate (Promega) to measure
luminescence using an Infinite M200 PRO (Tecan, GröDig, Austria).
2.4. Inhibition of MERS-CoV S Protein-Mediated Cell–Cell Fusion
MERS-CoV S protein-mediated cell–cell fusion was performed as previously described [5]. Briefly,
plasmid pAAV-IRES-MERS-EGFP encoding the MERS-CoV S protein was transfected into 293T cells
(293T/MERS/EGFP) using the transfection reagent, VigoFect (Vigorous Biotechnology, Beijing, China).
The target Huh-7 cells expressing DPP4were incubated at 2 × 104 cells/well in wells of a 96-well plate
for 12 h. The effector 293T/MERS/EGFP cells that express MERS-CoV S protein and EGFP or the
control 293T/EGFP cells that express EGFP only were preincubated at 104 cells/well with an inhibitor
at the indicated concentration or phosphate buffered saline (PBS) as control at 37 ◦C for 30 min. The
mixture of 293T/MERS/EGFP cells and an inhibitor or PBS were added to Huh-7 cells in the wells,
followed by a co-culture at 37 ◦C for 2 h. The 293T/MERS/EGFP cells fused or unfused with Huh-7
cells were fixed with 4% PFA and counted under an inverted fluorescence microscope (Nikon, Tokyo,
Japan). The fused cell showed much larger size and weaker fluorescence intensity than the unfused
cell because of the diffusion of EGFP from one cell to more cells (Figure 1). Almost no fused cells
could be observed in the groups of negative control (PBS+293T/EGFP+Huh-7) or peptide treatment
(HR2P-M2+293T/MERS/EGFP+Huh-7) (Figure 1). The concentration for 50% inhibition (IC50) was
calculated using CalcuSyn software kindly provided by Dr. T.C. Chou [22].
 
Figure 1. Images of Middle East respiratory syndrome coronavirus (MERS-CoV) S protein-mediated
cell–cell fusion. Huh-7 cells were co-cultured with 293T/EGFP cells (left) or 293T/MERS/EGFP cells
in the presence of PBS (middle) or 10 μM HR2P-M2 peptide (right) at 37 ◦C for 2h. The fused cells (one
of the fused cell is indicated by an arrow) and the unfused cells were counted under a fluorescence
microscope. Scale bars, 200 μm.
2.5. Inhibitory Activity of Sera from Mice Treated with m336 Alone, HR2P-M2 Alone, or m336/HR2P-M2 Combined
The animal experiment was performed under ethical guidelines for the care and use of laboratory
animals of Fudan University, and the protocol was approved by the Institutional Laboratory Animal
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Care and Use Committee at Fudan University (approval number 20160927-1, 27 September 2016).
Six-week-old female specific-pathogen-free (SPF) BALB/c mice (bodyweight about 20 g) were divided
into 3 groups of 3 mice each. Mice in group 1, 2, and 3 were intraperitoneally (i.p.) injected with
m336 (0.01 mg in 100 μL PBS) alone, HR2P-M2 (1 mg in 100 μL PBS) alone, and the combination of
m336 (0.01 mg in 100 μL PBS) and HR2P-M2 (1 mg in 100 μL PBS), respectively. Mice were sedated
with Nembutal (100 mg/kg body weight) before and 2 h after injection of the inhibitors, respectively,
and bled retro-orbitally. The blood was centrifuged at 6000 rpm for 10 min after standing at room
temperature for 3 h. The sera were collected and heat-inactivated at 56 ◦C for 30 min. Inhibitory
activity of the inhibitors on MERS-CoV pseudovirus was evaluated in serum as described above.
2.6. Inhibitor Combination Assay
To assess the potential synergistic effect, HR2P-M2 and m336 were mixed at the indicated molar
concentration ratio, while HR2P-M2 alone and m336 alone were included as controls. The mixtures
were serially diluted and tested for their inhibitory activity on MERS-CoV pseudovirus infection as
described above. Each sample was tested in triplicate, and data were analyzed for synergistic effect by
calculating the combination index (CI), using the CalcuSyn program. CI values of <1 and >1 indicate
synergy and antagonism, respectively, and synergy was divided into different strengths, according
to CI values, as follows: <0.1 indicates very strong synergism; 0.1–0.3 indicates strong synergism;
0.3–0.7 indicates synergism; 0.7–0.85 indicates moderate synergism; and 0.85–0.90 indicates slight
synergism [23,24]. Fold of potency enhancement was calculated with the ratio of concentrations of
inhibitor testing alone and in combination.
2.7. Statistical Analysis
To determine the significance of difference in sensitivity between wild-type and mutant viruses to
inhibitors and the inhibitory activity detected in sera from BALB/c mice treated with inhibitors alone
or combination, statistical analyses were performed using a two-tailed unpaired Student’s t-test, using
GraphPad Prism, version 5.0. Values with p < 0.05 and p < 0.01 were considered statistically significant
and very significant, respectively.
3. Results
3.1. Combining HR2P-M2 with m336 Exhibited Strong Synergism against MERS-CoV Pseudovirus Infection
We first investigated the potential cooperative effects of combining HR2P-M2 with m336 on
MERS-CoV pseudovirus infection. In our preliminary study, we found that IC50 values of HR2P-M2
and m336 for inhibiting MERS-CoV pseudovirus infection were about 600 nM and 0.06 nM, respectively.
Therefore, we tested the inhibitory activity of HR2P-M2 alone, m336 alone, and HR2P-M2/m336 in
combination at a molar concentration ratio of 10,000:1, respectively. As shown in Figure 2 and
Table 1, combining HR2P-M2 and m336 resulted in strong synergistic inhibitory activity against
MERS-CoV pseudovirus infection with CI values of 0.13–0.20 for 50–90% inhibition, including potency
enhancement of 12.9- to 18.9-fold for m336 and 8.4- to 12.9-fold for HR2P-M2. This result suggested
that the MERS-CoV fusion inhibitory peptide HR2P-M2 and the MERS-CoV neutralizing mAb m336
could be used in combination to enhance anti-MERS-CoV activity.
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Figure 2. Strong synergism of HR2P-M2 combined with m336 against MERS-CoV pseudovirus infection.
The effective concentrations for inhibiting MERS-CoV pseudovirus infection are plotted in two curves.
The blue curves represent inhibitors used alone, and the red curves represent each inhibitor used in
combination. The width between two curves represents the fold of enhancement between an inhibitor
used alone and in combination.
Table 1. Combination index (CI) and fold of enhancement for inhibiting MERS-CoV pseudovirus
infection by HR2P-M2 (μM) and m336 (nM) tested in combination.
% Inhibition CI
HR2P-M2 m336
Concentration (μM) Fold of Concentration (nM) Fold of
Alone in Mixture Enhancement Alone in Mixture Enhancement
50 0.197 0.574 0.069 8.36 0.066 0.005 12.94
60 0.183 0.874 0.097 9.05 0.099 0.007 13.88
70 0.168 1.381 0.140 9.87 0.155 0.010 14.98
80 0.152 2.415 0.220 10.96 0.268 0.016 16.44
90 0.131 5.598 0.436 12.85 0.610 0.032 18.92
Note: Each sample was tested in triplicate, and the mean values are presented. Ratio of molar concentration of
HR2P-M2 and m336 in combination is 10,000:1.
3.2. Combining HR2P-M2 with m336 Displayed Strong Synergism against MERS-CoV S Protein-Mediated
Cell–Cell Fusion
Next, we tested the potential synergistic activity of the HR2P-M2/m336 combination on
MERS-CoV S protein-mediated cell–cell fusion. We adjusted the molar concentration ratio of HR2P-M2
and m336 in the combination to 4500:1, since the IC50 values of HR2P-M2 and m336 for inhibiting
MERS-CoV S protein-mediated cell–cell fusion in our preliminary studies were about 700 nM and 0.15
nM, respectively. As shown in Figure 3 and Table 2, the combination also exhibited strong synergism
against MERS-CoV S protein-mediated cell–cell fusion (CI = 0.27) with enhancement of 18-fold for
m336 and 4-fold for HR2P-M2. This result confirms that combining HR2P-M2, a MERS-CoV fusion
inhibitor, with m336, a human neutralizing mAb, results in strong synergism on S protein-mediated
membrane fusion because they target the different stages of MERS-CoV fusion and entry processes.
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Figure 3. Strong synergism resulting from the HR2P-M2/m336 combination against MERS-CoV S
protein-mediated cell–cell fusion.
Table 2. Combination index and fold of enhancement for inhibiting MERS-CoV S protein-mediated
cell–cell fusion by the HR2P-M2/m336 combination.
% Inhibition CI
HR2P-M2 m336
Concentration (μM) Fold of Concentration (nM) Fold of
Alone in Mixture Enhancement Alone in Mixture Enhancement
50 0.271 0.511 0.110 4.64 0.440 0.024 17.96
60 0.274 0.713 0.156 4.57 0.625 0.035 18.04
70 0.278 1.025 0.228 4.50 0.918 0.051 18.12
80 0.282 1.596 0.362 4.41 1.466 0.080 18.22
90 0.288 3.106 0.726 4.28 2.965 0.161 18.38
Note: Each sample was tested in triplicate, and the mean values are presented. The molar concentration ratio of
HR2P-M2 and m336 in combination is 4500:1.
3.3. MERS-CoV Pseudoviruses with Mutations in RBD Mutant of MERS-CoV Were Resistant to
RBD-Specific mAb m336, While They Were Equally Sensitive to the HR1-Targeting Peptide HR2P-M2
Du et al. have previously shown that MERS-CoV pseudoviruses with mutations in RBD, such as
D509G and D510G detected in some MERS-CoV strains isolated from different regions and at different
times [17,18], are resistant to the neutralizing activity of an RBD-specific mouse mAb Mersmab1 [16].
In the present study, the sensitivity of pseudotyped MERS-CoV strains with key mutations in RBD,
as identified in some MERS-CoV mutants isolated during the 2012–2015 outbreaks [17], including
D509G, D510G, Q522H, and I529T, along with wild-type MERS-CoV, was compared between the
inhibitory activity of HR2P-M2 peptide alone and m336 neutralizing mAb alone. As shown in Table 3,
the resistance of MERS-CoV mutants to the neutralizing activity of m336 is about 2- to 8-fold, whereas
the pseudoviruses with or without mutations were equally sensitive to fusion inhibitory activity of
HR2P-M2. This result suggested that use of mAb m336 alone is unable to control the infection by
MERS-CoV strains with mutations in RBD.
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Table 3. Sensitivity of MERS-CoV pseudoviruses with or without mutations in the receptor-binding












Wild-type 0.055 ± 0.009 — — 0.553 ± 0.056 — —
D509G 0.116 ± 0.020 2.11 <0.01 0.619 ± 0.079 1.12 >0.05
D510G 0.450 ± 0.085 8.18 <0.05 0.679 ± 0.144 1.23 >0.05
Q522H 0.148 ± 0.051 2.69 <0.01 0.677 ± 0.071 1.22 >0.05
I529T 0.215 ± 0.055 3.91 <0.01 0.574 ± 0.209 1.04 >0.05
Note: Each sample was tested in triplicate. Data are presented as means ± SD. Resistance ratio (RR50) values are
based on IC50 of a mutant strain divided by IC50 of the wild-type stain. The significance of the difference between a
mutant strain and the wild-type strain was statistically analyzed by a two-tailed unpaired Student’s t-test using
GraphPad Prism, version 5.0. Values with p < 0.05 and p < 0.01 were considered statistically significant and very
significant, respectively.
3.4. Combining m336 with HR2P-M2 Exhibited Potent Synergism against MERS-CoV Pseudoviruses with or
without Mutations in RBD or Those in the HR1 Domain
To determine whether the combination of HR2P-M2 and m336 also exhibited synergistic antiviral
activity against infection of MERS-CoV strains with mutations in RBD or in the HR1 domain, we
constructed pseudoviruses bearing MERS-CoV S protein with mutations in RBD, including D509G,
D510G, Q522H, or I529T, and those in the HR1 domain, including Q1020H and Q1020R [25,26]. We
then tested their sensitivity to the inhibition of HR2P-M2 alone, m336 alone, and the HR2P-M2/m336
combination. As shown in Table 4, combining m336 with HR2P-M2 exhibited strong synergism against
infection by pseudotyped MERS-CoV strains with or without mutations in the RBD or HR1 domain
with CI value less than 0.3 and potency enhancement in the range of 6- to 25-fold, suggesting that
this combinational therapy has potential to be further developed for treatment of patients infected by
different MERS-CoV strains, including those with resistance to RBD-specific neutralizing antibodies.
Table 4. Combination index and fold of enhancement for inhibiting MERS-CoV pseudoviruses with or
without mutations in RBD in S1 subunit and HR1 in S2 subunit of MERS-CoV S protein by HR2P-M2
and m336.
HR2P-M2 m336
% Inhibition CI Concentration (μM) Fold of Concentration (μM) Fold of
Alone in Mixture Enhancement Alone in Mixture Enhancement
Wild type
50 0.197 0.574 0.069 8.36 0.066 0.005 12.94
60 0.183 0.874 0.097 9.05 0.099 0.007 13.88
70 0.168 1.381 0.140 9.87 0.155 0.010 14.98
80 0.152 2.415 0.220 10.96 0.268 0.016 16.44
90 0.131 5.598 0.436 12.85 0.610 0.032 18.92
D509G in RBD
50 0.296 0.912 0.155 5.88 0.273 0.034 7.91
60 0.29 1.335 0.217 6.15 0.379 0.048 7.87
70 0.282 2.023 0.313 6.47 0.544 0.070 7.83
80 0.274 3.358 0.489 6.87 0.844 0.109 7.77
90 0.263 7.199 0.956 7.53 1.635 0.213 7.69
D510G in RBD
50 0.137 0.962 0.088 10.96 0.429 0.020 21.96
60 0.145 1.523 0.153 9.96 0.763 0.034 22.43
70 0.155 2.512 0.280 8.97 1.429 0.062 22.97
80 0.169 4.625 0.586 7.90 3.075 0.130 23.63
90 0.194 11.59 1.777 6.52 9.74 0.395 24.67
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Table 4. Cont.
HR2P-M2 m336
% Inhibition CI Concentration (μM) Fold of Concentration (μM) Fold of
Alone in Mixture Enhancement Alone in Mixture Enhancement
Q522H in RBD
50 0.135 0.799 0.045 17.59 0.129 0.010 12.76
60 0.143 1.243 0.067 18.67 0.166 0.015 11.21
70 0.153 2.012 0.101 19.93 0.219 0.022 9.74
80 0.168 3.619 0.168 21.57 0.306 0.037 8.21
90 0.199 8.757 0.36 24.30 0.508 0.08 6.34
I529T in RBD
50 0.256 0.864 0.098 8.81 0.153 0.022 7.03
60 0.242 1.295 0.139 9.32 0.23 0.031 7.45
70 0.227 2.013 0.203 9.90 0.358 0.045 7.92
80 0.211 3.449 0.323 10.67 0.614 0.072 8.55
90 0.188 7.752 0.649 11.94 1.383 0.144 9.58
Q1020H in HR1
50 0.186 0.762 0.086 8.83 0.088 0.006 13.82
60 0.189 0.954 0.106 9.04 0.100 0.008 12.84
70 0.192 1.218 0.131 9.27 0.115 0.010 11.85
80 0.198 1.642 0.172 9.56 0.137 0.013 10.74
90 0.208 2.571 0.257 10.01 0.176 0.019 9.27
Q1020R in HR1
50 0.293 0.69 0.119 5.79 0.073 0.009 8.30
60 0.28 0.905 0.143 6.32 0.087 0.011 8.19
70 0.268 1.216 0.175 6.95 0.104 0.013 8.06
80 0.254 1.743 0.223 7.80 0.131 0.017 7.92
90 0.238 2.997 0.323 9.29 0.184 0.024 7.70
Note: The molar concentration ratio of HR2P-M2 and m336 in combination against wildtype virus, viruses with
mutations in RBD, and those in HR1 is 10,000:1, 4500:1, and 10,000:1, respectively.
3.5. Sera from Mice Treated with the m336/HR2P-M2 Combination Showed More Efficacy in Inhibiting
MERS-CoV Pseudovirus Infection than Either HR2P-M2 or m336 Alone
To determine whether the HR2P-M2/m336 combination could sustain its efficacy in vivo
compared to HR2P-M2 or m336 alone, we tested the anti-MERS-CoV pseudovirus activity of the
inhibitors in sera of mice treated with i.p. injection of HR2P-M2, m336, and the HR2P-M2/m336
combination, respectively. As shown in Figure 4, the inhibitory activity detected in sera from mice
treated with HR2P-M2 or m336 alone was significantly higher than that detected in sera from mice
before inhibition of any inhibitor. On the other hand, the anti-MERS-CoV activity detected in sera from
mice treated with the HR2P-M2/m336 combination was significantly more potent than that detected
in sera of mice administered with HR2P-M2 or m336 alone. This result confirms that combining
HR2P-M2 with m336 affords synergism against MERS-CoV S infection, both in vitro and in vivo.
Figure 4. MERS-CoV pseudovirus inhibitory activity as determined from sera of BALB/c mice treated
with m336 (0.01 mg) alone, HR2P-M2 (1 mg) alone, or m336 (0.01 mg)/HR2P-M2 (1 mg) in combination.
Data are presented as means ± SD. **, and *** represent p < 0.01, and p < 0.001, respectively.
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4. Discussion
The high mortality of MERS-CoV-infected patients [27–29] calls for the development of highly
effective anti-MERS-CoV therapeutics. Although we and others have previously identified a
MERS-CoV fusion inhibitory peptide (HR2P-M2) targeting the MERS-CoV S2 protein HR1 domain and
a highly potent human neutralizing mAb (m336) targeting the MERS-CoV S1 protein RBD [10,26,30],
their further development is limited by low potency in the case of HR2P-M2 and low efficacy to
neutralize MERS-CoV strains with RBD mutations in the case of m336 [10,31–33].
The combinatorial use of drugs with different mechanisms of action, i.e., cocktail regimen, has
been widely applied in clinics [22]. For example, the combinatorial use of HIV reverse transcriptase
(RT) inhibitors and protease inhibitors, known as highly active anti-retrovirus therapy (HAART), has
shown significant synergism in inhibiting HIV-1 infection, reducing adverse effects and delaying the
emergence of drug resistance, thus extending the lifespan of millions of HIV/AIDS patients [34–36].
Moreover, we previously showed that combining HIV-1 attachment inhibitors with RT inhibitors, or
combining the 1st, 2nd, and/or 3rd generation HIV fusion inhibitors that target different sites in the
HIV-1 gp41 HR1 domain, exhibited synergistic and complementary effect against infection by a broad
spectrum of HIV-1 strains, including those resistant to HIV attachment inhibitors, fusion inhibitors,
and RT inhibitors [37–39].
In this study, we compared the anti-MERS-CoV activity of HR2P-M2 alone and m336 alone with
that of HR2P-M2/m336 in combination and found that the inhibitory activity of the HR2P-M2/m336
combination was significantly more potent than either one administered alone against MERS-CoV
S protein-mediated cell–cell fusion and MERS-CoV pseudovirus infection, suggesting synergistic
activity based on the dual mechanisms of action whereby HR2P-M2 targets the S2 subunit HR1 domain
for inhibiting S2-mediated virus–cell or cell–cell fusion [5] and m336 targets the S1 subunit RBD for
inhibiting virus–cell binding or virus attachment [10]. It has been well known that drug synergism can
be expected when drugs that act by different mechanisms of action are mixed together [22]. While
MERS-CoV pseudoviruses with mutations in RBD were resistant to the RBD-specific mAb m336, they
were equally sensitive to HR1-targeting peptide HR2P-M2. Notably, however, the HR2P-M2/m336
combination exhibited strong synergistic antiviral activity against all pseudotyped MERS-CoV strains,
including those with mutations in RBD of S protein, which are even resistant to an RBD-specific mouse
mAb Mersmab1 [16]. We also demonstrated that sera from mice treated with the HR2P-M2/m336
combination revealed significant efficacy in inhibiting MERS-CoV pseudovirus infection compared to
HR2P-M2 or m336 alone. Collectively, these results suggest that the combinatorial strategy overcomes
the weaknesses of HR2P-M2 peptide and m336 mAb, while, at the same time, takes advantage of the
unique mechanism of action of each to provide, by the sum of both, much more effective inhibitory
activity against MERS-CoV infection than either peptide or mAb used alone. The strong synergy of
the combination is expected to reduce the dosage of the individual inhibitor in such combinational
therapy, resulting in decreased cost and toxicity, thus making the final product more affordable and
safer. Therefore, this combinational therapy shows promise for further clinical development.
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Abstract: Middle East respiratory syndrome coronavirus (MERS-CoV) is a highly pathogenic virus
with a crude mortality rate of ~35%. Previously, we established a human DPP4 transgenic (hDPP4-Tg)
mouse model in which we studied complement overactivation-induced immunopathogenesis. Here,
to better understand the pathogenesis of MERS-CoV, we studied the role of pyroptosis in THP-1
cells and hDPP4 Tg mice with MERS-CoV infection. We found that MERS-CoV infection induced
pyroptosis and over-activation of complement in human macrophages. The hDPP4-Tg mice infected
with MERS-CoV overexpressed caspase-1 in the spleen and showed high IL-1β levels in serum,
suggesting that pyroptosis occurred after infection. However, when the C5a-C5aR1 axis was blocked
by an anti-C5aR1 antibody (Ab), expression of caspase-1 and IL-1β fell. These data indicate that
MERS-CoV infection induces overactivation of complement, which may contribute to pyroptosis and
inflammation. Pyroptosis and inflammation were suppressed by inhibiting C5aR1. These results will
further our understanding of the pathogenesis of MERS-CoV infection.
Keywords: MERS-CoV; inflammation; pyroptosis; complement
1. Introduction
Middle East respiratory syndrome coronavirus (MERS-CoV), the second highly pathogenic
coronavirus to emerge after severe acute respiratory syndrome coronavirus (SARS-CoV), causes
severe acute respiratory failure and extra-pulmonary multi-organ damage accompanied by severe
systemic inflammation [1–3]. However, the pathogenesis of MERS-CoV still needs to be explored.
Complement activation and pyroptosis are two proteolytic cascades that defend the host against
dangerous pathogens. They are important parts of the innate immune system and have some similar
characteristics, including pore-formation and proinflammatory characteristics.
Pyroptosis is a lytic and inflammatory mode of regulated cell death catalyzed by the caspase
family [4]. Activation of caspase-1 relies on assembly of inflammasome complexes, which
contain NLRP1b, NLRC4, NLRP3, and AIM2. Different inflammasomes are activated by different
pathogen-associated molecular patterns (PAMPs) or danger-associated molecular patterns (DAMPs)
via particular pattern recognition receptors (PRRs). The best-characterized inflammasome is the
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NLRP3 inflammasome, which responds to a variety of bacterial, viral, and fungal agents [5,6], DAMPs
(e.g., ATP, monosodium urate crystals, and amyloid-β aggregates) [7,8], and even environmental
and industrial particles such as silica and asbestos [9]. The NLRP3 inflammasome comprises the
NLRP3 scaffold, the ASC (PYCARD) adaptor, and pro-caspase-1. The activated NLRP3 inflammasome
promotes transformation of pro-caspase-1 to its active form, which proteolytically cleaves gasdermin D,
pro-IL-1β, and pro-IL-18 to yield their bioactive forms. The N-terminal domain of cleaved gasdermin
D perforates the cell membrane, resulting in osmotic lysis [10], whereas mature IL-1β and IL-18 act as
proinflammatory cytokines [11].
The complement system is an ancient molecular cascade; indeed, homologs have been found
in sea urchin [12] and mosquitoes [13]. Complement is activated via three pathways: the classical,
lectin, and alternative pathways. During the process of activation, an enzyme named C3 convertase
cleaves C3 to C3a and C3b, which are recruited to the C3 convertase to form the C5 convertase. C5
convertase catalyzes cleavage of C5 to C5a and C5b to initiate the terminal complement pathway,
resulting in formation of the membrane attack complex, which has pore-forming properties. During
this process, two split products, C3a and C5a (known as anaphylatoxins), promote inflammation or
serve as chemoattractants by engaging their cognate receptors [14,15].
In a previous study we demonstrated that aberrant complement activation contributes to severe
outcomes in hDPP4 transgenic mice infected with MERS-CoV, and that preventing over-activation
of the complement system may be an effective clinical therapy for MERS [16]. Here, we examined
the role of pyroptosis in the pathogenesis of MERS, along with the relationship between pyroptosis
and complement. The results may help us to better understand the mechanism underlying severe
outcomes after MERS-CoV infection.
2. Materials and Methods
2.1. Ethics Statement
All animal experiments were approved by the Institutional Animal Care and Use Committee
(IACUC) of the Beijing Institute of Microbiology and Epidemiology (IACUC Permit No: BIME
2017-0011; Permit Date: 8 March 2017). Animal studies were carried out in strict accordance with the
recommendations set out in the Guide for the Care and Use of Laboratory Animals.
2.2. Cells
Human monocytic cells (THP-1) were purchased from the American Type Culture Collection
(Manassas, VA, USA, ATCC Number: TIB-202) and cultured in RPMI 1640 medium supplemented
with 10% heat-inactivated fetal bovine serum (FBS), 100 U/mL penicillin, 100 μg/mL streptomycin
sulfate, 1× Glutamax-I (L-glutamine alternate), and 0.05 mM 2-mercaptoethanol. THP-1 (differentiated)
macrophages were obtained by exposing the cells to 60 nM phorbol-12-myristate-13-acetate (PMA) for
12 h, followed by culture for a further 24 h in complete growth medium without PMA.
2.3. Virus Infection
MERS-CoV (HCoV-EMC/2012 strain) was propagated and titrated on Vero cells in an approved
biosafety level 3 laboratory. THP-1 differentiated macrophages cultured in 75-cm2 flasks were infected
with MERS-CoV at a multiplicity of infection of 0.1. The virus was adsorbed at 37 ◦C for 1 h and
unbound virus was washed away.
HDPP4-Tg mice (6 weeks old, female) [17] were maintained in a pathogen-free facility and housed
in cages containing sterilized feed and drinking water. Following intraperitoneal anesthetization with
sodium pentobarbital (5 mg/kg body weight), mice were inoculated intranasally with MERS-CoV
(103.3 50% tissue culture infectious dose (TCID50)) in 20 μL Dulbecco’s modified Eagle’s medium
(DMEM). Mice in the sham group received the same volume of DMEM. For the experiments of C5aR1
inhibition, mice were received an intravenous (i.v.) injection (600 μg/kg) of a monoclonal Ab (mAb)
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specific for mouse C5aR1 (Hycult Biotech, Uden, the Netherlands) to block the interaction of C5a to
C5aR1 or an injection of phosphate-buffered saline (PBS) (sham treatment control) at the same time
as MERS-CoV inoculation. All infectious experiments related to MERS-CoV were performed in an
approved biosafety level 3 facility.
2.4. Isolation of RNA and Proteins
THP-1 differentiated macrophages were lysed in TRIzol™ Reagent (Life Technologies, Carlsbad,
CA, USA) at 24 h post-infection with MERS-CoV. Total RNA and proteins were isolated according to
the reagent user guide.
Mice were euthanized by overdose inhalation of carbon dioxide at different time points after
infection with MERS-CoV. Lungs were harvested and total RNA was extracted and purified using an
RNeasy Extraction Kit (Qiagen, Hilden, Germany).
2.5. Quantitative Reverse Transcription-PCR
To detect expression of inflammasomes and complement components in MERS-CoV-infected
THP-1 differentiated macrophages and hDPP4-Tg mice, 2 μg of total RNA from cells or the lung of
mice we used as template for first-strand cDNA synthesis. The resulting cDNA was subjected to
quantitative PCR using Power SYBR® Green PCR Master Mix (Life Technologies, Carlsbad, CA, USA)
to determine the relative abundance of inflammasome and complement components. The forward and
reverse primers used for each component are listed in the Table 1. The relative amount of each gene
was obtained by normalization against an endogenous control gene (GAPDH) and calculated using
the comparative 2−ΔΔCT method. Sham-infected monocytes and sham-infected hDPP4-Tg mice were
used as respective calibrators. An identical amplification reaction comprising (i) polymerase activation
and DNA denaturation at 95 ◦C for 10 min, (ii) 40 cycles each of the denaturation at 95 ◦C for 10 s, and
(iii) an annealing/extension step at 60 ◦C for 30 s, was used for each gene analyzed.
Table 1. Primers used to amplify inflammasome and complement components.































2.6. Western Blot Analysis
Proteins isolated from THP-1 monocytic cells and THP-1 differentiated macrophages were
electrophoresed in a 12% SDS-PAGE gel and transferred to a PVDF membrane (GE Healthcare,
Dassel, Germany). PVDF membranes were then blocked for 1 h at room temperature in 5% non-fat
milk. Membranes were incubated overnight at 4 ◦C with primary antibodies, followed by secondary
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antibodies for 1 h at room temperature. The primary antibodies used for analysis were: mouse
anti-caspase 1 (1:200; Santa Cruz Biotechnology, Cat: sc-392736, Santa Cruz, CA, USA), mouse
anti-IL-1β (1:200; Santa Cruz Biotechnology, Cat: sc-32294), rabbit anti-cleaved IL-1β (1:2000; Cell
Signaling, Cat: #83186, Danvers, MA, USA), rabbit anti-MERS-CoV Nucleocapsid Protein (1:2000; Sino
Biological Inc., Cat: 40068-RP02, Beijing, China), and rabbit anti-β-actin (1:2000; Cell Signaling, Cat:
#4970). The secondary antibody was anti-rabbit secondary (1:5000; TransGen, Cat: HS101-01, Beijing,
China) or anti-mouse secondary (1:5000; TransGen Cat: HS201-01). Blots were developed using a
Pierce ECL Western Blotting Substrate (Thermo Scientific, Waltham, MA, USA) and protein bands
were detected using an Amersham Imager 600 (GE Healthcare, Chicago, IL, USA).
2.7. Analysis of Inflammatory Cytokines
Cytokines in mouse serum were measured using a Milliplex Mouse Cytokine/Chemokine
Magnetic Panel Kit (Merck Millipore, Burlington, MA, USA). A panel of inflammatory cytokines
(IL-1β, IL-6, TNF-α, and IFN-γ) was detected according to the manufacturer’s protocol.
2.8. Immunohistochemistry (IHC)
Sections of paraffin-embedded spleen and lung tissues (4 μm thick) were prepared and stained
to detect antigen expression. Briefly, retrieved sections were incubated overnight at 4 ◦C with the
following antibodies: mouse anti-caspase-1 mAb (AdipoGen, San Diego, CA, USA), polyclonal rabbit
anti-CD68 (Abcam, Cambridge, MA, USA), and polyclonal anti-IFN-γRα (Santa Cruz Biotechnology).
Biotinylated immunoglobulin G was then added, followed by an avidin–biotin–peroxidase conjugate
(Beijing Zhongshan Biotechnology Co., Ltd., Beijing, China). Immunoreactivity was detected using
3,3′ diamino benzidine (DAB). Slides were counter-stained with hematoxylin.
2.9. Statistical Analysis
Statistical analyses were performed using GraphPad Prism software, version 5.01 (GraphPad
Software, San Diego, CA, USA). Student’s t test was used to compare two groups with respect to
relative expression of mRNA and cytokine levels in serum. p values < 0.05 were considered significant.
3. Results
3.1. MERS-CoV Infection Induced Pyroptosis in THP-1 Macrophages
Unlike abortive infection of SARS-CoV in human macrophages, MERS-CoV can establish a
productive infection in macrophages and induce production of proinflammatory cytokines and
chemokines [18]. Many RNA viruses, such as EV71, H1N1, H7N9 influenza A virus, and Zika
virus, can infect macrophages and trigger IL-1β secretion via the NLRP3 inflammasome [19–22].
To evaluate the response of macrophages to MERS-CoV infection, we inoculated THP-1 monocytic
cells and THP-1 differentiated macrophages with MERS-CoV or RPMI 1640 medium (sham-infection).
We then examined expression of NLRP3, pro-caspase-1, and pro-IL-1β 24 h later by RT-qPCR. As shown
in Figure 1, MERS-CoV infection induced relatively higher expression of pro-caspase-1 (Figure 1A)
and pro-IL-1β (Figure 1B), but not NLRP3 (Figure 1C), in both THP-1 monocytes and macrophages.
Expression of pro-IL-1β in monocytes increased by 170-fold, whereas that in macrophages increased
by 26-fold (on average).
We verified expression of caspase-1, IL-1β, and MERS nucleocapsid protein (NP) by Western
blotting (Figure 1D). MERS-CoV-infected THP-1 macrophages expressed higher levels of pro-caspase-1,
pro-IL-1β, and activated IL-1β (p17) than sham-infected THP-1 macrophages or MERS-CoV-infected
THP-1 monocytes. MERS NP was detected in both MERS-CoV-infected THP-1 monocytes and
macrophages. These results indicate that MERS-CoV infection induces high levels of proinflammatory
IL-1β secretion and THP-1 macrophage pyroptosis.
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Figure 1. MERS-CoV infection induces pyroptosis in THP-1 macrophages. THP-1 monocytes and
macrophages were infected with MERS-CoV for 24 h. Total RNA and protein was then extracted
from the cells using TRIzol Reagent. (A–C) Total RNA was used for RT-qPCR to detect transcription
of pro-caspase-1, pro-IL-1β, and NLRP3. Data are expressed as means ± SEM (n = 2 per group).
(D) Samples of total protein were subjected to Western blotting to detect pro-caspase-1, pro-IL-1β,
activated IL-1β, and MERS NP.
3.2. Pyroptosis in Mice Infected with MERS-CoV
To determine whether MERS-CoV infection induces pyroptosis in mice, we used RT-qPCR to
detect mRNA encoding NLRP3, pro-caspase-1, and pro-IL-1β in lung tissue from hDPP4 transgenic
mice at Day 3 post-MERS-CoV infection. Although there was no significant difference in expression of
NLRP3 and pro-caspase-1 between the sham-infected and MERS-CoV-infected groups (Figure 2A,B),
expression of pro-IL-1β mRNA was significantly higher after MERS-CoV infection (Figure 2C).
In addition, we measured the concentration of IL-1β in serum. The results showed that MERS-CoV
infection induced production of IL-1β (Figure 2D). Furthermore, we examined expression of caspase-1
in the lung and spleen at Day 7 post-MERS-CoV infection by IHC. In line with the mRNA results,
there was no significant difference in expression of caspase-1 in the lung of sham-infected and
MERS-CoV-infected mice. However, the spleens of mice infected with MERS-CoV showed higher
expression of caspase-1 than those of mice in the sham group (Figure 2E). The results indicated that
MERS-CoV infection could induce pyroptosis in mice.
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Figure 2. MERS-CoV infection induces pyroptosis in hDPP4-transgenic mice. (A–C) Transcription of
NLRP3, pro-caspase-1, and pro-IL-1β in lung tissue at Day 3 post-MERS-CoV infection (n = 5–6 per
group). (D) Concentration of IL-1β in serum at Day 3 post-MERS-CoV infection. Data are expressed
as means ± SEM (n = 5–6 per group). * p < 0.05, ** p < 0.01 (Student’s t test with Welch’s correction).
(E) Representative images of immunohistochemical staining of caspase-1 in lung tissue on Day 7
post-challenge of sham-infected and MERS-CoV-infected mice (scale bars = 100 μm).
3.3. Inflammatory Responses in Mice Infected with MERS-CoV
IL-1β plays an important role in mediating autoinflammatory diseases and in generating
inflammatory responses to infection [23]. Therefore, to assess the inflammatory responses in mice,
we measured TNF-α, IFN-γ, and IL-6 in serum at Day 3 post-MERS-CoV infection. As shown in
Figure 3A–C, serum from mice in the MERS-CoV-infected group contained more TNF-α, IFN-γ, and
IL-6 than that from sham-infected mice. IHC examination of CD68 and IFN-γ receptor expression
also suggested greater macrophage infiltration and activation in the lung and spleen of mice at 7 days
post-MERS-CoV infection (Figure 3D). These results indicate that MERS-CoV infection causes systemic
inflammation, as reported in clinical MERS patients and MERS-CoV infected animal models [17,24].
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Figure 3. MERS-CoV infection induces systemic inflammation in hDPP4-transgenic mice. (A–C)
Concentration of TNF-α, IFN-γ, and IL-6 in serum at Day 3 post-MERS-CoV infection. Data are
expressed as means ± SEM (n = 5–6 per group). * p < 0.05, ** p < 0.01 (Student’s t test with
Welch’s correction). (D) Macrophage infiltration and expression of IFN-γ receptor were assessed
by immunohistochemical staining of lung and spleen at 7 days post-challenge (scale bars = 100 μm).
3.4. MERS-CoV Infection Alters Expression of Complement in THP-1 Monocytes and Macrophages
The complement system links activation of Toll-like receptors to transcription of IL-1β
mRNA [25,26]. It has been studied that intracellular C3 is converted to biologically active C3a and C3b
by the protease cathepsin L [27], and C3a activates NLRP3 and triggers IL-1β production in human
monocytes by regulating efflux of ATP [28]. In addition, C5a is believed to induce a proinflammatory
or anti-inflammatory response when ligated to C5aR1 or C5aR2 respectively [29–31]. Thus, we used
RT-qPCR to examine expression of complement components and their receptors C3aR, C5aR1, and
C5aR2. As shown in Figure 4, C3 and C3aR expression by both THP-1 monocytes and macrophages
was highly upregulated (by 5–20-fold) after MERS-CoV infection. C5aR1 was upregulated, whereas
C5aR2 was downregulated, after MERS-CoV infection.
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Figure 4. MERS-CoV infection alters complement expression in monocytes and macrophages. (A–D)
Transcription of C3, C3aR, C5aR1, and C5aR2 in THP-1 monocytes and macrophages at 24 h
post-MERS-CoV infection. Data are expressed as means ± SEM (n = 2 per group).
3.5. Inhibiting C5aR1 Reduces Pyroptosis in Mice Infected with MERS-CoV
Our previous study demonstrated that MERS-CoV infection results in dysregulated host immune
responses and severe tissue damage [17] and inhibiting C5aR1 alleviates MERS-CoV infection-induced
tissue damage by regulating host immune responses [16]. Here, we used an anti-C5aR1 Ab to block
the C5a-C5aR1 axis. The antibody was administered at the same time as MERS-CoV infection. We then
measured expression of caspase-1 in the spleen and IL-1β in the lung and serum. Compared with the
PBS-treated group, mice receiving the anti-C5aR1 Ab expressed less caspase-1 in the spleen at Day 7
post-MERS-CoV infection (Figure 5A). Although there was no significant difference between the two
groups with respect to pro-IL-1β mRNA expression (Figure 5B), serum levels of IL-1β were lower in
the anti-C5aR1 Ab-treated group than in the PBS-treated group at Day 1 (Figure 5C) and Day 3 [16]
post-MERS-CoV infection. These results suggest that complement inhibition decreased the expression
of pyroptosis indicators, IL-1β and caspase-1, in mice infected with MERS-CoV.
Figure 5. Blocking the C5a-C5aR1 axis reduces pyroptosis in hDPP4-transgenic mice. (A) Representative
images of immunohistochemical staining of caspase-1 in lungs from PBS-treated and anti-C5aR1
Ab-treated groups on Day 7 post-challenge (scale bars = 100 μm). (B) Transcription of pro-IL-1β
in lung tissues from PBS-treated and anti-C5aR1 Ab-treated groups at Day 7 post-infection (n = 4–5 per
group). (C) Concentration of IL-1β in serum at Day 1 post-MERS-CoV infection. Data are expressed as
means ± SEM (n = 4–5 per group). ** p < 0.01 (Student’s t test with Welch’s correction).
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3.6. Inhibiting C5aR1 Reduces Inflammation in Mice Infected with MERS-CoV
At 1 day after MERS-CoV infection, we measured proinflammatory cytokines (IFN-γ, TNF-α,
and IL-6) in serum. IFN-γ levels in mice treated with the anti-C5aR1 Ab were much lower than those
in the PBS-treated group (Figure 6A). To further evaluate the effect of complement inhibition on the
local inflammation at later time after MERS-CoV infection, we examined expression of CD68 and
IFN-γ receptor in lung and spleen at 7 days post-MERS-CoV infection. IHC revealed that macrophage
infiltration and activation were lower in the anti-C5aR1 Ab-treated group (Figure 6D). Taken together,
these results suggest that inhibiting complement dampens the over-activated inflammatory response
in mice infected with MERS-CoV.
Figure 6. Blockade of the C5a-C5aR1 axis reduces pyroptosis in hDPP4-transgenic mice.
(A–C) Concentration of IFN-γ, TNF-α, and IL-6 in serum at Day 1 post-MERS-CoV infection. Data are
expressed as means ± SEM (n = 4–5 per group). * p < 0.05 (Student’s t test with Welch’s correction).
(D) Infiltration of the lungs and spleen by macrophages and expression of IFN-γ receptor were assessed
by immunohistochemical staining 7 days after challenge (scale bars = 100 μm).
4. Discussion
Macrophages play important roles in host defense by clearing dead cells, ingesting and destroying
microbes, and presenting antigens to T lymphocytes. In addition, macrophages produce the full
array of complement components [32] and PRRs, which are closely associated with inflammasome
activation and pyroptosis. The accumulated studies indicate that macrophages play an important
role in the pathogenesis of SARS and MERS [18,33]. Macrophages infected with MERS-CoV secrete
proinflammatory cytokines and chemokines [18]. Widespread distribution of these macrophages
throughout many organs is one of the reasons underlying multi-organ damage and systemic
inflammation after virus infection. Pyroptosis or inflammasome activation plays an important role
in virus-mediated pathogenesis. For example, abortive HIV-1 infection in quiescent lymphoid CD4
T cells leads to CD4 T cell pyroptosis independent of the NLRP3 inflammasome [34]. EV71 3D and
ZIKV NS5 activate the NLRP3 inflammasome by interacting with NACHT and the LRR domain of
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NLRP3 [19,22]. The PB1-F2 protein of avian influenza A virus H1N1 or H7N9 induces inflammation
by activating the NLRP3 inflammasome [35,36], and deficiency of NLRP3 or caspase-1 protects mice
against H7N9 infection-associated morbidity and mortality [21]. Here, we demonstrate that the
dysregulated macrophage-mediated immune responses after MERS-CoV infection may contribute to a
severe outcome.
Several studies demonstrate relationships between complement and inflammasomes. For example,
C3-/- mice display reduced inflammasome activation in an intracerebral hemorrhage (ICH) model [37].
Engagement of C5a and C5aR1 on CD4+ T cells generates reactive oxygen species, which are a
classical DAMP, thereby triggering inflammasome assembly [38]. In monocytes, C3a alters metabolic
programming and increases ATP efflux, leading to NLRP3 activation and IL-1β generation via the
receptor P2 × 7 [28]. Thus, the complement system is considered to be an essential regulatory
component of the cellular alarm system that controls inflammasome activation [39]. Here, we inhibit
MERS-CoV infection-induced inflammation and pyroptosis by blocking the C5a-C5aR1 axis with an
anti-C5aR1 antibody.
In our study, we first demonstrated that virus infection leads to pyroptosis by measuring activation
of caspase-1 and IL-1β in human macrophages infected with MERS-CoV (Figure 1). Next, we found
that MERS-CoV infection induced transcription of pro-IL-1β in the lung and expression of caspase-1
in the spleen. Activated caspase-1 could be released into the extracellular space and delivered to the
lung via exosomes [40] or the systemic circulation; it then cleaves pro-IL-1β into its bio-activated form,
which is secreted into the serum (Figure 2D). We cannot exclude the possibility that pyroptosis occurs
in the spleen because we did not detect expression of pro-IL-1β. Meanwhile, examination of CD68 and
IFN-γ receptor expression revealed macrophage infiltration and activation in the lungs and spleen
(Figure 3D). Thus, pyroptosis could occur in both organs.
In our previous study, we showed that inhibiting C5aR1 increased splenic cell regeneration and
decreased splenic cell apoptosis, thereby alleviating MERS-CoV infection-induced tissue damage [16].
The spleen happens to be a large reservoir for myeloid lineage cells such as macrophages, dendritic cells
and CD4+ T cells in which pyroptosis mainly occurred [4,34,41]. Here, we studied and demonstrated
that inhibiting C5aR1 suppressed caspase-1 activation (Figure 5A) and macrophage infiltration and
activation in the spleen (Figure 6D), and thereby reduced the secretion of IL-1β into the serum
(Figure 5C) and the systemic inflammation (Figure 6). However, in the lung tissue, there was no
significant difference of pro-IL-1β transcription between the Ab and sham-treated groups (Figure 5B),
which may due to the limited macrophages, the main cell type in which pyroptosis occurred, when
compared to that in spleen.
Although many studies have focused on the link between complement and pyroptosis, the
pathways that link them remain unclear. Here, our results showed that MERS-CoV infection induces
pro-IL-1β transcription, and complement activation, which leads to pyroptosis in macrophages.
Induction of pyroptosis was related with complement activation and may be promoted by ligation of
C5a and C5aR1, which was confirmed by the blockade of anti-C5aR1 antibody (Figure 7).
In summary, these data indicate that MERS-CoV infection induces overactivation of complement,
which may contribute to pyroptosis and inflammation. Pyroptosis and inflammation were suppressed
by inhibiting C5aR1. These research will further our understanding of the pathogenesis of
MERS-CoV infection.
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Figure 7. Diagram illustrating the relationship between complement and pyroptosis during MERS-CoV
infection. MERS-CoV infection induces activation of complement and transcription of pro-IL-1β.
Activated complement component C5a is released into the extracellular space where it interacts with
C5aR1, which triggers assembly of the NLRP3 inflammasome. Activated caspase-1 cleaves pro-IL-1β
into its active form thereby triggering pyroptosis. An anti-C5aR1 antibody prevents interaction between
C5a and C5aR1, thereby ameliorating pyroptosis.
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Abstract: Middle East respiratory syndrome coronavirus (MERS-CoV) with potential to cause global
pandemics remains a threat to the public health, security, and economy. In this review, we focus
on advances in the research and development of small-molecule MERS-CoV inhibitors targeting
different stages of the MERS-CoV life cycle, aiming to prevent or treat MERS-CoV infection.
Keywords: MERS-CoV; mechanism of action; small-molecule inhibitor
1. Introduction
Middle East respiratory syndrome coronavirus (MERS-CoV) has posed a serious threat to public
health worldwide because it can cause severe respiratory disease in humans with high mortality (about
36%) [1]. As of 27 November 2018, a total of 2266 human MERS-CoV infections with 804 deaths had
been reported from 27 countries in the Middle East, North Africa, Europe, Asia, and North America to
the World Health Organization (WHO), with 83% reported by the Kingdom of Saudi Arabia (Figure 1)
(https://www.who.int/emergencies/mers-cov/en/).
Phylogenetic and sequencing data strongly suggest that MERS-CoV belongs to the C-lineage
of the genus betacoronavirus, the first known lineage C betacoronavirus associated with human
infections [2]. The clinical features of MERS-CoV infection range from asymptomatic infection to
rapidly progressive acute hypoxemic respiratory failure and extrapulmonary organ dysfunction [3–5].
At present, no effective vaccine or therapeutics are available for the prevention or treatment of
MERS-CoV infection [6–8]. However, many basic and clinical studies on anti-MERS-CoV agents
have been completed or are ongoing. In this review, we focus on current progress in the research
and development of small-molecule MERS-CoV inhibitors, either peptides or compounds, targeting
different stages of the MERS-CoV life cycle, aiming to prevent or treat MERS-CoV infection.
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Figure 1. Summary of morbidity statistics with country- and quarter-level panel data.
2. MERS-CoV Life Cycle and Potential Targets for the Development of Small-Molecule Inhibitors
Against MERS-CoV Infection
MERS-CoV enters host cells through two pathways. The first involves plasma membrane
fusion, which relies on spike (S) protein activation by secreted or surface proteases, such as the
transmembrane protease serine 2 (TMPRSS2) and the human airway trypsin-like protease (HAT).
The second involves endosomal membrane fusion, in which spike protein activation is facilitated by
the pH-dependent endosomal protease cathepsin L (CTSL) [9,10]. The spike protein plays a key role
in MERS-CoV attachment to host cells and virus-cell membrane fusion [11]. It contains 1353 amino
acids within the viral envelope in trimeric state [12]. Spike protein consists of S1 and S2 subunits.
The S1 subunit contains the receptor binding domain (RBD), while the S2 subunit contains the fusion
peptide (FP), a long heptad repeat 1 domain (HR1) and a short heptad repeat 2 domain (HR2) [13,14].
MERS-CoV enters the host cell by binding the viral particle via the RBD in spike protein to the cellular
receptor dipeptidyl peptidase-4 (DPP4) on the surface of the host cell [12,15]. Then, S2 changes its
conformation and inserts its FP into the plasma membrane, or the endosomal membrane if the virion
is in the endosome. The HR2 binds to the HR1 to form a six-helix bundle (6-HB) fusion core, which
brings viral and cell membranes into close apposition for fusion [14,16,17]. During this process, RBD,
DPP4, HR1, HR2, and the related proteases, e.g., HAT and TMPRSS2, can all serve as targets for the
development of MERS-CoV fusion/entry inhibitors.
After MERS-CoV entry into the host’s cells, the positive RNA genome is translated in the
cytoplasm. The genome can be translated into two polyproteins: ppla and pplb, which are cleaved into
16 nonstructural proteins by PLpro (papain-like protease) and 3CLpro (3-chymotrypsin-like protease).
Hence, the proteases that are critically important for MERS-CoV replication can also be considered as
targets for developing MERS-CoV replication inhibitors. However, information about the enzymes
required for producing more genome copies and subgenomic mRNA for virus replication is limited.
Then, the RNA genome and structural proteins are packaged into viral particles in host cells, and
the progeny virus particles are finally released from host cells (Figure 2). Although these steps can
also be used as targets for the development of MERS-CoV maturation-and-release inhibitors, no such
inhibitors have been reported so far.
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Figure 2. Schematic diagram of Middle East respiratory syndrome coronavirus (MERS-CoV) infection.
MERS-CoV enters host cells by plasma membrane fusion (membrane fusion) or endosomal membrane
fusion (endocytosis), and then releases the viral RNA into the cytoplasm. The RNA genome is replicated
and viral proteins are produced. The progeny virus is generated and released from the infected cells.
3. Current Small-Molecule Inhibitors Against MERS-CoV Infection and Their Mechanisms
of Action
3.1. MERS-CoV Entry Inhibitors
MERS-CoV S protein plays a key role in mediating virus entry into host target cells. This process
includes binding to host receptors, viral fusion, and final entry into host cells. MERS-CoV pseudovirus
expressing S protein, which allows for single-cycle infection in cells expressing receptor DPP4, can be
used for screening MERS-CoV fusion/entry inhibitors.
HR2P, spanning residues 1251–1286 in the HR2 domain, with low or no toxic effect in vitro,
can effectively inhibit MERS-CoV replication by interacting with the HR1 domain to block spike
protein-mediated cell–cell fusion and MERS-CoV pseudovirus entry (Table 1; Figure 3) [16]. To increase
its stability, solubility, and anti-MERS-CoV activity, Lu et al. introduced a Glu, Lys, or Arg residue
into HR2P, generating a new peptide, HR2P-M2 (Table 1). HR2P-M2 was indeed found to be more
stable and soluble than HR2P. It blocked fusion core formation between HR1 and HR2 peptides by
binding to the viral S protein HR1 domain and inhibiting S protein-mediated membrane fusion with
an EC50 of 0.55 μM (Figure 4) [16,23]. HR2P-M2 is highly effective in inhibiting MERS-CoV infection
in both Calu-3 and Vero cells with an EC50 of about 0.6 μM. Intranasal application of HR2P-M2 could
significantly reduce the titers of MERS-CoV in the lung of Ad5-hDPP4 (adenovirus serotype-5–human
dipeptidyl peptidase 4)-transduced mice [16,18]. Furthermore, intranasal administration of HR2P-M2
before viral challenge fully protected hDPP4-transgenic mice from MERS-CoV infection, whereas all
untreated mice died 8 days after viral challenge [24]. Furthermore, by combining HR2P-M2 with
interferon β, protection was enhanced for Ad5-hDPP4-transduced mice against infection by MERS-CoV
strains with or without mutations in the HR1 region of the S protein, with >1000-fold reduction of viral
titers in lung [18].
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Figure 3. Schematic representation of MERS-CoV S (spike) protein S1 subunit and S2 subunit. RBD,
receptor binding domain; FP, fusion peptide; HR1, heptad repeat 1 domain; HR2, heptad repeat 2
domain; TM, transmembrane domain; CP, cytoplasmic domain. The residue numbers of each region
correspond to their positions in the S protein of MERS-CoV. HR2P, the peptide derived from the HR2
domain of MERS-CoV S protein S2 subunit; HR2P-M2, HR2P analogous peptide with mutations.
Figure 4. Schematic representation of the inhibition mechanism of HR2P and HR2P-M2. 1© Target
cell membrane; 2© MERS-CoV; 3© dipeptidyl peptidase-4 (DPP4). (A) Mechanism of normal binding
between a host cell and MERS-CoV. MERS-CoV enters the host cell by binding the viral particle via the
RBD in spike protein to the cellular receptorDPP4 on the surface of the host cell. The HR2 binds to the
HR1 to form a six-helix bundle (6-HB) fusion core, which brings viral and cell membranes into close
apposition for fusion. (B) HR2P and HR2P-M2 block six-bundle fusion core formation between HR1
and HR2 peptides by binding to the viral S protein HR1 domain.
P21S10, the most effective fusion inhibitor of MERS-CoV, can inhibit MERS-CoV pseudovirus
infection with an EC50 of about 1 μM in Huh-7 cells and a CC50 of >100 μM in Huh-7 cells by CCK8
(Cell Counting Kit-8) assay (Table 1) [20]. In addition, a series of synthesized stapled peptides, such as
P21S10, P21S2, P21S4, P21S5, P21S8, P21S9, P21S8F, P21S8ZF, etc., could effectively inhibit infection by
MERS-CoV pseudovirus and its spike protein-mediated cell fusion by blocking helix-mediated NHR
(N-terminal heptad repeats) /CHR (C-terminal heptad repeats) interactions with a low EC50 and a
high CC50 in Huh-7 cells [20].
P9, a short peptide, exhibited potent and broad spectrum antiviral effects against multiple
respiratory viruses in vitro and in vivo [21,25]. P9 inhibited MERS-CoV with an EC50 of about 5 μg/mL
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in Madin-Darby canine kidney (MDCK) cells, obtained by plaque assay, and a CC50 of 380 μg/mL in
MDCK cells obtained by MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide)
assay (Table 1) [21].
Lipopeptides are bioactive peptides that replicate the α-helical chain from the viral fusion
machinery [22]. All 12 lipopeptides inhibit cell−cell fusion mediated by MERS-CoV S protein with
EC50 values ranging from 0.1 to >10.0 μM in Huh-7 cells (Table 1) [22]. Among these lipopeptides, LLS
and IIS were found to be the most potent MERS-CoV fusion inhibitors with EC50 values of 0.24 μM
and 0.1 μM, respectively [22]. Other lipopeptides such as AAS, FFS, YYS, IIY, IIW, IIH, IIQ, IIK, and
IIE can also inhibit cell−cell fusion mediated by MERS-CoV S protein with variable EC50 values [22].
Three neurotransmitter inhibitors, including chlorpromazine, fluphenazine, and promethazine,
were moderate inhibitors of cell–cell fusion with EC50 values of about 23, 15, and 17 μM, respectively
(Table 2; Figure 5(5), (45), (46)) [26]. They can also disrupt clathrin-mediated endocytosis to inhibit
MERS-CoV [26].
A small-molecule HIV entry inhibitor targeting gp41 ADS-J1 (Figure 5(1)) at the concentration
of 20 μM could inhibit >90% of MERS-CoV pseudovirus infection in NBL-7 and Huh-7 cells. ADS-J1
could interrupt the interactions between the HR1 and HR2 of MERS-CoV to form the six-helix bundle,
thus inhibiting the entry of pseudotyped MERS-CoV with an EC50 of 0.6 μM in the DPP4-expressing
cell line and with a CC50 of 26.9 μM in NBL-7 and Huh-7 cells by MTT assay (Table 2) [27].
The elucidation of MERS-CoV interaction with its host cell is critical to the development of
antiviral interventions. In order to gain entry into host cells, MERS-CoV not only uses DPP4 as a
functional virus receptor, but also utilizes certain cellular proteases, such as TMPRSS2 and members of
the cathepsin family, as activators of the S glycoprotein [9]. TMPRSS2 is expressed in epithelial cells
of the human respiratory and gastrointestinal tracts [28–31]. The respective enzymes from host cells
are also excellent targets for the identification of small-molecule MERS-CoV inhibitors. The serine
protease inhibitor camostat mesylate (camostat) could completely block syncytium formation, but only
partially block virus entry into TMPRSS2-expressing Vero cells (Figure 5(2)) [31].
K11777, a compound known to inhibit cruzain, a cathepsin-like protease from the protozoan
parasite Trypanosoma cruzi, can inhibit MERS-CoV with an EC50 of 46 nM (Figure 5(3)) [32,33].
Chloroquine inhibited MERS-CoV replication and blocked infection at an early step with an
EC50 of 3 μM and a CC50 of 58 μM (Table 2; Figure 5(4)) [34]. Chlorpromazine inhibited MERS-CoV
replication at both early and post-entry stages with an EC50 of about 5 μM and a CC50 of 21 μM
(Table 2; Figure 5(5)) [34]. However, high cytotoxicity narrowed the therapeutic window in both
monocyte-derived macrophages (MDMs) and dendritic cells (MDDCs) [34].
Ouabain and bufalin can inhibit MERS-CoV entry by blocking clathrin-mediated endocytosis
(Figure 5(6), (7)) [25,35]. The addition of small amounts of ouabain (50 nM) or bufalin (10 to 15 nM)
inhibited infection with MERS-CoV and VSV (vesicular stomatitis virus) (Table 2), but only when the
drug was added prior to inoculation in Huh-7 cells [35].
Dihydrotanshinone, a lipophilic compound, showed a decimal reduction at 0.5 μg/mL and
excellent antiviral effects at ≥2 μg/mL with a reduction in titer from 6.5 Log to 1.8 Log TCID50/mL by
using a pseudovirus expressing MERS-CoV spike protein (Figure 5(8)) [36].
During the biosynthesis of MERS-CoV S protein, the furin inhibitor
decanoyl-RVKR-chloromethylketone (dec-RVKR-CMK) at 75 μM can lead to a decrease of the
85-kDa cleaved product in MERS-CoV S wt and S2′ mutant (Figure 5(9)) [37].
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Figure 5. Chemical structure formulae of small-molecule inhibitors of MERS-CoV described in
this review.
3.2. MERS-CoV Replication Inhibitors
3.2.1. MERS-CoV Inhibitors Targeting Papain-Like Protease
Papain-like protease is a cysteine protease that uses the thiol group of cysteine as a nucleophile
to attack the carbonyl group of the scissile peptide bond [38,39]. The genome of MERS-CoV encodes
two polyproteins, ppla and pplb, which are processed by papain-like protease (PLpro) and 3C-like
protease (3CLpro) [40]. MERS-CoV has only one papain-like protease, as does SARS-CoV, while other
coronaviruses have two enzymes [41,42]. MERS-PLpro is a part of the nonstructural protein nsp3,
which includes three domains—namely, ubiquitin-like domain (UBL), a catalytic triad consisting
of C1594–H1761–D1776, and the ubiquitin-binding domain (UBD) at the zinc finger—according
to the homology model [40,43]. MERS-PLpro is a multifunctional enzyme with deISGylating and
deubiquitinating (DUB) activities [43], but it can also block the interferon regulatory factor 3 (IRF3)
pathway [43,44].
Disulfiram, a drug used in alcohol aversion therapy, has been approved by the U.S. Food and
Drug Administration (FDA) since 1951 (Figure 5(10)). It can inhibit the activity of some enzymes, such
as urease [45], methyltransferase [46], and kinase [45], all by reacting with cysteine residues, suggesting
broad-spectrum characteristics [47]. Notably, disulfiram also acts as an allosteric inhibitor of MERS-CoV
papain-like protease [47]. Multiple inhibition assays also support a kinetic mechanism by which
disulfiram, together with 6TG (6-thioguanine) and/or MPA (mycophenolic acid), can synergistically
inhibit MERS-CoV papain-like protease [47]. Hence, the recombination of three clinically available
drugs could feasibly be used to treat MERS-CoV infection.
3.2.2. MERS-CoV Inhibitors Targeting 3C-Like Protease
The active site of MERS-3CLpro can be divided into subsites S1–S6 [48]. Subsite S1 consists of
vital catalytic residue Cys145 with His41 to process polyproteins at 11 conserved Gln sites, followed
by small amino acids like Ala, Ser, or Gly [49]. Another crucial component of the S1 subsite is the
oxyanion hole formed by the interaction of a carboxylate anion of conserved Gln with Gly143, Ser144,
and Cys145, which stabilizes the transition state during proteolysis [50,51]. Glu166 at the entrance of
the pocket interacts via H-bond with the Nε2 of the conserved Gln [50]. The S2 and S4 subsites contain
hydrophobic and bulky side chains such as Val, Leu, or Phe. Subsites S5 and S6 are near the surface of
the active site and have little participation in substrate binding [48].
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Polyproteins pp1a and pp1b are processed by 3CLpro (11 cleavage sites) and PLpro (3 cleavage
sites), resulting in 16 mature nonstructural proteins, including RNA-dependent RNA polymerase
(RdRp) and helicase, which play important roles in the transcription and replication of
coronaviruses [40,52]. Therefore, both proteases are essential for viral replication, making them
attractive targets for drug development [52].
The analogues of hits of neuraminidase (NA) inhibitors on MERS-CoV 3CLpro have been
synthesized and showed average-to-good inhibition of MERS-3CLpro. The better one is the compound
3k with an EC50 of 5.8 μM (Table 2; Figure 5(11)) [48]. Another two are compounds 3h (Figure 5(12))
and 3i (Figure 5(13)) with EC50 values of 7.3 and 7.4 μM, repsectively (Table 2) [48]. Furthermore,
researchers have concluded that pharmacophores phenyl at R3 and carboxylate, either at R1 or R4,
are essential for the antiviral activity [48]. Since the modification of rings A and B is well tolerated,
these rings can be further altered to enhance the activity of the compounds. The SARS-CoV 3CLpro
inhibitor CE-5 can block the function of the MERS-CoV 3CLpro (Figure 5(14)) [53]. Treatment with
CE-5 inhibited the activity of MERS-CoV 3CLpro to 30% of that of DMSO-treated cells at a maximum
dose of 50 μM [53]. The endpoint evaluation of CE-5 indicated an EC50 of ~12.5 μM in cell culture
(Table 2) [53].
Peptidomimetic inhibitors of enterovirus (6b, 6c, and 6d) inhibit MERS-CoV with EC50 values
ranging from 1.7 to 4.7 μM, as shown by enzymatic assay (Figure 5(15), (16), (17)) [54]. As shown in
Table 1, compounds 6b, 6c, and 6d efficiently suppressed viral replication with EC50 values of 1.4, 1.2,
and 0.6 μM, respectively, after performing a cytopathic inhibition assay using MERS-CoV-infected
Huh-7 cells (Table 2) [54].
GC376, a dipeptidyl transition state 3CLpro inhibitor, can substantially inhibit the activity of
MERS-CoV 3CLpro with an EC50 of 1.6 μM by fluorescence resonance energy transfer (FRET) assay
(Table 2; Figure 5(18)) [55].
GC813 as well as its synthesizing extended compounds 10a and 10c exhibit inhibition for
MERS-CoV with EC50 values of 0.5 μM, 0.5 μM, and 0.8 μM in cell culture (Table 2; Figure 5(18),
(19), (20), (21)) [52].
N3, a broad-spectrum anti-CoV inhibitor, can inhibit the proteolytic activity of MERS-CoV 3CLpro
by binding with the interface of domain I and II of MERS-CoV 3CLpro with an EC50 of about 0.3 μM
(Table 2; Figure 5(22)) [56].
3.3. Other Small-Molecule Inhibitors with Defined or Undefined Mechanisms of Action
Silvestrol, an eIF4A inhibitor, can inhibit MERS-CoV infection with an EC50 of 1.3 nM, as shown
by plaque assay in MRC-5 cells and CC50 of 400 nM by MTT assay in peripheral blood mononuclear
cells (PBMCs) (Table 2; Figure 5(23)) [57]. Silvestrol has broad-spectrum antiviral activity via the
inhibition of the expression of CoV structural and nonstructural proteins (N, nsp8) and the formation
of viral replication/transcription complexes [57].
The combination of interferon-α2b and ribavirin can effectively reduce MERS-CoV replication
in vitro and in vivo (Table 2; Figure 5(24)) [6]. Rhesus macaques treated with IFN-α2b and ribavirin
8 h after MERS-CoV infection showed improved clinical parameters with no or very mild radiographic
evidence of pneumonia compared with untreated macaques [6]. Moreover, treated macaques showed
lower levels of systemic (serum) and local (lung) proinflammatory markers in addition to fewer viral
genome copies, distinct gene expression, and less severe histopathological changes in the lungs [6].
GS-5734 (Remdesivir), the monophosphoramidate prodrug of the C-adenosine nucleoside
analogue GS-441524, can inhibit the replication of the model β-coronavirus murine hepatitis virus
(MHV) and RNA synthesis in wild-type (WT) virus, while an nsp14 ExoN (-) mutant lacking
proofreading demonstrated increased susceptibility to GS-5734 (Figure 5(25)) [58]. GS-5734 also
inhibits MERS-CoV infection with an EC50 of 0.074 ± 0.023 μM and a CC50 of >10 μM in human
amniotic epithelial (HAE) cells (Table 2) [58]. Furthermore, GS-5734 acts at the early post-infection
stage to decrease viral RNA levels, whereas delaying the addition of GS-5734 until 24 h post-infection
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resulted in decreased viral titer in HAE cell cultures at 48 and 72 h post-infection [58]. The nucleotide
analogue GS-441524 also inhibits the infection of MERS-CoV with an EC50 of 0.9 μM and a CC50 of
>100 μM in HAE cells (Table 2; Figure 5(26)) [58].
Resveratrol was found to significantly inhibit MERS-CoV infection as well as prolong cellular
survival after virus infection (Figure 5. (27)) [66]. It was found that resveratrol could reduce RNA
levels and infection titers in Vero cells [66]. Although resveratrol has minimal cytotoxicity, even at the
high concentration of 250 μM, it can be ignored when compared to the much more severe toxicity of
MERS-CoV infection [66].
A series of FDA-approved compounds were screened against MERS-CoV (Table 2) by cell-based
ELISA assay (Figure 5(28–56)) [7]. Pharmaceuticals that inhibit MERS-CoV include neurotransmitter
inhibitors, estrogen receptor antagonists, kinase signaling inhibitors, inhibitors of lipid or sterol
metabolism, protein processing inhibitors, inhibitors of DNA synthesis/repair, as well as inhibitors of
ion transport, cytoskeleton (specifically tubulin), and apoptosis [7]. Antiparasitics and antibacterials
are two classes of pharmaceuticals, the functions of which are not obviously linked to coronaviruses,
or viruses in general, but nonetheless show antiviral activity against MERS-CoV.
Nocodazole, targeting the cytoskeleton, specifically interferes with microtubule polymerization.
It is an antimitotic drug developed for the treatment of cancer, but it was found to show high activity
against MERS-CoV (Figure 5(57)) [67,68]. Monensin and salinomycin sodium, two of the nine ion
channel inhibitors, have inhibitory activity against MERS-CoV, indicating that MERS-CoV may be
susceptible to ionophore activities (Figure 5 (58), (59)). Chlorpromazine and chloroquine appear to
target host factors, rather than viral proteins specifically, and the treatment of viral infections in patients
aimed at host factors could reconfigure overt manifestations of viral pathogenesis into a less virulent
subclinical infection and lower adverse disease outcome (Figure 5(60), (29)) [34,69].
Loperamide, an antidiarrheal opioid receptor agonist that reduces intestinal motility, also
inhibits the replication of MERS-CoV at low-micromolar concentrations (3.3–6.3 μM) in vitro (Table 2;
Figure 5(55)) [34]. Lopinavir, the HIV-1 protease inhibitor, inhibits MERS-CoV replication with an EC50
of 8 μM (Table 2; Figure 5(56)) [34].
SSYA10-001 inhibits MERS-CoV replication with an EC50 of ~25 μM in Vero E6 cells (Table 2;
Figure 5(61)) [70]. Molecular modeling data suggest that SSYA10-001 can be docked with a comparable
“Glide” score [70].
ESI-09 can reduce virus yield by inhibiting cAMP signaling in a cell type-independent manner
(Figure 5(62)) [61]. The concentration of MERS-CoV inhibition by ESI-09 was found with an EC50 of 5
to 10 μM and a CC50 > 50 μM for both Calu-3 and Vero E6 cells by using the lactate dehydrogenase
(LDH)-based cytotoxicity assay [62]. In addition, the undetectable cytopathic effect (CPE) and
minimal expression of viral antigen indicated that Calu-3 cells treated with ESI-09 were almost
fully protected [61].
Mycophenolic acid (MPA) can strongly reduce MERS-CoV replication by inhibiting inosine
monophosphate dehydrogenase (IMPDH) and guanine monophosphate synthesis with an EC50 of
2.87 μM by cell-based ELISA in Vero E6 cells (Table 2; Figure 5(63)) [60].
K22 is a spectrum inhibitor which can inhibit MERS-CoV replication by reducing the formation
of double membrane vesicles (DMVs) and by the near-complete inhibition of RNA synthesis
(Figure 5(64)) [25,71].
BCX4430, an adenosine analogue that acts as a non-obligate RNA chain terminator to inhibit viral
RNA polymerase function, can inhibit MERS-CoV infection with EC50 of 68.4 μM in Vero E6 cells
by highly charged ions (HCIs)-based analysis and CC50 of >100 μM by neutral-red uptake (Table 2;
Figure 5(65)) [25,62].
Fleximer nucleoside analogues of acyclovir are doubly flexible nucleoside analogues based
on the acyclic sugar scaffold of acyclovir and the flex-base moiety in fleximers responsible for
inhibiting RNA-dependent RNA polymerase (RdRp) [25,63]. The target fleximer analogue 2 can
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inhibit MERS-CoV infection with EC50 of 27 μM and CC50 of 149 μM in Huh-7 cells, but EC50 of 23 μM
and CC50 of 71 μM in Vero cells (Table 2; Figure 5(66)) [63].
Interferon alpha1 (IFN-α1) and cyclosporine (CsA) have additive or synergistic effects in
limiting MERS-CoV replication in ex vivo cultures of human bronchus (Figure 5(67)) [72]. In
addition, the combined treatment of IFN-α1 and CsA has the most potent effect on inducing
interferon-stimulated genes (ISGs) in both lung (24 hpi) and bronchial (56 hpi) tissues [72].
Saracatinib, a potent inhibitor of the Src-family of tyrosine kinases (SFK), potently inhibits
MERS-CoV with an EC50 of about 3 μM in Huh-7 cells (Table 2; Figure 5(68)) [64]. It possibly inhibits
MERS-CoV replication through the suppression of SFK signaling pathways at the early stages of
the viral life cycle [64]. In addition, another seven compounds, primarily classified as antiprotozoal,
anticancer, and antipsychotic, were also determined by complete dose-response analyses (Table 2;
Figure 5(69–75)) [64].
A spectrum-inhibitor, FA-613, can inhibit MERS-CoV with an EC50 of ~10 μM in the
interferon-competent cell line of Huh-7 cells, as shown by MTT assay (Table 2; Figure 5(76)) [65].
4. Strategies for Developing Small-Molecule MERS-CoV Inhibitors
The luciferase-based biosensor assay is a cell-based screening assay for selecting
MERS-CoV-specific or broad-spectrum coronavirus PLpro and 3CLpro inhibitors [53]. HEK293T
cells were transfected by two artificial plasmids: protease expression plasmids and biosensor
expression plasmids [53]. Protease expression plasmids contain the sequence of MERS-CoV PLpro,
the nonstructural proteins nsp4 and nsp5, as well as the N-terminal 6 region. Biosensor expression
plasmids contain a circularly permuted Photuris pennsylvanica luciferase and the amino sequence of
cleavage site of PLpro or 3CLpro [53]. After cell transfection and coexpression of a MERS-CoV protease
domain with a cleavage-activated luciferase substrate, transfected live cells allow for both endpoint
evaluation and live cell imaging profiles of protease activity [53]. This novel method can be performed
in a biosafety level 2 research laboratory to evaluate the ability to inhibit the CoV protease activity of
existing and new drugs [53].
Pseudovirus-based screening assays have been developed for identifying antiviral compounds in
the MERS-CoV life cycle without using infectious viruses. The MERS-CoV pseudovirus allows for
single-cycle infection of a variety of cells expressing DPP4, and results are consistent with those from a
live MERS-CoV-based inhibition assay. More importantly, the pseudovirus assay can be carried out in
a BSL-2, rather than a BSL-3 facility [9]. VSV- and HIV-luciferase pseudotyped with the MERS-CoV S
protein are two more approaches [27].
Structure-Guided Design and Optimization of Small Molecules is a strategy that involves
embodying a piperidine moiety as a design element to attain optimal pharmacological activity and
protein kinase property [52]. This strategy permits the resultant hybrid inhibitor to participate in
favorable binding interactions with the S3 and S4 subsites of 3CLpro by attaching the piperidine moiety
to a dipeptidyl component [52].
Ubiquitin-like domain 2 (Ubl2) is immediately adjacent to the N-terminus of the PLpro domain in
coronavirus polyproteins. In the past, the role of Ubl2 in PLpro has remained undefined. However,
evidence indicates that removing the Ubl2 domain from MERS PLpro has no effect on its ability to
process the viral polyprotein or act as an interferon antagonist, which involves deubiquitinating and
deISGylating cellular proteins [73].
Analyzing the transcriptome of hosts infected with MERS-CoV can provide insight into how
MERS-CoV infection influences and interacts with host cells. Josset et al. [74] infected a lung epithelial
cell line, Calu3, with MERS-CoV and analyzed the transcriptome to identify inhibitory compounds
resident in host factors that could be exploited as antiviral therapeutics. This approach can be used to
identify host factors beneficial for virus propagation, thus establishing appropriate targets for existing
or new antiviral inhibitors.
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5. Conclusions
As a positive-sense, single-stranded RNA virus, MERS-CoV utilizes host cellular components
to accomplish various physiological processes, including viral entry, genomic replication, and the
assembly and budding of virions, thereby resulting in pathological damage to the host. Therefore,
various stages of virus life cycle could be potential targets for developing small-molecule antiviral
inhibitors. Inhibitors blocking MERS-CoV entry into host cells, viral protease inhibitors, and inhibitors
targeting host cells and many other small-molecule inhibitors with defined or undefined mechanisms
of action are summarized in this review.
Any compounds that interfere with virus infection may be harmful to host cells. Therefore, the
establishment of a safety profile is essential. Furthermore, an antiviral inhibitor should effectively
inhibit the growth of the virus because a small amount of virion replication can lead to resistant
mutations. The advantages of small-molecule inhibitors include low price, stability, and the
convenience of oral administration. Three main approaches are currently used to develop MERS-CoV
small-molecule inhibitors. The first is the de novo synthesis of inhibitors targeting the unique structure
in the proteins of MERS-CoV appearing in its infection process. The second approach involves
screening inhibitors against MERS-CoV infection from an existing drug database by various chemical
synthesis strategies. The third approach involves changing the chemical group of a fully developed
drug to enhance its pharmacological activity against MERS-CoV. More novel strategies in improving
the efficacy of screening small-molecule inhibitors are anticipated to reduce the threat of future
MERS-CoV infections.
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